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Abstract 
Duchenne muscular dystrophy is a highly complex multi-system disorder caused by 
primary abnormalities in the Dmd gene encoding the membrane cytoskeletal protein 
dystrophin. The resulting loss of the dystrophin protein triggers a concomitant 
disintegration of the dystrophin-associated glycoprotein complex at the sarcolemma. 
This complex links intracellular actin to components of the extracellular matrix and 
serves as a stabilising support network during normal muscle excitation-contraction-
relaxation cycles. In Duchenne muscular dystrophy, the loss of dystrophin and its 
associated protein complex leads to membrane instability and micro-rupturing, the 
influx of excessive levels of calcium ions, the activation of proteases, sterile 
inflammation and eventually muscle degeneration and infiltration of adipose and 
connective tissue. Affected children suffer from severe and progressive skeletal 
muscle wasting with a loss of independent ambulation occurring during the early 
teenage years. In addition to muscle wasting, other manifestations of the disease 
include cardiomyopathy, respiratory insufficiency and scoliosis, along with non-
progressive cognitive impairments in a subset of patients. Proteomics represents an 
ideal bioanalytical tool for the elucidation of the molecular mechanisms that underlie 
muscular dystrophy and for the identification of novel biomarker candidates. The 
research presented here has employed label-free liquid chromatography mass 
spectrometry along with chemical cross-linking mass spectrometry to characterise 
alterations in protein abundance and protein interaction patterns, respectively, in the 
mdx-4cv animal model of Duchenne muscular dystrophy. Proteins of particular 
interest have been further verified by biochemical assays including comparative 
immunoblotting and enzyme-linked immunosorbent assays. In-depth analyses have 
been performed on skeletal muscle, the aged heart, and brain tissue to investigate 
proteome-wide changes in the skeletal musculature, the cardiorespiratory system and 
the central nervous system. In addition, proteomic profiling of serum and saliva 
samples from dystrophic mdx-4cv mice has been conducted to identify potential 
minimally invasive biomarker candidates for the improved diagnosis, prognosis and 
therapy-monitoring of X-linked muscular dystrophy.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter One 
 
Introduction 
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1.1 Muscle Biology  
Representing one of the most dynamic and plastic tissues in the human body, muscle 
accounts for approximately 40% of the total body mass. Composed of myofibres, 
nerves, blood vessels and connective tissue, the body musculature is highly complex 
and has a range of integral functions; primarily related to posture, locomotion, heat 
homeostasis and metabolism (Ohlendieck, 2011b). Four main types of muscle exist; 
skeletal muscle, cardiac muscle, smooth muscle and myoepithelial cells. Skeletal 
muscle contains 50-75% of all proteins in the body, and it is primarily involved in 
metabolism and mechanical support (Frontera and Ochala, 2015). From a mechanical 
perspective skeletal muscle converts chemical energy to mechanical energy, provides 
support to the whole body and enables movement. From a metabolic point of view, 
skeletal muscle contributes to the basal metabolic rate, is responsible for the 
production of heat to maintain core body temperature and acts as a reservoir for amino 
acids and carbohydrates for intra-muscular utilisation (Wolfe, 2006). Skeletal muscle 
is multi-nucleated, striated (due to the organisation of the sarcomeres) and under 
voluntary control. Cardiac muscle is found only in the heart, is under the control of 
the autonomic nervous system, and while also striated differs from skeletal muscle by 
the presence of intercalated discs (Kostetskii et al., 2005), which support synchronised 
cardiac muscle contraction. The high concentration of mitochondria make cardiac 
muscle resistant to fatigue (Dorn, 2013). Smooth muscle is an involuntary, non-
striated muscle type found in the lining of blood vessels and in internal organs. 
Myoepithelial cells are typically found in glandular epithelia. They exist as a thin layer 
between the basement membrane and the luminal cells, and their contractile ability 
enables them to expel glandular secretions. Given muscle tissue is under extreme stress 
due to high energy demands and the strain of excitation-contraction-relaxation cycles, 
muscle is highly adaptable, plastic, and has efficient molecular chaperones and cellular 
repair mechanisms (Murphy and Ohlendieck, 2016).  
 
1.1.1 Muscle Structure 
Skeletal muscle has a highly organised architecture of muscle fibres and associated 
connective tissue. Individual muscles are surrounded by a layer of connective tissue 
called the epimysium. Groups of fibres within an individual muscle are surrounded by 
a second layer of connective tissue called the perimysium, while individual muscle 
fibres are surrounded by the endomysium and the sarcolemma (Gillies and Lieber, 
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2011). Each muscle fibre contains thousands of myofibrils and individual myofibrils 
are composed of a series of sarcomeres; the basic contractile unit of muscle. Figure 
1.1 illustrates a single myofibril containing the typical A-bands and I-bands of skeletal 
muscle and an enlarged view of an individual sarcomere with its associated protein 
constellation.  The arrangement of the filament systems of the sarcomere give skeletal 
muscle its distinctive striated appearance. Four principal filament systems exist in 
skeletal muscle; actin-containing thin filaments, myosin-containing thick filaments, 
titin-containing filaments which span half the sarcomere and the giant protein nebulin 
which spans the length of the actin filaments (Clark et al., 2002). The sarcomeres are 
delineated by the Z-discs which is also the site at which the thin filaments, titin 
filaments and nebulin filaments are anchored. The thin filaments, which also contain 
the regulatory proteins tropomyosin and troponin, and the thick filaments are 
responsible for muscle contraction, the large elastic protein titin acts as a “molecular 
spring” and is responsible for stabilising and aligning the thick filament and may help 
generate force (Fukuda et al., 2008) while nebulin is suggested to regulate the length 
of the thin filaments (Kruger et al., 1991).  
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Figure 1.1: Structure of skeletal muscle  
Shown in the upper part of the image is a portion of a muscle myofibril depicting some 
of its key features; the M-line, Z-line, A-band, I-band and H-zone. Depicted 
underneath is an enlarged image of a sarcomere, which contains the thin and thick 
filaments that are responsible for skeletal muscle contraction. The thin filaments are 
composed of actin, tropomyosin and a troponin complex (consisting of troponin I, 
troponin T and troponin C), while the thick filaments are composed of myosin.  
 
*Image adapted from Frontera and Ochala, 2015 
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1.1.2 Muscle Fibre Types 
Skeletal muscle is highly plastic and dynamic, and its adaptability to changed 
functional demands is largely due to enormous diversity in contractile proteins and 
bioenergetic enzymes. In human skeletal muscle, skeletal muscle fibres are classified 
as slow oxidative (type I), moderately fast oxidative glycolytic (type IIa) and fast 
glycolytic (type IIb) (Ohlendieck, 2011c). The majority of adult skeletal muscles are 
characterised by a complex arrangement of fast-twitching fibres, slow-twitching 
fibres, and hybrid fibres, whereby the ratio of slow-to-fast-to-hybrid fibres is related 
to the functional status of the individual muscle (Dowling et al., 2016b). Skeletal 
muscle fibres can be typically classified by colour, fibre diameter, resistance to fatigue, 
metabolism, capillary density, triglyceride concentration, levels of myoglobin and 
glycogen, and the density, ultrastructure and enzyme activity of mitochondria 
(Schiaffino and Reggiani, 2011). Muscle proteins can also be used as markers to 
determine general trends in fibre-type distributions. As illustrated in Figure 1.2 below, 
although the overall protein banding pattern is similar between the predominantly slow 
soleus muscle, and the predominantly fast gastrocnemius and extensor digitorum 
longus muscles from  12-month old C57/BL10 mice, the intensity of immuno-labelled 
bands for the slow myosin heavy chain (MyHC)-I(β), and the fast SERCA1 and slow 
SERCA2 isoforms of the sarcoplasmic reticulum Ca2+-ATPase clearly shows 
differences in the expression of fibre-type-specific protein isoforms. 
 A number of neuromuscular disorders and muscle co-morbidities can induce 
fibre-type transitions in skeletal muscle, either directly as a result of active fibre 
conversions or indirectly through a heightened susceptibility of certain fibre types to 
cellular degeneration and muscle atrophy. Slow-to-fast fibre transitions are evident in 
response to muscular atrophy (denervation, disuse, immobilisation), diabetes and 
obesity. Fast-to-slow transitions are detected in cancer cachexia, inflammatory 
myopathies and sarcopenia of old age (Dowling et al., 2016b). 
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Figure 1.2: Protein markers of skeletal muscle fibre types 
Shown is a silver stained gel (A) of tissue homogenates from the individual muscle 
types gastrocnemius (GAS), soleus and extensor digitorum longus (EDL) from 12-
month old C57/BL10 mice. Illustrated also are immunoblots to the equal loading 
protein laminin (B), the slow myosin heavy chain MyHC-I(β) isoform (C), and the fast 
SERCA-1 (D) and the slow SERCA-2 (E) isoforms of the sarcoplasmic reticulum 
Ca2+-ATPase.  
 
*Image adapted from Dowling et al., 2016b 
 
 
 
 
 
 
 
B) Laminin A) Silver Stain C) Slow MyHC-1(β) 
D) Fast Ca2+-ATPase E) Slow Ca2+-ATPase 
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1.1.3 Muscle Excitation-Contraction Coupling 
During skeletal muscle development, skeletal muscle fibres are innervated to form a 
motor unit. The motor unit is the basic functional component of the neuro-motor 
system and is defined as a motor neuron and all the skeletal muscle fibres that it 
innervates. The innervation ratio can range from a few fibres in some extraocular 
muscles to thousands of fibres per motor neuron in some limb muscles (Monti et al., 
2001). Muscle contraction is therefore linked to the motor neuron system in which an 
action potential travels along a motor neuron until it reaches the axon terminal where 
it activates calcium voltage gated channels. The subsequent release of calcium ions, 
Ca2+, causes the release of the neurotransmitter acetylcholine (ACh) from nerve 
terminals where it enters the synaptic cleft and acts as the stimulus for muscle 
contraction. ACh binds to the post-synaptic acetylcholine receptors (AChR) located 
within the motor end plate at the muscle sarcolemma, which facilitates the opening of 
voltage-gated sodium channels and the influx of sodium ions, Na+, into the cell 
(Stephenson et al., 1998). This event results in membrane depolarisation and the 
propagation of the action potential along the muscle sarcolemma until it is detected by 
the α1s-subunit of the dihydropyridine receptor (DHPR) in sarcolemmal invaginations 
known as the transverse tubules (T-tubules). This induces a conformational change in 
the DHPR, in which the cytoplasmic loop between repeats II and III in the α1s-subunit 
has been found to be crucial for the propagation of the action potential to the 
sarcoplasmic reticulum (SR) (Stephenson et al., 1998). The conformational change in 
the DHPR enables it to interact directly with the ryanodine receptor (RyR1), a high 
molecular weight (~550 kDa per monomer) homo-tetramer resident in the SR 
membrane. This binding facilitates the opening of the RyR1 calcium channels, 
enabling an influx of Ca2+ from the lumen of the SR into the cytoplasm of the muscle 
cell (Calderón et al., 2014).  
However, not all RyRs are coupled to DHPR receptors. These single receptors 
are likely activated by excess Ca2+ released by neighbouring RyRs. This amplification 
of the Ca2+ signal is referred to as calcium-induced-calcium-release and is dominant 
in cardiac tissue (Froemming and Ohlendieck, 2001). The released Ca2+ ions bind to 
regulatory Ca2+-specific binding sites on the calcium-binding troponin C (TnC), which 
exposes a series of hydrophobic residues in its N-terminus. This facilitates the 
interaction of TnC with inhibitory troponin I (TnI) and tropomyosin-binding troponin 
T (TnT). This structural change in the troponin complex promotes the translocation of 
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the troponin-tropomyosin complex away from the outer domain of actin filaments 
(Gomes et al., 2002). In the presence of ATP, the myosin head of the thick filament 
can then interact with the myosin-binding site on actin. As the actin filaments and the 
myosin heads couple they cause sliding of the thin filaments past the thick filaments, 
creating a cross-bridge and muscle contraction. Removal of Ca2+ from the N-terminal 
Ca2+-binding site of TnC inhibits the interaction of myosin heads and actin filaments.  
The removal of Ca2+ from the cytoplasm is first mediated by calcium-buffering 
proteins such as the 12 kDa protein parvalbumin and later by sarcoplasmic reticulum 
calcium transport ATPase (SERCA), which mediate the pumping of Ca2+ from the 
cytoplasm back to the SR (Calderón et al., 2014). The sarcolemma returns to its resting 
potential, the interaction between the DHPR and RyR1 dissociates and the muscle 
relaxes.  
 Mutations in genes that encode proteins directly involved in the excitation-
contraction-relaxation cycle are responsible for a number of hereditary myopathies. 
Mutations in the calcium release RyR1 are largely responsible for malignant 
hyperthermia and central core disease. Hypokalemic periodic paralysis is associated 
with genetic abnormalities in the voltage-sensing α1s-subunit of the DHPR, which may 
affect interactions with RyR1, and thus interfere with normal excitation-contraction 
coupling (Froemming and Ohlendieck, 2001). Brody disease is characterised by 
muscle cramping and exercise-induced impairment of muscle contraction and has been 
linked to reduced activity of SERCA1, resulting in delayed muscle relaxation. 
Reduced SERCA1 activity is accompanied by mutations in the ATP2A1 gene in some 
but not all patients, indicating that Brody disease is genetically heterogeneous 
(Voermans et al., 2012).  
 
1.1.4 Muscle Development 
Myogenesis is the process by which muscle is generated during embryonic 
development. During gastrulation a mesodermal layer is created between the 
endoderm and the ectoderm and this mesoderm gives rise to muscle, along with blood 
vessels, connective tissue and bone (Grefte et al., 2007). Muscle originates from 
distinct mesodermal tissues; the trunk and limb skeletal muscles are formed from the 
dermomyotome and the dermomyotome-derived myotome, whereas muscles of the 
head are formed from the cranial mesoderm. Transcription factors are key players in 
the development of skeletal muscle. This network of signalling molecules includes the 
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myogenic regulatory factors (MRFs) MyoD, Myf5, MRF4 and myogenin, which 
influence myogenic determination and differentiation, and the paired-box 
transcription factors Pax3 and Pax7 involved in myogenic specification (Endo, 2015). 
Muscle progenitor cells delaminate from the dermomyotome and also migrate into 
limb buds, where through the activation of the MRFs they become myoblasts. 
Myogenin, MyoD and MRF4 then cause the differentiation of myoblasts into 
myocytes, where they eventually fuse and mature into multinucleated myotubes 
(Grefte et al., 2007). Innervation and the expression of muscle specific proteins such 
as the full-length Dp427 dystrophin isoform, muscle myosin heavy and light chains, 
and the nicotinic acetylcholine receptor, are involved in the transition to an innervated 
mature myofibre which can then form a functional motor unit (Holland and 
Ohlendieck, 2013). The adult motor unit is composed of numerous muscle fibres and 
is highly plastic, resulting in an ability of skeletal muscle to adapt to a variety of 
stimuli, including but not limited to alterations in neuromuscular activity levels, 
endurance exercise, denervation, disuse, trauma and the natural aging process.  
 
1.1.5 Muscle Regeneration 
Since myonuclei are post-mitotic, muscle repair and regeneration require de novo 
myotube formation, which is facilitated by satellite cells. Satellite cells initially 
provide myoblasts for muscle growth before becoming mitotically quiescent during 
muscle maturation (Relaix and Zammit, 2012). They are located between the basal 
lamina and the sarcolemma of myofibres, and express Pax7 and M-cadherin. While 
normally in a dormant state, satellite cells are activated upon injury to facilitate muscle 
regeneration. The exit from quiescence into a proliferative state is mediated by various 
extracellular signalling factors released from damaged muscle fibres which bind to 
receptors on quiescent satellite cells to stimulate their activation. These include 
fibroblast growth factor 2, hepatocyte growth factor, insulin-like growth factor 1 and 
TNF-α (Dumont et al., 2015). The activation process is similar to embryonic 
development, in which the activated satellite cells upregulate the expression of MyoD 
and Myf5 to become proliferative. Down-regulation of Pax3 and Pax7 and up-
regulation of myogenin and MRF4 lead to the terminal differentiation of these 
myoblasts, which then either fuse to one another to generate new muscle fibres or 
attach to damaged muscle fibres to aid muscle repair (Grefte et al., 2007).  
10 
 
 Satellite cells also demonstrate a capacity for self-renewal, where satellite cell 
division results in one progeny which becomes a myonucleus and the other remains as 
a satellite cell to maintain the satellite cell population (Moss and Leblond, 1971) in a 
process known as asymmetrical cell division. While this ability to self-renew earned 
them the status of stem cell, there is little evidence to suggest that satellite cells can 
give rise to other cell lineages and so they can be considered as a monopotent 
myogenic stem cell (Relaix and Zammit, 2012). While satellite cells represent the 
principal myogenic precursor cell and their ablation severely impairs the regenerative 
capacity of skeletal muscle, other non-satellite cells exist which can support 
myogenesis. Positive interstitial cells (PICs) are a population of Pax7 negative, PEG3 
(paternally expressed gene 3) positive cells which reside in mature skeletal muscle. 
They can acquire Pax7 and MyoD expression, which enables them to contribute to 
myogenesis and skeletal muscle regeneration in vivo. Unlike satellite cells, PICs are 
bipotent with an ability to give rise to both smooth and skeletal muscle (Mitchell et 
al., 2010). While Pax7 expression is a requirement for myogenic specification of PICs, 
it is not necessary for the smooth muscle fate of PICs. In addition, a contractile cell 
population named pericytes have been shown to fuse to myofibres and contribute to 
myogenesis (Dumont et al., 2015).  
 The natural aging process and muscle disease have an impact on the 
regenerative capacity of satellite cells. In senescence there is a decrease in both 
satellite cell numbers and the myogenic capacity of individual satellite cells, which is 
postulated to be influenced by both intrinsic and extrinsic factors (Dumont et al., 
2015). Duchenne muscular dystrophy is a chronic disease of muscle degeneration, 
where continuous cycles of muscle damage result in the constant activation of satellite 
cells, leading to premature exhaustion of the satellite stem cell pool. However, the 
observation that satellite cell numbers in dystrophic muscle are equal to or higher than 
the number found in age-matched healthy muscle, led to the hypothesis that intrinsic 
defects in satellite cells may contribute to the severity of muscular dystrophy. 
Dystrophin and other members of the dystrophin-glycoprotein complex (DGC) are 
expressed in activated satellite cells. In the absence of dystrophin, cell polarity and 
asymmetric cell division (the process by which two cells with different cellular fates 
are generated) is lost, resulting in a reduction in the number of myogenic progenitor 
cells (Dumont and Rudnicki, 2016). Impaired cell polarity of dystrophin-deficient 
satellite cells also increases the proportion of abnormal cell divisions and satellite cells 
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may be targeted for senescence or apoptosis, as seen in satellite cells from the mdx 
mouse model of Duchenne muscular dystrophy (Chang et al., 2016). Thus, future 
therapeutic strategies for Duchenne muscular dystrophy should take into account the 
need to restore cell polarity and satellite cell function. 
 
1.1.6 Muscle Aging and Sarcopenia 
During the natural aging process, the majority of individuals will experience an age-
dependent decline in muscle mass accompanied by a loss of strength and/or physical 
performance. This loss of muscle mass termed sarcopenia (sarx=flesh and penia=loss) 
occurs in both sexes with advanced age, and is complicated by sedentary lifestyle, 
poor nutrition and co-morbidities such as cancer and diabetes (Ohlendieck, 2011a). 
Sarcopenia is strongly suggested to be a result of a multi-factorial pathology. There is 
an age-dependent decrease in the number of motor neurons due to apoptosis, which is 
accompanied by cycles of denervation and re-innervation. Sprouting of nearby 
surviving motor neurons results in the re-innervation of some but not all denervated 
muscle fibres, and results in in the formation of very large motor units and a 
concomitant decrease in fine motor skills (Aagaard et al., 2010). This axonal sprouting 
is proposed to compensate for the loss of motor neurons until approximately 50% of 
them have died (McNeil et al., 2005).  After this stage, and/or when axonal sprouting 
becomes inadequate or absent a drastic reduction in muscle fibre numbers and size can 
be seen in skeletal muscle. Other contributing factors to muscle aging include a decline 
in muscle protein synthesis, uncoupling between excitation and contraction, impaired 
regenerative capacity and a decline in the number of satellite cells, altered metabolic 
pathways, increased oxidative stress, and perturbed levels of growth factors and 
cytokines (Aagaard et al., 2010, Edström et al., 2007).  
 Mass spectrometry-based proteomics is an unbiased analytical tool for 
identifying alterations in protein expression patterns and such an approach has 
detected altered abundance and post-translational modifications for numerous proteins 
in aged muscle. Proteomic surveys of muscle extracts from aged human and animal 
muscle has identified a fast-to-slow fibre type transition, as indicated by increased 
abundance of slow isoforms of myosin heavy chains, myosin light chains, actin and 
tropomyosin (Gelfi et al., 2006, Gannon et al., 2009). This muscle transformation is 
accompanied by a decrease in certain glycolytic enzymes including enolase and 
pyruvate kinase and increases in mitochondrial enzymes such as malate 
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dehydrogenase, prohibitin, and succinate dehydrogenase, indicating a glycolytic to 
oxidative shift in senescent muscle (Gelfi et al., 2006, O'Connell and Ohlendieck, 
2009). However, variances do exist in the expression of certain glycolytic enzymes, 
indicating that complex metabolic alterations occur in aged muscle (O'Connell et al., 
2007). In addition to fibre type transitions, alterations in the cellular stress response 
are also found to occur in senescent skeletal muscle. The family of heat shock proteins 
(HSP) are involved in molecular chaperoning by preventing protein mis-folding, 
helping to keep proteins in their native conformation, and counter-acting the 
development of inactive protein aggregates (Doran et al., 2009a). Many muscle 
associated HSPs are increased in abundance in response to stress and disease. Twenty-
four hours following a period of non-damaging isometric contractions, gastrocnemius 
muscle from adult rats showed a significant increase in the abundance of HSP70 as 
determined by western blot analysis but no difference in HSP70 abundance was 
detected in aged rats. Since the initial resting level of HSP70 was comparable between 
adult and aged rats, this suggests a potential diminished cellular stress response in aged 
muscle fibres (Vasilaki et al., 2002). This is supported by the observation that 
transgenic overexpression of HSP70 in adult and aged mice helps protect against 
contraction-induced damage and aids a more rapid and complete recovery following 
muscle damage (McArdle et al., 2004). While these studies reveal a potential deficit 
in HSP70 in aged muscle, other proteomic studies have identified elevated levels of 
the ‘α-crystallin’ domain containing HSPs in senescent rat fibres.  Increased 
abundance of the small HSPs αB-crystallin, cardiovascular HSP/HSPB7 and HSP20, 
but reduced levels of the high molecular mass stress proteins HSP60 and HSP70 were 
identified in 30-month old rat skeletal muscle (Doran et al., 2007). The co-appearance 
of ubiquitin conjugate and αB-crystallin immunoreactivity at the onset of myotome 
development in early chicken embryos, a time of intense morphological 
rearrangement, suggests that these proteins may be involved in cytoskeletal 
reorganisation (Scotting et al., 1991). Thus, the elevated abundance of the αB-
crystallin in aged muscle may be linked to the major cellular re-structuring involved 
in the fast-to-slow transition process in senescent muscle.  
 Proteomic surveys of aged skeletal muscle have identified fast-to-slow muscle 
transitions, glycolytic-to-oxidative metabolic shifts and changes in molecular 
chaperoning. Such studies are beneficial in elucidating the molecular mechanisms of 
muscle aging and it is hoped that this would translate into improved diagnostic 
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procedures and treatment strategies to promote healthy aging in the face of extended 
human longevity.  
 
1.2 Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is the most frequently inherited neuromuscular 
disease of childhood, affecting approximately 1 in every 3,500 live male births 
(Falzarano et al., 2015). This X-linked disorder is the result of primary abnormalities 
in the Dmd gene encoding the membrane cytoskeletal protein dystrophin. Mutations 
include deletions (~65%), duplications (~10%) and other small mutations, including 
nonsense and missense point mutations (~25%) (Ferlini et al., 2013). Mutations which 
change the open reading frame of the Dmd gene result in DMD while mutations which 
do not alter the reading frame result in the milder allelic disorder Becker muscular 
dystrophy (BMD), which is characterised by a later onset and a milder myopathy. 
 As reviewed in detail by Tyler, early cases of DMD were likely first described 
by Richard Partridge, Edward Meryon and William Little who examined male patients 
who exhibited muscle weakness (particularly affecting the proximal muscles of the 
arms and legs), enlarged muscles associated with muscle hypertrophy, curvature of 
the spine, delayed motor milestones and histological signs of fatty deposition (Tyler, 
2003, Meryon, 1852). Importantly, histological analyses of the brain and spinal cord 
by Meryon and Little showed no detectable abnormalities leading to the hypothesis 
that it was primarily a disease of the musculature (Meryon, 1852). Characterisation of 
the disease is most classically associated with Duchenne, who identified six main 
pathological features of “pseudohypertrophic paralysis”; i) decrease in muscle 
strength, ii) inward curvature of the spine, iii) increased volume of affected muscles, 
iv) progressive nature, v) diminished electromuscular contractility in advanced stages 
and vi) no sign of fever, sensory abnormalities nor impaired function of the bladder 
nor intestine (Duchenne, 1867, Tyler, 2003). The English clinician Sir William 
Richard Gowers is most associated with describing the unusual way in which afflicted 
patients rise from the floor, termed Gowers’ sign and for observing i) that it primarily 
affected males, with males also exhibiting more severe symptoms than affected 
females, ii) that it was heritable based on observations that the disease affected 
multiple members of the same family and iii) that the disease seemed to always come 
from the mother’s side of the family; observations now known to be due to the X-
linked nature of DMD (Clarke and Gowers, 1874, Tyler, 2003).  
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 Despite these very early descriptions of DMD, it was not until 1987 that the 
defective gene and the protein it encodes were identified. Initially, while there were 
no clues regarding the identity of the defective gene, it was known to be located on 
the X chromosome because the disease primarily affected boys, and studies involving 
a small number of females with balanced X-autosome translocations with breakpoints 
at Xp21, who manifested signs of muscular dystrophy, suggested that the gene may be 
located at Xp21 (Boyd et al., 1986, Verellen-Dumoulin et al., 1984, Zatz et al., 1981). 
Restriction fragment length polymorphisms analysis was used to confirm that the Dmd 
gene was localised to the short arm of the X chromosome (Davies et al., 1983). The 
gene was identified through analysis of a patient with a deletion of part of band Xp21 
that resulted in four X-linked disorders; DMD, chronic granulomatous disease, 
retinitis pigmentosa and the McLeod red cell phenotype (Francke et al., 1985, Guiraud 
et al., 2015). Subsequently, in 1987 the Kunkel lab cloned the complete cDNA of the 
Dmd gene and identified the protein product dystrophin (Koenig et al., 1987, Hoffman 
et al., 1987), which paved the way for a new era in muscular dystrophy research.  
 Clinical manifestations of the disease are undetectable at birth, although serum 
creatine kinase levels are already elevated, and so DMD is usually diagnosed in 
children around 2-5 years of age when the first symptoms appear (Blake et al., 2002). 
Initial signs of DMD include a delay in achieving motor milestones, delay in walking, 
waddling gait, unsteadiness and difficulty running and jumping. Subsequent 
symptoms include hypertrophy of proximal limb muscles (particularly the calf 
muscles), limb muscle weakness and Gowers’ sign (Emery, 2002). The disease is 
highly progressive, with a loss of independent ambulation in the early teenage years. 
This is accompanied by curvature of the spine and weakness of the muscles of the arm. 
The disease is ultimately fatal, with death occurring in the early twenties often due to 
respiratory complications (Blake et al., 2002). However, given improvements in 
respiratory care in afflicted patients (Simonds et al., 1998), cardiomyopathy is 
increasingly becoming a significant source of mortality (Falzarano et al., 2015).  
 The effects of dystrophin deficiency are most clearly observed in the skeletal 
muscle as illustrated by difficulties with motor development. This is also seen in 
histological analyses of dystrophic skeletal muscle, where muscle fibre necrosis, 
infiltration of immune cells, alterations in fibre size, central nucleation (indicating 
muscle regeneration), deposition of adipose and connective tissue and reduced blood 
supply are evident (Haslett et al., 2002). However, not all skeletal muscles are affected 
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equally by dystrophin deficiency, with intrinsic laryngeal muscles, certain distal 
muscles and extraocular muscle spared from X-linked muscular dystrophy (Marques 
et al., 2007). Proteomic analyses of these spared muscle groups reveal increased 
abundance of the dystrophin homolog utrophin and a concomitant rescue of β-
dystroglycan and calcium-buffering proteins such as calsequestrin (Lewis and 
Ohlendieck, 2010b, Dowling et al., 2003). Understanding the molecular basis behind 
these protected phenotypes may facilitate the development of new treatment strategies 
for DMD. In addition to severe and progressive skeletal muscle wasting, 
cardiomyopathy is a major clinical feature of X-linked muscular dystrophy. The 
absence of dystrophin triggers a loss of membrane integrity and affects L-type calcium 
channels and mechanical stretch activated receptors in the heart (Woolf et al., 2006). 
In a similar process to that seen in skeletal muscle, this then leads to altered calcium 
fluxes and the activation of calpain proteases which degrade contractile proteins, 
ultimately culminating in cell death, inflammation and fibrosis (Spurney, 2011). The 
cardiomyocyte degeneration and infiltration of connective tissue particularly affects 
the posterobasal segment of the left ventricle (LV), where an increase in wall stress 
and susceptibility to pressure overload is seen. Systolic LV function decreases, oxygen 
consumption increases and this leads to LV dilation and dysfunction (Fayssoil et al., 
2010).  
One of the principal extra-muscular manifestations of DMD is mild, non-
progressive cognitive impairment which is seen in approximately one-third of patients. 
On average the intelligence quotient of DMD patients is one standard deviation below 
the population mean (Emery and Muntoni, 2003), with cognitive deficits particularly 
affecting verbal intelligence, attention span and memory (Marsh and Munsat, 1974, 
Wicksell et al., 2004). Interestingly, a number of groups have suggested that the 
specific dystrophin mutation may have an effect on the severity of cognitive defects. 
Patients with mutations located in the distal portion of the Dmd gene (involving the 
Dp140 brain isoform) are generally more severely affected than patients with 
mutations located in the proximal portion of the gene (not affecting Dp140) (D'Angelo 
et al., 2011). Daoud and colleagues found a similar correlation between mental 
impairments and mutation location, whereby patients with mutations affecting all 
dystrophin isoforms including the Dp71 brain isoform displayed cognitive 
performances significantly below average (clinically regarded as mentally retarded) 
while patients with mutations affecting all dystrophin isoforms except Dp71 had either 
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normal or borderline cognitive performances (Daoud et al., 2009). Dystrophin 
deficiency thus induces a range of pathological secondary defects affecting skeletal 
muscle, the heart and cognition.  
 
1.2.1 Dystrophin and its isoforms 
The Dmd gene spanning 2.5 Mb and 79 exons, which represents the largest identified 
gene in the human genome, encodes the membrane cytoskeletal protein dystrophin. 
The gene is located at the Xp21 locus. Expression of the dystrophin protein is under 
the control of 7 promoters, which produce three full-length Dp427 isoforms of 
dystrophin and four shorter isoforms named Dp260, Dp140, Dp116 and Dp71 
(Muntoni et al., 2003), as shown in Figure 1.3. Expression of dystrophin is tissue 
specific; the independent muscle (M), brain (B) and Purkinje (P) promoters are 
responsible for Dp427 expression in striated skeletal and cardiac muscle, the brain and 
Purkinje neurons respectively. The four shorter isoforms of 260 kDa, 140 kDa and 116 
kDa are expressed in the retina (Pillers et al., 1993), brain and kidney (Lidov et al., 
1995), and Schwann cells respectively (Saito et al., 1999), while the 71 kDa isoform 
is found ubiquitously with particularly high levels in the central nervous system 
(Garcia-Tovar et al., 2001). These shorter isoforms lack the actin binding terminus 
associated with full-length dystrophin but retain the cysteine rich and carboxy 
terminus domains responsible for dystrophin’s interaction with β-dystroglycan, 
dystrobrevin and syntrophin, as depicted in Figure 1.4.  
 Pioneering work by the Kunkel lab using positional cloning for the genetic 
analysis of X-linked muscular dystrophy led to the discovery of the dystrophin gene 
(Koenig et al., 1987). The 427 kDa isoform of dystrophin was identified as a member 
of the β-spectrin/α-actinin family (Koenig et al., 1988), leading to the establishment 
of dystrophin as a stabilising linker at the sarcolemma capable of connecting the actin 
cytoskeleton to the extracellular matrix (Ervasti and Campbell, 1993). This membrane 
cytoskeletal protein is divided into four main domains; i) the amino terminal domain 
with a pair of calponin homology units capable of binding filamentous actin (Norwood 
et al., 2000), ii) a central rod domain containing 24 spectrin-like repeats interspersed 
by four proline-rich hinge domains (SLR 1-3, SRL 4-19 and SLR 20-24) (Koenig and 
Kunkel, 1990), iii) a tryptophan (WW) domain, and iv) a unique carboxy terminus 
which contains a syntrophin binding site in exon 74 (Ahn and Kunkel, 1995) and binds 
dystrobrevin through its two α-helical coiled coils (Sadoulet-Puccio et al., 1997). The 
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WW domain is a short conserved region which folds as a triple-stranded β-sheet and 
is usually involved in signalling through interactions with proline-rich or 
phosphorylated peptide sequences, and which is proposed to be responsible for 
binding to a Pro-Pro-x-Tyr core motif in the carboxy terminus of β-dystroglycan 
(Huang et al., 2000, Rentschler et al., 1999). A cysteine-rich domain, containing a ZZ 
module, which contains a second binding site for β-dystroglycan (Vulin et al., 2014) 
and two EF-hand motifs responsible for binding to calmodulin in a calcium-dependent 
manner, follow the WW domain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Different promoter regions for dystrophin isoforms 
Dystrophin, located on Xp21, has multiple gene promoters giving rise to alternatively 
spliced isoforms. Expression of full-length dystrophin isoforms is controlled by three 
distinct promoters upstream of exon 2. This generates three Dp427 isoforms; Dp427-
M (expressed in muscle), Dp427-B (expressed in brain tissue) and Dp427-P (expressed 
in cerebellar Purkinje fibres). Internal tissue-specific promoters transcribe smaller 
dystrophin isoforms; Dp260, Dp140, Dp116 and Dp71. Alternative dystrophin 
isoforms can also be generated through alternative splicing events or by using an 
alternative poly-(A) addition site in intron 70 (Dp40 isoform). 
 
*Image modified from Blake et al., 2002.   
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Figure 1.4: Structural characteristics of full-length dystrophin and its isoforms 
Schematic illustrating the various isoforms of dystrophin which exist; Dp427 is the 
full-length isoform, while Dp260, Dp140, Dp116 and Dp71 are shorter in size and lack 
some of the features seen in full-length dystrophin. Expression of dystrophin isoforms 
is tissue specific; Dp427-M in muscles, Dp427-B in the brain, Dp427-P in cerebellar 
Purkinje cells, Dp260-R in the retina, Dp140-B/K in the brain and kidney, Dp116-S in 
Schwann cells and Dp71 in brain and non-muscle tissues.  
 
*Image adapted from McGreevy et al., 2015 
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1.2.2 Dystrophin and the dystrophin-glycoprotein complex  
The identification of the dystrophin gene on the X chromosome and the subsequent 
discovery of its encoded protein dystrophin heralded the beginning of a new era in 
muscular dystrophy research (Hoffman et al., 1987). Shortly afterwards, work by the 
Campbell lab demonstrated that dystrophin could be enriched from detergent 
solubilised muscle membranes using wheat germ agglutination, despite not being 
glycosylated itself, due to interactions with wheat germ agglutinin binding 
glycoproteins (Campbell and Kahl, 1989). Serial anion exchange chromatography and 
sucrose gradient centrifugation of this dystrophin-enriched fraction resulted in the 
identification of several interacting proteins of 156 kDa, 50 kDa, 35 kDa and 25 kDa 
along with a triplet of 59 kDa and a doublet of 43 kDa (Ervasti et al., 1990). Since 
these proteins co-purified with dystrophin, co-localised with dystrophin at the 
sarcolemma and the 156 kDa protein was found to be significantly reduced in muscle 
samples from the dystrophic mdx mouse and from biopsy samples from DMD patients, 
the authors suggested that dystrophin existed as a hetero-oligomeric complex 
consisting of dystrophin, a 59 kDa triplet and four sarcolemmal proteins (156 kDa, 50 
kDa, 43 kDa and 35 kDa) (Ervasti et al., 1990). These proteins have since been 
identified as α-dystroglycan (156 kDa), β-dystroglycan (one of the 43 kDa proteins) 
(Ibraghimov-Beskrovnaya et al., 1992), syntrophin (59 kDa) (Adams et al., 1993), the 
sarcoglycans; α-sarcoglycan (50 kDa), β-sarcoglycan (the other 43 kDa protein), δ-
sarcoglycan (35 kDa) and γ-sarcoglycan (35 kDa) (Yoshida et al., 1994), and 
sarcospan (25 kDa) (Crosbie et al., 1997).  
 The structural organisation of the DGC has been debated and refined over a 
number of years, and is now considered to consist of dystrophin, the sarcolemmal 
proteins β-dystroglycan, α-sarcoglycan, β-sarcoglycan, δ-sarcoglycan, γ-sarcoglycan 
and sarcospan, the cytosolic proteins nNOS (neuronal nitric oxide synthase), 
syntrophins and dystrobrevins and the extracellular matrix proteins α-dystroglycan 
and laminin. The findings that i) α-dystroglycan and β-dystroglycan exist in a complex 
(Yoshida et al., 1994), ii) that α-dystroglycan had the capacity to bind to extracellular 
laminin (Ibraghimov-Beskrovnaya et al., 1992), iii) that β-dystroglycan could directly 
interact with dystrophin at its cysteine rich and C-terminal domains and iv) that 
dystrophin contained actin-binding domains (Levine et al., 1992), strengthened the 
initial hypothesis that in striated muscle the DGC plays a pivotal role in linking the 
actin cytoskeleton to the extracellular matrix (Ervasti and Campbell, 1993). The 
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current working model depicts dystrophin as a long rod-shaped cytoskeletal protein 
on the cytoplasmic side of the sarcolemma, which binds to actin at its N-terminus and 
at a second site within its rod domain, and which interacts with β-dystroglycan at 
binding sites on its cysteine-rich domain. β-dystroglycan in turn binds to α-
dystroglycan, oligosaccharides on which are responsible for binding to laminin-2 of 
the extracellular matrix. α-dystroglycan can also bind the proteoglycans agrin, 
perlecan and biglycan (Durbeej and Campbell, 2002). The sarcolemmal sarcoglycan-
sarcospan complex serves to strengthen the non-covalent interactions of dystrophin 
and α-dystroglycan with β-dystroglycan. α-dystrobrevin couples the sarcoglycan-
sarcospan complex with dystrophin while the syntrophins serve as adaptor molecules, 
responsible for the recruitment of signalling molecules to the sarcolemma (Blake et 
al., 2002), as illustrated in Figure 1.5.  
 Whilst the core DGC is largely similar in skeletal and cardiac muscle, some 
differences in protein composition and subcellular localisation do exist (Lapidos et al., 
2004). The cardiac DGC has an altered composition of syntrophin and dystrobrevin 
proteins, with reduced levels of β1 syntrophin and α1 dystrobrevin associated with the 
cardiac DGC and a stronger association between α3 dystrobrevin and the cardiac DGC 
than that of the skeletal muscle (Johnson et al., 2012). In addition, the cardiac DGC 
has a number of different binding partners, including cavin-1, ahnak-1, αB-crystallin 
and cypher (Johnson et al., 2012). Additional complexes which exist solely in the DGC 
in skeletal muscle include caveolin-3 and the signalling molecule nNOS. Similar to 
other caveolin isoforms, caveolin-3 can form small membrane invaginations, named 
caveolae, which can act as a scaffold for signalling molecules. Indeed, caveolin-3 has 
been shown to directly bind to nNOS (Venema et al., 1997), which plays a role in 
vasoconstriction.  In contrast, in the cardiac DGC it is endothelial NOS that is 
recruited, where it interacts with γ-sarcoglycan and δ-sarcoglycan (Heydemann et al., 
2004). In terms of localisation differences, the skeletal DGC is restricted to the 
sarcolemma, whereas the cardiac DGC is also found in T-tubule invaginations 
(Klietsch et al., 1993).  
 Given the primary role of the DGC in linking the sub-sarcolemmal 
cytoskeleton to the extracellular matrix and thus acting as a stabilising support network 
during normal muscle excitation-contraction-relaxation cycles, mutations in its protein 
components lead to neuromuscular disease. Specifically, mutations in the genes 
encoding dystrophin, α-, β-, δ- and γ-sarcoglycans, caveolin-3 and laminin-α2 lead to 
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Duchenne muscular dystrophy/Becker muscular dystrophy/X-linked dilated 
cardiomyopathy, limb-girdle muscular dystrophy types 2C-F, limb girdle muscular 
dystrophy type 1C and congenital muscular dystrophy respectively (Rahimov and 
Kunkel, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: The dystrophin-glycoprotein complex 
Pictured is the DGC in skeletal muscle, consisting of the full-length Dp427 dystrophin 
isoform (Dp427), linked to the sarcoglycan-sarcospan complex (α-SG, β-SG, γ-SG, δ-
SG and SSPN), and the dystroglycan complex (β-DG and α-DG). α-dystroglycan 
binds to laminin, which links with collagen fibrils in the extracellular matrix. Other 
extracellular matrix proteins such as proteoglycans (PG) also interact with the 
complex. Cytoplasmic proteins include α-syntrophin (α-SYN), β-syntrophin (β-SYN), 
dystrobrevin (DYB) and actin. Overall this tight interaction of proteins lends stability 
to the sarcolemma during normal muscle excitation-contraction-relaxation cycles.  
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1.2.3 Structural roles of the DGC 
A large body of evidence supports a structural role for the DGC. Firstly the similarities 
between dystrophin and spectrin, such as the presence of 24 spectrin-like repeats in 
the full-length dystrophin isoform, and dystrophin’s links with the sub-sarcolemmal 
actin cytoskeleton, led to the hypothesis of dystrophin as a stabilising structure capable 
of resisting or decreasing mechanical strain on striated muscle during muscle 
contraction, similar to the role of the spectrin network in acting as a shock absorber in 
the red blood cell cytoskeleton (McGough, 1999). Later studies utilising yeast two-
hybrid screens,  illustrated linkage of the DGC with the desmin intermediate filaments 
through the proteins syncoilin (which binds to α-dystrobrevin) and dysbindin (which 
interacts with α-dystrobrevin and β-dystrobrevin), which added further weight to a 
mechanical role of the DGC (Newey et al., 2001, Benson et al., 2001). In addition, 
dystrophin is enriched at costameres, protein assemblies that are likely responsible for 
the lateral transmission of contractile forces from the sarcomeres to the sarcolemma 
to the extracellular matrix and finally to neighbouring cells (Danowski et al., 1992). A 
mechanical role for the DGC is also implied by the fact that the dystrophin-deficient 
sarcolemma is extremely fragile and permeable, with physical exercise aggravating 
this sarcolemmal permeability (Vilquin et al., 1998), and immobilisation of 
dystrophin-deficient muscle reduces signs of muscle pathology and muscle 
degeneration (Mokhtarian et al., 1999). Collectively, the data suggests that dystrophin, 
and its associated glycoprotein network, is involved in protection against mechanical 
stress, which has important implications for dystrophin-deficient muscle (Deconinck 
and Dan, 2007).  
 
1.2.4 Signalling roles of the DGC 
While initial studies focused primarily on the structural role of the DGC, the presence 
of multiple binding sites within the DGC suggests it may act as a scaffold for the 
recruitment of signalling molecules, and thus the DGC may regulate such signalling 
cascades. The dystroglycans and syntrophins have been particularly implicated for a 
role in cellular signalling. The interaction of β-dystroglycan with MEK (mitogen-
activated protein kinase kinase) and ERK (extracellular signal-regulated kinase) 
suggests a role for the DGC in ERK-MAP signalling. While β-dystroglycan associates 
with active ERK1, it itself is not phosphorylated by ERK nor does it have any effect 
on the ability of ERK to phosphorylate its substrate myelin basic protein (Spence et 
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al., 2004). In addition, β-dystroglycan has no effect on MEK activity, and within its 
cytoplasmic tail it contains a motif previously identified as a conserved docking motif 
for MAP (mitogen-activated protein) kinases (Tanoue et al., 2000). Taken together 
this data therefore suggests that β-dystroglycan acts as a membrane anchor for 
signalling components of the ERK-MAP pathway. Tyrosine phosphorylation of the 
PPxY motif within β-dystroglycan results in the recruitment of a number of SH2 (Src 
homology 2) domain containing proteins including c-Src, Fyn, Csk, NCK, and SHC 
(Sotgia et al., 2001). β-dystroglycan has also been shown to interact with the adaptor 
molecule growth factor receptor-bound protein 2, Grb2, (Yang et al., 1995). This 
interaction between the proline-rich domain in β-dystroglycan’s C-terminus and the 
SH3 domain of Grb2 may be involved in extracellular matrix-mediated signal 
transduction and/or cytoskeletal organisation.  Further studies have demonstrated that 
laminin binding by dystroglycan recruits a Grb2-Sos1 (growth factor receptor-bound 
protein 2-son of sevenless) complex to the DGC via syntrophin and β-dystroglycan, 
resulting in activation of the downstream adaptor Rac1 (Ras-related C3 botulinum 
toxin substrate 1) which, through the Cdc42-Race effector p21 activated kinase 
1, activates the JNK-p46 isoform of JNK (c-Jun NH2-terminal kinase), while laminin 
depletion results in the activation of JNK-p54 (Oak et al., 2003). The role of this 
laminin signalling could be to promote cell proliferation, an effect observed in C2C12 
myoblasts (Oak et al., 2003). Collectively these studies indicate that the DGC has a 
key function in the recruitment of signalling molecules and thus may have a role in 
modulating a variety of signalling cascades.  
 The syntrophins are a class of scaffold proteins characterised by the presence 
of two pleckstrin homology (PH) domains, a PDZ domain (Post Synaptic Density 
protein-95, Drosophila discs large protein, and the Zona occludens protein 1), and a 
C-terminal domain exclusive to the syntrophins. The ability of the PH and PDZ 
domains to bind to a variety of proteins indicates a role for the syntrophins in cellular 
signalling (Constantin, 2014). For instance the PDZ domain of α1-syntrophin binds to 
nNOS, which produces nitric oxide which exerts multiple effects on skeletal muscle 
including mitochondrial respiration, contractile ability, glucose metabolism and 
neuromuscular transmission (Grozdanovic and Baumgarten, 1999). In addition, 
various signalling molecules have been shown to associate with different syntrophin 
isoforms, leading to the proposal that the primary role of the syntrophins is to link 
signalling molecules to the DGC. These signalling molecules include phosphatidyl 
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inositol-4,5-bisphosphate (Chockalingam et al., 1999), stress-activated protein kinase-
3 (Hasegawa et al., 1999), microtubule associated serine/threonine kinase (Lumeng et 
al., 1999) and diacylglycerol kinase ζ (Hogan et al., 2001). The presence of the integral 
membrane protein aquaporin-4 at the sarcolemma has also been shown to be 
dependent on interactions with the PDZ domain of α-syntrophin (Adams et al., 2001). 
More recent studies have identified that α1-syntrophin also interacts with a number of 
heterotrimeric G protein α subunits in the brain, suggesting that it could possibly be 
involved in signalling pathways which utilise G-protein-coupled receptors (Okumura 
et al., 2008). In agreement with a role for the syntrophins in G-protein-coupled 
receptor signalling, Chen and colleagues identified an interaction between the PDZ 
domain of syntrophin (α-syntrophin, β1-syntrophin and β2-syntrophin) and the C-
terminal domain of α1-adrenergic receptors (Chen et al., 2006), G-protein-coupled 
receptors which operate in the cardiovascular system. A later study demonstrated that 
in mouse aortic smooth muscle cells α-syntrophin and β2-syntrophin associate with 
α1D-adrenergic receptor to form a signalling complex (in the proposed model the 
syntrophins anchor the α1D-adrenergic receptor at the sarcolemma through interactions 
with dystrophin-utrophin and dystrobrevin), with this complex shown to be involved 
in vascular smooth muscle contraction and regulation of blood pressure (Lyssand et 
al., 2008). Such studies provide further support for a role for the syntrophins in 
regulating G-protein-coupled receptor signalling.  
 The sarcoglycan complex in cardiac and striated skeletal muscle consists of 
four sarcoglycan isoforms; α-sarcoglycan, β-sarcoglycan, γ-sarcoglycan and δ-
sarcoglycan, and the 25 kDa transmembrane protein sarcospan (Crosbie et al., 1997). 
The primary role of the sarcoglycan complex appears to be to strengthen the 
interaction of β-dystroglycan with α-dystroglycan and dystrophin, with mutations in 
any of the four sarcoglycan isoforms leading to autosomal recessive limb girdle 
muscular dystrophy type 2 C-F. Aside from providing structural integrity, the 
sarcoglycan complex may be involved in signalling cascades, through the ability of α-
sarcoglycan and γ-sarcoglycan to bind to the small leucine rich repeat proteoglycan 
biglycan (Rafii et al., 2006), an extracellular matrix protein involved in signalling 
pathways pertaining to muscle regeneration (Casar et al., 2004), tissue remodelling 
and stress fibre formation (Tufvesson and Westergren-Thorsson, 2003). γ-sarcoglycan 
has also been implicated in membrane signalling pathways affecting cell contractile 
ability, apoptosis and MAP kinase activation as γ-sarcoglycan deficiency in primary 
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skeletal myoblasts and in mice is associated with increased apoptosis, increased 
contractile pre-stress and alterations in the phosphorylation and activation of MAP 
kinase-pathway proteins. Hyper-activation was particularly seen for p38 MAP kinase 
and MAPKAPK2 (MAP kinase-activated protein kinase 2) in stretched γ-sarcoglycan 
null tibialis anterior muscle, suggesting a role for p38 MAPK pathway in stretch-
induced mechano-transduction (Griffin et al., 2005).  
Sarcospan, the last of the core dystrophin-interacting proteins to be identified, 
is also involved in cellular signalling. Sarcospan is suggested to influence muscle 
regeneration through activation of the Akt (protein kinase B) signalling cascade. Such 
a role for sarcospan is supported by studies indicating that over-expression of 
sarcospan (by two-three fold) helps to ameliorate the dystrophic phenotype in mdx 
mice by increasing protein abundance of utrophin, α-dystroglycan, β-dystroglycan, α-
sarcoglycan, β-sarcoglycan and γ-sarcoglycan and stabilising a utrophin-glycoprotein 
complex at the sarcolemma (Peter et al., 2008), and that sarcospan-null muscle shows 
decreased Akt signalling, decreased utrophin expression and is incapable of efficient 
muscle regeneration following cardiotoxin injury (Marshall et al., 2012). Since pre-
treatment of sarcospan-null muscle with adenovirus expressing constitutively active 
Akt results in normal utrophin abundance and improved regeneration following 
cardiotoxin injury, the authors proposed a molecular mechanism in which sarcospan 
regulates utrophin levels in an Akt-dependent manner, and this pathway may prove 
necessary for efficient muscle regeneration following injury (Marshall et al., 2012).  
 Since the discovery of dystrophin and its interacting proteins, the importance 
of the DGC as a stabilising structure for the muscle plasma membrane has been 
highlighted. However, newer lines of evidence such as those described above, have 
shown that in addition to its role in the mechano-protection of the sarcolemma, the 
DGC also plays a crucial role in a variety of signalling cascades.  
 
1.2.5 The mechanical and calcium hypotheses of Duchenne Muscular Dystrophy 
The mechanical hypothesis and the calcium hypothesis are the two main theories 
regarding how the loss of a single protein dystrophin results in the range and severity 
of symptoms seen in afflicted patients. As described in 1.2.1, dystrophin is a structural 
protein. The discovery of dystrophin and subsequent identification of a DGC 
(Hoffman et al., 1987), members of which also show reduced abundance in 
dystrophin-deficient muscle (Ohlendieck and Campbell, 1991a, Ohlendieck et al., 
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1993), supports a role for structural deficits in the pathogenesis of DMD. The DGC 
interacts with a range of stabilising structural proteins such as desmin, spectrin and 
vinculin to form costameres, lattice structures located on the cytoplasmic side of the 
sarcolemma which are responsible for the lateral transmission of force from the 
sarcolemma to the basal lamina (Danowski et al., 1992). Along with disrupting the 
DGC, dystrophin deficiency affects this costameric lattice causing destabilisation of 
costameric actin’s interaction with the sarcolemma (Rybakova et al., 2000), resulting 
in sarcolemmal instability and frailty. This increase in membrane permeability is 
evident by the infiltration of proteins, such as albumin and immunoglobulins, and the 
incorporation of dyes, such as Evans Blue Dye, into muscle fibres (Deconinck and 
Dan, 2007). In addition, dystrophic muscle demonstrates reduced capacity to sustain 
eccentric contraction (Moens et al., 1993), and sarcolemmal permeability, muscle 
weakness and necrosis are worsened following mechanical stress (Petrof et al., 1993, 
Ervasti, 2007), which is alleviated following transgenic full-length dystrophin 
expression in mdx mice (Cox et al., 1993b). Thus, dystrophin appears to provide 
mechanical support and stabilisation to the sarcolemma during normal muscle 
excitation-contraction-relaxation cycles, and so dystrophin deficiency has a negative 
impact on the ability of the sarcolemma to withstand mechanical stress (Ervasti, 2007).  
 Calcium has also been implicated in the pathophysiology of DMD, initially 
based on the observations that i) total calcium content is increased in muscle biopsies 
from Duchenne patients (Bodensteiner and Engel, 1978) and ii) the influx of Ca2+ 
through the sarcolemma is increased in dystrophic muscle (Tutdibi et al., 1999). This 
elevated Ca2+ influx through the dystrophin deficient membrane appears to occur 
through micro-lesions in the sarcolemma induced by mechanical stress and through 
mechano-sensitive calcium independent channels (Vandebrouck et al., 2002, Tutdibi 
et al., 1999, Deconinck and Dan, 2007). Micro-rupturing of the destabilised DGC-
deficient sarcolemma triggers a Ca2+-dependent membrane re-sealing process at leaky 
sites in the membrane. With increasing rounds of sarcolemmal wounding and re-
sealing, localised Ca2+ influx results in calcium-mediated proteolytic alterations 
leading to the activation of Ca2+ leak channels near these sarcolemmal patches, which 
further increases the inflow of Ca2+ (Alderton and Steinhardt, 2000, Fong et al., 1990). 
Increased intracellular Ca2+ concentrations activate proteases called calpains which 
degrade contractile proteins and destroy membrane constituents thus further 
increasing Ca2+ influx into muscle fibres, eventually leading to cell death (Spencer et 
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al., 1995). A role for calcium in the disease pathology is further supported by the 
observations that mdx mice display reduced abundance of a range of calcium buffering 
proteins (Culligan et al., 2002, Doran et al., 2006a, Dowling et al., 2004), thus 
aggravating the Ca2+ overload in muscle fibres, and that inhibition of calpain (through 
over-expression of calpastatin or administration of leupeptin) reduces muscle necrosis 
in the mdx mouse model (Badalamente and Stracher, 2000, Spencer and Mellgren, 
2002). However, the use of calpain inhibitors has been refuted by others (Briguet et 
al., 2008, Selsby et al., 2010), and a role for calpains in disrupting specific regulatory 
mechanisms rather than non-specific proteolysis in dystrophic muscle has been 
suggested (Tidball and Spencer, 2000). 
 
1.2.6 The role of sterile inflammation in the progression of dystrophinopathy 
A body of evidence exists which implicates the role of the immune system in the 
progression of dystrophic pathophysiology; mainly the observation that the onset of 
muscle histopathology coincides with the onset of inflammation and the suggestion 
that the beneficial effects of corticosteroids, such as Prednisone (Beenakker et al., 
2005, Merlini et al., 2003), are due to the immunosuppressant activity of this class of 
drugs (Hussein et al., 2006). The absence of the full-length Dp427 isoform of 
dystrophin triggers sarcolemmal micro-rupturing, the influx of excessive Ca2+, altered 
ion homeostasis, increased proteolysis and increased extracellular ATP levels 
(Deconinck and Dan, 2007). Such alterations in muscle homeostasis may act as 
DAMPS (danger-associated molecular patterns) resulting in the activation of the 
immune system. The role of the innate immune response in this sterile inflammation 
in DMD has been reviewed extensively (Spencer and Tidball, 2001, Villalta et al., 
2015). The initial response is a classical Th1 mediated immune response, with the 
infiltration of neutrophils and M1 macrophages with a pro-inflammatory phenotype. 
These macrophages play a crucial role in the phagocytosis of myofibre debris and also 
secrete cytokines to promote myoblast proliferation (Madaro and Bouché, 2014). 
However, they also secrete pro-inflammatory cytokines such as IL-6, IL-1β and TNF-
α which can further propagate the inflammatory response leading to acute 
inflammation in the early stages of the disease. In particular, the pro-inflammatory 
environment in dystrophic muscle can result in the transcriptional activation of NF-
κB, which further promotes inflammation, and which can inhibit myogenesis by 
preventing myoblast differentiation (Bakkar et al., 2008). Indeed, the pharmacologic 
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inhibition of NF-κB reduces inflammation, promotes muscle regeneration and can 
rescue contractile dysfunction in the dystrophic diaphragm (Kornegay et al., 2014, 
Peterson et al., 2011). In dystrophic muscle there is a transition from a Th1-mediated 
immune response to a Th2 response. This results in the infiltration of the alternatively 
activated M2 macrophages, largely associated with tissue repair and regeneration. 
Three subsets of M2 macrophages exist; M2a, M2b and M2c. M2a macrophages are 
associated with advanced stages of tissue repair and regeneration while both M2b and 
M2c macrophage subsets are associated with anti-inflammatory activity (Kharraz et 
al., 2013). In general M2 macrophages secrete IL-4 and IL-10, which have two main 
roles; they reduce the population of M1 macrophages (Villalta et al., 2011) and they 
promote myoblast differentiation and fusion. Thus, while the Th1 response is 
associated with muscle necrosis, the Th2 response is involved in muscle regeneration 
(Tidball and Villalta, 2010).  
 M1 macrophages contain iNOS (inducible nitric oxide synthase) which utilises 
the substrate arginine to produce nitric oxide which is responsible for nitric oxide-
mediated muscle cell lysis in dystrophinopathy (Nguyen and Tidball, 2003). Unlike in 
acute tissue injury, a population of M2a macrophages accompany the influx of M1 
macrophages in dystrophic tissue (Tidball and Villalta, 2010). These M2a 
macrophages contain arginase-1, which shares the common substrate arginine. 
Therefore, the infiltration of this macrophage population may reduce muscle lysis 
through competition for arginine. However, arginase may also be involved in 
promoting tissue fibrosis as illustrated by Wehling-Henricks and colleagues (Wehling-
Henricks et al., 2010). 
 While the innate immune response has been extensively reviewed, the role of 
the adaptive immune response requires further investigation. While muscle 
regeneration in healthy skeletal muscle is not thought to involve an adaptive immune 
response, T cells are present in degenerating muscle fibres following injury (Madaro 
and Bouché, 2014). Depletion of either CD4⁺ or CD8+ T-cells results in a significant 
reduction in muscle pathology (Spencer et al., 2001). The crossing of T-cell null mice 
with mdx mice generates a dystrophin-deficient/T-cell null mouse model which 
displays reduced fibrosis and decreased/delayed collagen deposition in the diaphragm 
(Morrison et al., 2000) suggesting a role for the adaptive immune response in fibrosis. 
Others have suggested a role for autoimmunity in the disease aetiology. Dystrophic 
muscle, due to its leaky nature, releases a number of proteins into the bloodstream that 
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would normally be sequestered from the immune response. Thus, their release may 
trigger an immune response as they may be recognised as “foreign” and taken up by 
antigen-presenting cells to activate a T-cell mediated immune response.  
 Although gene therapy to restore dystrophin expression to all muscles of the 
body represents the ideal treatment for dystrophinopathy, it is currently hindered by a 
number of biological and technical difficulties. Researchers and clinicians have 
instead focused some of their attention to methods of ameliorating the secondary 
pathologies of fibrosis and inflammation (Mah, 2016). However, immunomodulation 
may prove to be a double-edged sword in DMD with a number of suggested 
mechanisms proposed to have beneficial effects on muscle necrosis and acute 
inflammation but detrimental impacts on tissue repair and regeneration. For example 
the inhibition of TNF-α, a major pro-inflammatory cytokine, by pharmacological 
means reduces muscle lysis and fibrosis (Hodgetts et al., 2006). However, TNF-α also 
acts as a chemoattractant for satellite cells and mesangioblasts (Lolmede et al., 2009), 
cells responsible for muscle regeneration, and thus TNF-α inhibition may hinder their 
recruitment to dystrophic muscle.  
  
1.2.7 Current and Emerging Therapies for Duchenne Muscular Dystrophy 
At present there is no cure for the genetic disorder DMD. However, intensive research 
into both dystrophin-dependent and dystrophin-independent strategies is currently 
underway. First suggested in 1974 (Drachman et al., 1974), administration of 
corticosteroids has become the gold standard treatment for slowing the progression of 
DMD, particularly by reducing inflammation (Wehling-Henricks et al., 2004) and 
influencing muscle regeneration and differentiation (Anderson et al., 1996, Anderson 
and Vargas, 2003). Duchenne patients treated with corticosteroids display improved 
muscle strength and function, a delay in respiratory dysfunction, scoliosis and loss of 
ambulation, improved cardiac function and a general improved quality of life (Balaban 
et al., 2005, Markham et al., 2005, Bushby et al., 2010). However, several side effects 
are associated with prolonged corticosteroid use, in particular weight gain, metabolic 
dysfunction, cushingoid appearance and osteoporosis (Angelini and Peterle, 2012, 
Bushby et al., 2010). The two main corticosteroids in use are Prednisone/Prednisolone 
and Deflazacort, an oxazoline derivative of prednisolone, which is associated with less 
side effects than prednisone (Bonifati et al., 2000).  
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 While dystrophin gene therapy may represent the most logical of choices for 
the treatment of DMD, the large size of dystrophin cDNA (11 kb) prevents its insertion 
into most viral vectors, and with the exception of the small adeno-associated viral 
(AAV) vectors (which are too small to accommodate full-length dystrophin cDNA), 
the uptake of most viral vectors into skeletal muscle has been limited (Guiraud et al., 
2015). Observations that patients with BMD who produce truncated dystrophin 
isoforms display a much milder phenotype than Duchenne patients led to the 
emergence of mini- and micro-dystrophins (Fairclough et al., 2013). The smaller 
cDNAs associated with these dystrophin isoforms can be packaged into recombinant 
AAV vectors, and have shown promise in animal models of the disease (Harper et al., 
2002). However, their potential in humans is still uncertain with issues regarding 
immune responses to the AAV vector still to be resolved, given relatively high titres 
of virus are necessary to induce effective dystrophin expression (van Westering et al., 
2015). A chimeric vector named rAAV2/8 has been described, and lower titres of this 
viral vector containing codon optimised micro-dystrophin was capable of restoring 
dystrophin expression in the heart and skeletal muscle of mdx mice without eliciting 
an immune response (Foster et al., 2008).  
An alternative approach, also based on BMD, is that of exon skipping. This 
approach takes advantage of the smaller size of complementary RNA or DNA anti-
sense oligonucleotides (AONs) which are easier to deliver than full-length dystrophin.  
These AONs target exons in the pre-mRNA preventing their inclusion into mRNA, 
thus restoring the reading frame, enabling the production of truncated dystrophin 
isoforms and converting DMD to the milder BMD (Aartsma-Rus and van Ommen, 
2007). Initial beneficial effects in the mdx mouse (Aoki et al., 2010, Lu et al., 2003) 
led to subsequent clinical trials using 2-O-methyl-phosphothioate chemistry 
(drisapersen) and orpholino-phosphorodiamidate oligomer chemistry (eteplirsen), 
which demonstrated an increase in dystrophin-positive fibres, restoration of the 
sarcoglycans and nNOS to the sarcolemma and an improvement in the six minute walk 
test in treated patients compared to placebo controls (Mendell et al., 2013, Guiraud et 
al., 2015, Voit et al., 2014). While the FDA declined approval for drisapersen, 
eteplirsen (brand name Exondys 51) was granted accelerated FDA approval in 
September 2016, making it the first FDA approved drug specifically for the treatment 
of DMD (Lim et al., 2017). While this was welcomed by patients and advocacy 
groups, the approval was controversial given clinical trial results have shown only a 
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marginal improvement in DMD symptoms. In addition, exon skipping as a strategy is 
intrinsically specific, with eteplirsen and its associated skipping of exon 51 beneficial 
for only 13% of patients (Guiraud et al., 2015), and so in future other exons will need 
to be targeted in order for this type of therapy to be applicable to a greater number of 
patients.  
 Approximately 10-15% of patients have a non-sense mutation resulting in a 
premature stop codon and abrogation of dystrophin synthesis (van Westering et al., 
2015). Aminoglycosides, traditionally a class of antibacterial drugs, have been 
exploited for their ability to “read-through” premature stop codons without affecting 
normal stop codons, thus restoring functional dystrophin production (Falzarano et al., 
2015). Gentamicin was initially tested in Duchenne patients and its use resulted in 
significantly lower serum levels of creatine kinase and dystrophin restoration in a 
subset of patients (Malik et al., 2010). However, side effects render its chronic use 
unfeasible and a second compound PTC124 (ataluren or Translarna) was investigated 
instead. A phase 2b clinical study of ataluren in ambulatory Duchenne patients 
demonstrated that ataluren at 40 mg/kg/day slowed the rate of decline of walking 
ability and achieved a mean 30-meter difference between placebo and treated patients 
in the six minute walk test over 48 weeks (Bushby et al., 2014). This drug has since 
been granted orphan drug status by the European Medicines Agency and the FDA 
(Falzarano et al., 2015).  
 Mutations may also be corrected by gene editing through the cell’s own repair 
machinery and this forms the basis of the novel CRISPR-Cas9 system (clustered 
regularly interspaced short palindromic repeat-CRISPR-associated protein 9). In this 
method the nuclease Cas9 is guided by a single-guide RNA to a specific targeted 
genomic locus where it generates a double-stranded break. This is either repaired by 
non-homologous end joining (NHEJ), which generates insertion/deletion mutations 
and can lead to exon skipping, or by homology-directed repair (HDR), where an 
exogenous template is included and used to precisely modify a target locus (Mali et 
al., 2013, Long et al., 2014). Initially CRISPR-Cas9 methodologies were used to edit 
germline DNA in the mdx mouse model where the point mutation was corrected during 
embryonic development, which produced mosaic mdx-corrected mice displaying 
between 2-100% correction of the Dmd gene. Importantly, correction of just 17% of 
mutant Dmd alleles by HDR was sufficient to induce dystrophin expression in the 
majority of myofibres and at levels comparable to wild-type mice (Long et al., 2014). 
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Since genomic editing within the germ line is not possible in humans, the CRISPR-
Cas9 system has been tested in post-natal mdx-4cv mice using the AAV delivery 
system. Work by Bengtsson and colleagues used two main approaches; i) use of NHEJ 
to excise exons 52 and 53, thus restoring the dystrophin opening reading frame and 
producing a dystrophin isoform missing 110 amino acids and ii) direct targeting of the 
mutation in exon 53 by including a “mutation-corrected” DNA template to enable 
possible HDR following Cas9-induced excision, thus facilitating the production of 
full-length dystrophin (Bengtsson et al., 2017). Both strategies enabled dystrophin 
production, which in turn led to localisation of nNOS to the sarcolemma and increases 
in specific force generating capacity. Excision of exons 52 and 53 (strategy i above) 
also induced dystrophin expression in the heart (Bengtsson et al., 2017). Since post-
mitotic cells are only modestly amenable to HDR, Long and colleagues focused on 
exon skipping mediated by NHEJ to remove the disease-causing mutation in mdx 
mice. Similar results were achieved by this work, whereby dystrophin levels increased 
in the heart and skeletal muscle but not the brain (due to an inability of AAV to cross 
the blood-brain barrier) and serum creatine kinase levels and grip strength tests 
revealed an improvement in muscle function (Long et al., 2016). While CRISPR-Cas 
9 is a promising strategy for the treatment of DMD, further research is required to 
determine the possibility of and risk associated with potential off-target effects.  
 Dystrophin-independent methods are also under investigation, principally 
involving modulation of the dystrophin homolog utrophin. The potential of utrophin 
as a therapy for dystrophin-deficiency in DMD is suggested by the fact that i) it shares 
significant homology with dystrophin, ii) significant increases in the abundance of 
utrophin are seen in a number of myopathies including DMD, iii) initial muscle 
necrosis in mdx mice only commences when the high levels of perinatal utrophin 
decline to levels seen in adult tissue suggesting a protective role for utrophin in the 
absence of dystrophin (Khurana et al., 1991) and iv) utrophin null-mdx dko (double-
knockout) mice display an extremely severe myopathy (Deconinck et al., 1997, 
Perkins and Davies, 2002). The potential of utrophin as a disease modulator was first 
investigated in 1996 where transgenic mdx mice expressing a utrophin transgene under 
the control of a constitutive muscle promoter displayed a drastic improvement in the 
dystrophic phenotype characterised by a reduction in serum creatine kinase levels, 
reduced fibrosis, necrosis and central nucleation, and restoration of components of the 
DGC to the sarcolemma (Tinsley et al., 1996). More recently, AAV mediated mini-
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utrophin gene transfer into the golden retriever model of muscular dystrophy (GRMD) 
has been achieved and shown to reduce fibrosis and increase abundance of β-
dystroglycan and β-sarcoglycan, although immunosuppression was required to 
prevent an immune response to viral antigens and to achieve transgene persistence 
(Cerletti et al., 2003). Aside from transgenic expression of utrophin, an alternative 
therapeutic approach is to induce increased expression of the endogenous utrophin 
gene (Perkins and Davies, 2002). Based on this a utrophin modulator named SMT 
C1100/Ezutromid has recently undergone a phase 1 clinical trial to test safety, 
tolerability and pharmacokinetics (Ricotti et al., 2016) and a phase 2 clinical trial to 
test efficacy is currently underway. 
 A range of other strategies exist including decreasing the inflammatory 
response, reducing proteolysis by inhibiting calcium-dependent proteases (Tidball and 
Wehling-Henricks, 2004), increasing muscle mass by modulating the activity of 
myostatin (a negative regulator of muscle mass) (Bogdanovich et al., 2002) and 
increasing the expression levels of a number of genes; most notably nNOS (Lai et al., 
2014), laminin and α7-integrin (Rooney et al., 2009). The identification of the 
dystrophin gene has led to much improved insight into the pathophysiology of DMD 
and paved the way for the discovery of novel therapeutic approaches. Ultimately 
whilst genetic manipulations may be the only “cure” for DMD, these approaches are 
still in their infancy and at present modulation of the downstream abnormalities may 
provide the best opportunity for improving the quality of life of patients with DMD.  
  
1.2.8 Animal Models of Duchenne Muscular Dystrophy 
Both naturally occurring and engineered animal models exist for the comprehensive 
study of the pathophysiology of DMD, and which can be utilised for the development 
of novel therapeutics. While the available models also include non-mammalian 
models, such as Drosophila melanogaster and Caenorhabditis elegans, the most 
frequently used models in research are the mouse and canine models. Some newly 
developed models include the rat and pig DMD models.  
 The most widely used animal model in muscular dystrophy research is the mdx 
mouse. Identified in a colony of C57BL/10ScSn mice in the early 1980s (Bulfield et 
al., 1984), it displays elevated creatine kinase and pyruvate kinase levels and 
histological features of muscular dystrophy. The molecular basis of this dystrophic 
phenotype was subsequently identified as a nonsense point mutation (C-T transition) 
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in exon 23, resulting in a stop codon instead of a glutamine codon, which prevents 
expression of full-length dystrophin (Sicinski et al., 1989). Despite extensive rounds 
of muscle necrosis between 3-6 weeks of age (McGreevy et al., 2015), this mouse 
model represents a relatively mild phenotype in comparison to the human condition; 
the majority of skeletal muscle enters a stable phase due to a high regenerative capacity 
(Turk et al., 2005), mice have a reduced lifespan of approximately 19% as opposed to 
75% reduction in humans (murine lifespan reduced from approximately 26.5 months 
to 21.5 months) (Chamberlain et al., 2007), and severe clinical features of 
dystrophinopathy such as muscle wasting, fibrosis and cardiac failure only appear to 
come into play in aged mdx mice (Van Erp et al., 2010, Pastoret and Sebille, 1995). 
The only exception is the mdx diaphragm, which like in human patients, shows severe 
and progressive deterioration (Stedman et al., 1991, Holland et al., 2015a, Doran et 
al., 2006b).   
 Four chemical variants of the mdx mouse were described in 1989 (Chapman et 
al., 1989). These mice were generated on the C57/BL6 background by chemical 
mutagenesis using N-ethyl-nitrosourea, and are referred to as mdx-2cv, mdx-3cv, mdx-
4cv and mdx-5cv strains. These mice harbour different point mutations and have 
different characteristics. The mutation in mdx-2cv mice is a single base change in 
intron 42 (Im et al., 1996). The mdx-3cv mice is a result of a mutant splice acceptor 
site in intron 65 (Cox et al., 1993a). A C to T transition in exon 53 generates a 
premature stop codon and results in the mdx-4cv mouse (Im et al., 1996). An A to T 
transition in exon 10, which doesn’t alter the encoded amino acid but which generates 
a new splice donor site resulting in a frameshift in the processed mRNA, is responsible 
for the mdx-5cv mouse (Im et al., 1996). Low levels of a dystrophin protein missing 
cysteine rich domain sequences are found to accumulate in the mdx-3cv model, due to 
alternative splicing events (Rafael et al., 1996). However, this dystrophin protein is 
non-functional and thus the mdx-3cv mice displays the same muscle phenotype as the 
other chemical variant mdx mice. In addition, the mdx-3cv mouse fails to express the 
71 kDa isoform of dystrophin normally found in the brain and other non-muscle tissue, 
but this Dp71 isoform of dystrophin is expressed in the other mdx chemical variant 
strains (Im et al., 1996). The mdx-4cv and mdx-5cv mouse models contain 10-fold 
fewer dystrophin-positive revertant fibres than the mdx mouse (Danko et al., 1992), 
and so are particularly suited for the evaluation of novel therapeutics for DMD.  
35 
 
 Given the relatively mild disease phenotype in mdx and mdx chemical variant 
mouse models, several double-knockout mice which show a more severe myopathy 
have been developed. Since increased abundance of the dystrophin homologue 
utrophin in mdx mice appears to ameliorate the dystrophic phenotype (Tinsley et al., 
1998), dystrophin/utrophin dko mice have been generated. This dko strain displays a 
far greater clinical pathology, characterised by reduced weight, progressive curvature 
of the spine, early onset of muscle pathology (necrotic fibres and connective tissue 
evident in the diaphragm of dko mice at six days old), a reduction in force generation 
by the sternomastoid muscle, a significant reduction in membrane folding at the 
myotendinous junction which may affect force transmission between the muscle fibre 
and the tendon, histological evidence of myocyte damage in cardiac tissue of older 
mice reminiscent of that seen in DMD patients, and premature death (20 weeks 
compared to 21.5 months for mdx mice) (Deconinck et al., 1997, Grady et al., 1997). 
However, while these mice may more closely mirror the severity of clinical symptoms 
seen in patients with DMD, it is important to take into consideration that these mice 
carry mutations in genes other than the dystrophin gene, which is not the case for the 
human counterparts they attempt to mimic.  
Another factor thought to be involved in the slowly progressive nature of 
dystrophinopathy in mdx mice is robust regeneration. Two dko strains have thus been 
produced to hamper this regenerative capacity in order to produce a model with severe 
myopathy. MyoD/dystrophin dko strains demonstrate severe and progressive 
cardiomyopathy, with cardiac fibrosis particularly affecting the left ventricle. The 
severe disease phenotype in this strain, which leads to premature death at 
approximately 12-months, is due to impaired muscle regeneration (Megeney et al., 
1999), where in the absence of MyoD there is a 2-fold increase in the number of 
satellite cells which self-renew instead of entering myogenesis (Megeney et al., 1996). 
Crucial to muscle regeneration is the ability of cells to undergo repeated rounds of cell 
division, a process linked to telomere length, with telomere shortening associated with 
replicative senescence of somatic cells (Allsopp et al., 1992). Increased telomere 
length in laboratory mice compared to humans (5-15 kb in humans versus >40 kb in 
mice) (Kipling and Cooke, 1990) likely plays a role in the greater regenerative 
capacity and milder dystrophic phenotype of mdx mice compared to DMD patients. 
To investigate this Blau and colleagues have crossed mdx-4cv mice with mice lacking 
the RNA component of telomerase, and these dko mice have shortened telomeres and 
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a progressive muscular dystrophy phenotype leading to premature death (Sacco et al., 
2010). These mice display elevated serum creatine kinase levels, reduced muscle 
performance, increased myofiber permeability as assessed by Evans Blue Dye uptake, 
infiltration of immune cells and muscle necrosis and fibrosis (Sacco et al., 2010). In 
particular these dko mice show extensive fibrosis and tissue scarring in cardiac tissue 
particularly localised to the left ventricle, impairment of left ventricular contractility 
and elevated markers of cardiac failure (atrial natriuretic peptide and brain natriuretic 
peptide); features reminiscent of the cardiac abnormalities seen in DMD patients 
(Mourkioti et al., 2013). In addition, telomerase dysfunction in this dystrophin 
deficient mouse strain appears to induce mitochondrial abnormalities and increased 
oxidative stress which is suggested to be responsible for lethal cardiomyopathy, since 
anti-oxidant treatment helps ameliorate the cardiac dystrophic phenotype (Mourkioti 
et al., 2013). Thus, these studies indicate that i) while initiated by dystrophin 
deficiency, the exhaustion of the muscle stem cell pool may be at least partly 
responsible for the progressive nature of DMD and ii) that the telomerase deficient 
mdx mouse represents an improved model, with potential applications in the testing of 
therapeutic options.  
 Canine X-linked muscular dystrophy is the result of a spontaneous mutation 
and is best  characterised in the Golden Retriever breed (GRMD), in which the genetic 
basis of the disease is a single base change (A-G transition) in the 3’ splice site of 
intron 6, which causes exon 7 to be deleted from the dystrophin transcript (but not the 
gene), and the ensuing frameshift results in the production of a truncated dystrophin 
protein (Sharp et al., 1992). This model possesses a number of clinical hallmarks of 
muscular dystrophy including elevated serum creatine kinase levels, muscular 
atrophy, curvature of the spine, fibrosis and histological evidence of muscle necrosis 
and regeneration (Valentine et al., 1992). Since the GRMD model more closely 
mirrors DMD patients than other animal models particularly in terms of size and 
disease pathophysiology, it has become especially useful for the evaluation of 
therapeutic approaches. In recent years the GRMD model has been used to assess the 
ability of mesangioblast stem cells (Sampaolesi et al., 2006), oligonucleotide therapy 
(Bartlett et al., 2000), adenovirus mediated utrophin transfer (Cerletti et al., 2003) and 
exon skipping (Vulin et al., 2012) to ameliorate the dystrophic phenotype.  
 The rationale behind the development of a porcine model of DMD was that 
given its larger size it could be useful for determining the logistics for the scale up of 
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novel therapeutics, such as dosing regime, titres and injection sites (Selsby et al., 
2015). This model could therefore enable thorough pre-clinical trials which may be 
more predictive of the outcome in human counterparts, a major issue at present given 
that a number of potential therapies which showed promise in mouse models have 
been largely unsuccessful in human patients. Such a porcine model was generated in 
2013 in which the exon corresponding to exon 52 in humans was replaced with a 
neomycin resistance cassette. This results in a +1 frameshift after the splicing of exon 
51 to 53 (Klymiuk et al., 2013). This transgenic porcine model shows some of the 
main features of dystrophinopathy including a complete loss of dystrophin and 
compensatory increases in utrophin, elevated serum creatine kinase levels and muscle 
weakness. Histological analysis revealed alterations in fibre size, hypertrophic fibres, 
centrally nucleated fibres indicative of muscle regeneration, fibrosis and immune cell 
infiltration consistent with myopathy. The DMD pig also reflects the human pathology 
on a molecular level, with muscle proteome and transcriptome changes in 3-month old 
dystrophic pigs very similar to those reported in human patients (Fröhlich et al., 2016, 
Klymiuk et al., 2013). However, disease progression is significantly accelerated in the 
DMD pig compared to DMD patients, which is possibly due to accelerated growth 
after birth in pigs which may aggravate the dystrophin-deficient phenotype (Klymiuk 
et al., 2013). 
 While there is currently no one model which perfectly mirrors the dystrophic 
phenotype seen in afflicted patients, the large (and increasing) variety of animal 
models available offers enormous opportunity for the pathobiochemical 
characterisation of DMD and the testing of emerging treatment options. 
 
1.3 Proteomics 
Proteomics is the large-scale analysis of proteins from an organism, cell, tissue or 
biofluid and encompasses protein identification, expression, structure, post-
translational modifications and protein interactions. The emergence of proteomics as 
a key technology was driven in part by the observations that i) in the human genome 
the approximately 20,700 genes present can be translated into more than 100,000 
different protein isoforms (Lander, 2011), ii) proteins are the direct functional 
molecules in a living organism and iii) that while genomics has been incredibly 
important in understanding health and disease, the genome is relatively static whereas 
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proteomics offers the opportunity to study the response of an organism and its cells 
and tissues to stimuli, stress, changing environments and disease. 
 Proteomic workflows typically involve the separation of proteins, by gel or 
gel-free methods, followed by mass spectrometry analysis of protein/peptide 
fragments. Mass spectrometry data can be searched against the Uniprot database of 
protein sequences to identify proteins, and a variety of analytical software tools can 
then be used to measure protein abundance and protein modifications, such as 
phosphorylation. Two principal strategies exist for the mass spectrometric 
identification of proteins; top-down and bottom-up approaches. In the bottom-up 
approach proteins are first enzymatically digested to peptides and subjected to liquid 
chromatography mass spectrometry (LC-MS/MS). The peptides are identified by 
comparing the tandem mass spectra determined by LC-MS/MS with theoretical 
tandem mass spectra generated from in silico digestion of a protein database. The 
identified peptides are then assigned to a protein to give the protein components of the 
original sample (Zhang et al., 2013). This method has been more universally adopted 
as peptides are more easily fractionated, ionized and fragmented than intact proteins. 
The alternative approach of top-down proteomics analyses intact proteins which 
generally gives improved sequence coverage and better characterisation of post-
translational modifications (Catherman et al., 2014). While the technical challenge of 
achieving proteome-wide analysis at the intact protein level has slowed the progress 
of this technique, improvements in protein separation, mass spectrometry 
instrumentation and bioinformatics tools may enable top-down proteomics to become 
a powerful approach. Indeed in 2011 Tran and colleagues used a novel four 
dimensional separation system to identify a total of 1,043 intact proteins of up to 105 
kDa from nuclear and cytosolic extracts from HeLa S3 cells (Tran et al., 2011).  
 The field of proteomics in human biology has been aided substantially by the 
establishment of the Human Proteome Organization (HUPO) in 2001. Of particular 
importance has been the development of the human proteome project, a collaborative 
effort which aims to map the entire human proteome, which would be instrumental in 
enhancing understanding of human biology in health and disease. In particular, 
proteomic profiling of urine and serum has been extensively pursued given the 
perceived benefit of these biofluids as a source of minimally invasive protein 
biomarkers (Farrah et al., 2014).  The development of the Cell Atlas has also been 
important in enhancing knowledge of the spatial distribution of the human proteome 
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at the subcellular level (Thul et al., 2017). While organelle proteomics can also be 
used to map proteins to particular cellular compartments, the immunofluorescence 
imaging approach used by Cell Atlas is advantageous in the identification of proteins 
found in compartments which are difficult to purify, and/or which possess distinct sub-
structures. The approach therefore provides complementary data to that obtained by 
transcriptomics and proteomics. An alternative mass spectrometry-based approach to 
studying protein localisation is that of hyper-plexed localization of organelle proteins 
by isotope tagging (hyperLOPIT), which has been successfully used to unambiguously 
assign over 50% of detected proteins in a mouse pluripotent stem cell population to 
14 distinct organellar and sub-organellar compartments including the plasma 
membrane, endosome, lysosome, mitochondrion, actin cytoskeleton, peroxisome and 
extracellular matrix (Christoforou et al., 2016). The remaining proteins were found to 
be localised to more than one compartment. Thus, the use of spatial proteomics has 
also highlighted the presence of “moonlighting” proteins, whereby proteins can 
localise to more than one cellular compartment where they may have context specific 
functions (Min et al., 2016). This increases the overall functional diversity of the 
proteome and illustrates the need for proteomics to not only identify proteins but to 
also understand their localisation, temporal expression and interaction patterns.   
 
1.3.1 Gel electrophoresis 
Gel electrophoresis is an analytical tool used for protein separation which became 
synonymous with mass spectrometry-based analyses in the early days of proteomics. 
One dimensional-gel electrophoresis (1D-GE) separates proteins based on their 
molecular mass, whereas two-dimensional gel electrophoresis (2D-GE) offers 
enhanced protein resolution by combining isoelectric focusing with gel 
electrophoresis to separate proteins first by their isoelectric point and second by their 
molecular mass (O'Farrell, 1975). In the first dimension protein samples are passively 
loaded onto thin strips of polyacrylamide gel with a fixed pH gradient during strip 
rehydration. The strips are then subjected to isoelectric focusing, during which 
proteins migrate through the gel until they reach their pI value, the pH at which the 
protein has no net charge. The focused strips are reduced and alkylated and loaded 
onto a polyacrylamide slab gel for further separation based on their molecular mass 
(Rabilloud and Lelong, 2011). Smaller proteins migrate through the gel more quickly 
than larger proteins, thus giving separation in the second dimension. A staining 
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process is required to visualise the proteins, which can be done pre- or post-
electrophoresis, depending on the protein concentration used and the downstream 
applications. Protein spots of interest, for example those with differential abundance 
in different conditions as determined by software, can then be excised, digested into 
their constituent peptides and identified by mass spectrometry.  
 One major disadvantage of the 2D-GE approach is that of gel-to-gel variation, 
which was addressed in 1997 by the development of fluorescence difference in-gel 
electrophoresis (DIGE) (Unlü et al., 1997). In this approach the samples of interest are 
fluorescently tagged prior to isoelectric focusing with two different cyanine CyDye 
DIGE fluor dyes so that they can be run on the same 2D gel, thus circumventing the 
reproducibility issues associated with traditional 2D-GE. In addition, the inclusion of 
an internal standard, formed from equal amounts of every sample in the experiment 
and labelled with a third CyDye, enables assessment of biological and experimental 
variation and accurate quantification of changes in protein expression (Tannu and 
Hemby, 2006). 2D-DIGE has been used in various applications ranging from 
investigations into skeletal muscle biology (Staunton et al., 2012), cancer metastasis 
(Linge et al., 2012) and the efficiency of Chinese hamster ovary cell lines in 
bioprocessing (Meleady et al., 2011).      
  
1.3.2 Label-free liquid chromatography mass spectrometry 
In contrast to gel-based methods, LC-MS/MS uses “in-solution” digestion whereby 
the proteins of interest are extracted, precipitated to remove contaminating agents and 
digested to peptides prior to being separated by liquid chromatography and analysed 
by tandem mass spectrometry. This technique can identify a broader range of proteins; 
including low abundance proteins, integral membrane proteins, high molecular mass 
proteins and those proteins with extreme isoelectric points, thus circumventing some 
of the inherent caveats of 2D-GE (Murphy et al., 2016a). While gel-free quantitative 
proteomics can often incorporate metabolic and chemical labelling of proteins or 
peptides prior to mass spectrometric analysis, such as SILAC (Stable Isotope 
Labelling with Amino acids in Cell culture), iTRAQ (isobaric Tags for Relative and 
Absolute Quantitation) and ICAT (Isotope-Coded Affinity Tag), label-free 
quantitative proteomics can also be achieved (Xie et al., 2011). In metabolic and 
chemical labelling analyses, quantitation is determined by the mass increase provided 
by the labels and the relative signal intensities between labelled and unlabelled 
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samples. In a label-free experiment, quantitation is based on direct comparison of the 
mass spectrometry peptide ion intensities or spectral counts between the different 
samples (Ramasamy et al., 2014). An overview of the different proteomic methods is 
given in Figure 1.6. Sophisticated bioinformatics technologies are used to identify and 
quantify the peptides, to assign the identified peptides to proteins, and perform 
statistical analysis to generate lists of differentially abundant proteins. Label-free LC-
MS/MS has been adopted by a number of researchers and used in diverse applications, 
such as generating proteomic maps of organs (Doll et al., 2017), understanding disease 
mechanisms (Holland et al., 2013) and identifying potential protein biomarkers for 
disease diagnosis and prognosis (Dowling et al., 2014b).  
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Figure 1.6: Overview of gel versus gel-free mass spectrometric approaches 
Depicted above is a flow-chart showing the main steps involved in proteomic analyses 
of a protein sample of interest, using either a gel-based or gel-free approach. In a gel-
free approach, samples can either be labelled, metabolically or chemically, or analysed 
in a label-free fashion.  
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1.3.3 Skeletal muscle proteomics 
Skeletal muscle proteomics attempts to characterise the entire protein complement of 
the skeletal musculature. Such analyses have been paramount in understanding 
skeletal muscle maturation and aging (Murgia et al., 2017), in profiling physiological 
adaptations such as those seen in disuse atrophy and intense exercise (Holloway et al., 
2009), and in identifying the molecular mechanisms involved in primary 
neuromuscular disorders, such as DMD and facioscapulohumeral muscular dystrophy 
(Fuller et al., 2016). Despite the importance of profiling the skeletal muscle proteome 
in health and disease, progress has been limited by the complexity and heterogeneity 
of skeletal muscle. Muscle is highly heterogeneous, composed of muscle fibres of 
varying contractile abilities (slow oxidative type I fibres, intermediate fast 
glycolytic/oxidative type IIa  fibres and fast glycolytic type IIb fibres), and containing 
layers of connective tissue, capillaries and nerve cells (Murphy et al., 2016a). Thus 
homogenised muscle, which is used as the starting material for most comparative 
surveys, contains a highly varied mix of muscle, along with cells derived from the 
tendon, epimysium, endomysium, perimysium, blood vessels, motor neurons and 
satellite cells (Murphy et al., 2016a). This contamination of muscle fibres by other cell 
types must be taken into account when interpreting data from proteomic surveys of 
skeletal muscle. For this reason, it is also of upmost importance to verify proteomic 
data using independent bioanalytical techniques such as immunoblotting, biochemical 
assays, enzyme linked immunosorbent assays and/or microscopy.  
In addition, contractile tissue contains a number of large protein complexes, 
including the DGC of the sarcolemma, the voltage-sensing DHPR of the transverse 
tubules, the RyR Ca2+-release channel of the triad junctions, and the highly abundant 
actomyosin machinery (Ohlendieck, 2011c). The presence of these supramolecular 
protein complexes can represent a technical difficulty in muscle proteomics. Deep 
proteome analysis of mouse skeletal muscle suggests that the protein dynamic range 
in skeletal muscle spans over eight orders of magnitude from very high abundance 
proteins such as myosin to low abundance proteins including transcription factors. The 
top twelve most abundant proteins in muscle make up 50% of the total protein mass 
(Deshmukh et al., 2015). This renders mass spectrometry analyses quite challenging, 
whereby low abundance peptides are suppressed by high abundance peptides and thus 
are not selected for fragmentation. The contractile proteins titin and nebulin, which 
represent two of the top three most abundant proteins in muscle, are giant proteins 
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with molecular masses of 3,400 kDa and 800 kDa respectively (Murphy et al., 2016a). 
This represents a problem particularly for 2D-GE proteomic approaches where 
extremely large proteins can suffer from poor resolution and under-estimation of 
abundance. Analysis of the skeletal muscle proteome is further complicated by the 
plasticity of muscle, which is nonetheless crucial for its ability to adapt to changed 
functional demands. In particular, a number of genes may be differentially spliced, 
resulting in the production of a large number of protein isoforms, which may be then 
post-translationally modified, thus vastly increasing the number of proteins present in 
the muscle proteome. For instance, although the family of sarcoendoplasmic reticulum 
Ca2+-ATPase  pumps are encoded by three genes, alternative splicing and various post-
translational modifications result in the production of more than ten different protein 
isoforms (Ohlendieck, 2011c).  
 Urea or detergent based protein extractions of total muscle tissue are the 
predominant methods used for the extraction of the near-to-complete muscle 
proteome. However, issues relating to protein dynamic range, sample complexity and 
the under-representation of integral membrane proteins have been addressed by i) the 
use of subcellular fractionation, as seen in organelle proteomics (Ohlendieck, 2011c), 
ii) protein or peptide fractionation such as ion exchange chromatography for proteins 
and strong cation or ion exchange chromatography for peptides (Deshmukh, 2016) 
and iii) affinity purification of target protein complexes (Turk et al., 2016).   
 
1.4 Biomarkers 
A biomarker is a naturally occurring molecule, gene or characteristic, which can be 
quantified accurately and reproducibly, and which can be evaluated objectively as an 
indicator of normal biological processes, pathological processes and/or pharmacologic 
responses to therapy (Strimbu and Tavel, 2010). Since proteins are the effector 
molecules in the body, and proteomics offers a large-scale, unbiased, bioanalytical 
approach to detect and quantify proteins, protein biomarkers are of particular interest 
in modern medicine. Such protein biomarkers could have potential uses in i) disease 
screening, ii) disease diagnosis and monitoring, iii) monitoring response to therapy, 
iv) guiding personalised medicine, and v) serving as surrogate clinical end-points in 
drug trials (Rifai et al., 2006). While both tissue samples and biofluids may be used 
for the identification of proteomic biomarkers, biofluids such as plasma, urine, and 
saliva are preferred given they can be obtained non- or minimally invasively. Proximal 
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fluids, fluid located in close proximity to the tissue of interest, may offer some 
advantages over the use of serum samples, whereby the discovery of biomarkers may 
be facilitated by the estimated high abundance of proteins in proximal fluid that may 
otherwise be highly diluted in peripheral circulation (Teng et al., 2010). While 
proteomic biomarkers have held much promise, a number of challenges exist in 
proteomic biomarker discovery: i) the complexity and dynamic range of plasma and 
other biofluids, ii) the predicted relative low abundance of disease-specific biomarkers 
and iii) variation in the human population (Rifai et al., 2006). The biomarker pipeline 
generally involves four key stages; i) the discovery stage, where candidate biomarkers 
are identified, often by comparative mass spectrometry approaches, ii) qualification 
stage where the differential abundance of a select number of candidate biomarkers of 
interest are confirmed in a larger number of samples and using alternative targeted 
methods, iii) verification, where the specificity of the candidate markers is examined, 
usually in population-derived human samples and iv) validation and clinical assay 
development, where the specificity and sensitivity of the marker/s is determined and 
a clinical assay is optimised (Paulovich et al., 2008, Rifai et al., 2006). While the initial 
discovery phase is generally successful in generating large lists of candidate proteins, 
very few proteins successfully pass the subsequent stages of the pipeline, with a major 
bottleneck occurring at the verification stage, during which the variation that occurs 
naturally in the human population, but which was minimised in the discovery phase, 
is re-introduced (Rifai et al., 2006).  
Another compounding factor is limited resources (such as high-quality 
antibody assays) and access to clinical samples, which may prevent all putative 
biomarkers from being evaluated. Instead the most likely candidates are chosen based 
upon the availability of ELISA assays and knowledge of how the potential biomarker 
may relate to the disease, although biological understanding of many diseases is often 
too limited to rely on this. An alternative approach which may aid the current 
bottlenecks in the biomarker pipeline is the use of multiple reaction monitoring to 
quantitatively evaluate 100s of biomarker candidates simultaneously (Makawita and 
Diamandis, 2010). Ideally a reliable protein biomarker should be i) highly specific for 
the disease, ii) sensitive, iii) minimally invasive, iv) easy and cost effective to assay, 
v) expressed at high levels, and vi) minimally influenced by patient age, gender, 
ethnicity and lifestyle (Murphy et al., 2018b). The key characteristics will also be 
determined by the purpose of the biomarker. For example, a biomarker for screening 
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purposes of a healthy population must be highly sensitive to detect early symptoms, 
while a biomarker for evaluating patients will require a high degree of specificity 
(Ohlendieck, 2013). A cautionary tale comes from the paediatric plasma proteome, 
where a comprehensive longitudinal study illustrated that it varies extensively from 
neonate to adolescence, and thus proper age-matched controls in biomarker studies 
involving childhood disease are warranted (Liu et al., 2017). Despite the numerous 
issues associated with biomarkers and their poor transition into the clinic, with only 
one to two protein biomarkers being approved each year by the FDA across all 
diseases, proteomics is only in its infancy and still holds much promise for improving 
disease diagnosis, prognosis and therapeutic evaluation.  
 
1.4.1 Biomarkers for neuromuscular disease 
In the conventional diagnosis of neuromuscular disease histological, histochemical 
and immunohistochemical analysis of muscle biopsies are of crucial importance. 
Small angular atrophic fibres indicate denervation, small rounded atrophic and 
hypertrophic fibres along with increased central nucleation, replacement of muscle 
with adipose and connective tissue, and scattered pockets of de- and re-innervation 
reflect primary muscle disease, while special staining techniques are capable of 
detecting glycogen storage and lipid accumulation, nemaline bodies and the ragged 
red fibres of mitochondrial myopathies (Murphy et al., 2018b). However, while tissue 
biopsy can yield important information, its invasive nature precludes the possibility of 
repeat sampling and thus alternative methods of monitoring disease progression have 
been sought. Imaging technologies have been considered as they represent a safe and 
non-invasive means of monitoring neuromuscular disease (Scotton et al., 2014). 
Magnetic resonance imaging (MRI) has recently been shown to be useful in evaluating 
the progression of disease pathology in individual muscles in DMD patients, and it 
has thus been suggested that MRI represents an attractive option for guiding the 
selection of sufficiently well-preserved muscles for the evaluation of induced 
dystrophin production, which is a primary outcome assessed in many early stage 
clinical trials (Kinali et al., 2011).  Proteomic biomarkers have also gained much 
interest, particularly for the monitoring of disease progression and response to therapy, 
as proteins can provide direct information regarding cellular pathways, and they can 
be identified and quantified in accessible bodily fluids, such as serum, saliva and urine 
(Scotton et al., 2014).  In neuromuscular disease, protein markers of interest may 
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originate from degenerating muscle fibres and their surrounding tissues in addition to 
signalling factors from other organs in response to inflammation and systemic 
alterations (Murphy et al., 2018b). Increased abundance of creatine kinase is currently 
used in the diagnosis of DMD and in carrier detection. However, its levels are also 
increased in response to vigorous exercise and muscle damage in general and so is not 
specific for DMD. Additionally, its levels decrease over time as muscle is replaced by 
fibrous and adipose tissue and so it has limited utility in evaluating disease progression 
and response to therapy (Hathout et al., 2016). Numerous proteomic studies have been 
undertaken to find alternative protein biomarker candidates. Both targeted 
immunochemical analyses and large-scale mass spectrometry-based proteomic 
surveys of blood samples from Duchenne patients and from animal models of the 
disease have identified a variety of new biomarker candidates. They include 
fibronectin (Cynthia Martin et al., 2014); the myofibrillar proteins titin, myomesin 3, 
and filamin C, the glycolytic enzymes aldolase and glycogen phosphorylase and the 
transport proteins myoglobin and fatty acid binding protein-3 (Hathout et al., 2014); 
troponin I (fast skeletal muscle and cardiac), fibrinogen, osteomodulin, and disintegrin 
& metalloproteinase domain-containing protein 9 (Hathout et al., 2015); the acute 
phase protein haptoglobin (Murphy et al., 2017b); as well as titin fragments in urine 
(Rouillon et al., 2014).  
An overview of some potential protein biomarkers of neuromuscular disease 
is illustrated in Figure 1.7. While comparative biofluid proteomics has been 
recognised as a swift and reliable screening approach in biomarker discovery, for a 
biomarker to give effective readouts of therapy effects and to act as predictors of 
benefit a good correlation between therapy-induced changes in the biomarker 
abundance and clinical benefit needs to be established (Hathout et al., 2016). A 
number of recent studies have attempted to identify such markers in animal models. 
Using wild-type, mdx and Fiona mice (transgenic mdx mice over-expressing utrophin), 
a panel of potential protein biomarkers to evaluate utrophin-based therapies has been 
identified. 80 proteins were detected as being highly differentiated in serum obtained 
from wild-type, mdx and Fiona animals and of these 80 proteins 60 of them were 
partially or fully rescued towards a wild-type level in the Fiona mice due to the 
increased abundance of utrophin (Guiraud et al., 2017). Similarly, myomesin-3, a 
marker of membrane leakage, has been shown to decrease towards normal levels in 
mdx mice treated with AON-mediated exon skipping therapy, and this correlated well 
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to restoration of dystrophin levels (Rouillon et al., 2015).  Overall the use of protein 
biomarkers in neuromuscular disease diagnosis, prognosis, and therapy monitoring is 
extremely promising and may be useful in i) monitoring disease progression, ii) 
evaluating patient response to therapy, and iii) serving as surrogate endpoints in 
clinical trials. While large-scale proteomic approaches have been successful in 
identifying putative biomarkers in tissue samples and biofluids, more work is still 
needed to bridge the gap between identifying candidate protein markers and validating 
them for translation to clinical applications.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Overview of potential protein biomarker candidates in Duchenne 
muscular dystrophy 
Depicted above are some of the major classes of protein biomarker candidates which 
reflect many of the main abnormalities seen in dystrophic skeletal muscle, primarily 
sarcolemmal instability and leakage of cytosolic proteins, sterile inflammation and the 
invasion of immune cells, muscle regeneration and the replacement of muscle with 
connective tissue in myofibrosis. 
 
*Image adapted from https://atlasofscience.org/serum-osteopontin-as-a-novel-
biomarker-for-muscle-regeneration-in-duchenne-muscular-dystrophy/ 
 
Protein biomarkers of 
Duchenne muscular 
dystrophy 
Creatine kinase, pyruvate kinase, 
lactate dehydrogenase 
Leakage from damaged and 
degenerating muscle fibres 
Matrix metalloproteinase (MMP)-9, 
haptoglobin, phospholipase A2 
Indicators of muscle inflammation 
MYH3, MYH8, MYL4, osteopontin 
Markers of muscle regeneration 
Periostin, collagen, fibronectin 
Indicators of myofibrosis 
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1.5 Aims of the project 
DMD is a devastating neuromuscular disorder characterised by severe and progressive 
skeletal muscle wasting, cardiorespiratory complications and premature death. Since 
the discovery of genetic mutation in the dystrophin gene as the cause of DMD in 1986, 
intensive research has aimed to improve understanding of the disease pathogenesis on 
one hand and to identify potential therapies on the other. Mass spectrometry-based 
proteomics offers a large-scale, unbiased, technology-driven approach for the 
identification of alterations in the dynamic proteome. This research aimed to use new 
advances in mass spectrometry-based analyses to characterise proteomic alterations in 
the mdx-4cv animal model of DMD. Dystrophin deficiency and its associated 
histopathological features in the mdx-4cv mouse model used in this research were 
established by immunofluorescence microscopy and haematoxylin and eosin staining, 
which is illustrated in Figure 1.8. 
 Since dystrophin deficiency severely affects skeletal muscle, it was of interest 
to obtain a global overview of alterations in the skeletal muscle proteome. In order to 
determine such changes in muscle-derived proteins in the skeletal muscle, crude 
homogenates from the hind leg were analysed by LC-MS/MS. However, alterations in 
the dystrophic proteome consist not only of changes in protein abundance but also 
differences in protein oligomerisation. Thus, a chemical cross-linking study of tissue 
homogenates from skeletal muscle was undertaken with the purpose of elucidating 
changes in protein interaction patterns as a result of dystrophin deficiency.  
 One major challenge with the proteomic analysis of skeletal muscle is that its 
complexity and the high abundance of the contractile proteins can mask the mass 
spectrometric identification of other muscle proteins, which may otherwise provide 
novel insights into the disease pathophysiology and/or identify new protein 
biomarkers. Therefore, a focused subcellular proteomic study was performed on an 
enriched sarcolemma fraction using a lectin agglutination affinity procedure. This 
study was useful in providing a deeper understanding of proteomic alterations at the 
muscle sarcolemma, the site at which the DGC is located. Following this, an on-
membrane digestion study of a dystrophin complex enriched fraction was carried out 
to identify new proteins which may exist in close proximity and/or interact with the 
DGC.  
 Cardiac dysfunction is a hallmark of DMD, particularly evident in patients 18 
years and older, and which frequently contributes to mortality. For this reason, 
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proteome profiling of the senescent heart of 20-month old mice was carried out in an 
attempt to facilitate enhanced understanding of the molecular mechanisms underlying 
cardiomyopathy.  
 Approximately one-third of patients with DMD display non-progressive mild 
cognitive impairments, yet despite the large incident rate few molecular studies have 
been performed. To counteract this gap in the literature, a label-free LC-MS/MS study 
was conducted on whole brain homogenates from 12-month old mice.  
 There is an urgent requirement for new circulatory protein biomarkers of DMD 
for disease diagnosis, prognosis and therapy monitoring. At present, disease 
progression and response to therapeutic intervention are largely monitored by physical 
examination, including the six-minute walk test and the North Star Ambulatory 
Assessment. However, these tests are limited to ambulatory patients. To circumvent 
this issue, label-free proteomic profiling was employed to identify disease biomarkers 
in serum and saliva samples from the mdx-4cv mouse.  
 Thus, the overall aim of this body of research is to use mass spectrometry-
based proteomics to generate an in-depth characterisation of alterations in the 
proteome of a variety of tissues and biofluids to comprehensively characterise the 
mdx-4cv animal model of DMD. Such a proteomic profile can enhance our 
understanding of the molecular mechanisms involved in the progression of disease in 
the skeletal muscle, the heart and the brain, establish altered protein oligomerisation 
patterns, identify novel interaction partners of the DGC and identify potential 
circulating protein biomarker candidates in serum and saliva which may be useful for 
monitoring disease progression and response to treatment.  
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Figure 1.8: Histological and immunofluorescence microscopical analysis of 
dystrophic mdx-4cv skeletal muscle 
Shown are transverse sections of gastrocnemius muscle from 6-month old wild-type 
(a, c; wt) and dystrophic (b, d; mdx-4cv) mice. Cryosections were stained with 
hematoxylin and eosin (a, b), and were immuno-labelled with an antibody to the full-
length dystrophin isoform Dp427 (c, d). Bar equals 50μm.  
 
*Image from Murphy et al., 2018a 
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2.1 Materials 
2.1.1 General chemicals and reagents 
Distilled H₂O was purified using a Millipore Milli-Q apparatus to obtain milli-Q water 
18MΩ. Complete mini tablets containing protease inhibitors were supplied by Roche 
Diagnostics (Mannheim, Germany). Bradford reagent for protein quantification and 
PrepReady™ 2D clean-up kit were obtained from Biorad Laboratories (Hemel-
Hempstead, Hertfordshire, UK). Thermo Fisher Scientific provided the cross-linker 
BS3 (bis(sulfosuccinimidyl)suberate). All other general chemicals used were of 
analytical/electrophoretic/proteomic grade and were purchased from Sigma Chemical 
Company (Dorset, UK).  
 
2.1.2 1D Gel Electrophoresis 
Protein molecular mass markers and Laemmli-type buffer were purchased from 
Biorad Laboratories (Hemel-Hempstead, Hertfordshire, UK). Ultrapure Protogel 
acrylamide stock and 4X Protogel Resolving Buffer stock solutions were obtained 
from National Diagnostics (Atlanta, GA, USA). Protein staining of SDS-PAGE gels 
was performed using either silver nitrate from Sigma Chemical Company (Dorset, 
UK) or Coomassie Brilliant Blue G250 from Thermo Fisher Scientific (UK). 
 
2.1.3 Mass Spectrometry 
Sequencing grade modified trypsin and LysC were from Promega (Madison, WI, 
USA). Formic acid and acetonitrile were obtained from Fluka (Dorset, UK). C18 spin 
filters were purchased from Thermo Fisher Scientific (UK) and FASP vivacon 500 
spin filters were obtained from Sartorius (Gӧttingen, Germany). LC-MS/MS vials and 
vial caps were purchased from VWR (PA, USA). All other analytical grade chemicals 
used for mass spectrometry were obtained from Thermo Fisher Scientific (UK), 
BioRad Laboratories (Hemel-Hempstead, Hertfordshire, UK) and Sigma Chemical 
Company (Dorset, UK).  
    
2.1.4 Immunoblotting 
Whatman nitrocellulose transfer membrane was obtained from Invitrogen (Carlsbad, 
CA, USA). Chemiluminescence substrate was from Roche Diagnostics (Mannheim, 
Germany). X-ray film was purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). GBX Developer/Replenisher, GBX Fixer/Replenisher and Ponceau S-Red 
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Staining Solution were from Sigma Chemical Company (Dorset, UK). Commercially 
available antibodies used in this research were obtained from Abcam (Cambridge, 
UK), Novus Biologicals (Cambridge, UK), Sigma Chemical Company (Dorset, UK), 
EMD Millipore (Schwalbach am Taunus, Germany), BD Transduction Laboratories 
(Heidelberg, Germany), and Santa Cruz Biotechnology (Santa Cruz, CA, USA). All 
antibodies used are listed in Table 2.1. Peroxidase-conjugated secondary antibodies 
were from Merck (Kenilworth, NJ, USA). 
 
2.1.5 ELISA 
ELISA kits were purchased from Abcam (ab157714 to haptoglobin) and R&D 
Systems (FABP-1/L-FABP). 
 
2.1.6 Immunofluorescence Microscopy 
For immunofluorescence microscopy, normal goat serum, goat anti-rabbit Alexa Fluor 
488 and goat anti-mouse IgG RRX (Rhodamine Red-X) antibodies were purchased 
from Molecular Probes, Life Technologies (Darmstadt, Germany). Cy3-conjugated 
goat anti-rabbit antibodies were from Jackson ImmunoResearch (West Grove, PA, 
USA). NovoCastra, Leica Biosystems (Newcastle Upon Tyne, UK) provided the 
NCL-Dys2 antibody to the carboxy terminus of dystrophin isoform Dp427 and Agilent 
Technologies (Hamburg, Germany) provided the Z033429 antibody to glial fibrillary 
acidic protein. The embedding medium Fluoromount G was from Southern Biotech 
(Birmingham, AL, USA). The DNA binding dye bis-benzimide Hoechst-33342 was 
obtained from Sigma Chemical Company (Dorset, UK). 
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Table 2.1: Antibodies 
List of all commercially available antibodies used for this project including company 
and catalogue number, antibody specificity and host species.  
 
Antibody Species Specificity Company Catalogue 
Albumin Chk pAb Abcam ab14225-200 
Annexin A2 Ms mAb BD Transduction 
Laboratories 
A14020 
Annexin A2 Rb pAb Abcam ab41803 
Annexin A5 Rb pAb Abcam ab14196 
Asporin Rb pAb Novus Biologicals NBP2-15492 
β-dystroglycan Rb pAb Abcam ab43125 
Biglycan Gt pAb Abcam ab58562 
Cardiac myosin light chain 
2  
Rb mAb Abcam ab92721 
Calcium pump ATPase 2 Rb pAb Abcam ab3529 
Collagen VI Rb pAb Abcam ab6588 
Desmin Rb pAb Abcam ab8592 
Desmoglein isoform DSG1 Rb mAb Abcam ab124798 
Dysferlin Rb mAb Abcam ab124684 
Fatty acid binding protein 1 Rb mAb Abcam ab129203 
Fibronectin Rb pAb Abcam ab2413 
Glial fibrillary acidic 
protein 
Rb pAb Abcam ab7260 
Haptoglobin Rb mAb Abcam ab131236 
Lactate dehydrogenase Rb mAb Abcam ab52488 
Lamin-B1 Rb pAb Abcam ab16048 
Laminin Rb pAb Sigma Chemical 
Company 
L9393 
Lumican Rb mAb Abcam ab168348 
Myelin PO protein Rb pAb EMD Millipore ABN363 
Myoglobin Rb pAb Santa Cruz sc-25607 
Parvalbumin Rb pAb Abcam ab11427 
Periostin Rb pAb Novus Biologicals NBP1-30042 
Transferrin Shp pAb Abcam ab9033-1 
Tubulin, β-V subunit Ms pAb Abcam ab21754 
Voltage-dependent anion 
channel VDAC-1 
Ms mAb Abcam ab14734 
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2.2 Methods 
2.2.1 mdx and mdx-4cv mouse models of Duchenne Muscular Dystrophy, and 
wobbler mouse model of Amyotrophic lateral sclerosis 
The mdx mouse is an established animal model which displays signs of 
dystrophinopathy due to a point mutation in exon 23 and loss of the full-length Dp427 
dystrophin isoform (Sicinski et al., 1989). The mdx mouse and control wild-type mice 
used in experimental procedures described here were bred on a C57/BL10 
background. Quadriceps femoris and longissimus dorsi from 100-day old mdx mice 
and control C57/BL10 mice were obtained from the Animal Facility of the University 
of Greifswald, Germany, and were used for the immunoblot analysis of desmoglein-1 
abundance in Chapter 4.  
 The mdx-4cv mouse is an alternative animal model of DMD. First described in 
1989, the mdx-4cv mouse model was generated by chemical mutagenesis using N-
ethyl-nitrosourea (Chapman et al., 1989). The induced C to T transition at base 7916 
in exon 53 of the dystrophin gene generates a premature stop codon, thus abrogating 
dystrophin synthesis. These mice demonstrate a number of histopathological features 
of dystrophinopathy and have the added advantage of possessing 10-fold fewer 
dystrophin-positive revertant fibres than the conventionally used mdx mouse model 
(Danko et al., 1992). The mdx-4cv mouse and control wild-type mice used in 
experimental procedures described here were bred on a C57/BL6 background. Skeletal 
muscle (Chapters 3 and 4), senescent cardiac tissue (Chapter 5), brain tissue (Chapter 
6), and serum and saliva samples (Chapter 7) from mdx-4cv mice and control C57/BL6 
mice were obtained from the Animal Facility of the University of Bonn, Germany.  
 The wobbler mouse is an animal model for human motor neuron disease, 
including amyotrophic lateral sclerosis. The spontaneous, recessive wobbler mutation 
has been identified as a mis-sense mutation in the ubiquitously expressed Vps54 gene, 
which codes for a component of the Golgi-associated retrograde protein complex 
(Schmitt-John, 2015). The wobbler mouse and control wild-type mice used in this 
research were bred on a C57/BL6 background. Brain samples from two-month old 
wobbler and age-matched C57/BL6 mice, used in Chapter 6, were obtained from the 
Animal Facility of University of Bielefeld, Germany. 
 All mice (mdx, mdx-4cv, wobbler and their control counterparts) were kept 
under standard conditions and all procedures were carried out according to German 
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and Irish legislation on the use of animals in scientific research. Mice were sacrificed 
by cervical dislocation and tissue samples were removed and snap-frozen in liquid 
nitrogen. Samples were transported to Maynooth University, Ireland on dry ice and 
stored at -80℃ prior to experimental use.  
 
2.2.2 Sample preparation of crude tissue extracts 
Optimised protocols were used for the extraction of the accessible protein 
constellation from tissues from control and dystrophic mice (Murphy et al., 2015b, 
Holland et al., 2013). All of the following procedures were performed on ice to 
minimise the degradation of muscle-derived proteins. For the same purpose all buffers 
used for tissue homogenisation were supplemented with a protease inhibitor cocktail. 
100 mg of tissue (heart, brain, and various muscles of the hind leg) were finely 
chopped and homogenised in 10 volumes of buffer. A description of the various 
buffers and the tissue for which they were used is listed in Table 2.2. Tissues were 
homogenised using a hand-held IKA T10 Basic Homogeniser (IKA Labortechnik, 
Staufen, Germany). Following homogenisation, crude homogenates were incubated at 
4℃ for between 1.5 to 2 h with gentle shaking using a Thermomixer from Eppendorf 
(Hamburg, Germany). Homogenates were then centrifuged at 14,000 x g for 20 min 
using an Eppendorf 5417 R centrifuge (Eppendorf, Hamburg, Germany). The resulting 
supernatant was isolated taking care to disturb neither the uppermost fatty layer nor 
the pellet. Protein extracts were then stored at -20℃ until required for further analysis.  
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Table 2.2 Composition of buffers used for protein extraction 
Study Buffer Buffer Composition 
Crude hind limb extracts Homogenisation buffer 20 mM sodium pyrophosphate,  
20 mM sodium phosphate,  
1 mM MgCl₂, 0.303 M sucrose, 
0.5 mM EDTA, pH 7.0 
Crude microsomes Homogenisation buffer 20 mM sodium pyrophosphate,  
20 mM sodium phosphate,  
1 mM MgCl₂, 0.303 M sucrose, 
0. 5mM EDTA, pH 7.0 
Aged cardiac samples Lysis buffer 7 M urea, 2 M thiourea, 4% 
CHAPS, 2% DTT, 2% IPG buffer 
pH 3-10 
Brain tissue extracts Brain lysis buffer 8 M urea, 50 mM Tris-HCl pH 
8.0, 1 mM EDTA 
 
 
2.2.3 Sample preparation for the isolation of crude microsomes 
A larger volume of starting material was required for this type of sub-cellular 
fractionation procedure than for crude tissue preparations. For this reason crude 
microsomes were isolated from combined muscles of the whole mouse hind leg 
(Carberry et al., 2014). 750 mg of tissue was finely chopped and homogenised as 
described in section 2.2.2. Following the isolation of the protein containing middle 
layer, this supernatant then underwent differential centrifugation using an Optima L-
100 XP ultracentrifuge from Beckman Coulter, Inc. (Fullerton, CA, USA). 
Supernatants were centrifuged at 100,000 x g for 1 h at 4℃. Following ultra-
centrifugation the resulting supernatant was isolated and the pellet containing crude 
microsomes was re-suspended in an appropriate volume of homogenisation buffer 
(Murphy et al., 2015a). The crude microsomal fractions were then stored at -20℃.  
 
2.2.4 Wheat germ agglutination for the purification of sarcolemma vesicles from 
crude microsomes 
Wheat germ agglutination was employed to purify sarcolemma vesicles from crude 
microsomes, as described in detail by Ohlendieck and co-workers (Ohlendieck et al., 
1991). Crude microsomes were prepared as described in 2.2.3 with the exception that 
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4 g tissue was initially homogenised and re-suspended in 7.5 volumes of 
homogenisation buffer and that microsomal pellets were re-suspended in 50 mM 
sodium phosphate, 0.16 M NaCl, pH 7.4 (buffer C) to give a final protein 
concentration of 1 mg/ml. An equal volume of 1 mg/ml wheat germ lectin (in buffer 
C) was added to the crude microsomes and mixed gently. Following a 10 min 
incubation on ice, the mixture was pelleted at 14,000 x g for 90 s. The supernatant 
from this centrifugation contained non-agglutinated vesicles, referred to as WGA void. 
The pellet was re-suspended in 20 mM Tris-HCl, pH 7.4, 0.303 M sucrose (buffer D), 
and centrifuged again at 14,000 x g for 90 s. This step was repeated once more to wash 
the pellet. The pellet was re-suspended in buffer D and de-agglutinated by incubation 
with 0.2 M N-acetyl-D-glucosamine in buffer D for 20 min at room temperature. The 
de-agglutinated suspension was centrifuged at 14,000 x g for 90 s, and the resulting 
supernatant was pelleted at 150,000 x g for 20 min at 4℃ in an Optima L-100 XP 
ultracentrifuge from Beckman Coulter, Inc. (Fullerton, CA, USA). The pellet from 
this centrifugation step was re-suspended in buffer D and centrifuged again at 150,000 
x g for 20 min at 4℃. This pellet, corresponding to purified sarcolemma vesicles, was 
re-suspended in an appropriate volume of label-free solubilisation buffer (6 M urea, 2 
M thiourea, 10 mM Tris, pH 8.0 in LC-MS grade water) for subsequent label-free 
liquid chromatography mass spectrometry.  
 
2.2.5 Chemical cross-linking of wild-type versus mdx-4cv crude microsomes 
For the chemical cross-linking analysis described in Chapter 3, crude microsomes 
from wild-type and mdx-4cv skeletal muscle were diluted to a concentration of 2 
mg/ml with 50 mM HEPES, pH 8.0 The water-soluble cross-linker BS³ 
[bis(sulfosuccinimidyl)suberate] was dissolved in 50 mM citrate buffer, pH 5.0, to 
minimise hydrolysis, at a concentration of 1 mg/ml (Murray and Ohlendieck, 2000). 
Initial optimisation studies tested various concentrations of BS³, including 0.1, 0.5, 1, 
2, 5, 7.5, and 10 µg cross-linker per mg protein. 10 µg BS³ per mg protein was selected 
for the main study. Following the addition of BS³, samples were incubated at 25℃ for 
30 min. The cross-linking reaction was quenched by the addition of 50 µl 1 M 
ammonium acetate per ml reaction mixture (Murray and Ohlendieck, 1997). An equal 
volume of reducing sample buffer was added and the samples were subsequently 
heated at 50℃ for 10 min. Cross-linked samples were then electrophoresed alongside 
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their non-cross-linked counterparts on 1D SDS-PAGE gels. For silver stain analysis 
total loading was 10 µg protein per well, while 30 µg protein was loaded per well for 
Coomassie staining and subsequent in-gel digestion.  
 
2.2.6 Sample preparation and immuno-depletion of murine serum 
The large dynamic range of serum and plasma is a major stumbling block for the 
effective proteomic profiling of biofluids as the high abundance of proteins such as 
albumin and immunoglobulins can mask the detection of lower abundance proteins in 
a data-dependent mass spectrometry experiment (Anderson and Anderson, 2002). The 
Proteome Purify Mouse Serum Protein Immunodepletion Resin from R&D Systems 
was used in this experiment to remove albumin and IgG from murine serum samples. 
10 µl of serum was added to a micro-centrifuge tube containing 1 ml of 
immunodepletion resin. The tubes were mixed on a rotary shaker for 1 h at room 
temperature. Following the incubation period, the mixture of serum and resin was 
added to the upper chamber of a Spin-X filter unit (centrifuge tube with a 0.22 µm 
cellulose acetate membrane) and centrifuged for 2 min at 2,000 x g. The filtrate 
(immuno-depleted serum) was retained and stored at -20℃ before further analysis.  
 
2.2.7 Acetone Precipitation 
Prior to mass spectrometric analysis immuno-depleted serum samples were purified 
by acetone precipitation. 4 volumes of cold 100% acetone was added to each sample 
and stored overnight at -20℃. Samples were centrifuged at 15,000 x g for 30 min at 
4℃. The supernatant was decanted and replaced with 4 volumes of cold 50% acetone. 
The pellet was re-suspended by vortexing for 1 min. Samples were centrifuged again 
at 15,000 x g for 30 min at 4℃. The supernatant was once again decanted and replaced 
by 4 volumes of cold 50% acetone. Samples were vortexed and centrifuged once more 
at 15,000 x g for 30 min at 4℃. The supernatant was discarded, and the resulting pellet 
was allowed to air-dry for 10 min. Pellets were re-suspended in an appropriate volume 
of label-free solubilisation buffer (6 M urea, 2 M thiourea, 10 mM Tris, pH 8.0 in LC-
MS grade water), and vortexed and sonicated, using a Sonoplus HD 2200, Bandelin 
(Berlin, Germany), to ensure full re-suspension.  
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2.2.8 2D CleanUp (BioRad) 
The commercially available Ready Prep 2D clean up kit from Bio-Rad Laboratories 
(Hemel-Hempstead, Hertfordshire, UK) was used as an alternative to acetone 
precipitation for crude tissue extracts and sub-cellular fractions. The kit removes 
contaminants from protein extracts which may otherwise interfere with downstream 
mass spectrometric analysis. The purification was carried out as per the 
manufacturer’s guidelines.  
 
2.2.9 Protein quantification using the Bradford assay system 
Protein quantification was carried out using the method of Bradford (Bradford, 1976). 
A standard curve was generated using a 1:1 serial dilution of a stock solution of 2 
mg/ml BSA to give the following standards: 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 
mg/ml, 0.125 mg/ml and 0 mg/ml. Protein samples were appropriately diluted prior to 
quantification. Both standards and samples were constituted in the protein buffer. 5 µl 
of sample and standards were added to a 96-well plate. 250 µl of diluted Bradford 
reagent (diluted 1:4) was added to each well. The plate was left to incubate for 10 min 
at room temperature in the dark to allow for complete binding and the associated 
colour development. Absorbance of standards and samples was read at λ=595 nm 
using a Synergy HT BIO-TEK unit and KC4 software from Mason Technology Ltd. 
(Dublin, Ireland).  Protein concentrations were determined using the standard curve, 
whilst multiplying by the dilution factor. Standards were analysed in duplicate while 
protein samples were analysed in triplicate.  
 
2.2.10 1D Gel Electrophoresis 
One dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis, 1D 
SDS-PAGE, was employed for examining protein banding patterns, to help confirm 
equal protein loading and for transfer to nitrocellulose membranes for comparative 
immunoblotting. 1D SDS-PAGE was conducted with a BioRad Mini-Protean III gel 
system (Biorad Laboratories, Hemel-Hempstead, Hertfordshire, UK). In general, 10% 
resolving gels with a 5% stacking gel were used. The APS and TEMED cause the gel 
to polymerise quite quickly so these were added to the resolving and stacking gel 
solutions just prior to use. The gels were made as listed in Tables 2.3 and 2.4. The 
resolving gel was poured into 1.0 mm glass plates, 1 ml of 100% methanol was 
pipetted along the top of the gel, and the gel was allowed to polymerise for 
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approximately 30 min at room temperature. The methanol overlay was removed with 
filter paper and the stacking gel was poured on top of the polymerised resolving gel. 
A 10 well comb was inserted before polymerisation of the stacking gel. Gels were 
either used after polymerisation was complete or were stored in damp tissue at 4℃ for 
up to one week. Samples for electrophoresis were diluted 1:1 with Laemmli buffer 
supplemented with 350 mM DTT, boiled at 97℃ for 7 min and then cooled on ice 
prior to loading (Laemmli, 1970). Alternatively, some gels were run under non-
reducing conditions (where indicated). In this case samples were diluted 1:1 with 
Laemmli buffer which had not been supplemented with DTT nor any other reducing 
agent. Samples were then incubated at 37℃ for 10 min prior to loading onto the gel. 
Typically, between 5-25 µg protein was loaded per well, with lower amounts for silver 
staining and higher concentrations for subsequent transfer to nitrocellulose 
membranes for immunoblot analysis. Molecular weight markers (Biorad Laboratories, 
Hemel-Hempstead, Hertfordshire, UK) ranging in molecular weight from 10-250 kDa 
were also ran on each gel. The gel rig was filled with SDS running buffer (25 mM tris 
base, 192 mM glycine, 0.1% (w/v) SDS) and electrophoresis was carried out at 60 V 
until protein samples entered the resolving gel at which stage voltage was increased to 
120 V. Electrophoresis was terminated once the bromophenol blue tracking dye 
reached the end of the gel. Gels were carefully removed from the glass plates and were 
either placed in fixing solution (10% (v/v) acetic acid, 30% (v/v) ethanol) for protein 
staining or were transferred onto nitrocellulose membranes.  
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Table 2.3: SDS-PAGE gel components for 10% resolving gels  
Reagent 10% Resolving Gel 
Protogel (30% (w/v) Acrylamide/bis) 7.5 ml 
4X Protogel Resolving Buffer 6 ml 
Deionised water 10.25 ml 
10% (w/v) APS 225 µl 
TEMED 22.5 µl 
 
Table 2.4: SDS-PAGE gel components for 5% stacking gels 
Reagent 5% Stacking Gel 
Protogel (30% (w/v) Acrylamide/bis) 2.25 ml 
0.5 M Tris, pH 6.8 1.35 ml 
Deionised water 7.5 ml 
20% (w/v) SDS 135 µl 
10% (w/v) APS 135 µl 
TEMED 13.5 µl 
 
 
2.2.11 Gel staining techniques 
Gel staining techniques enable the visualisation of separated protein bands. Post-
electrophoretic stains include Coomassie staining and silver staining. While silver 
staining is more sensitive than Coomasssie staining, Coomassie staining is more 
compatible with subsequent mass spectrometric analysis of gel plugs of interest. Thus, 
a combination of staining techniques was used, depending on the downstream 
application.  
 
2.2.11.1 Colloidal Coomassie Stain 
The method of Neuhoff was used to perform colloidal Coomassie staining of 
polyacrylamide gels (Neuhoff et al., 1988). Following gel electrophoresis gels were 
briefly washed in MilliQ water and then were incubated overnight in colloidal 
Coomassie staining solution (1 part stock staining solution A [10% (w/v) ammonium 
sulphate, 2% (v/v) phosphoric acid], 40 parts stock staining solution B (5% Coomassie 
brilliant blue G-250, and 10 parts methanol). Gels were transferred to neutralisation 
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buffer (0.1 M tris, pH 6.5) for 1-3 min and then washed with 25% methanol for 1 min. 
This step could be repeated to remove any excess staining solution. Gels were then 
placed in fixation solution (20% (w/v) ammonium sulphate) until ready to scan. 
Colloidal Coomassie stained gels were scanned using a GE heathcare image scanner 
III (Little Chalfont, UK).  
 
2.2.11.2 Silver Stain 
Silver staining was the predominant staining technique used and the method of 
Chevallet was followed (Chevallet et al., 2006). Once gel electrophoresis was 
terminated, gels were placed in fixer (30% (v/v) ethanol, 10% (v/v) acetic acid) for a 
minimum of 30 min to fix proteins within the polyacrylamide gel. Gels were rinsed 
twice in 20% (v/v) ethanol for 10 min each time and rinsed twice in 100% MilliQ for 
10 min each time. Gels were placed in sensitiser (0.8 mM sodium thiosulphate) for 1 
min and then were rinsed again with 100% MilliQ for 10 min. Gels were transferred 
to silver staining solution (12 mM silver nitrate) for 30 min – 2 h. Following staining 
gels were briefly rinsed in 100% MilliQ, and then developed (15 g sodium carbonate, 
125 µl formaldehyde, 62.5 µl of 10% (w/v) sodium thiosulphate, brought up to 500 
ml with MilliQ) until distinct protein bands were visible. The staining was stopped 
upon the addition of stopper solution (20 g tris, 10 ml acetic acid, brought up to 500 
ml with MilliQ). Gels were then scanned using a GE heath care image scanner III 
(Little Chalfont, UK).  
 
2.2.12 Sample preparation for label-free liquid chromatography mass 
spectrometry 
Following the determination of protein concentration using the Bradford assay system, 
sample volumes were equalised with label-free solubilisation buffer. Protein samples 
were reduced with 10 mM DTT for 30 min at room temperature with gentle shaking 
and alkylated with 25 mM IAA in 50 mM ammonium bicarbonate for 20 min at room 
temperature in the dark (Dowling et al., 2014a). To quench any unreacted IAA and 
thus prevent the alkylation of trypsin, a further 10 mM DTT was added to each sample 
and samples were incubated for 15 min at room temperature in the dark. Proteolytic 
digestion was achieved using a combination of the enzymes Lys-C and trypsin. 
Samples were initially digested with sequencing grade Lys-C at a ratio of 1:100 
(protease: protein) and incubated at 37℃ for 4 h. Samples were then diluted with four 
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times the initial sample volume using 50 mM ammonium bicarbonate to dilute the 
urea molarity to a range at which trypsin is active (Proc et al., 2010). Samples were 
then incubated with sequencing grade modified trypsin at a ratio of 1:25 (protease: 
protein) overnight at 37℃. The proteolytic digestion was halted by the addition of 2% 
trifluoroacetic acid (TFA) in 20% acetonitrile (ACN) (3:1 (v/v) dilution). The peptides 
were purified using Pierce C18 spin columns from Thermo Fisher Scientific (Dublin, 
Ireland), dried through vacuum centrifugation and re-suspended in loading buffer (2% 
ACN, 0.05% TFA in LC-MS grade water) (Murphy et al., 2015a). Peptide suspensions 
were vortexed and sonicated to aid full re-suspension. Samples were centrifuged 
briefly at 14,000 x g and the supernatant transferred to mass spectrometry vials. Any 
remaining peptide suspension was stored at -80℃. 
 
2.2.13 Filter Aided Sample Preparation 
Protein concentrations were equalised with label-free solubilisation buffer and 30 µg 
of protein was processed by the filter aided sample preparation (FASP) method 
(Wiśniewski et al., 2009) using a trypsin to protein ratio of 1:25 (protease: protein). 
Following overnight digestion and elution of peptides from the spin filter, 2% TFA in 
20% ACN was added to the filtrates (3:1 (v/v) dilution). The peptides were then 
purified using Pierce C18 spin columns from Thermo Fisher Scientific (Dublin, 
Ireland), dried through vacuum centrifugation and re-suspended in mass spectrometry 
loading buffer (2% ACN, 0.05% TFA in LC-MS grade water). Peptides were vortexed, 
sonicated and briefly centrifuged at 14,000 x g and the supernatant transferred to mass 
spectrometry vials for label-free LC-MS/MS. 
 
2.2.14 On-membrane digestion 
For on-membrane digestion analysis, protein fractions underwent gel electrophoresis 
and transfer to nitrocellulose membranes prior to trypsin digestion, for which 
nitrocellulose membrane strips corresponding to the entire lane of proteins was used. 
Membrane strips were placed in 15 ml falcon tubes, de-stained with PBS and washed 
five times with dH₂O. The strips were subsequently blocked with 0.5% PVP-40 
(polyvinylpyrrolidone) for 40 min at 37℃ with agitation (Luque-Garcia and Neubert, 
2009) to prevent non-specific binding of trypsin to the membrane. Since PVP-40 
would have a negative impact on mass spectrometric analysis, excess PVP-40 was 
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removed by extensive washing with dH₂O and transfer of membrane strips to new 15 
ml falcon tubes. 4 ml of reconstituted sequencing grade trypsin in digestion buffer 
(100 mM ammonium bicarbonate/10% ACN [1:1, v/v]) was added to each 
nitrocellulose strip; corresponding to a 1:20 ratio of trypsin to protein. The strips were 
digested overnight at 37℃ with agitation. 4 ml of extraction buffer (5% formic 
acid/ACN [1:2, v/v]) was added to trypsin-digested membrane strips and incubated at 
37℃ for 15 min with agitation (Luque-Garcia and Neubert, 2009, Shevchenko et al., 
2006). The supernatant was subsequently transferred to 1.5 ml micro-centrifuge tubes 
and dried by vacuum centrifugation. Dried peptides were re-suspended in 0.5% 
TFA/5% ACN and centrifuged in 22-µm acetate cellulose spin filter tubes for 20 min 
to remove any membrane particles (Lewis and Ohlendieck, 2010a). Peptides were 
purified using C18 spin columns and dried by vacuum centrifugation. Dried peptides 
were stored at -80℃ until ready for mass spectrometric analysis.  
 
2.2.15 In-gel digestion 
In-gel digestion for mass spectrometric analysis was performed as per the method of 
Shevchenko (Shevchenko et al., 2006). Coomassie-stained 1D gels were washed twice 
in dH2O for 10 min. Gel bands of interest were excised and placed in Eppendorf micro-
centrifuge tubes. Individual Coomassie-stained gel zones were de-stained by the 
addition of 100 µl of 100 mM ammonium bicarbonate: neat acetonitrile (1:1) solution 
and incubated at 37℃ for 30 min with gentle agitation. The solution was removed and 
500 µl neat acetonitrile was added to each gel zone and incubated at room temperature 
for 10 min with gentle agitation. The solution was removed, and gel pieces were then 
subjected to in-gel trypsin digestion. 50-100 µl of re-suspended trypsin was added to 
each gel zone and incubated at 4℃ for 30 min to allow slow diffusion of trypsin into 
the gel. A further 20 µl of trypsin buffer was added, and gel zones were incubated for 
90 mins at 4℃. 40 µl of a 50 mM ammonium bicarbonate solution was added and left 
to incubate overnight at 37℃. 100 µl extraction buffer [5% formic acid/neat 
acetonitrile (1:2)] was added to gel pieces and incubated at 37℃ for 15 min with 
agitation. The supernatant, containing peptides, was transferred to fresh tubes, and 
dried down by vacuum centrifugation. Dried peptides were re-suspended in 0.5% 
TFA/5% ACN, purified by C18 spin columns and dried by vacuum centrifugation. 
Dried peptides were stored at -80℃ prior to mass spectrometric analysis.  
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2.2.16 Label-free liquid chromatography mass spectrometry 
LC-MS/MS was achieved using two different mass spectrometers. An Ultimate 3000  
NanoLC system (Dionex Corporation, Sunnyvale, CA, USA) coupled to a Q-Exactive  
mass spectrometer (Thermo Fisher Scientific) in the Proteomics Suite at Maynooth 
University was used for studies involving proteins derived from hind-limb tissue 
(crude extracts and sarcolemma-enriched), cardiac tissue, serum and saliva. An 
Ultimate 3000 nanoLC system (Dionex Corporation, Sunnyvale, CA, USA) coupled 
to an LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific) in the 
Proteomics Facility of the National Institute for Cellular Biotechnology, Dublin City 
University was used for the analysis of brain-derived proteins.  
 
2.2.16.1 LC-MS/MS using a Q-Exactive mass spectrometer 
Re-suspended peptide mixtures (a maximum load of the equivalent 1 µg pre-digested 
protein) were loaded by an autosampler onto a C18 trap column (C18 PepMap, 300 
µm id × 5 mm, 5 µm particle size, 100 Å pore size; Thermo Fisher Scientific). The 
trap column was switched on-line with an analytical Biobasic C18 Picofrit column 
(C18 PepMap, 75 µm id × 500 mm, 2 µm particle size, 100 Å pore size; Dionex). The 
peptides generated were eluted over either 65 min or 180 min using the following 
binary gradients: solvent A [2% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS 
grade water] and 0-90% solvent B [80% (v/v) ACN and 0.1% (v/v) formic acid in LC-
MS grade water]. The column flow rate was set to between 0.25 – 0.3 µL/min (Murphy 
et al., 2015a, Murphy et al., 2016b). The Q-Exactive was operated in positive, data-
dependent mode and was externally calibrated. Survey MS scans were conducted in 
the 300-1700 m/z range with a resolution of 140,000 (m/z 200) and lock mass set to 
445.12003. CID (collision-induced dissociation) fragmentation was carried out with 
the fifteen most intense ions per scan and at a resolution of 17,500. A dynamic 
exclusion window was applied within 30 s. An isolation window of 2 m/z and one 
micro-scan were used to collect suitable tandem mass spectra.  
 
2.2.16.2 LC-MS/MS using an LTQ Orbitrap XL mass spectrometer 
Digested peptide samples (a maximum of 1 µg) were loaded onto a C18 trap column 
(C18 PepMap, 300 µm id × 5 mm, 5 µm particle size, 100 Å pore size; Dionex). The 
first step in the LC-MS/MS protocol involved desalting, which was performed at a 
flow rate of 25 µl/min in 0.1% TFA / 2% ACN for 10 min (Holland et al., 2015a). The 
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trap column was then switched on-line with an analytical PepMap C18 column (75 
µm id × 500 mm, 3 µm particle and 100 Å pore size; Dionex). Peptides were eluted 
with the following binary gradients: solvent A [2% (v/v) ACN and 0.1% (v/v) formic 
acid in LC–MS grade water] and 0-25% solvent B [80% ACN and 0.08% (v/v) formic 
acid in LC–MS grade water] for 240 min and 25-50% solvent B for a further 60 min, 
with a column flow rate set to 0.35 µl/min (Meleady et al., 2012a). Data were acquired 
with Xcalibur software, version 2.0.7 (Thermo Fisher Scientific). The LTQ Orbitrap 
XL mass spectrometer was operated in positive, data-dependent mode and was 
externally calibrated. Survey MS scans were carried out in the 400-1200 m/z range 
with the resolution set to a value of 30,000 (m/z 400) and lock mass set to 445.120025. 
CID fragmentation was carried out with the three most intense ions per scan (Holland 
et al., 2014). Within 60 s a dynamic exclusion window was applied. A normalized 
collision energy of 35%, an isolation window of 3 m/z and one micro-scan were used 
to gather suitable tandem mass spectra.  
 
2.2.17 Qualitative proteomic profiling of mass spectrometric data 
Qualitative data analysis was used for protein identification. Mass spectrometry raw 
files were processed using the Proteome Discoverer 1.4 (Thermo Fisher Scientific) 
software with Sequest HT as the search engine and the UniProt sequence database. 
The following search parameters were used for protein identification: (i) peptide mass 
tolerance set to 10 ppm, (ii) MS/MS mass tolerance set to 0.02 Da, (iii) up to two 
missed cleavages, (iv) carbamidomethylation set as a fixed modification and (v) 
methionine oxidation set as a variable modification. Mass spectrometry raw files were 
searched against the Mus musculus database (Chapters 3, 4, 5, 6 and 7) or the 
Oryctolagus cuniculus database and the Mammalia database (Chapter 4) (Liu et al., 
2016). Peptides were filtered using a minimum XCorr score of 1.5 for +1, 2.0 for +2, 
2.25 for +3 and 2.5 for +4 charge states, with peptide probability set to high 
confidence.  
 
2.2.18 Quantitative proteomic profiling of mass spectrometric data using 
Progenesis QI for Proteomics Software 
Irrespective of the mass spectrometer used, all raw data generated from LC-MS/MS 
was analysed using Progenesis QI for Proteomics software (versions 2.0 and 3.1; Non-
Linear Dynamics, a Waters Company, Newcastle upon Tyne, UK). In order to account 
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for any drift in retention time between samples, a reference run was selected and the 
retention times of all other runs were aligned to this run (Holland et al., 2015b). The 
reference run selected was that which contained the highest number of peptide ions. 
The data was filtered using set criteria prior to exportation to Proteome Discoverer 2.0 
(Thermo Scientific) as a mascot generic file (mgf). The following criteria was used: 
(i) peptide features with ANOVA ≤ 0.05 between experimental groups, (ii) mass peaks 
with charge states from +1 to +5 and (iii) greater than one isotope per peptide (Meleady 
et al., 2012b). This exported mgf file containing MS/MS spectra was used for peptide 
identification using Proteome Discoverer 2.0 against the search engines Mascot 
(version 2.3, Matrix Science, Boston, MA, USA) and Sequest HT (SEQUEST HT 
algorithm, licence Thermo Scientific, registered trademark University of Washington, 
USA) (Murphy et al., 2015b). The data was searched against the UniProtKB-
SwissProt database (taxonomy: Mus musculus). A number of search parameters were 
used for proper protein identification:  (i) peptide mass tolerance set to 10 ppm, (ii) 
MS/MS mass tolerance set to 0.02 Da, (iii) an allowance of up to two missed 
cleavages, (iv) carbamidomethylation set as a fixed modification and (v) methionine 
oxidation set as a variable modification (Murphy et al., 2017b). For re-importation 
back into Progenesis LC-MS software for further analysis, only high confidence 
peptides and those peptides with ion scores of 40.00 or more (from Mascot) and/or 
XCorr scores of 1.5 or more (from Sequest HT) were selected. The following criteria 
were applied to designate a protein as properly identified and with differential 
abundance: (i) an ANOVA score between experimental groups of ≤0.05, and (ii) 
proteins with ≥2 peptides matched (Dowling et al., 2016a).  
 
2.2.19 Quantitative proteomic profiling of mass spectrometric data using 
MaxQuant and Perseus Software 
For quantitative analysis mass spectrometry files were analysed in MaxQuant (version 
1.6.1.0), with the Andromeda search engine used to search the detected features 
against the UniProtKB-SwissProt database for Mus musculus. The following search 
parameters were used: i) first search peptide tolerance of 20 ppm, ii) main search 
peptide tolerance of 4.5 ppm, iii) cysteine carbamidomethylation set as a fixed 
modification, iv) methionine oxidation set as a variable modification, v) a maximum 
of two missed cleavage sites and vi) a minimum peptide length of seven amino acids. 
The FDR was set to 1% for both peptides and proteins using a target-decoy approach 
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(Grassl et al., 2016). Relative quantification was performed using the MaxLFQ 
algorithm (Cox et al., 2014). The “proteinGroups.txt” file produced by MaxQuant was 
further analysed in Perseus (version 1.5.1.6). Proteins that matched to the reverse 
database or a contaminants database or that were only identified by site were removed. 
The label-free quantification (LFQ) intensities were log2 transformed, and only 
proteins found in all replicates in at least one group were used for further analysis. 
Data imputation was performed to replace missing values with values that simulate 
signals from peptides with low abundance chosen from a normal distribution specified 
by a downshift of 1.8 times the mean standard deviation of all measured values and a 
width of 0.3 times this standard deviation (Deslyper et al., 2016). A two sample t-test 
was performed using p≤0.05 on the post imputated data to identify statistically 
significant differentially abundant proteins.  
 
2.2.20 Generation of heat maps using Perseus 
Heat maps illustrating protein abundances for statistically significant differentially 
abundant proteins were designed using Perseus software. The normalised abundances 
of differentially abundant proteins determined using Progenesis QI for Proteomics 
were loaded as a txt file into Perseus and the data was log2 transformed. Hierarchical 
clustering was then performed on Z-score normalised intensity values by clustering 
both samples and proteins using Euclidean distance and average linkage. 
 
2.2.21 Bioinformatics analysis of proteomic data 
A number of bioinformatics software packages were used to give comprehensive 
analyses of identified proteins with differential abundance. Such bioinformatics tools 
were used to i) classify the types of proteins identified, ii) give meaningful insights 
into the potential roles of identified proteins in disease pathophysiology and iii) 
identify potential associations between identified proteins. The PANTHER database 
of protein families (http://pantherdb.org; version 10.0) was used to group proteins 
based on their protein class (Mi et al., 2013). Differentially abundant proteins were 
also analysed by version 10.5 of the STRING database (http://string-db.org/) for 
medium (0.4) or high confidence (>0.7) interactions using the evidence view. 
STRING analysis clusters proteins based on known and predicted protein interactions 
that include direct physical and indirect functional protein associations (Szklarczyk et 
al., 2017). The DAVID bioinformatics resource (https://david.ncifcrf.gov/) was used 
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to identify enriched functionally related protein groups and KEGG pathway 
(http://www.genome.jp/ kegg/pathway.html) was employed to map proteomic data 
onto pathway maps to enable biological interpretation of large proteomic datasets. The 
web-based gene set analysis toolkit (http://www.webgestalt.org/) was also used to 
interrogate proteomic datasets. Over-representation enrichment analysis was 
performed, with genome_protein-coding as the reference list, non-redundant gene 
ontology terms, a minimum of 2 genes for a category, an FDR ≤ 0.05 and with the 
Benjamini & Hochberg method used for multiple test adjustment. The ClueGO app in 
the Cytoscape bioinformatics package was used to identify enriched GO categories, 
using a two-sided hypergeometric test and a Benjamini-Hochberg p value correction.  
 
2.2.22 Comparative immunoblot analysis 
Comparative immunoblot analysis was carried out for the independent verification of 
a number of important protein hits identified by LC-MS/MS. Immunoblotting was 
performed under routine conditions (Holland et al., 2013), typically using 25 µg 
protein per lane. Proteins were first separated on hand-cast 10% polyacrylamide gels 
by SDS-PAGE and were subsequently transferred by the method of Towbin (Towbin 
et al., 1979) to Whatman nitrocellulose membranes in a Trans-Blot cell from Bio-Rad 
laboratories by wet transfer (transfer buffer: 25 mM tris, 192 mM glycine, 20% 
methanol) at 100 V for 70 min at 4℃. Transfer efficiency was assessed using Ponceau 
reversible stain (0.1% PonceauS, 5% acetic acid). To prevent non-specific binding, 
membranes were blocked for 1 h at room temperature using a milk protein solution 
(2.5% (w/v) fat-free milk powder in 10% PBS), and then incubated with appropriately 
diluted primary antibodies overnight at 4℃ with gentle agitation. The following day 
membranes were washed twice in the milk protein solution for 10 min, and then 
incubated with appropriately diluted peroxidase-conjugated secondary antibodies for 
1.5 h at room temperature with gentle agitation (Murphy et al., 2015a). Membranes 
were washed with the milk protein solution for 10 min twice and with 10% PBS for 
10 min twice, and enhanced chemiluminescence was used for the visualisation of 
immuno-decorated protein bands (O'Connell and Ohlendieck, 2009). Densitometric 
scanning and statistical analysis of immunoblots was performed using a HP PSC-2355 
scanner and ImageJ software (NIH, Bethesda, MD, USA) along with Graph-Pad Prism 
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software (San Diego, CA, USA), in which a p value ≤ 0.05 was deemed to be 
statistically significant.  
 
2.2.23 Enzyme linked immunosorbent assay 
ELISA assays were employed to independently verify some potential circulatory 
protein markers as identified by label-free LC-MS/MS. Crude serum samples were 
screened using quantitative sandwich enzyme immunoassays to haptoglobin and fatty 
acid binding protein 1. Serum samples were diluted appropriately (1:1,000 for 
haptoglobin assay and 1:400 for FABP-1) and were added to antibody-coated 
microtiter wells and incubated at room temperature as directed by the manufacturers’ 
recommendations (20 min for haptoglobin and 2 h for FABP-1). After the incubation 
period wells were washed and a HRP labelled secondary detector antibody was added. 
After incubation at room temperature for 20 min in the dark, TMB chromogen 
substrate was added. The reaction was stopped after exactly 10 min (for haptoglobin) 
or 30 min (for FABP-1) and absorbance was measured at 450 nm on a microplate 
reader (Cynthia Martin et al., 2014). The quantity of protein in the test samples was 
interpolated from a generated standard curve and was corrected for sample dilution. 
All test samples were assayed in triplicate. The intra-plate % coefficient of variation 
(CV) was calculated and was found to be less than 10% for all assays (Murphy et al., 
2017b). 
 
2.2.24 Immunofluorescence microscopy 
All immunofluorescence microscopy was performed by Margit Zweyer at the 
University of Bonn, Germany. Freshly dissected tissue specimens were quick-frozen 
in liquid nitrogen-cooled isopentane and 10 μm sections cut in a cryostat. For collagen 
VI immuno-staining tissue sections were fixed in a 1:1 (v/v) mixture of methanol and 
acetone for 10 min at room temperature. For GFAP immuno-staining sagittal brain 
sections were fixed for 5 min in ice-cold 4 % (v/v) paraformaldehyde in PBS.  For 
dystrophin immuno-staining, unfixed cryosections were boiled in PBS for 5 min. 
Tissue sections were permeabilised in 0.1% (v/v) Triton X-100 for 10 min (collagen 
VI and dystrophin) or 30 min (GFAP), and then blocked with 1:20 diluted normal goat 
serum for 30 min at room temperature. Primary antibodies to dystrophin, collagen VI 
and GFAP were diluted 1:20, 1:20 and 1:300, respectively, in PBS for overnight 
incubation at 4 °C. Specimens were carefully washed and then incubated with 
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fluorescently-labelled secondary antibodies, using 1:200 diluted anti-rabbit Alexa 
Fluor 488 antibody (collagen VI), 1:200 diluted anti-mouse RRX antibody 
(dystrophin) or 1:300 diluted anti-rabbit Cy3-conjugated antibody (GFAP) for 30 min 
(GFAP) or 45 min (collagen VI and dystrophin) at room temperature. Nuclei were 
counter-stained with 1 μg/ml bis-benzimide Hoechst 33342. Following antibody 
labelling, tissue sections were embedded in Fluoromount G medium and viewed under 
a Zeiss Axioskop 2 epifluorescence microscope equipped with a digital Zeiss 
AxioCam HRc camera (Carl Zeiss Jena GmbH, Jena, Germany). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Chapter Three 
 
Proteomic evaluation of alterations in protein abundance 
and protein interactions in hind limb extracts from the mdx-
4cv mouse model of Duchenne muscular dystrophy
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3.1 Introduction 
DMD is a highly progressive and ultimately lethal neuromuscular disorder 
characterised by deficiency of dystrophin, a 427 kDa cytoskeletal protein encoded by 
the Dmd gene on chromosome Xp21 (Nallamilli et al., 2014, Koenig et al., 1987) . 
This rod-shaped protein is located on the inner side of the cell membrane of muscle 
fibres, where it provides an anchor between cytoskeletal actin and the extracellular 
matrix. This is achieved through interactions with a variety of binding partners 
(Ibraghimov-Beskrovnaya et al., 1992), to form a highly organised dystrophin-
glycoprotein complex (DGC). One of the primary roles of the DGC is the maintenance 
of sarcolemmal integrity, but it is also suggested to have regulatory roles through its 
interactions with signalling molecules such as nNOS (Ramachandran et al., 2013). In 
the absence of dystrophin the DGC is compromised. This results in a fragile 
sarcolemma which is prone to micro-rupturing during mechanical stress (Ohlendieck 
and Campbell, 1991a). This in turn leads to excessive influx of calcium ions and 
elevated intracellular calcium concentrations (Batchelor and Winder, 2006). This 
calcium hypothesis of DMD postulates that high intracellular calcium levels are 
responsible for the activation of proteases which lead to cell death, altered ion 
homeostasis and altered cell signalling (Deconinck and Dan, 2007).  
 Gel-based techniques for large-scale protein separation prior to mass 
spectrometric identification has been a mainstay of proteomics for many years. The 
power of gel-based techniques for comparative proteomics was greatly enhanced by 
the introduction of 2D-DIGE. The capacity to run multiple samples on the same gel 
removed the issue of gel-to-gel variation and thus improved the reproducibility of 
results (Marouga et al., 2005). However, gel electrophoresis is restricted by its limited 
resolving power for very large proteins, very small proteins, highly acidic proteins, 
highly basic proteins and hydrophobic proteins (Issaq and Veenstra, 2008, Vélez et 
al., 2015). Liquid-chromatography coupled to mass spectrometry has helped to 
improve this bioanalytical issue, but many comparative proteomic surveys have still 
failed to identify the membrane-associated protein dystrophin in total skeletal tissue 
extracts. The application of organelle proteomics to reduce sample complexity in 
skeletal muscle and enrich for membrane proteins has proved successful in identifying 
a number of components of the DGC including the full-length Dp427 isoform of 
dystrophin, dystroglycan, α1-syntrophin, γ-sarcoglycan and δ-sacroglycan (Murphy et 
al., 2015a). However, while this optimised methodology used minimal centrifugation 
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steps, subcellular fractionation may introduce artefacts in comparative proteomic 
studies. Thus, the identification of dystrophin deficiency and its associated secondary 
abnormalities by highly sensitive mass spectrometry in total skeletal tissue extracts 
from the mdx-4cv animal model of X-linked dystrophinopathy was attempted. The use 
of crude muscle extracts to identify potential muscle-associated biomarker candidates 
represents a more promising avenue for the establishment of a superior marker 
signature. In addition, the findings from this new study, using whole tissue proteomics, 
are important verification results in relation to previous sub-proteomic investigations. 
Since the mdx-4cv animal model used in this proteomic survey exhibits substantial 
myofibrosis (Danko et al., 1992), similar to that seen in the human condition, this 
proteomic study aimed to simultaneously study dystrophin deficiency and secondary 
fibrotic changes within the same tissue sample and the same analytical run.  
 While comparative proteomics can reveal significant insights into the 
molecular basis of neuromuscular disease, also of critical importance is the 
establishment of altered protein interactions in response to disease. The assembly of 
protein complexes and dynamic interactions between proteins are instrumental in 
many developmental, metabolic and physiological processes, and impaired protein 
complex formation can underlie many pathological processes (Murphy and 
Ohlendieck, 2016). This occurs in the case of DMD whereby the loss of the Dp427 
full-length isoform of dystrophin results in a collapsed DGC and ultimately leads to 
membrane instability, abnormal Ca2+ influx and progressive skeletal muscle wasting. 
To investigate potential alterations in protein oligomerisation in dystrophic skeletal 
muscle membranes, chemical cross-linking using the agent 
bis[sulfosuccinimidyl]suberate (BS3) was coupled with mass spectrometry. The BS3 
cross-linker (XL) used in this study is a member of the amine-reactive group of cross-
linkers. Containing an N-hydroxysulfosuccinimide ester at each end of an 8-carbon 
spacer arm, BS3 is a water-soluble, homo-bifunctional, non-cleavable and amine-
reactive cross-linker, thus rendering it particularly useful for the stabilisation of 
protein complexes (Sinz, 2006). Additionally, the protein-XL conjugation reaction can 
be performed under experimental conditions which are relatively close to normal 
physiological conditions. The analytical workflow consisted of i) the subcellular 
enrichment of microsomal membranes from wild-type versus dystrophic skeletal 
muscle, ii) the stabilization of protein-protein interactions via the 11.4-Å cross-linker 
BS3, iii) the comparative one-dimensional gel electrophoretic separation of cross-
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linked versus control microsomes for the detection of cross-linked protein complexes, 
iv) in-gel digestion to generate distinct peptide populations, and v) mass spectrometric 
identification of proteins that exist in apparent supramolecular complexes, and thus 
demonstrate a reduced electrophoretic mobility. The altered electrophoretic mobility 
of protein species in wild-type versus dystrophic muscle membranes in the presence 
of an XL agent was investigated in relation to specific high molecular mass ranges in 
polyacrylamide gels. Overall this analytical approach identified a variety of proteins 
with an enhanced tendency for oligomerisation in the dystrophic microsomal fraction, 
which are mostly involved in membrane repair, cytoskeletal remodelling, fibre 
regeneration, molecular chaperoning and oxidative metabolism. These findings 
suggest that distinct adaptations in critical protein-protein interaction patterns exist 
that may help counter-act progressive fibre wasting in muscular dystrophy.   
 
3.1.1 Experimental Design 
Skeletal muscle is severely affected in DMD, with muscle weakness and atrophy first 
evident in the proximal muscles, with later involvement of lower legs, forearms, neck 
and trunk. A loss of ambulation usually occurs around the early teenage years. Given 
the severity of skeletal muscle degeneration, it was of interest to obtain a global 
overview of proteomic alterations in skeletal muscle which may give novel insights 
into the disease pathology. To achieve this, label-free LC-MS/MS was performed on 
crude homogenates from the entire hind-leg of 6-month old wild-type and age-
matched mdx-4cv mice (n=4). Proteomic profiling was performed using an Ultimate 
3000 NanoLC system (Dionex Corporation, Sunnyvale, CA, USA) coupled to a Q-
Exactive mass spectrometer (Thermo Fisher Scientific). Skeletal muscle-derived 
peptides were eluted using the following binary gradient: solvent A [2% (v/v) ACN 
and 0.1% (v/v) formic acid in LC-MS grade water] and 0-90% solvent B [80% (v/v) 
ACN and 0.1% (v/v) formic acid in LC-MS grade water]: 2% solvent B for 10.5 min, 
2-40% solvent B for 110 min, 40-90% solvent B for 2.5 min, 90% solvent B for 9 min 
and 2% solvent B for 43 min. Relative quantification and identification was performed 
with Progenesis QI for Proteomics software, using Sequest HT and MASCOT search 
engines and the UniProtKB-SwissProt database. Bioinformatics analysis was 
conducted using the PANTHER database of protein families, and STRING software. 
Heatmaps of differentially abundant proteins were generated using Perseus software.  
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Using a panel of select antibodies, the abundance changes of number of proteins were 
independently verified by comparative immunoblotting.  
 In addition to alterations in protein abundance, it is likely that dystrophin 
deficiency and concomitant secondary abnormalities also affect protein interaction 
patterns. In order to investigate this possibility chemical cross-linking was combined 
with mass spectrometric analysis. For this study crude microsomes were prepared by 
ultracentrifugation of homogenates from 5-month old wild-type and age-matched 
mdx-4cv entire hind legs (n=4). The biochemical stabilisation of protein interactions 
was carried out with 10 µg of the homo-bifunctional and amine-reactive agent 
bis[sulfosuccinimidyl]suberate per mg protein, followed by protein shift analysis in 
one-dimensional gels. In-gel digestion was performed, and peptides were analysed by 
mass spectrometry using an Ultimate 3000 NanoLC system (Dionex Corporation, 
Sunnyvale, CA, USA) coupled to a Q-Exactive mass spectrometer (Thermo Fisher 
Scientific). Peptides were eluted using a 65 min method over the following binary 
gradient [solvent A: (2% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade water 
and solvent B: 80% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade water]: 
3% solvent B for 5 min, 10-40% solvent B for 30 min, 40-90% solvent B for 5 min, 
90% solvent B for 5 min and 3% solvent B for 10 min. Protein identification was 
achieved using Proteome Discoverer 1.4 against Sequest HT and the UniProtKB-
SwissProt database. Venny 2.1 software was used to generate Venn diagrams to 
identify common and unique proteins between wild-type control, wild-type cross-
linked, mdx-4cv control and mdx-4cv cross-linked proteins. Potential protein 
interactions amongst unique cross-linked proteins in mdx-4cv samples were analysed 
by version 10.5 of the STRING database for medium confidence (0.4) interactions 
using the evidence view. 
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3.2 Results  
3.2.1 Label-free LC-MS/MS analysis of dystrophin-deficient hind-limb muscle  
A label-free LC-MS/MS approach was used to identify potential changes in protein 
expression in the hind-limb muscle of the mdx-4cv animal model of X-linked muscular 
dystrophy. Since skeletal muscle is highly heterogeneous many comparative 
proteomic surveys have focused their efforts on identifying proteomic changes within 
individual muscles (Carberry et al., 2013). This approach has revealed that disease 
severity is also highly heterogeneous, with different muscle displaying varying 
degrees of neuromuscular damage. The heart and diaphragm are severely dystrophic 
and fibrotic in comparison to the leg, but the extent of muscle damage also varies 
greatly even within the skeletal muscles of the leg;  soleus and extensor digitorum 
longus muscles are moderately affected, while interosseus and flexor digitorum brevis 
muscles are more mildly affected (Holland et al., 2015b).  Hence this proteomic survey 
utilised tissue extracts from whole hind-limb muscle to attain a global analysis of 
proteomic alterations within the dystrophic leg.  
 The comparative proteomic study revealed major protein alterations in the 
dystrophic hind-leg. A total of 199 proteins were identified as having altered 
abundance of 2-fold or greater in mdx-4cv muscle preparations, and the abundance 
profile of these proteins is illustrated in Figure 3.1. Of these proteins, 156 proteins 
were increased in abundance (Table 3.1 and Table A3.1), while 43 proteins displayed 
decreased levels (Table 3.2). Proteins with drastically increased abundance include 
fibronectin, collagen α-2 (VI) chain, fibrinogen-γ chain and fibrinogen-β chain. 
Elevated levels of such proteins are indicative of fibrosis in mdx-4cv muscle. A 
number of tubulin isoforms also displayed increased expression which suggests 
compensatory up-regulation of cytoskeletal components to counter-act mechanical 
weakness in dystrophin-deficient cells. This study was also successful in identifying 
dystrophin as the protein with the highest reduction in dystrophic skeletal muscle, 
along with identifying reduced levels of α-1 syntrophin, another constituent of the 
DGC. Thus, this global proteomic analysis of hind-leg can unequivocally correlate the 
decrease in components of the DGC with the massive infiltration of connective tissue 
in dystrophic muscle.  
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Table 3.1: List of identified proteins with ≥ 3.5-fold increased abundance in 6-month 
old mdx-4cv hind-limb versus age-matched wild-type hind-limb as determined by 
label-free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
Q61879 Myh10  Myosin-10  2 89.20 4.14E-
06 
Infinity 
P11276 Fn1  Fibronectin  2 133.42 2.67E-
03 
271.96 
Q00898 Serpina1e  Alpha-1-antitrypsin 1-
5  
5 571.06 4.00E-
06 
187.00 
Q922F4 Tubb6  Tubulin beta-6 chain  1 187.33 5.12E-
04 
59.01 
Q02788 Col6a2  Collagen alpha-2(VI) 
chain  
2 102.60 9.94E-
04 
44.37 
P28653 Bgn  Biglycan  4 232.44 4.17E-
03 
17.82 
Q8R5J9 Arl6ip5  PRA1 family protein 3  2 45.72 2.12E-
04 
16.11 
Q9ESD7 Dysf  Dysferlin  2 62.55 4.13E-
03 
16.08 
Q8VDD5 Myh9  Myosin-9  4 267.70 9.13E-
03 
15.76 
Q9D154 Serpinb1a  Leukocyte elastase 
inhibitor A  
9 608.03 1.20E-
04 
12.59 
P09541 Myl4  Myosin light chain 4  7 467.03 1.70E-
07 
12.04 
Q8VCM7 Fgg  Fibrinogen gamma 
chain  
3 75.57 3.42E-
04 
11.00 
Q8K0E8 Fgb  Fibrinogen beta chain  11 586.97 2.03E-
04 
10.97 
P62835 Rap1a  Ras-related protein 
Rap-1A  
2 111.67 4.82E-
03 
10.62 
P99024 Tubb5  Tubulin beta-5 chain  4 211.97 1.02E-
03 
9.81 
Q3TMP8 Tmem38a  Trimeric intracellular 
cation channel type A  
2 192.70 4.05E-
03 
8.94 
P21981 Tgm2  Protein-glutamine 
gamma-
glutamyltransferase 2  
2 98.65 2.33E-
02 
8.77 
P13542 Myh8  Myosin-8  1 499.88 1.39E-
02 
8.63 
O89053 Coro1a  Coronin-1A  2 83.25 4.52E-
03 
8.10 
P51881 Slc25a5  ADP/ATP translocase 
2  
2 56.47 4.10E-
03 
8.06 
P97449 Anpep  Aminopeptidase N  2 60.65 2.56E-
03 
7.80 
Q9D1G3 Hhatl  Protein-cysteine N-
palmitoyltransferase 
HHAT-like protein  
5 363.57 9.73E-
03 
6.55 
P28665 Mug1  Murinoglobulin-1  15 759.77 2.46E-
03 
6.51 
P03921 Mtnd5  NADH-ubiquinone 
oxidoreductase chain 5  
3 200.00 1.89E-
02 
6.28 
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Q8VDN2 Atp1a1  Sodium/potassium-
transporting ATPase 
subunit alpha-1  
5 274.26 1.51E-
02 
6.07 
P68433 Hist1h3a  Histone H3.1  3 261.41 1.17E-
02 
5.98 
P11087 Col1a1  Collagen alpha-1(I) 
chain  
4 205.30 1.65E-
02 
5.92 
Q99JY9 Actr3  Actin-related protein 3  3 152.92 8.37E-
05 
5.59 
Q7TSH2 Phkb  Phosphorylase b 
kinase regulatory 
subunit beta  
2 72.79 3.58E-
02 
5.50 
Q99MQ4 Aspn  Asporin  5 354.06 5.47E-
04 
5.43 
Q61233 Lcp1  Plastin-2  6 251.30 1.09E-
04 
5.39 
P41216 Acsl1  Long-chain-fatty-acid-
-CoA ligase 1  
5 242.74 2.00E-
02 
5.19 
Q91V79 Fitm1  Fat storage-inducing 
transmembrane protein 
1  
2 114.05 1.23E-
02 
5.15 
Q6PIE5 Atp1a2  Sodium/potassium-
transporting ATPase 
subunit alpha-2  
6 279.16 1.10E-
02 
5.02 
P10107 Anxa1  Annexin A1  5 349.43 7.52E-
04 
4.99 
Q68FD5 Cltc  Clathrin heavy chain 1  10 600.25 4.17E-
04 
4.82 
Q00623 Apoa1  Apolipoprotein A-I  14 959.82 3.86E-
04 
4.63 
A2AMM0 Murc  Muscle-related coiled-
coil protein  
4 173.61 1.74E-
04 
4.60 
Q9CR62 Slc25a11  Mitochondrial 2-
oxoglutarate/malate 
carrier protein  
2 61.54 3.21E-
02 
4.60 
P14094 Atp1b1  Sodium/potassium-
transporting ATPase 
subunit beta-1  
2 99.15 1.07E-
02 
4.39 
Q9DBG6 Rpn2  Dolichyl-
diphosphooligosacchar
ide--protein 
glycosyltransferase 
subunit 2  
2 123.21 1.78E-
02 
4.26 
P13020 Gsn  Gelsolin  10 696.42 1.54E-
06 
4.18 
P62908 Rps3  40S ribosomal protein 
S3  
3 191.57 1.56E-
02 
4.16 
Q6ZWV3 Rpl10  60S ribosomal protein 
L10  
2 130.31 3.57E-
02 
4.12 
Q01339 Apoh  Beta-2-glycoprotein 1  3 76.33 1.62E-
02 
4.11 
Q61147 Cp  Ceruloplasmin  2 104.55 5.98E-
03 
4.09 
Q60854 Serpinb6  Serpin B6  13 834.53 1.05E-
04 
4.00 
Q99P72 Rtn4  Reticulon-4  2 145.75 7.71E-
03 
3.96 
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Q8BH59;
Q9QXX4 
Slc25a12  Calcium-binding 
mitochondrial carrier 
protein Aralar1  
7 511.83 1.41E-
02 
3.91 
P20918 Plg  Plasminogen  2 160.21 1.84E-
02 
3.89 
O09161 Casq2  Calsequestrin-2  3 162.35 4.14E-
04 
3.87 
Q61838 A2m  Alpha-2-
macroglobulin  
27 1386.61 4.62E-
03 
3.79 
P16546 Sptan1  Spectrin alpha chain, 
non-erythrocytic 1  
5 348.06 6.92E-
03 
3.75 
O89104 Sypl2  Synaptophysin-like 
protein 2  
2 236.00 9.84E-
03 
3.73 
E9PZQ0 Ryr1  Ryanodine receptor 1  27 1821.46 9.26E-
03 
3.72 
Q71LX4 Tln2  Talin-2  2 46.72 2.45E-
02 
3.69 
P68369 Tuba1a  Tubulin alpha-1A 
chain  
12 719.04 6.41E-
03 
3.68 
P22752 Hist1h2ab  Histone H2A type 1  4 199.02 1.92E-
03 
3.67 
P29621 Serpina3c  Serine protease 
inhibitor A3C  
2 240.90 2.56E-
03 
3.66 
P01872 Ighm  Ig mu chain C region  3 242.28 4.58E-
03 
3.65 
Q9EQK5 Mvp  Major vault protein  2 108.45 2.87E-
03 
3.59 
P07356 Anxa2  Annexin A2  9 662.88 9.17E-
04 
3.55 
P00405 Mtco2  Cytochrome c oxidase 
subunit 2  
3 118.86 1.54E-
02 
3.52 
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Table 3.2: List of identified proteins with a significantly decreased abundance in 
mdx-4cv hind-limb versus age-matched wild-type hind limb as determined by label-
free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
P11531 Dmd  Dystrophin, Dp427 9 457.77 5.25E-
05 
14.61 
Q8VCT4 Ces1d  Carboxylesterase 1D  4 175.05 1.94E-
03 
5.85 
O55137 Acot1  Acyl-coenzyme A 
thioesterase 1  
2 139.31 2.28E-
03 
4.35 
P19096 Fasn  Fatty acid synthase  3 198.37 6.24E-
03 
4.00 
Q9JJW5 Myoz2  Myozenin-2  2 67.37 1.66E-
02 
3.98 
Q8C0M9 Asrgl1  Isoaspartyl peptidase/L-
asparaginase  
3 202.68 8.71E-
04 
3.98 
P97823 Lypla1  Acyl-protein 
thioesterase 1  
2 115.76 1.73E-
02 
3.96 
P32848 Pvalb  Parvalbumin alpha  4 262.00 4.00E-
02 
3.95 
Q61234 Snta1  Alpha-1-syntrophin  3 101.64 8.73E-
04 
3.69 
P51667 Myl2  Myosin regulatory light 
chain 2, 
ventricular/cardiac 
muscle isoform  
6 319.15 2.95E-
02 
3.64 
Q08642 Padi2  Protein-arginine 
deiminase type-2  
10 498.35 3.33E-
03 
3.55 
P09542 Myl3  Myosin light chain 3  8 548.51 1.60E-
02 
3.51 
P16015 Ca3  Carbonic anhydrase 3  21 1652.17 1.54E-
03 
3.44 
Q8QZS1 Hibch  3-hydroxyisobutyryl-
CoA hydrolase, 
mitochondrial  
3 202.77 2.45E-
03 
3.15 
Q64105 Spr  Sepiapterin reductase  7 515.05 2.04E-
03 
3.14 
P70695 Fbp2  Fructose-1,6-
bisphosphatase isozyme 
2  
9 592.73 3.22E-
03 
3.09 
Q9DAK9 Phpt1  14 kDa 
phosphohistidine 
phosphatase  
2 208.62 2.64E-
04 
3.02 
P04247 Mb  Myoglobin  16 1768.39 6.53E-
04 
2.93 
Q8BVI4 Qdpr  Dihydropteridine 
reductase  
5 336.05 3.15E-
04 
2.91 
Q9DBB8 Dhdh  Trans-1,2-
dihydrobenzene-1,2-
diol dehydrogenase  
2 119.58 2.63E-
02 
2.90 
Q9D358 Acp1  Low molecular weight 
phosphotyrosine protein 
phosphatase  
2 115.63 2.47E-
03 
2.89 
P06801 Me1  NADP-dependent malic 
enzyme  
8 348.26 5.72E-
03 
2.85 
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P21107 Tpm3  Tropomyosin alpha-3 
chain  
3 113.68 2.45E-
02 
2.72 
O55103 Prx  Periaxin  2 5.10 1.46E-
02 
2.67 
Q8R1G2 Cmbl  Carboxymethylenebute
nolidase homolog  
4 418.47 5.83E-
03 
2.64 
Q9D0K2 Oxct1  Succinyl-CoA:3-
ketoacid coenzyme A 
transferase 1, 
mitochondrial  
2 143.49 9.92E-
03 
2.61 
Q9WUZ5 Tnni1  Troponin I, slow 
skeletal muscle  
2 114.05 3.34E-
02 
2.50 
P56375 Acyp2  Acylphosphatase-2  3 227.82 5.51E-
04 
2.40 
P17563 Selenbp1  Selenium-binding 
protein 1  
7 398.91 7.34E-
04 
2.36 
P14152 Mdh1  Malate dehydrogenase, 
cytoplasmic  
8 588.67 4.42E-
04 
2.33 
Q9CRB9 Chchd3  Coiled-coil-helix-
coiled-coil-helix 
domain-containing 
protein 3, mitochondrial  
2 191.91 8.31E-
03 
2.28 
P70349 Hint1  Histidine triad 
nucleotide-binding 
protein 1  
6 504.12 4.70E-
03 
2.27 
P11404 Fabp3  Fatty acid-binding 
protein, heart  
5 407.23 1.14E-
02 
2.21 
Q01768 Nme2  Nucleoside diphosphate 
kinase B  
3 216.20 2.94E-
02 
2.21 
Q9D0S9 Hint2  Histidine triad 
nucleotide-binding 
protein 2, mitochondrial  
2 88.74 7.99E-
03 
2.15 
Q9CQR4 Acot13  Acyl-coenzyme A 
thioesterase 13  
2 155.36 9.68E-
03 
2.14 
P15626 Gstm2  Glutathione S-
transferase Mu 2  
5 300.40 1.95E-
02 
2.13 
P08228 Sod1  Superoxide dismutase 
[Cu-Zn]  
5 206.00 4.58E-
03 
2.09 
Q8BZA9 Tigar  Fructose-2,6-
bisphosphatase TIGAR  
2 106.59 4.00E-
03 
2.08 
Q91ZJ5 Ugp2  UTP--glucose-1-
phosphate 
uridylyltransferase  
15 949.23 2.70E-
03 
2.08 
P63017 Hspa8  Heat shock cognate 71 
kDa protein  
4 465.80 3.12E-
03 
2.03 
P15327 Bpgm  Bisphosphoglycerate 
mutase  
3 213.38 1.34E-
02 
2.02 
Q60864 Stip1  Stress-induced-
phosphoprotein 1  
3 175.87 1.85E-
03 
2.01 
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Figure 3.1: Label-free quantitative proteomic analysis of wild-type versus mdx-
4cv crude hind-limb extracts  
Depicted is the result from hierarchical clustering of the median protein expression 
values of all 199 statistically significant differentially abundant proteins, performed 
using Perseus software. Hierarchical clustering of z-score normalised intensity values 
resolved the four replicates of each sample group and illustrates diagrammatically the 
alterations in protein abundance between wild-type and mdx-4cv skeletal muscle.  
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3.2.2 Distribution of protein changes in mdx-4cv hind-limb 
To explore the biological significance of the proteins displaying altered expression in 
dystrophic hind-leg, bioinformatics was employed. Both proteins with increased 
abundance (Figure 3.2) and proteins with reduced abundance (Figure 3.3) were 
grouped based on their protein class. The fact the class of cytoskeletal proteins is 
observed in both proteins with increased and decreased expression suggests that i) X-
linked dystrophinopathy is primarily a cytoskeletal disease whereby dystrophin 
deficiency results in a concomitant decrease in other structural components of the 
DGC and ii) in dystrophic muscle there is a compensatory up-regulation of other 
cytoskeletal proteins to rescue the load-bearing capacity of the dystrophic hind-leg.  
Enzymatic activity also appears to be significantly affected in mdx-4cv muscle, with 
just over half (56%) of decreased proteins belonging to the class of hydrolases, 
oxidoreductases, transferases and phosphatases.  
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Figure 3.2: PANTHER analysis of the 156 proteins with increased abundance in 
mdx-4cv skeletal muscle 
Proteins with elevated abundance in total tissue extracts from mdx-4cv hind-limb, as 
identified by label-free LC-MS/MS, were grouped into protein class using the 
bioinformatics package PANTHER. 
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Figure 3.3: PANTHER analysis of the 43 proteins with decreased abundance in 
mdx-4cv skeletal muscle 
Summary of proteins with reduced levels in total tissue extracts from mdx-4cv hind-
limb as identified by label-free LC-MS/MS. Proteins with reduced abundance were 
classified by protein class using the bioinformatics software PANTHER.  
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Potential protein interactions were also examined using STRING analysis, which 
generates interaction maps based on direct physical and indirect functional protein 
linkages. Figure 3.4 depicts the global analysis of the 199 proteins with altered 
abundance in crude extracts from the dystrophic hind-limb. In analogy to the 
PANTHER bioinformatics analysis, a major protein cluster was identified for the 
cytoskeletal proteins, including vimentin, desmin, obscurin, filamin A, filamin C and 
various isoforms of myosin heavy chains and myosin light chains, indicating that the 
deficiency in dystrophin in X-linked dystrophinopathy has major implications for the 
cytoskeletal structure of cells. Other interesting protein clusters include the 
mitochondria and the ribosome, suggesting bioenergetic adaptations and increased 
protein synthesis respectively. Fibrotic pathways, a major hallmark of DMD, and 
wound healing were also detected, as indicated in Figure 3.4.  
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Figure 3.4: Bioinformatics analysis of altered protein expression in dystrophic 
skeletal muscle 
The bioinformatics STRING database identified a number of interesting protein 
clusters, including the ribosome, the cytoskeleton, mitochondrial part, wound healing 
and myofibrosis. 
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3.2.3 Verification of proteomic findings by comparative immunoblotting  
Comparative immunoblotting using a panel of antibodies against select muscle-
derived proteins was employed to independently verify some of the key proteomic hits 
that have been identified by label-free LC-MS/MS. Figure 3.5 shows a silver-stained 
gel of wild-type versus mdx-4cv muscle preparations, which indicates comparable 
protein banding patterns between control and dystrophic hind-leg. Immunoblotting 
with an antibody against the equal loading protein laminin, demonstrated comparable 
levels of this protein between wild-type and mdx-4cv samples (Figure 3.5). This, in 
conjunction with the silver stain analysis, illustrates equal protein loading. In contrast, 
altered abundance was detected for a range of proteins. Elevated levels of the 
cytoskeletal proteins β-tubulin and desmin was also determined (Figures 3.6 and 3.7), 
indicating the loss of dystrophin has a major impact on the cytoskeletal lattice. 
Increased annexin A2 abundance is indicative of membrane perturbations (Figure 3.6), 
while massive increases in the abundance of the extracellular matrix glycoprotein 
fibronectin was also detected by immunoblotting (Figure 3.7). Parvalbumin displays 
reduced abundance in mdx-4cv preparations, suggesting a reduction in the cytosolic 
calcium-buffering capacity of dystrophic muscle fibres (Figure 3.8). Taken together 
the comparative immunoblot analysis verifies the proteomic data in this report and 
illustrates the secondary abnormalities evident in dystrophic skeletal muscle. 
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A) Silver                     B) Laminin  
   
                                                             
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Electrophoretic and immunoblot analysis of wild-type and mdx-4cv 
muscle  
Shown is a silver stained 1D gel (A) and immunoblot and statistical analysis of bands 
labelled with laminin (B). The silver stained gel shows comparable protein banding 
patterns for wild-type and mdx-4cv muscle preparations. Molecular weight marker is 
given on the left-hand-side of the image in kDa. Laminin immunoblotting did not show 
significant changes in concentration between wild-type and mdx-4cv samples and so 
it serves as a loading control for comparative immunoblotting. Graphical 
representation of the immuno-decoration level for laminin is shown (mean values ± 
SEM, Student’s t-test; unpaired; n=4). 
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Figure 3.6: Comparative immunoblot analysis of proteins with an increased 
abundance in dystrophic mdx-4cv hind-limb skeletal muscle 
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to the A2 isoform of annexin (A) and the microtubular protein β-tubulin 
(B). Statistical analysis of immuno-decoration was performed with Student’s t-test 
(mean values ± SEM; unpaired; n=4, *p≤0.05). 
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Figure 3.7: Comparative immunoblot analysis of proteins with an increased 
abundance in dystrophic mdx-4cv hind-limb skeletal muscle 
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to the intermediate filament protein desmin (A) and the extracellular matrix 
protein fibronectin (B). Statistical analysis of immuno-decoration was performed with 
Student’s t-test (mean values ± SEM; unpaired; n=4, *p≤0.05, ***p≤0.001). 
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3.4 Immunofluorescence and immunoblotting analysis of myofibrosis in dystrophic 
skeletal muscle 
 
 
Figure 3.8: Comparative immunoblot analysis of proteins with a decreased 
abundance in dystrophic mdx-4cv hind-limb skeletal muscle 
Shown is a representative immunoblot with immuno-decorated bands labelled with an 
antibody to parvalbumin (A). Statistical analysis of immuno-decoration was 
performed with Student’s t-test (mean values ± SEM; unpaired; n=4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   wt     mdx- 
             4cv  
A 
 
Parvalbumin 
 
12 kDa 
 
Parvalbumin
w
t
m
dx
-4
cv
0
50
100
150
%
 C
o
n
tr
o
l
96 
 
While the pathogenesis of DMD is largely attributed to two main processes; 
mechanical stress in dystrophin-deficient muscle fibres and elevated cytoplasmic 
calcium levels, fibrosis is also a major contributing factor to the pathology. Since this 
proteomic survey has for the first time identified dystrophin as the main down-
regulated protein in total tissue extracts from skeletal muscle, we aimed to investigate 
myofibrosis in the same samples to place dystrophin deficiency in its proper 
pathophysiological context. Fibrosis was examined by a combination of 
immunofluorescence and immunoblotting of the collagen isoform COL-VI, as shown 
in Figure 3.9. In contrast to comparable levels of overall protein and laminin, collagen 
levels were found to be significantly increased in mdx-4cv skeletal muscle. 
Immunofluorescence microscopy verified this finding, with clearly elevated levels of 
collagen evident in Dp427-deficient muscle preparations.  
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Figure 3.9: Immunofluorescence and immunoblot analysis of collagen in normal 
versus dystrophic mdx-4cv muscle 
Shown is a representative silver stained gel (A), the unchanged abundance of laminin 
(B) and the increased abundance in collagen VI (C, D, E). Statistical analysis of 
immuno-decoration was performed with Student’s t-test (mean values ± SEM; 
unpaired; n=4, *p≤0.05). The immunofluorescence microscopy shows the labelling 
of the extracellular matrix in wild-type and mdx-4cv gastrocnemius muscle using 
antibodies to collagen VI (D, E). Nuclei were counter-stained with the DNA binding 
dye bis-benzimide Hoechst 33342.  
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3.2.4 Gel electrophoretic analysis of chemically cross-linked muscle microsomes 
In order to optimise the ratio of protein to XL, microsomal fractions were treated with 
increasing amounts of XL from 0.1 µg XL per mg protein up to 10 µg XL per mg 
protein. Increasing amounts of XL induced the appearance of a band at approximately 
150 kDa as determined by silver stain analysis of one-dimensional gels in both wild-
type and dystrophic membranes. In addition, more intense protein staining was evident 
at high molecular masses with increasing amounts of XL, especially at 5 µg, 7.5 µg 
and 10 µg XL per mg protein, suggesting a potential shift of protein complexes to 
higher molecular masses, as depicted in Figure 3.10. Based upon these results 10 µg 
XL per mg protein was chosen for the main study. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Gel based chemical cross-linking analysis of skeletal muscle 
microsomes  
Shown are silver stained SDS-PAGE gels which represent the analysis of wild-type 
and mdx-4cv microsomes that were incubated with 0, 0.1, 0.5, 1, 2, 5, 7.5 and 10 µg 
BS3 XL per mg protein. Molecular mass standards (kDa) are indicated on the left-
hand-side of the gel image.  
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3.2.5 Mass spectrometric identification of proteins with altered electrophoretic 
mobility 
Based on the initial optimisation study, wild-type and mdx-4cv microsomes were 
incubated with either 0 µg XL per mg protein (control) or 10 µg XL per mg protein 
(cross-linked) (n=4 for each condition) and separated on one-dimensional SDS-PAGE 
gels. As illustrated in Figure 3.11, each lane was divided into five sections, labelled 
A-E, and trypsin-digested, and the resulting peptide populations were analysed by 
mass spectrometry. Qualitative data analysis identified a total of 346 proteins in wild-
type samples (A-E inclusive) and a total of 370 proteins in mdx-4cv samples (A-E 
inclusive). Venn diagrams were used to identify common and unique proteins for wild-
type control versus cross-linked samples for each gel zone A-E, and for mdx-4cv 
control versus cross-linked samples for each gel zone A-E. Only proteins identified by 
two or more unique peptides were used in the analysis. For the identification of 
common versus unique proteins, proteins were only considered to be unique if they 
were detected in all four replicates of one condition and in none of the four replicates 
in the other condition. Proteins which are considered common or shared between 
control and cross-linked lanes are those which are detected in all four of the control 
replicates and all four of the cross-linked replicates for a given gel piece. Figure 3.11 
summarises these results and suggests that a considerable number of proteins exhibit 
tight protein-protein interaction patterns that can be stabilized by incubation with an 
XL agent. Although the majority of microsomal proteins did not undergo a drastic 
alteration in electrophoretic mobility following XL treatment, distinct cohorts of 
protein species do exhibit a BS3-dependent shift to higher molecular masses. The focus 
of this proteomic investigation was on the class of very high-molecular-mass 
complexes, denoted A-C, where the most visible changes in protein banding patterns 
is seen and where the highest number of proteins uniquely found in cross-linked 
samples is evident.  
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Figure 3.11: Mass spectrometric identification of cross-linked muscle proteins 
with an altered electrophoretic mobility 
Shown is a Coomassie-stained SDS-PAGE gel with chemically cross-linked 
microsomes from wild-type versus dystrophic mdx-4cv skeletal muscle. Lanes 1 to 4 
are non-treated wild-type muscle versus 10 g BS³/mg protein-incubated wild-type 
muscle versus non-treated mdx-4cv muscle versus 10 g BS³/mg protein-incubated 
mdx-4cv muscle preparations, respectively. The number of common and unique MS-
identified proteins in the high to low molecular mass zones A-E of the analysed gel 
lanes is illustrated by Venn diagrams. 
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3.2.6 Mass spectrometric identification and bioinformatics analysis of altered 
protein interactions in muscular dystrophy in gel zone A 
The comparison of proteins found exclusively in wild-type cross-linked samples in gel 
zone A with the proteins found exclusively in mdx-4cv cross-linked samples in gel 
zone A identified 11 proteins unique to wild-type samples, 15 proteins unique to mdx-
4cv samples and 8 proteins in common as shown in Tables 3.3, 3.4 and 3.5 
respectively. The detection of the Dp427 full-length isoform of dystrophin solely in 
wild-type samples confirmed the mutant status of the mdx-4cv mouse used. Other 
proteins of the DGC which were expected to cross-link with dystrophin were not 
detected. However, this is most likely due to their relatively low abundance and 
hydrophobicity, which are particular issues for gel electrophoretic analyses. However, 
delta-sarcoglycan was detected in gel zone B in both wild-type and mdx-4cv cross-
linked microsomes (Table 3.8). Perilipin-4, a member of the perilipin family of 
proteins which associate with the surface of lipid droplets, was also detected in the 
wild-type cross-linked samples. This finding is consistent with previous 
immunofluorescence microscopy which revealed that perilipin-4 was located at or 
close to the muscle sarcolemma (Pourteymour et al., 2015). Additional proteins with 
a tendency to from large protein clusters in healthy skeletal muscle include molecular 
chaperones (HSP-90), metabolic enzymes (adenylate kinase isoenzyme 1), structural 
proteins (myosin-11) and transporters (myoglobin). The 15 proteins exclusively 
detected in mdx-4cv cross-linked microsomes suggest potential alterations in protein 
interactions in muscular dystrophy. As shown in Figure 3.12, STRING analysis of 
these proteins identifies two major protein clusters; one of the structural proteins 
myosin-3, myosin-9, vimentin, tubulin-beta-5, actin and the scaffolding protein 
caveolin-1, and another of mitochondrial enzymes including trifunctional enzyme 
subunit alpha, isoform 2 of 2-oxoglutarate dehydrogenase, elongation factor Tu, 
trifunctional enzyme subunit beta and dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex. Also of interest is the 
identification of the membrane repair protein myoferlin.  
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Table 3.3: Mass spectrometric identification of proteins with a reduced 
electrophoretic mobility detected in gel zone A following chemical cross-linking of 
the microsomal fraction from wild-type mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
Unique 
peptides 
P11531 Dystrophin, Dp427 5.98 17 
Q3V1D3 AMP deaminase 1  19.06 9 
P11499 Heat shock protein HSP 90-beta  8.98 6 
O08638-2 Isoform 2 of Myosin-11  5.83 6 
Q9Z1E4 Glycogen [starch] synthase, muscle  8.27 5 
Q91YQ5 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1  
9.05 4 
Q9R0Y5 Adenylate kinase isoenzyme 1  23.2 3 
P97447 Four and a half LIM domains protein 1  11.07 3 
P43274 Histone H1.4  15.53 2 
P04247 Myoglobin  21.43 2 
O88492 Perilipin-4  12.83 2 
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Table 3.4: Mass spectrometric identification of proteins with a reduced gel 
electrophoretic mobility detected in gel zone A following chemical cross-linking of 
the microsomal fraction from mdx-4cv mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
Unique 
peptides 
Q8BMS1 Trifunctional enzyme subunit alpha, mitochondrial  19.92 13 
Q8VDD5 Myosin-9  7.4 13 
Q7TQ48 Sarcalumenin  17.25 12 
Q60597-2 Isoform 2 of 2-oxoglutarate dehydrogenase, mitochondrial  14.71 12 
Q60847-4 Isoform 4 of Collagen alpha-1(XII) chain  5.1 7 
Q8BFR5 Elongation factor Tu, mitochondrial  16.81 6 
Q99JY0 Trifunctional enzyme subunit beta, mitochondrial  12.84 6 
Q9D2G2 Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial  
8.37 4 
Q7TSH2 Phosphorylase b kinase regulatory subunit beta  5.25 4 
P13541 Myosin-3  19.38 3 
P49817-2 Isoform 2 of Caveolin-1  19.05 3 
Q69ZN7-4 Isoform 4 of Myoferlin  1.92 3 
P60710 Actin, cytoplasmic 1  26.4 2 
P99024 Tubulin beta-5 chain  15.32 2 
P20152 Vimentin  9.23 2 
 
 
 
 
Table 3.5: Mass spectrometric identification of proteins with a reduced gel 
electrophoretic mobility in gel zone A following chemical cross-linking of the 
microsomal fraction from both wild-type and mdx-4cv mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
wt 
Unique 
peptides 
wt 
% 
Coverage 
mdx-4cv 
Unique 
peptides 
mdx-4cv 
Q91Z83 Myosin-7  32.87 25 25.68 17 
Q8CAQ8-2 Isoform 2 of MICOS 
complex subunit Mic60  
14.75 8 24.4 13 
Q9D6R2 Isocitrate dehydrogenase 
[NAD] subunit alpha, 
mitochondrial 
21.58 6 13.11 4 
P13542 Myosin-8  45.07 6 38.26 4 
Q02788 Collagen alpha-2(VI) chain  5.13 5 8.03 7 
P10493 Nidogen-1  3.05 3 1.77 2 
P0CG49 Polyubiquitin-B  32.79 2 32.79 2 
P68372 Tubulin beta-4B chain  17.3 2 15.28 2 
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Figure 3.12: Bioinformatics analysis of proteomic changes detected in gel zone A 
in the microsomal fraction from dystrophic muscle 
Shown are the findings from the bioinformatics analysis of protein interactions using 
STRING software program. 
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3.2.7 Mass spectrometric identification and bioinformatics analysis of altered 
protein interactions in muscular dystrophy in gel zone B 
The comparison of proteins found exclusively in wild-type cross-linked samples in gel 
zone B with the proteins found exclusively in mdx-4cv cross-linked samples in gel 
zone B identified 17 proteins unique to wild-type samples, 48 proteins unique to mdx-
4cv samples and 19 proteins in common as shown in Tables 3.6, 3.7 and 3.8 
respectively. Similar to gel zone A, the proteins detected in wild-type microsomes 
include transporters (long-chain fatty acid transport protein 1), molecular chaperones 
(60 kDa heat shock protein) and the sarcolemma-associated protein perilipin-4. Other 
proteins with a reduced electrophoretic mobility pattern include the cellular adhesion 
proteins membrane primary amine oxidase and integrin beta-1, the adaptor protein 
LIM domain-binding protein 3, and the mitochondrial proteins apoptosis-inducing 
factor 1, ATP synthase F(0) complex subunit B1, atypical kinase COQ8A, and 
succinate--CoA ligase [ADP/GDP-forming] subunit alpha. The largest number of 
proteins unique to mdx-4cv cross-linked microsomes was detected in gel zone B. 
Augmented tendency for oligomerisation was seen for proteins associated with the 
mitochondria, including succinate-Coenzyme A ligase, electron transfer flavoprotein 
beta polypeptide, CDGSH iron-sulfur domain-containing protein 1, acyl-Coenzyme A 
dehydrogenase, and glycerol-3-phosphate dehydrogenase 1, which may indicate 
metabolic alterations in the dystrophic skeletal muscle. STRING analysis, as depicted 
in Figure 3.13, identified enriched levels of proteins associated with the proteasome 
and with protein processing in the endoplasmic reticulum, including 26S proteasome 
non-ATPase regulatory subunit 1, 26S proteasome non-ATPase regulatory subunit 2, 
26S proteasome regulatory subunit 8, ATP-binding cassette sub-family B member 8, 
calnexin, UDP-glucose glycoprotein glucosyltransferase 1 and hypoxia up-regulated 
protein 1, indicating a potential increase in molecular chaperoning activity to limit 
proteotoxic effects in the dystrophin deficient muscle. Another interesting protein 
cluster is that of the integrins integrin alpha-7, integrin beta-2 and isoform 2 of integrin 
alpha-M with alpha-actinin-2 and vimentin.  
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Table 3.6: Mass spectrometric identification of proteins with a reduced gel 
electrophoretic mobility detected in gel zone B following chemical cross-linking of 
the microsomal fraction from wild-type mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
Unique 
peptides 
O70423 Membrane primary amine oxidase  13.2 8 
P63038 60 kDa heat shock protein, mitochondrial  13.26 5 
Q6PA06 Atlastin-2  11.66 5 
Q91ZJ5-2 Isoform 2 of UTP--glucose-1-phosphate 
uridylyltransferase  
13.68 5 
P61027 Ras-related protein Rab-10  27.5 5 
Q9Z0X1 Apoptosis-inducing factor 1, mitochondrial  10.62 4 
P43274 Histone H1.4  15.07 4 
Q9CQQ7 ATP synthase F(0) complex subunit B1, mitochondrial  11.72 3 
Q60936 Atypical kinase COQ8A, mitochondrial  5.43 3 
P09055 Integrin beta-1  5.76 3 
P18572-2 Isoform 2 of Basigin  11.72 3 
O88492 Perilipin-4  16.75 3 
Q9WUM5 Succinate--CoA ligase [ADP/GDP-forming] subunit 
alpha, mitochondrial  
12.43 3 
Q02053 Ubiquitin-like modifier-activating enzyme 1  3.69 3 
Q8CGC7 Bifunctional glutamate/proline--tRNA ligase  1.85 2 
Q9JKS4-4 Isoform 4 of LIM domain-binding protein 3  4.18 2 
Q60714 Long-chain fatty acid transport protein 1  3.87 2 
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Table 3.7: Mass spectrometric identification of proteins with a reduced gel 
electrophoretic mobility detected in gel zone B following chemical cross-linking of 
the microsomal fraction from mdx-4cv mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
Unique 
peptides 
Q6P5E4 UDP-glucose: glycoprotein glucosyltransferase 1  16.63 21 
Q9JI91 Alpha-actinin-2  27.4 14 
O35129 Prohibitin-2  44.15 11 
P20152 Vimentin  31.76 10 
O08749 Dihydrolipoyl dehydrogenase, mitochondrial  22 9 
P70170-3 Isoform SUR2C of ATP-binding cassette sub-family C 
member 9  
8.6 9 
Q9DCN2-2 Isoform 2 of NADH-cytochrome b5 reductase 3  38.49 8 
Q9D024 Coiled-coil domain-containing protein 47  20.08 7 
Q9DBG6 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2  
20.29 7 
Q3U7R1 Extended synaptotagmin-1  9.25 7 
Q3MI48-2 Isoform 2 of Junctional sarcoplasmic reticulum protein 1  42.81 7 
Q8BMK4 Cytoskeleton-associated protein 4  14.26 6 
P11835 Integrin beta-2  12.06 6 
Q61738-4 Isoform Alpha-7X2A of Integrin alpha-7  7.53 6 
P51174 Long-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
16.74 6 
Q8JZQ2 AFG3-like protein 2  6.61 5 
Q61102 ATP-binding cassette sub-family B member 7, 
mitochondrial  
7.31 5 
P35564 Calnexin  14.21 5 
Q6PA06-2 Isoform 2 of Atlastin-2  18.04 5 
P18826-2 Isoform 2 of Phosphorylase b kinase regulatory subunit 
alpha, skeletal muscle isoform  
5.15 5 
Q91WC3 Long-chain-fatty-acid--CoA ligase 6  8.75 5 
Q921I1 Serotransferrin  8.61 5 
Q3TXS7 26S proteasome non-ATPase regulatory subunit 1  6.4 4 
P62908 40S ribosomal protein S3  18.11 4 
P16015 Carbonic anhydrase 3  21.15 4 
O54724 Caveolae-associated protein 1  14.54 4 
Q8CHS7 Dehydrogenase/reductase SDR family member 7C  15.76 4 
Q9DCW4 Electron transfer flavoprotein subunit beta  20 4 
P13707 Glycerol-3-phosphate dehydrogenase [NAD(+)], 
cytoplasmic  
12.03 4 
Q9JKR6 Hypoxia up-regulated protein 1  5.61 4 
P05555-2 Isoform 2 of Integrin alpha-M  5.89 4 
Q9Z2I9 Succinate--CoA ligase [ADP-forming] subunit beta, 
mitochondrial  
7.56 4 
P68369 Tubulin alpha-1A chain  27.49 4 
P68368 Tubulin alpha-4A chain  25.45 4 
Q8VDM4 26S proteasome non-ATPase regulatory subunit 2  4.74 3 
P17182 Alpha-enolase  16.13 3 
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Q9DCX2 ATP synthase subunit d, mitochondrial  25.47 3 
Q9CXJ4 ATP-binding cassette sub-family B member 8, 
mitochondrial  
5.44 3 
P58252 Elongation factor 2  4.31 3 
Q923T9-3 Isoform 3 of Calcium/calmodulin-dependent protein 
kinase type II subunit gamma  
8.69 3 
Q8BI84-3 Isoform 3 of Melanoma inhibitory activity protein 3  5.51 3 
P51150 Ras-related protein Rab-7a  18.36 3 
P62196 26S proteasome regulatory subunit 8  10.84 2 
P62702 40S ribosomal protein S4, X isoform  8.37 2 
Q91WS0 CDGSH iron-sulfur domain-containing protein 1  22.22 2 
Q9CQC9 GTP-binding protein SAR1b  11.11 2 
Q922Q8 Leucine-rich repeat-containing protein 59  8.14 2 
Q9D1G1 Ras-related protein Rab-1B  28.86 2 
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Table 3.8: Mass spectrometric identification of proteins with a reduced gel 
electrophoretic mobility in gel zone B following chemical cross-linking of the 
microsomal fraction from both wild-type and mdx-4cv mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
wt 
Unique 
peptides 
wt 
% 
Coverage 
mdx-4cv 
Unique 
peptides 
mdx-4cv 
Q8BW75 Amine oxidase [flavin-
containing] B  
23.27 11 36.15 15 
G5E829 Plasma membrane calcium-
transporting ATPase 1  
12.79 10 12.7 13 
P97807-2 Isoform Cytoplasmic of 
Fumarate hydratase, 
mitochondrial  
31.05 9 32.98 15 
Q8BRK9 Alpha-mannosidase 2x  9.55 8 9.55 8 
Q9DB73 NADH-cytochrome b5 reductase 
1  
30.16 7 28.85 8 
Q6GQT9 Nodal modulator 1  6.43 7 9.64 10 
P05201 Aspartate aminotransferase, 
cytoplasmic  
17.19 6 18.16 7 
Q8C7X2-2 Isoform 2 of ER membrane 
protein complex subunit 1  
7.75 6 12.47 9 
P48678-2 Isoform C of Prelamin-A/C  13.07 6 28.05 13 
Q99MR8 Methylcrotonoyl-CoA 
carboxylase subunit alpha, 
mitochondrial  
8.79 5 9.62 5 
Q9CQF9 Prenylcysteine oxidase  15.05 5 17.03 6 
P67778 Prohibitin  24.63 5 21.69 5 
Q62351 Transferrin receptor protein 1  7.86 5 18.22 11 
Q9CRD2 ER membrane protein complex 
subunit 2  
17.51 4 11.78 3 
P28665 Murinoglobulin-1  3.32 4 5.01 6 
P82347 Delta-sarcoglycan  9 2 9 2 
Q3TDQ1 Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit STT3B  
2.55 2 5.35 3 
Q9QYG0-2 Isoform 2 of Protein NDRG2  8.96 2 8.96 2 
Q9CRB9 MIC complex subunit Mic19  8.37 2 21.59 6 
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Figure 3.13: Bioinformatics analysis of proteomic changes detected in gel zone B 
in the microsomal fraction from dystrophic muscle 
Shown are the findings from the bioinformatics analysis of protein interactions using 
STRING software program. 
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3.2.8 Mass spectrometric identification and bioinformatics analysis of altered 
protein interactions in muscular dystrophy in gel zone C 
The comparison of proteins found exclusively in wild-type cross-linked samples in gel 
zone C with the proteins found exclusively in mdx-4cv cross-linked samples in gel 
zone C identified 12 proteins unique to wild-type samples, 30 proteins unique to mdx-
4cv samples and 12 proteins in common as shown in Tables 3.9, 3.10 and 3.11 
respectively. The detection of β-sarcoglycan in wild-type cross-linked samples in gel 
zone C suggests a potential for β-sarcoglycan to form protein complexes, especially 
since it is detected in both wild-type control and cross-linked samples in gel zone E. 
Oligomerisation is also evident for the mitochondrial proteins medium-chain specific 
acyl-CoA dehydrogenase, elongation factor Tu, and succinate--CoA ligase [ADP-
forming] subunit beta. Detected here and in wild-type cross-linked samples in gel zone 
B is isoform 2 of basigin, a multi-functional transmembrane protein involved in 
spermatogenesis, neural network development, tumour invasion, stimulation of 
fibroblasts to produce matrix metalloproteinases and targeting of the monocarboxylate 
transporters SLC16A1, SLC16A3, SLC16A8 and SLC16A11 to the plasma 
membrane. STRING analysis of the 30 proteins exclusively detected in mdx-4cv cross-
linked samples reveals a major cluster of mitochondrial proteins, which are 
particularly associated with the citric acid cycle and respiratory electron transport, as 
illustrated in Figure 3.14. These proteins include dihydrolipoyllysine-residue 
succinyltransferase component of 2-oxoglutarate dehydrogenase complex, fumarate 
hydratase, isocitrate dehydrogenase, ATP synthase subunit delta, NADH 
dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 and NADH 
dehydrogenase [ubiquinone] iron-sulfur protein 3. Also of significance is the detection 
of flotillin-1 and flotillin-2, which act as scaffolding proteins within caveolar 
membranes.  
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Table 3.9: Mass spectrometric identification of proteins with a reduced gel 
electrophoretic mobility detected in gel zone C following chemical cross-linking of 
the microsomal fraction from wild-type mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
Unique 
peptides 
P45952 Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
16.63 6 
Q3TVI8 Pre-B-cell leukemia transcription factor-interacting 
protein 1  
9.22 5 
P35293 Ras-related protein Rab-18  20.87 4 
P60710 Actin, cytoplasmic 1  37.07 3 
Q8BFR5 Elongation factor Tu, mitochondrial  10.4 3 
Q61743 ATP-sensitive inward rectifier potassium channel 11  5.9 2 
P82349 Beta-sarcoglycan  10 2 
P16015 Carbonic anhydrase 3  8.08 2 
Q8BSY0-2 Isoform 2 of Aspartyl/asparaginyl beta-hydroxylase  14.01 2 
P18572-2 Isoform 2 of Basigin  8.42 2 
Q9DB73-2 Isoform 2 of NADH-cytochrome b5 reductase 1  8.33 2 
Q9Z2I9 Succinate--CoA ligase [ADP-forming] subunit beta, 
mitochondrial  
4.1 2 
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Table 3.10: Mass spectrometric identification of proteins with a reduced gel 
electrophoretic mobility detected in gel zone C following chemical cross-linking of 
the microsomal fraction from mdx-4cv mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
Unique 
peptides 
O08917 Flotillin-1  39.95 14 
Q60634-3 Isoform 3 of Flotillin-2  43.27 12 
Q9D2G2 Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial  
26.21 12 
Q8R3Z5-4 Isoform 4 of Voltage-dependent L-type calcium channel 
subunit beta-1  
27.86 10 
P54071 Isocitrate dehydrogenase [NADP], mitochondrial  20.35 8 
Q8C7X2-2 Isoform 2 of ER membrane protein complex subunit 1  8.55 8 
Q02053 Ubiquitin-like modifier-activating enzyme 1  9.26 7 
Q9DB73 NADH-cytochrome b5 reductase 1  19.02 6 
P97807-2 Isoform Cytoplasmic of Fumarate hydratase, 
mitochondrial  
16.27 6 
P48678-2 Isoform C of Prelamin-A/C  10.8 5 
P58281 Dynamin-like 120 kDa protein, mitochondrial  6.46 5 
Q64727 Vinculin  6.1 5 
P68369 Tubulin alpha-1A chain  30.6 4 
Q9Z0X1 Apoptosis-inducing factor 1, mitochondrial  10.13 4 
Q3U7R1-2 Isoform 2 of Extended synaptotagmin-1  5.49 4 
P68372 Tubulin beta-4B chain  31.46 3 
Q9DCX2 ATP synthase subunit d, mitochondrial  19.88 3 
P82347 Delta-sarcoglycan  14.88 3 
Q9DCT2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, 
mitochondrial  
14.83 3 
P35564 Calnexin  8.12 3 
Q6DYE8 Ectonucleotide pyrophosphatase/phosphodiesterase family 
member 3  
6.52 3 
Q921I1 Serotransferrin  6.17 3 
Q9D1G1 Ras-related protein Rab-1B  29.86 2 
Q91WS0 CDGSH iron-sulfur domain-containing protein 1  22.22 2 
P10126 Elongation factor 1-alpha 1  20.35 2 
Q7TMF3 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 12  
20 2 
Q9D3D9 ATP synthase subunit delta, mitochondrial  13.69 2 
P53994 Ras-related protein Rab-2A  11.79 2 
P01868 Ig gamma-1 chain C region secreted form  6.79 2 
P28650 Adenylosuccinate synthetase isozyme 1  5.69 2 
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Table 3.11: Mass spectrometric identification of proteins with a reduced gel 
electrophoretic mobility in gel zone C following chemical cross-linking of the 
microsomal fraction from both wild-type and mdx-4cv mouse skeletal muscle 
 
Accession  Protein Name % 
Coverage 
wt  
Unique 
peptides 
wt 
% 
Coverage 
mdx-4cv 
Unique 
peptides 
mdx-4cv 
O35129 Prohibitin-2  35.12 9 35.12 9 
Q91ZJ5-2 Isoform 2 of UTP--glucose-
1-phosphate 
uridylyltransferase  
14.69 7 14.69 6 
P51150 Ras-related protein Rab-7a  28.5 5 23.19 4 
Q9CY27 Very-long-chain enoyl-CoA 
reductase  
16.23 5 17.21 8 
P17182 Alpha-enolase  23.04 4 49.31 14 
P51174 Long-chain specific acyl-
CoA dehydrogenase, 
mitochondrial  
10.93 4 14.88 6 
O54734 Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
48 kDa subunit  
7.03 3 7.03 3 
Q9DCN2-2 Isoform 2 of NADH-
cytochrome b5 reductase 3  
10.43 2 13.67 5 
Q6Q477-2 Isoform 2 of Plasma 
membrane calcium-
transporting ATPase 4  
9.03 2 8.31 2 
Q9CRB9 MIC complex subunit Mic19  11.45 2 16.74 3 
P99024 Tubulin beta-5 chain  18.02 2 33.56 3 
P20152 Vimentin  9.87 2 32.83 10 
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Figure 3.14: Bioinformatics analysis of proteomic changes detected in gel zone C 
in the microsomal fraction from dystrophic muscle 
Shown are the findings from the bioinformatics analysis of protein interactions using 
STRING software program. 
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3.3 Discussion      
Dystrophin is a sarcolemmal associated protein which together with a variety of other 
regulatory proteins forms the DGC, which acts as a stabilising bridge between 
intracellular actin and the extracellular matrix (Perronnet and Vaillend, 2010). DMD 
is characterised by mutations in the 79-exon spanning Dmd gene which encodes for 
dystrophin (Flanigan et al., 2009). Mutations in this gene result in negligible levels of 
dystrophin, causing destabilisation of the sarcolemma of muscle fibres, which leads to 
increased susceptibility to mechanical stress. Although this loss of dystrophin is the 
underlying pathobiochemical defect, it also triggers a number of secondary 
abnormalities; one of the most significant being that of myofibrosis (Zhou and Lu, 
2010). A longitudinal study of 25 Duchenne patients examined over a 10-year period 
revealed that among all the pathological features of DMD; myofibre atrophy, necrosis 
and fatty deposition, only endomysial fibrosis correlated significantly with poor motor 
performance (Desguerre et al., 2009). Thus, alterations in the extracellular matrix 
surrounding degenerating fibres is a clinical characteristic of X-linked muscular 
dystrophy. The proteomic analysis conducted here shows a high degree of fibrosis in 
the hind leg of the mdx-4cv model, thus linking the mass spectrometric identification 
of decreased dystrophin expression with the infiltration of connective tissue.  
The majority of previous comparative proteomic studies have failed to detect 
reduced expression of dystrophin in whole skeletal muscle extracts. This has been 
attributed to the technical difficulties associated with identifying dystrophin by 
proteomic means, such as its low abundance, large molecular size, close association 
with the sarcolemmal membrane and its existence within a heterogeneous protein 
complex (Brown et al., 2012). In contrast, using a careful extraction protocol and 
highly sensitive label-free LC-MS/MS, identification of the Dp427 isoform of 
dystrophin as the most reduced protein in mdx-4cv hind-limb has been achieved here. 
In addition, another member of the DGC, the adaptor protein α1-syntrophin, was also 
identified as having reduced expression in dystrophic skeletal muscle. Hence the 
reduced density of key components of the DGC can now be unequivocally linked to 
the secondary abnormalities in ion homeostasis, cytoskeletal restructuring, calcium 
homeostasis and myofibrosis. 
A number of other proteins of interest also displayed reduced abundance in 
dystrophic tissue. In particular, reduced levels of parvalbumin correlates the 
mechanical instability caused by dystrophin absence with the calcium hypothesis of 
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DMD pathogenesis, given that reduced expression of parvalbumin indicates impaired 
cytosolic buffering. Thus, calcium is a double-edged sword in the disease in that 
micro-rupturing of the weakened sarcolemma enables the influx of Ca2+ into the 
cytosol where they reach excessive levels given the impaired calcium buffering 
capacity of dystrophic fibres. Reduced densities of myoglobin, carbonic anhydrase 
CA3, glutathione S-transferase and fatty acid binding protein FABP-3 are also 
observed. Such alterations in the muscle proteome suggest altered CO₂-removal and 
leakage from damaged and/or necrotic muscle fibres, modified biotransformation 
capacity, and reductions in oxygen transportation and fatty acid metabolism 
respectively.  
While the mass spectrometry data correlates well with the two principal 
hypotheses of DMD pathobiochemistry (structural and calcium hypotheses), it also 
highlights the important role of myofibrosis in X-linked muscular dystrophy, evident 
by the large number of fibrotic proteins displaying increased abundance in dystrophic 
skeletal muscle. Crucial extracellular matrix proteins with an increased concentration 
were identified as collagen α1(VI) chain, collagen α2(VI) chain, collagen α1(I) chain, 
fibronectin, biglycan, asporin, decorin, prolargin, mimecan and lumican. This 
dramatic increase in components of the extracellular matrix indicates infiltration of 
connective tissue and the replacement of skeletal muscle with non-functional fibrotic 
tissue (Wynn, 2008). Thus, the simultaneous identification of reduced levels of 
dystrophin and elevated levels of fibrotic proteins within the same sample and same 
analytical run positions dystrophin in its proper pathophysiological context. Elevated 
abundance of the extracellular matrix protein biglycan agrees with the idea of reactive 
myofibrosis in response to dystrophin deficiency. However, biglycan has also been 
shown to influence the expression and sarcolemmal localisation of several dystrophin-
associated glycoproteins including nNOS, syntrophin and dystrobrevin, with 
biglycan-null mice displaying a mildly dystrophic phenotype (Nastase et al., 2012). 
Thus, elevated abundance of this proteoglycan may represent a compensatory 
mechanism to help counteract alterations in the DGC in dystrophic skeletal muscle. 
Indeed intraperitoneal injection of recombinant human biglycan into mdx mice 
increased the levels of utrophin, γ-sarcoglycan, nNOS and β2-syntrophin at the 
sarcolemma and improved muscle function, determined by a reduction in force drop 
after successive eccentric contractions (Amenta et al., 2011).   
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The dystrophinopathy-induced elevation of collagen type VI is important 
given that this protein is a major filament-forming collagen of the interstitial matrix 
that closely interacts with a number of other fibrotic proteins; including other 
collagens, fibronectin, biglycan, decorin and integrins (Lieber and Ward, 2013). 
Elevated levels of fibrinogen as identified by this study have also been identified in 
dystrophic skeletal muscle from animal models and clinical samples, where it has been 
shown to precede the deposition of collagen (Vidal et al., 2008). Thus, fibrinogen is 
suggested to represent a key driver of fibrosis in dystrophic muscle, a hypothesis 
largely supported by the observation that fibrinogen deficient mdx mice display 
significantly reduced levels of collagen (Vidal et al., 2008). While fibrosis in animal 
models has been largely reported in the severely dystrophic diaphragm (Holland et al., 
2015a, Ishizaki et al., 2008), this study highlights the existence of elevated levels of 
fibrosis-associated proteins in the more moderately affected limb muscles. This 
supports the concept that continuous regeneration/degeneration cycles in skeletal 
muscle results in chronic inflammation and infiltration of adipose and connective 
tissue (Mann et al., 2011). Figure 3.9 illustrates not only elevated expression of 
collagen VI but also a high degree of central nucleation; a hallmark of regenerated 
muscle fibres. At present, only palliative treatments are available for DMD patients 
and thus much research has focused on developing a primary treatment of DMD using 
strategies such as exon-skipping, stem cell transplantation and mini-dystrophin gene 
therapy. However, treatments aimed at diminishing the development of fibrosis may 
help prevent disease progression, while also increasing the success of cell- and gene-
based therapies by augmenting the amount of muscle available for therapy and repair 
(Kharraz et al., 2014, Pessina et al., 2014).  
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Figure 3.15: Schematic illustrating the fibrotic process in Duchenne muscular 
dystrophy 
Dystrophin deficiency disrupts the DGC of the cell membrane. Disruption of this 
stabilising protein network leads to increased susceptibility of the sarcolemma to 
contractile and mechanical strain and excessive Ca2+ influx. Elevated cytosolic Ca2+ 
levels activate proteases, such as the calpains, causing myofibre degeneration. This 
triggers an inflammatory response characterised by the secretion of pro-fibrotic 
cytokines. Subsequent excessive synthesis of extracellular matrix (ECM) proteins 
leads to tissue fibrosis which contributes directly to progressive muscle dysfunction.  
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The most highly increased protein was identified as myosin-10 (non-muscle 
myosin type IIB), an unconventional non-muscle type of myosin with specialised roles 
in cytokinesis (where it localises to both meiotic and mitotic spindles) (Woolner et al., 
2008), regulation of the actin cytoskeleton, cell adhesion and cell migration (Vicente-
Manzanares et al., 2009). Elevated levels of myosin-9 (non-muscle myosin type IIA) 
were also identified in this proteomic survey. Since myosin-9 exerts similar cellular 
functions to that of myosin-10 (Beach et al., 2014), their coordinated augmentation 
suggests enhanced cellular proliferation rates in dystrophic muscle (Hawke and Garry, 
2001). This excessive proliferation leads to premature senescence of satellite cells, 
which in turn reduces the regenerative capacity of dystrophic skeletal muscle (Decary 
et al., 2000). In addition to roles in cellular functions, myosin-10 has also been 
identified as being a key regulator of collagen I synthesis. Collagen I is synthesised as 
a heterotrimer of two α1(I) chains and one α2(I) polypeptide, for which intact non-
muscle myosin filaments are required (Cai et al., 2010). Thus, enhanced levels of 
myosin-9 and myosin-10 in dystrophic skeletal muscle indicates increased synthesis 
of components of the matrisome. This result correlates well with the observed increase 
in a number of proteins associated with the matrisome and extracellular matrix, seen 
in this study and other comparative surveys of dystrophic animal models (Holland et 
al., 2015a). 
One of the major compensatory mechanisms employed by dystrophin-deficient 
muscle is an increase in cytoskeletal proteins to maintain sarcolemmal integrity during 
contractile and mechanical strain (Law et al., 1994). This hypothesis is supported by 
the observed increase in various tubulin isoforms (β6, β5, α-1A, β4A, β2A, α-1B, α-
4A, and α8 chains), desmin, vinculin, talin and vimentin. Annexins also play a major 
role in the continued maintenance of the cytoskeletal network and in providing 
structural integrity to the extracellular matrix. In this capacity elevated levels of the 
A1, A2, A5, A6, A7 and A11 isoforms of annexin may serve to further stabilise the 
cytoskeletal system in the absence of the Dp427 isoform of dystrophin. In particular, 
elevated levels of annexins A1, A2 and A5 suggest the initiation of sarcolemmal repair 
mechanisms to counteract micro-rupturing of the deteriorated muscle surface 
membrane system (McNeil et al., 2006, Bouter et al., 2011). This is further verified 
by the enhanced expression of dysferlin, a known binding partner of annexins A1 and 
A2 involved in the membrane repair process (Lennon et al., 2003). Another highly 
elevated protein in dystrophic hind-limb is the major anti-protease α1-antitrypsin. 
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While it represents one of the most abundant serine proteases in the circulation it also 
has immuno-modulatory activities, in particular the suppression of inflammation 
(Jonigk et al., 2013). Thus, its increase in dystrophic tissue may be a protective 
reaction to limit inflammatory damage to dystrophin-deficient muscle fibres (Porter et 
al., 2002).  
In modern proteomics 2D-GE coupled to mass spectrometric identification of 
proteins of interest offers a highly robust and accurate system for identification of 
proteomic alterations between normal and pathological conditions. However, this 
system does have significant limitations such as poor separation of hydrophobic and 
highly acidic or alkaline proteins (Bunai and Yamane, 2005). In addition, it is highly 
sensitive to the dynamic range of the sample and thus many low abundance proteins 
are poorly represented on 2D gels (Rabilloud et al., 2010). LC-MS/MS aims to 
overcome these short-comings and has been successfully used to identify vast numbers 
of proteins irrespective of their molecular weight, abundance, hydrophobicity and pI 
(Washburn et al., 2001). This has been exemplified by this proteomic survey in which 
a number of proteins of high molecular weight and hydrophobic proteins were 
identified using an LC-MS/MS based experimental procedure. The identification of 
extremely large proteins included obscurin, a giant myofibrillar protein of 
approximately 720 kDa (Young et al., 2001), the molecular mass of which would be 
challenging for gel electrophoresis-based proteomic analysis. Other proteins of 
interest which were resolved by LC-MS/MS analysis include the sarcolemmal Na+/K+-
ATPase, the sarcoplasmic reticulum Ca2+-ATPase, the sarcoplasmic/endoplasmic 
reticulum RyR and the transverse tubule associated DHPR. Such membrane associated 
receptors are highly hydrophobic and thus would be poorly represented in 2D gel 
based proteomic investigations. Thus, a combination of separation techniques prior to 
mass spectrometric identification may provide the optimal opportunity of identifying 
the maximum number of proteins in complex samples. The DHPR is the voltage sensor 
for excitation-contraction coupling. In response to sarcolemmal depolarisation the 
DHPR sends a signal to the RyR resulting in Ca2+-release from the sarcoplasmic 
reticulum to trigger muscle contraction (Dulhunty et al., 2002). This interaction is 
responsible for all voluntary movement and cardiac contraction and respiration. The 
fast SERCA1 type Ca2+-ATPase meanwhile induces muscle relaxation through the re-
uptake of Ca2+ ions into the sarcoplasmic reticulum, while the Na+/K+-ATPase is 
responsible for maintaining the resting potential over the sarcolemma. The increased 
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abundance of these four ion-regulating proteins suggests disturbances in the regulatory 
pathways of mdx-4cv hind limb muscles. It would appear that dystrophic, degenerating 
muscle fibres elevate the levels of essential voltage sensors, ion release channels and 
ion pumps to maintain optimum excitation-contraction-relaxation cycles and stabilise 
the resting membrane potential over the dystrophin-deficient sarcolemma (Dunn et al., 
1995).  
In addition to alterations in protein abundance, muscular dystrophy induced 
changes may also encompass alterations in protein oligomerisation and interaction 
patterns. In order to investigate this possibility, chemical cross-linking of microsomal 
fractions from crude skeletal muscle, followed by gel electrophoretic shift analysis 
and mass spectrometry was employed. Proteomic analyses were particularly focused 
on high molecular mass ranges of approximately 100 kDa or more, which represent 
various supramolecular assemblies of the muscle membrane system and its associated 
intra- and extra- cellular structures. Comparison of proteins exclusively detected in 
wild-type cross-linked microsomes with proteins exclusively detected in mdx-4cv 
cross-linked microsomes was used to determine muscular dystrophy associated 
changes in protein interaction. In gel zone A increased tendency for oligomerisation 
was found for myosin-9, myosin-3, vimentin, tubulin-beta-5 chain, actin and caveolin-
1, indicating potential cytoskeletal re-structuring in response to dystrophin deficiency. 
The presence of embryonic myosin-3 in this protein cluster is indicative of the 
regenerative process seen in dystrophic skeletal muscle (Fitzsimons and Hoh, 1981). 
Although high levels of vimentin are usually only seen during the maturation of 
myotubes, this intermediate filament protein has recently been proposed as a universal 
marker of DMD as it shows elevated abundance in a range of tissue types from the 
severely affected diaphragm, to the moderately affected extensor digitorum longus 
muscle and the mildly affected interosseus muscle in the mdx mouse (Holland et al., 
2015b), and in crude extracts from mdx-4cv brain tissue (Murphy et al., 2015c). 
Vimentin has the capacity to act synergistically to the intermediate filament desmin, 
and the increased abundance of vimentin (2.42-fold increase) and desmin (2.09-fold 
increase) detected in the mass spectrometric analysis of crude skeletal muscle in this 
study (Table 3.1), coupled with the reduced gel electrophoretic mobility of vimentin 
in dystrophic cross-linked microsomes and its potential oligomerisation with myosin, 
actin and tubulin, suggests a vimentin-associated support of the structural backbone 
of intermediate filaments. This may help to partially restore the load-bearing function 
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of contractile fibres in the absence of the DGC. Myoferlin is a calcium/phospholipid 
binding protein which is expressed during muscle development during which it 
facilitates myoblast fusion. However, it also plays a role in the plasmalemma repair 
process which enables re-sealing of membranes disturbed by mechanical stress, and 
levels of both myoferlin mRNA and protein have been shown to be increased in 
muscular dystrophy (Demonbreun et al., 2010, Murphy et al., 2015a).  Therefore, the 
changes in myoferlin oligomerisation evident in this XL study are likely related to the 
initiation of cellular repair mechanisms, a process probably supported by the 
augmented interactions of myoferlin with various isoforms of myosin and actin. 
Caveolin-1 is a member of the caveolin family of crucial structural proteins of 
caveolar membranes, which are vesicular invaginations of the plasma membrane 
involved in vesicular trafficking and signal transduction. A study by Hernández-
Deviez and co-workers examined the trafficking of dysferlin in wild-type and 
caveolin1-/- mouse embryonic fibroblasts. This study determined that while dysferlin 
is not absolutely dependent on caveolin to reach the plasma membrane, it is more 
efficiently retained at the plasma membrane in the presence of caveolin, as in caveolin-
1 deficient cells dysferlin is internalised by endocytosis (Hernández-Deviez et al., 
2008). Thus, increased oligomerisation of caveolin-1 may represent a protective 
mechanism in muscular dystrophy to facilitate membrane repair processes at the 
muscle sarcolemma. This is supported by the concomitant oligomerisation of 
myoferlin, another member of the ferlin family of membrane repair proteins. Increased 
numbers of caveolae have been detected in muscle biopsies from DMD patients 
(Repetto et al., 1999) which agrees with the increased abundance of caveolin-3 
(Repetto et al., 1999) and caveolin-1 (Murphy et al., 2015a) detected in dystrophic 
skeletal muscle, and with the enhanced oligomerisation of caveolin-1 identified here 
in cross-linked dystrophin-deficient microsomes.  
Another interesting protein cluster in the uppermost region of the 1D SDS-
PAGE gel is that of the mitochondrial proteins. The 2-oxoglutarate dehydrogenase 
complex, represented in this study by isoform 2 of 2-oxoglutarate dehydrogenase and 
the dihydrolipoyllysine-residue succinyltransferase component, is a multi-enzyme 
assembly in the mitochondrial matrix which catalyses the overall conversion of 2-
oxoglutarate to succinyl-CoA and CO2. The complex is one of three intra-
mitochondrial dehydrogenases which is activated by Ca2+ ions in vertebrate 
mitochondria, along with pyruvate dehydrogenase and NAD-isocitrate dehydrogenase 
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(Armstrong et al., 2014). A 3.25-fold increase in the abundance of trifunctional 
enzyme subunit alpha was detected by proteomic analysis of crude skeletal muscle 
homogenates (Table A3.1), and both alpha and beta subunits of trifunctional enzyme 
have been shown to display enhanced oligomerisation in dystrophic microsomes. The 
mitochondrial trifunctional enzyme is a heterotrimeric protein which catalyses three 
of the four enzymatic reactions involved in the mitochondrial β-oxidation of long-
chain fatty acids (Rector et al., 2008). Fatty acid oxidation represents a major source 
of energy for skeletal muscle and the heart, and altered functionality has severe 
pathological consequences relating to non-ketotic hypoglycemia, liver abnormalities, 
and/or skeletal and cardiac myopathy (Rector et al., 2008). Thus, the increased 
complex formation of the mitochondrial trifunctional enzyme and the oxoglutarate 
dehydrogenase complex may signify an adaptive process by dystrophic muscle to 
counter-act impaired lipid metabolism and insufficient ATP production that has 
previously been observed in muscular dystrophy (Rybalka et al., 2014). Insufficient 
generation of ATP is related to both an increased demand for calcium buffering and 
regeneration, coupled with functional abnormalities in the mitochondria and in 
particular a reduced capacity for oxidative phosphorylation.  
A large number of proteins with reduced electrophoretic mobility in cross-
linked dystrophic microsomes were detected in gel zone B. Similar to gel zone A, a 
variety of these proteins have roles in metabolism, which again may embody a 
response of dystrophic muscle fibres to elevated functional demands. In particular, 
increased oligomerisation of long-chain-fatty-acid-CoA ligase 6, electron transfer 
flavoprotein subunit beta and long-chain specific acyl-CoA dehydrogenase may be 
indicative of enhanced fatty acid oxidation to meet energy demands. This may be an 
attempt to limit the detrimental impact of the dysregulation of energy metabolism, 
which includes i) reduced functionality of the contractile apparatus leading to deficits 
in muscle strength, ii) decreased rate of protein synthesis, satellite cell activity, and 
ultimately muscle regeneration, and iii) impaired Ca2+ buffering, thus further 
exacerbating Ca2+ induced activation of proteases, protein degradation, and muscle 
degeneration (Timpani et al., 2015). The increased oligomerisation of succinate--CoA 
ligase [ADP-forming] subunit beta involved in the citric acid cycle and CDGSH iron-
sulfur domain-containing protein 1 involved in the regulation of electron transport and 
oxidative phosphorylation also indicate compensatory mechanisms to possibly 
improve oxidative phosphorylation and the generation of ATP. Also of interest is a 
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clustering of sub-units of the 26S proteasome. The 26S proteasome is the core 
proteolytic powerhouse of the ubiquitin-proteasome-pathway, responsible for the 
removal of redundant and misfolded proteins (Gallastegui and Groll, 2010). The loss 
of the anchoring protein dystrophin in DMD, leads to the disarray of its associated 
glycoprotein complex, leaving those proteins susceptible to intracellular proteolysis, 
which is suggested to exacerbate the degenerative process. Indeed, proteasome 
inhibition using pharmaceutical agents restores α-sarcoglycan, β-dystroglycan, and α-
1-syntrophin abundance and expression at the muscle sarcolemma. Dystrophin of 120 
kDa, the predicted size of dystrophin based on the mdx mutation (premature stop 
codon in exon 23), was also detected by immunoblotting following proteasome 
inhibition (Gazzerro et al., 2010). This was accompanied by increased muscle 
regeneration, reduced inflammation and improved membrane integrity. Therefore, the 
clustering of components of the 26S proteasome as detected here by chemical cross-
linking analysis may reflect one of the major molecular pathways which contributes 
to the disease pathophysiology.  
Conversely, enhanced oligomerisation of the molecular chaperone calnexin, 
which has previously been shown to be increased in abundance in mdx-4cv crude 
microsomes (Murphy et al., 2015a), and its potential interactions with other proteins 
involved in protein re-folding such as UDP-glucose glycoprotein glucosyltransferase 
1 and hypoxia up-regulated protein 1, may indicate an increase in molecular 
chaperoning activity to limit proteotoxic effects in the dystrophin deficient muscle. 
The augmented tendency for protein oligomerisation seen for the ribosomal proteins 
40S ribosomal protein S3 and 40S ribosomal protein S4, along with elongation factor 
2 may be indicative of an increase in protein synthesis associated with major cellular 
remodelling and regeneration in dystrophin-deficient tissues (Murphy et al., 2018a). 
Vimentin is once again detected as a protein with an enhanced capacity for protein 
oligomerisation in mdx-4cv microsomes, since it is only detected in gel zone E in wild-
type control microsomes and mdx-4cv control microsomes, its expected location on an 
SDS-PAGE gel given a molecular mass of 54 kDa. The STRING analysis shown in 
Figure 3.13 illustrates a potential interaction of vimentin with alpha-actinin-2 and the 
integrins integrin beta-2, isoform alpha-7X2A of integrin alpha-7 and isoform 2 of 
integrin alpha-M. The integrins comprise a major family of cell surface adhesion 
receptors involved in both cell-cell and cell-matrix interactions (Hynes, 1992). Of 
special interest is integrin alpha-7 which is the main laminin receptor on skeletal 
126 
 
myoblasts and adult myofibers, where it plays a vital role in the maintenance of 
myofiber cyto-architecture, anchorage, and functional integrity. Since integrin alpha-
7 is involved in linking the extracellular matrix to the intracellular cytoskeleton, and 
its over-expression in transgenic dystrophin/utrophin knockout mouse extends 
survival, reduces spinal curvature, protects against contraction-induced damage and 
results in functional improvements in specific force generation (Heller et al., 2015), it 
is likely that the clustering of various integrin isoforms in dystrophic microsomes may 
reflect a compensatory mechanism to limit dystrophy-induced muscle damage.  
The most striking observation regarding the proteins with an augmented 
tendency for interactions in dystrophic microsomes in gel zone C is the enrichment of 
proteins associated with the citric acid cycle (dihydrolipoyllysine-residue 
succinyltransferase component of 2-oxoglutarate dehydrogenase complex, isocitrate 
dehydrogenase and fumarate hydratase) and those associated with oxidative 
phosphorylation (ATP synthase subunit delta, NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 12 and NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 3). Chemical cross-linking followed by gel shift analysis and mass 
spectrometry has thus clearly established increased protein interaction patterns for a 
number of metabolic proteins involved in fatty acid oxidation, the citric acid cycle and 
oxidative phosphorylation in dystrophic skeletal muscle. This likely represents 
metabolic changes and bioenergetic adaptations in the face of dystrophin deficiency 
and ATP insufficiency. Another significant finding is the amplified oligomerisation of 
the scaffolding proteins flotillin-1 and flotillin-2 involved in the formation of caveolae 
(Bickel et al., 1997), which agrees with the detection of caveolin-1 in gel zone A and 
caveolae-associated protein 1 in gel zone B. Their augmented interactions in 
dystrophic microsomes agrees with previous observations of increased numbers of 
caveolae in muscular dystrophy (Repetto et al., 1999). Increased abundance of 
flotillin-1 and flotillin-2 has also been previously detected in crude microsomes 
(Murphy et al., 2015a) and sarcolemma-enriched fractions (Murphy et al., 2018a) from 
the mdx-4cv mouse model of dystrophinopathy. In analogy to the detection of tubulin 
beta-5 chain in gel zone A, and tubulin alpha-1A chain and tubulin alpha-4A chain in 
gel zone B, tubulin alpha-1A chain and tubulin beta-4B chain were detected in cross-
linked dystrophic microsomes in gel zone C. This may indicate elevated interactions 
of tubulin proteins, which in combination with increased oligomerisation of the 
intermediate filament protein vimentin (gel zones A and B) and the cytoskeletal 
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protein vinculin (gel zone C), implies a compensatory stabilisation of the intracellular 
matrix in dystrophic skeletal muscle (Murphy and Ohlendieck, 2016). 
 
3.3.1 Conclusions 
DMD is a highly progressive muscle wasting disease, characterised by loss of 
ambulation in the early teenage years, respiratory and cardiac failure and premature 
death, usually in the second decade of life. While the primary genetic deficiency has 
long been established as mutations in the gene encoding the membrane cytoskeletal 
protein dystrophin, other secondary abnormalities contribute to the pathophysiological 
phenotype. Previous comparative proteomic studies using whole tissue have identified 
numerous alterations in protein expression but have largely failed to identify the 
primary deficiency in dystrophin and its associated glycoproteins. Organelle 
proteomics has been successfully used by our group to identify reduced levels of some 
of the key components of the DGC, and in this study reductions in dystrophin 
expression were identified by mass spectrometry-based proteomics in whole tissue 
extracts. Indeed, the full-length Dp427 isoform of dystrophin was found to be the most 
significantly reduced protein species in the mdx-4cv model of dystrophinopathy. Thus, 
this study enables the reduction in dystrophin to be directly related to secondary 
changes in dystrophic hind leg. Such secondary abnormalities were identified as being 
associated with Ca2+ buffering, the contractile apparatus, ion homeostasis, enzymatic 
activity, cell signalling and metabolism. Potential compensatory mechanisms to 
maintain cytoskeletal stability were reflected by the increased abundance of several 
cytoskeletal and stabilising proteins, including desmin, talin, tubulin, vimentin and 
vinculin. Importantly, some of the major protein increases were found for components 
of the ECM and the matrisome, suggesting a high degree of fibrosis in the mdx-4cv 
model. Such markers of myofibrosis include a variety of collagen isoforms, decorin, 
asporin, prolargin, biglycan, mimecan, lumican, fibrinogen and fibronectin. This is an 
important proteomic finding given that fibrotic changes in dystrophic muscle are 
directly correlated to motor performance in Duchenne patients. Thus, a subset of these 
fibrotic proteins may be suitable as potential biomarkers for monitoring disease 
progression. Targeting the fibrotic phenotype in muscular dystrophy may also prove 
crucial for enhancing the therapeutic value of cell- and gene-based treatments by 
increasing the amount of viable muscle for treatment. In addition to changes in protein 
abundances, alterations in protein interaction patterns have been established in the 
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mdx-4cv mouse model using a combination of chemical cross-linking, electrophoretic 
gel-shift analysis and mass spectrometry. A variety of muscle-associated protein 
species were shown to exhibit an elevated level of oligomerisation. This included 
proteins involved in oxidative metabolism, membrane repair, fibre regeneration, 
cytoskeletal stabilisation, molecular chaperoning and the ubiquitin-proteasome 
pathway. Many of these alterations in protein interaction patterns are probably in 
response to the loss of sarcolemmal integrity and represent compensatory mechanisms 
to rescue the dystrophic phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Four 
 
In-depth proteomic analysis of the dystrophin-associated 
glycoprotein complex and the sarcolemma-enriched fraction 
from normal and dystrophic muscle 
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4.1 Introduction 
The 2.4 Mb Dmd gene, the largest in the human genome, encodes the membrane 
cytoskeletal protein dystrophin. The presence of 7 promoter regions in this gene results 
in the production of a variety of distinct dystrophin isoforms ranging in molecular 
mass from 71 kDa to 427 kDa. Initial characterisation of the full length isoform of 427 
kDa showed that it could be enriched by wheat germ agglutination from muscle 
membranes (Campbell and Kahl, 1989), despite the absence of hydrophobic regions 
in its primary sequence. This led to experiments demonstrating that dystrophin is 
anchored in the sarcolemma through tight interactions with glycoproteins (Campbell 
and Kahl, 1989). This dystrophin-glycoprotein complex is now known to form a 
supramolecular complex consisting of dystrophin, the dystroglycan complex, the 
sarcoglycan-sarcospan complex, α-dystrobrevin and the syntrophins (Lapidos et al., 
2004). The complex serves to link intracellular actin to components of the extracellular 
matrix, maintain membrane integrity during muscle excitation-contraction-relaxation, 
and act as a scaffold for a variety of signalling proteins (Constantin, 2014, Le Rumeur 
et al., 2010). In DMD, primary abnormalities in the Dmd gene result in the almost 
complete absence of the full-length dystrophin isoform and cause concomitant 
decreases in the dystroglycans, sarcoglycans, sarcospan, dystrobrevin and syntrophins 
(Ohlendieck and Campbell, 1991a).  
Comparative proteomics has been used extensively in recent years to study the 
secondary abnormalities downstream of dystrophin deficiency in skeletal muscle and 
cardiac tissue in both animal models and clinical samples (Bernasconi et al., 1995, 
Holland et al., 2013, Fröhlich et al., 2016). Such studies have enabled the identification 
of a range of secondary defects relating to reactive myofibrosis (Fröhlich et al., 2016), 
muscle regeneration and remodelling (Guevel et al., 2011), sterile inflammation and 
infiltration of immune cells (Murphy et al., 2017b), energy metabolism, ion 
homeostasis and cellular stress (Lewis et al., 2009). However, fewer studies have used 
proteomics to study the core DGC itself nor the muscle sarcolemma. A number of 
technical issues have delayed such analyses of integral membrane proteins; i) the 
inherently insoluble nature of integral membrane proteins makes them difficult to 
manipulate and leads to poor resolution on 2D SDS-PAGE gels, ii) peptide sequences 
derived from mass spectrometric analyses usually exclude hydrophobic amino acids 
which make up the transmembrane domains of integral membrane proteins, and iii) 
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low abundance of membrane proteins means they may be masked by higher abundance 
contractile and metabolic proteins in mass spectrometric analyses (Turk et al., 2016). 
Despite these technical difficulties the proteomic survey of the sarcolemmal proteins 
is imperative given that the primary pathobiochemical insult in dystrophinopathy is 
located in the sub-sarcolemmal cytoskeleton. Recently, immuno-precipitation (Yoon 
et al., 2012) and extensive gradient centrifugation (Turk et al., 2016) have been 
employed to characterise the dystrophin complex by mass spectrometry. Building 
upon these previous studies, differential centrifugation, digitonin detergent 
solubilisation, ion exchange chromatography, lectin affinity chromatography and 
density gradient centrifugation has been employed to generate a dystrophin complex 
enriched fraction from wild-type rabbit skeletal muscle (Ohlendieck et al., 1991). This 
fraction was subsequently subjected to gradient one-dimensional gel electrophoresis, 
on-membrane digestion and LC-MS/MS to characterise its protein components, as 
illustrated in Figure 4.1. Sensitive mass spectrometric analysis of the dystrophin 
complex enriched fraction revealed a number of potential novel interaction partners of 
the complex or that at least exist in close proximity to it. The identification of the 
cytolinkers desmoglein-1 and desmoplakin is of considerable interest, given their 
association with desmosomes and cellular adhesion in the skin and the heart (Hammers 
and Stanley, 2013, Boyer et al., 2010). Comparative analysis of desmoglein-1 
abundance in normal and dystrophic mouse skeletal muscle uncovered significantly 
reduced levels of this cellular adhesion protein in the mdx mouse. This decrease is 
reminiscent of the fate of the other dystrophin-associated glycoproteins in dystrophin-
deficient muscle (Ervasti et al., 1990).  
 Also of great interest is the comparative analysis of the muscle sarcolemma 
itself, including both the DGC and other sarcolemmal proteins. In addition to the 
conventional roles of a cell membrane, the sarcolemma of skeletal muscle is also 
involved in synaptic transmission, excitation-contraction-coupling, the propagation of 
action potentials towards the transverse tubular system, signalling cascades and 
structural support (Campbell and Stull, 2003). The importance of the sarcolemma and 
its two associated protein complexes, the integrin complex and the DGC, is evident by 
the occurrence of muscular dystrophies arising from defects in sarcolemmal and sub-
sarcolemmal proteins. These include Duchenne and Becker muscular dystrophies, 
sarcoglycanopathies, dystroglycanopathies and dysferlinopathy, which are due to 
abnormalities in dystrophin, the sarcoglycans, dystroglycan and dysferlin respectively 
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(Nigro and Piluso, 2015). Although DMD is classified as a multi-system disorder due 
to secondary abnormalities including scoliosis and impairment of the cardio-
respiratory system, it originates at the muscle sarcolemma whereby the almost 
complete loss of the membrane cytoskeletal protein dystrophin and the concomitant 
reduction in the DGC results in the micro-rupturing of the sarcolemma and subsequent 
abnormal and uncontrolled influx of Ca2+. 
 In a similar manner to the lectin agglutination procedure used to generate the 
dystrophin complex enriched fraction, an enriched sarcolemmal fraction from 
combined hind limb muscles of wild-type and mdx-4cv mice was isolated, as 
illustrated in Figure 4.1. Mass spectrometric analysis of this sarcolemmal enriched 
fraction identified the core dystrophin-associated glycoproteins, along with a range of 
integral membrane proteins indicating successful sarcolemmal enrichment by the 
lectin agglutination procedure. Comparative proteomic profiling revealed altered 
abundance for a variety of proteins of the basement membrane-sarcolemma-
cytoskeleton axis in dystrophic muscle. This includes sarcolemmal proteins, protein 
components of the extracellular matrix, cytoskeletal proteins, protein markers of 
invading immune cells and proteins associated with the motor neuron and glia cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Flowchart illustrating the bio-analytical procedure for the proteomic 
characterisation of dystrophin and its associated glycoprotein complex and for 
the sarcolemma enriched fraction 
Following enrichment, the dystrophin complex underwent gradient gel 
electrophoresis, transfer to a nitrocellulose membrane, on-membrane digestion and 
LC-MS/MS. Following wheat germ agglutination, enriched sarcolemma fractions 
were subjected to in-solution trypsin digestion and the resulting peptides were 
analysed by LC-MS/MS. 
 
*Image adapted from Murphy and Ohlendieck, 2017a 
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4.1.1 Experimental Design 
The full-length Dp427 isoform of dystrophin forms a large protein complex with 
dystrophin-associated glycoproteins at the muscle sarcolemma. Loss of dystrophin in 
DMD results in disintegration of this protein complex and renders the muscle 
membrane more susceptible to damage during normal muscle excitation-contraction-
relaxation cycles. Proteomic investigations of the DGC are challenging as its low-
abundance, large size and membrane association make conventional 2D-GE analysis 
more difficult and can result in suboptimal identification of components of the 
complex. Since, in general, proteins absorbed onto nitrocellulose sheets are more 
accessible to proteases, on-membrane digestion of an enriched dystrophin complex 
may result in improved protein identification by mass spectrometry. A dystrophin 
complex enriched fraction was prepared by the supervisor of this research, Professor 
Kay Ohlendieck, using combined hind limb and back muscle tissues from normal adult 
New Zealand white rabbits. Crude microsomes were prepared from muscle 
homogenates by differential centrifugation. Membrane proteins were solubilised with 
the detergent digitonin and fractionated by ion exchange chromatography and wheat 
germ agglutinin chromatography. A dystrophin-enriched fraction was then isolated by 
ultracentrifugation with a sucrose gradient (Ervasti et al., 1990). SDS-PAGE was 
conducted using 16 cm-long and 1.5 mm-thick one-dimensional 3-12% gradient gels. 
The electrophoretically separated dystrophin fraction was then transferred to 
nitrocellulose for 90 min at 100 V. On-membrane protein digestion was performed, 
and peptides analysed by mass spectrometry using an Ultimate 3000 NanoLC system 
(Dionex Corporation, Sunnyvale, CA, USA) coupled to a Q-Exactive mass 
spectrometer (Thermo Fisher Scientific). Peptides were eluted using a 65 min method 
over the following binary gradient: solvent A [2% (v/v) ACN and 0.1% (v/v) formic 
acid in LC-MS grade water] and 0-90% solvent B [80% (v/v) ACN and 0.1% (v/v) 
formic acid in LC-MS grade water: 3% solvent B for 5 min, 10-40% solvent B for 30 
min, 40-90% solvent B for 5 min, 90% solvent B for 5 min and 3% solvent B for 10 
min. Protein identification was achieved using Proteome Discoverer 1.4 (Thermo 
Fisher Scientific) software with Sequest HT as the search engine and the UniProtKB 
sequence database. Since the rabbit genome is incomplete, mass spectrometry raw 
files were searched against both the Oryctolagus cuniculus database and the 
Mammalia database. Bioinformatics analysis was performed using STRING and the 
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web-based gene set analysis toolkit. The status of the potential dystrophin-complex 
interacting partner desmoglein-1 in dystrophic skeletal muscle was investigated by 
immunoblot analysis of quadriceps femoris and longissimus dorsi muscle from 100-
day old wild-type and age-matched mdx mice (n=4).  
 The DGC resides in the sarcolemma and the loss of the complex in 
dystrophinopathy renders the sarcolemma more susceptible to membrane damage and 
the formation of lesions. Here organelle proteomics has been performed to study 
proteomic perturbations in the closely associated sarcolemmal environment of the 
dystrophin network. Crude microsomes were prepared by ultracentrifugation of 
skeletal muscle homogenates from the entire hind leg of 5-month old wild-type and 
age-matched mdx-4cv mice (n=3). For each biological replicate three hind legs from 
three different mice were pooled. Sarcolemma vesicles were then enriched using 
wheat germ agglutination and ultracentrifugation. Samples were analysed by label-
free LC-MS/MS using an Ultimate 3000 NanoLC system (Dionex Corporation, 
Sunnyvale, CA, USA) coupled to a Q-Exactive mass spectrometer (Thermo Fisher 
Scientific). Peptides were eluted from the column using the following binary gradient: 
solvent A [2% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade water] and 0-
90% solvent B [80% (v/v) ACN and 0.1% (v/v) formic acid in LCMS grade water].  
The peptides were eluted as follows: 5-45% solvent B for the first 120 min, 45-90% 
solvent B for 2.5 min, 90% solvent B for 7 min and 3% solvent B for 43 min. Relative 
quantification and identification was performed with Progenesis QI for Proteomics 
software, using Sequest HT and MASCOT search engines and the UniProtKB-
SwissProt database, where an ANOVA p value ≤ 0.01 was used to determine 
significant differentially abundant proteins. Bioinformatics analysis was conducted 
using the PANTHER database of protein families, STRING software and the DAVID 
bioinformatics resource (version 6.8, https://david.ncifcrf.gov/). A number of proteins 
with altered abundance in the sarcolemma enriched fraction were verified by 
comparative immunoblot analysis.  
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4.2 Results 
4.2.1 Proteomic characterisation of the dystrophin complex enriched fraction 
On-membrane digestion of the accessible protein constellation of the enriched DGC 
from rabbit skeletal muscle identified 48 proteins (44 of which were characterised and 
had corresponding gene names), by searching against the Oryctolagus 
cuniculus database. This enriched fraction, isolated using an established method of 
sequential ion exchange chromatography, lectin affinity chromatography and sucrose 
gradient ultra-centrifugation (Ervasti et al., 1990), was shown to contain the full-length 
Dp427 isoform of dystrophin and its associated glycoproteins, including β-
dystroglycan, α-sarcoglycan, β-sarcoglycan, δ-sarcoglycan, γ-sarcoglycan, α1-
syntrophin, β1-syntrophin, β2-syntrophin and α-dystrobrevin (Table 4.1). 
Bioinformatics tools were used to characterise the protein components of the enriched 
dystrophin complex. Oryctolagus cuniculus uniprot identifiers for proteins identified 
in the dystrophin complex enriched fraction were manually converted to Homo 
sapiens uniprot identifiers to facilitate analysis using the web geneset analysis toolkit 
(freely available at http://www.webgestalt.org/webgestalt_2013/). Except for five 
proteins (the four uncharacterised proteins; G1U3Q6, G1TQ93, G1U6X0 and 
G1TL92, and hemoglobin subunit beta-1/2), corresponding Homo sapiens identifiers 
were found for all proteins identified in the dystrophin complex enriched fraction. An 
additional 8 proteins (keratin 9, keratin 19, desmoglein-1, albumin, actin gamma 
enteric smooth muscle, cadherin 13, dermcidin and desmocollin-1) that were identified 
by searching the mass spectrometry data against a mammalian database, and which 
had ≥ 2 unique peptides were included in the analysis, after identifying their 
corresponding Homo sapiens uniprot identifiers (proteins with ≥2 unique peptides but 
which were uncharacterised or with a high probability of being contaminants, for 
example bovine casein, were excluded) . These proteins are listed in Table 4.1b. The 
analysis toolkit was used to identify enriched GO terms in our data-set with homo 
sapiens_enterezgene_protein-coding applied as the reference set for enrichment 
analysis. Multiple test adjustment was performed with the method of Benjamini & 
Hochberg. Depicted in Figure 4.2 below are the top 10 cellular components with the 
most significant p values (coloured red) and their non-enriched parents (coloured 
black). This statistical analysis verifies the enrichment of dystrophin associated 
glycoproteins in our dystrophin complex enriched fraction, with the identification of 
137 
 
sarcolemma and dystrophin-associated glycoprotein as two of the top 10 enriched 
cellular components (Figure 4.2). 
 STRING analysis was also employed to visualise and assess protein-protein 
interactions, as seen in Figure 4.3. This analysis was performed using the Homo 
sapiens uniprot identifiers as described above and illustrates two major clusters; 
clustering of the known dystrophin-associated glycoproteins and a second cluster of 
the cytokeratins with the desmosomal proteins desmoplakin, plakoglobin, 
desmoglein-1, desmocollin and plakophilin. Enrichment analysis identified the 
cytoskeleton (28 proteins, false discovery rate (FDR) 1.44e-14), the sarcolemma (12 
proteins, FDR 1.44e-14) and the dystrophin-associated glycoprotein complex (8 
proteins, FDR 1.44e-14) as enriched cellular components, agreeing with a successful 
dystrophin complex enrichment procedure in this study. Cellular component 
enrichment was also seen for the desmosome (5 proteins, FDR 8.2e-08). 6 molecular 
functions were enriched in the data set, mostly related to structural activity, binding 
(protein binding and actin binding) and cellular adhesion.  
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Figure 4.2: Cellular component enrichment analysis of the DGC fraction 
The web gene set analysis toolkit was used to identify enriched cellular components 
of the proteins identified in the DGC membrane fraction. Bioinformatics confirms the 
successful enrichment of the DGC in this fraction. 
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Figure 4.3: STRING analysis of DGC proteins 
The freely available STRING database was used to visualise protein-protein 
interactions, both known and predicted. Depicted is the high confidence evidence 
view. Analysis reveals clustering of several protein species, particularly of the 
dystrophin-associated proteins and the cytokeratins.  
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4.2.2 Mass spectrometric identification of dystrophin co-purifying proteins 
Following the confirmation of dystrophin complex enrichment, the data obtained from 
the dystrophin complex enriched fraction was searched for co-purifying proteins. All 
the 56 proteins (48 from Oryctolagus cuniculus database, and an additional 8 from the 
Mammalia database) identified by mass spectrometry are listed in Tables 4.1a and 
4.1b. Aside from the established protein components of the DGC, various other 
proteins were identified in this enriched fraction. Although all these proteins may have 
a link with proteins of the DGC, either directly or indirectly, the anion exchange 
protein, cytokeratin 3 and the cytolinkers desmoglein-1 and desmoplakin are the most 
plausible candidates. A number of the other proteins detected possibly represent 
contaminating proteins from the highly abundant sarcoplasmic reticulum (fast 
SERCA1 Ca2+-ATPase) and the contractile apparatus (myosin heavy chain isoform 
MyHC-IIb). A number of keratins were also identified as seen in Tables 4.1a and 4.1b 
below, but of particular interest was the detection of keratin 19, as Stone and 
colleagues have previously illustrated specific interactions between the actin-binding 
domain of dystrophin and intermediate filaments containing keratin 19 (Stone et al., 
2005). Such interactions between dystrophin and cytokeratin 19 may be particularly 
important in linking dystrophin to the contractile apparatus at all costameres and not 
just those overlaying the Z disc (Stone et al., 2005). While several filamentous 
proteins, including actin and desmin, are responsible for connecting the contractile 
apparatus to the dystrophin complex at costameres, these proteins are concentrated at 
the Z disc and so are unlikely to mediate connections at costameres along the M-line 
or those orientated longitudinally along the sarcolemma (O'Neill et al., 2002). Thus, 
cytokeratins may play a key role in sarcolemmal organisation in striated muscle, 
through mediating connections between the sarcolemma and contractile apparatus at 
all three costamere domains. 
 Desmoglein represents one of the desmosomal cadherins, which are critical for 
cellular motility and integrity. One segment of the desmoglein cytoplasmic tail has 
homology to the classical cadherins. This segment is responsible for binding to 
plakoglobin, which in turn binds to desmoplakin (Hammers and Stanley, 2013). On-
membrane digestion of the dystrophin complex enriched fraction identified all three 
of these desmosomal proteins, although plakoglobin was only identified by a single 
unique peptide. Since desmoglein-1 is generally associated with stratified squamous 
epithelia cells (King et al., 1997), such as those in the skin and cornea, its mass 
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spectrometric identification in the skeletal muscle is of considerable interest. For this 
reason, it was decided to investigate this protein in skeletal muscle obtained from 
healthy control wild-type mice and dystrophic mdx mice.  
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Table 4.1a: Mass spectrometric identification of protein components of the dystrophin 
complex enriched fraction from rabbit skeletal muscle 
 
Accession Gene 
Name 
Protein Name Coverage Unique 
Peptides 
MW 
[kDa] 
calc. 
pI 
G1T1Y7 KRT14  Keratin, type I cytoskeletal 
14 
25.06 3 48.3 4.93 
G1T4R6 KRT16  Keratin, type I cytoskeletal 
16 
19.15 2 49.5 5.19 
G1T1V0 KRT10  Keratin, type I cytoskeletal 
10 
18.28 12 58.1 5.03 
G1SGL0 SGCD  Delta-sarcoglycan 15.57 4 32.1 8.85 
G1SI34 ATP2A1  Calcium-transporting 
ATPase  
13.76 9 107.9 5.31 
G1SKE6 SGCG  Gamma-sarcoglycan 12.37 3 32 5.25 
G1T8Y6 DMD  Dystrophin 12.06 10 111.5 6.52 
G1TD51 HIST1H4D  Histone H4  11.54 1 11.5 11.3
6 
G1TB55 SNTB1  Beta-1-syntrophin 11.3 4 58.3 8.31 
Q28686 SGCA  Alpha-sarcoglycan  11.11 4 42.5 6.19 
Q28635 SGCB  Beta-sarcoglycan  10.06 3 34.7 8.76 
G1SK59 ACTG2  Actin, gamma-enteric 
smooth muscle precursor 
9.84 3 41.8 5.48 
G1U9I8 KRT1  Keratin, type II 
cytoskeletal 1  
9.33 3 64.2 8.47 
P16973 LYZ  Lysozyme C  9.23 1 14.7 8.62 
G1SKD7 DTNA  Dystrobrevin  8.01 3 63.3 8.15 
G1TDN6 KRT5  Keratin, type II 
cytoskeletal 2 epidermal 
7.14 4 62.2 7.81 
G1SUH8 KRT2  Keratin, type II 
cytoskeletal 2 epidermal 
7.12 2 63.2 8.81 
G1T281 SNTA1  Alpha-1-syntrophin  6.97 2 51.8 6.64 
A0A140T
AV6 
HBB2  Hemoglobin subunit beta-
1/2  
6.8 1 16.1 8.21 
G1SLY0 SLC4A1  Anion exchange protein  6.31 4 102.1 5.24 
G1T375 MYL3  Myosin light chain 3  6.22 1 23.1 5.19 
G1TL92 
 
Uncharacterized protein  5.9 2 48.4 5.4 
G1T6S0 TPM1  Tropomyosin alpha-1 chain  4.8 1 31.3 4.81 
G1T1Q1 NCCRP1  F-box only protein 50 4.53 1 29.8 5.99 
G1TJG6 GAPDH  Glyceraldehyde-3-
phosphate dehydrogenase  
4.5 1 35.8 8.35 
G1TI00 SNTB2  Beta-2-syntrophin 4.45 2 58.4 8.09 
G1SPP3 KRT4  Keratin, type II 
cytoskeletal 4 
4.36 1 63.8 7.5 
G1TDN8 KRT73  Keratin, type II 
cytoskeletal 73 
4.3 1 58.4 7.81 
P00883 ALDOA  Fructose-bisphosphate 
aldolase A  
4.12 1 39.3 8.09 
G1TV17 ADIPOQ  Adiponectin 4.1 1 26.3 6.15 
Q29426 KRT3  Keratin, type II 
cytoskeletal 3  
3.82 4 64.3 7.75 
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Q28685 DAG1  Dystroglycan  3.58 2 97 8.27 
G1U6X0 
 
Uncharacterized protein  3.55 1 42.9 7.72 
G1TQ93 
 
Uncharacterized protein  3.11 6 253.8 6.04 
G1SKT4 ATP5A1  ATP synthase subunit 
alpha  
2.71 1 59.7 9.11 
G1SQA8 ATP5B  ATP synthase subunit beta  2.47 1 60.5 5.67 
G1T2J0 JUP  Junction plakoglobin 2.42 1 81.7 6.14 
G1U6W1 EEF1A1 Elongation factor 1-alpha  2.38 1 50 8.62 
G1T1V9 HSPA2  Heat shock-related 70 kDa 
protein 2 
2.05 1 69.6 5.67 
G1TM19 PKP1  Plakophilin-1 2 1 82.8 9.13 
Q28641 MYH4  Myosin-4  1.96 2 222.9 5.81 
P22758 TGM1  Protein-glutamine gamma-
glutamyltransferase K  
1.91 1 91.9 6.05 
G1U3Q6 
 
Uncharacterized protein  1.69 1 70.4 4.86 
G1U2Z6 CACNA1S  Voltage-dependent L-type 
calcium channel subunit 
alpha-1S  
1.42 2 176.5 6.44 
G1TW48 MYH7  Myosin-7  1.34 1 222.9 5.74 
G1U8M6 ATP1A2  Sodium/potassium-
transporting ATPase 
subunit alpha  
1.18 1 112.1 5.71 
G1SN83 LAMB2  Laminin subunit beta-2 0.78 1 196 6.6 
G1T4V7 DSP  Desmoplakin 0.63 1 224.5 6.93 
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Table 4.1b: Mass spectrometric identification of 8 additional protein components of 
the dystrophin complex enriched fraction from rabbit skeletal muscle, identified by a 
Mammalia database 
 
Accession Gene 
Name 
Protein Name Coverage Unique 
Peptides 
MW 
[kDa] 
calc. 
pI 
H2QCZ6 KRT9 Keratin 9 28.73 11 62.1 5.24 
V8P8L1 KRT19 Keratin, type 1 
cytoskeletal 19 
1 2 436.1 5.14 
H2QEE3 DSG1 Desmoglein-1 5.92 4 113.7 5.06 
A0A140T
897 
ALB Serum albumin 5.27 3 69.3 6.18 
R7VT75 ACTG2 Actin, gamma-enteric 
smooth muscle 
11.75 3 35 5.1 
M1EH65 CDH13 Cadherin 13, H-cadherin 17.69 2 16.3 5.2 
P81605 DCD Dermcidin 12.73 2 11.3 6.54 
G3SCF2 DSC1 Desmocollin-1 3.45 2 93.7 5.48 
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4.2.3 Comparative immunoblotting of desmoglein-1 in wild-type and mdx 
quadriceps femoris and longissimus dorsi  
Leading on from the mass spectrometric identification of desmoglein-1 in the 
dystrophin complex enriched fraction from skeletal muscle, it was decided to 
investigate the status of this cytolinker protein in dystrophic skeletal muscle. Silver 
stain analysis and immunoblotting to the extracellular matrix protein laminin showed 
similar protein banding patterns and equal protein loading respectively between 100-
day old wild-type and age-matched mdx quadriceps femoris and longissimus dorsi 
muscle. However, comparative immunoblot analysis revealed a statistically significant 
reduction in the abundance of desmoglein-1 in both dystrophic quadriceps femoris and 
longissimus dorsi skeletal muscle (Figures 4.4 and 4.5). This cytolinker suffers the 
same fate as a number of core dystrophin-associated glycoproteins in the absence of 
dystrophin.  
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A) Silver Gel             B) Laminin        C) Desmoglein-1  
 
 
 
 
 
 
 
 
 
 
                                                 
 
 
 
 
 
Figure 4.4: Immunoblot analysis of the cytolinker desmoglein-1 in dystrophic 
quadriceps femoris skeletal muscle 
Shown is a silver stained gel (A) and immunoblot and statistical analysis of bands 
labelled with laminin (B). The silver stained gel shows comparable protein banding 
patterns for 100-day old wild-type and mdx quadriceps femoris muscle. Molecular 
weight marker is given on the left-hand-side of the image in kDa. Laminin 
immunoblotting did not show significant changes in concentration between wild-type 
and mdx samples and so it serves as a loading control for comparative immunoblotting. 
Also shown is an immunoblot to desmoglein-1 (C). Graphical representation of the 
immuno-decoration levels for laminin and desmoglein-1 is shown (mean values ± 
SEM, Student’s t-test; unpaired; n=4; **p≤0.01).  
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             A) Silver Gel             B) Laminin               C) Desmoglein-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Immunoblot analysis of the cytolinker desmoglein-1 in dystrophic 
longissimus dorsi skeletal muscle 
Shown is a silver stained gel (A) and immunoblot and statistical analysis of bands 
labelled with laminin (B). The silver stained gel shows comparable protein banding 
patterns for 100-day old wild-type and mdx longissimus dorsi muscle. Molecular 
weight marker is given on the left-hand-side of the image in kDa. Laminin 
immunoblotting did not show significant changes in concentration between wild-type 
and mdx samples and so it serves as a loading control for comparative immunoblotting. 
Also shown is an immunoblot to desmoglein-1 (C). Graphical representation of the 
immuno-decoration levels for laminin and desmoglein-1 is shown (mean values ± 
SEM, Student’s t-test; unpaired; n=4; **p≤0.01). 
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4.2.4 Qualitative analysis of wild-type versus mdx-4cv enriched sarcolemma 
Prior to comparative analysis to identify differentially abundant proteins in wild-type 
versus mdx-4cv enriched sarcolemma, qualitative analyses were performed to confirm 
sarcolemmal enrichment using the wheat germ agglutination procedure. 793 proteins 
were identified in mdx-4cv preparations, of which 512 proteins had ≥ 2 unique 
peptides. 738 proteins were identified in wild-type samples, with 470 of those 
containing ≥ 2 unique peptides. The identified proteins with ≥ 2 unique peptides were 
loaded into the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) and searched 
using GO annotation to evaluate whether the lectin agglutination procedure had 
efficiently enriched for proteins in, and associated with, the membrane. 395 of 470 
uniprot-swissprot accession numbers for wild-type sarcolemma and 429 of 512 
uniprot-swissprot accession numbers for mdx-4cv sarcolemma were successfully 
mapped to unique Entrez gene IDs and were used in the analysis. Shown in Figure 4.6 
is a bar chart illustrating the top 12 cellular components as identified by GO analysis 
in wild-type and mdx-4cv datasets.  This analysis revealed just under two-thirds of 
identified proteins were associated with the membrane (64% for wild-type and 65% 
for mdx-4cv), suggesting overall enrichment of membrane proteins. More specifically, 
the enrichment analysis tool in the WebGestalt software identified the sarcolemma as 
an enriched cellular component in both wild-type and mdx-4cv muscle preparations 
(FDR 1.26e-06 for mdx-4cv samples and FDR 1.45e-09 for wild-type samples), 
indicating successful enrichment of the muscle sarcolemma. The core dystrophin 
complex was represented by dystrophin isoform Dp427, α/β-dystroglycan, α-
sarcoglycan, β-sarcoglycan, γ-sarcoglycan, δ-sarcoglycan, and α1-syntrophin. Key 
sarcolemmal marker proteins identified in multi-consensus qualitative data included 
dysferlin, the plasma membrane Ca2+-transporting ATPase isoform Atp2b1, various 
subunits of the Na+/K+-ATPase (α1, α2, β1 and β2 subunits), integrins (isoform 
α6X1A of integrin α6, isoform α7X2A of integrin α7, integrin β1 and integrin β2), 
annexins A1 and A2 and the sarcolemmal chloride channel protein. However, 
agglutinated vesicle preparations from skeletal muscle are most often contaminated by 
abundant membranes and protein populations from mitochondria, the sarcoplasmic 
reticulum, transverse tubules, the ribosome, the nucleus, serum, the Golgi apparatus, 
the cytosol, lysosomes and the contractile apparatus (Murphy and Ohlendieck, 2017). 
As seen in Figure 4.6, the sarcolemma-enriched fraction isolated here contains other 
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abundant cellular components including mitochondria, macromolecular complexes, 
the nucleus, the endoplasmic reticulum and the cytoskeleton. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Cellular component analysis of wild-type versus mdx-4cv sarcolemma 
data 
Shown are the top 12 cellular components identified by GO analysis of the identified 
proteins in wild-type and mdx-4cv enriched sarcolemma fractions.  
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4.2.5 Quantitative analysis of wild-type versus mdx-4cv enriched sarcolemma 
The proteomic survey of two technical repeats each of three biological samples 
revealed altered abundance for 190 proteins. Of these proteins 163 were elevated in 
abundance in mdx-4cv samples and the remaining 27 proteins were decreased in 
abundance in mdx-4cv sarcolemma enriched fractions. The 163 increased abundance 
proteins and 27 decreased abundance proteins are listed in Tables 4.2, A4.1 and 4.3 
respectively. A number of confirmatory proteins were identified, with reductions seen 
for dystrophin, β-dystroglycan, α-sarcoglycan and δ-sarcoglycan, in agreement with 
the known dystrophic phenotype. In addition, several previously identified proteins of 
increased abundance in dystrophic tissue were also verified here, including collagen 
α(VI), fibronectin, biglycan and the embryonic myosin isoforms myosin-4 and 
myosin-3. A variety of novel proteins of interest were also identified and investigated 
further. Of particular interest was the 21.8-fold decrease in the abundance of the 
scaffolding protein periaxin which functions as part of a dystrophin-related protein 
DRP2-dystroglycan complex in Schwann cells.  
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Table 4.2: List of proteins with ≥ 4-fold increased abundance in 5-month old mdx-
4cv enriched sarcolemma versus age-matched wild-type enriched sarcolemma as 
determined by label-free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
P49290 Epx  Eosinophil peroxidase  2 3.56 1.60E-
13 
Infinity 
P04441 Cd74  H-2 class II 
histocompatibility 
antigen gamma chain  
2 3.20 1.32E-
04 
117.39 
Q9D1I2 Card19  Caspase recruitment 
domain-containing 
protein 19  
2 57.00 7.26E-
04 
60.65 
Q5SX39 Myh4  Myosin-4  5 115.59 5.01E-
03 
32.91 
Q9D0E1 Hnrnpm  Heterogeneous nuclear 
ribonucleoprotein M  
2 45.79 5.08E-
03 
32.26 
Q5SX40 Myh1  Myosin-1  15 800.40 8.51E-
04 
27.12 
P13541 Myh3  Myosin-3  2 3.68 4.28E-
03 
22.75 
P01901 H2-K1  H-2 class I 
histocompatibility 
antigen, K-B alpha 
chain  
4 202.65 1.68E-
07 
20.09 
P06800 Ptprc  Receptor-type tyrosine-
protein phosphatase C  
3 213.96 2.87E-
07 
20.03 
P97457 Mylpf  Myosin regulatory light 
chain 2, skeletal muscle 
isoform  
2 143.61 9.78E-
04 
17.18 
P62918 Rpl8  60S ribosomal protein 
L8  
3 104.98 1.05E-
06 
13.33 
P47964 Rpl36  60S ribosomal protein 
L36 
2 3.31 9.55E-
03 
12.96 
Q8BMD8 Slc25a24  Calcium-binding 
mitochondrial carrier 
protein SCaMC-1  
4 214.42 2.91E-
05 
12.72 
Q62230 Siglec1  Sialoadhesin  6 302.81 6.83E-
05 
10.82 
P62301 Rps13  40S ribosomal protein 
S13  
2 62.73 2.35E-
05 
10.55 
P51881 Slc25a5  ADP/ATP translocase 2  2 97.29 1.98E-
05 
10.32 
Q8BMK4 Ckap4  Cytoskeleton-associated 
protein 4  
7 228.98 2.47E-
05 
10.26 
Q9D8E6 Rpl4  60S ribosomal protein 
L4  
4 97.00 1.01E-
05 
9.89 
P47911 Rpl6  60S ribosomal protein 
L6  
3 162.39 4.38E-
07 
9.43 
P43276 Hist1h1b  Histone H1.5  4 61.99 1.14E-
05 
8.89 
P62245 Rps15a  40S ribosomal protein 
S15a  
3 158.76 4.86E-
06 
8.48 
P11835 Itgb2  Integrin beta-2  3 102.80 1.04E-
04 
7.95 
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Q69ZN7 Myof  Myoferlin  5 121.44 1.62E-
04 
7.81 
P01872 Ighm  Ig mu chain C region  3 149.11 4.53E-
05 
7.37 
Q7TPR4 Actn1  Alpha-actinin-1  2 42.54 2.98E-
05 
6.75 
Q6ZWV7 Rpl35  60S ribosomal protein 
L35  
2 47.05 2.17E-
05 
6.66 
P14148 Rpl7  60S ribosomal protein 
L7  
3 109.44 5.97E-
08 
6.57 
Q9D8H7 Oma1  Metalloendopeptidase 
OMA1, mitochondrial  
2 4.03 8.43E-
07 
6.55 
P49300 Clec10a  C-type lectin domain 
family 10 member A  
3 101.98 6.37E-
05 
6.49 
P47963 Rpl13  60S ribosomal protein 
L13  
2 47.63 3.83E-
08 
6.43 
Q9WV54 Asah1  Acid ceramidase  3 105.42 1.62E-
07 
6.40 
P28653 Bgn  Biglycan  2 116.02 3.31E-
04 
6.38 
P62754 Rps6  40S ribosomal protein 
S6  
2 43.95 5.97E-
07 
6.35 
P43274 Hist1h1e  Histone H1.4  6 68.95 1.83E-
06 
6.32 
P35979 Rpl12  60S ribosomal protein 
L12  
2 64.42 3.07E-
04 
6.11 
Q9CR57 Rpl14  60S ribosomal protein 
L14  
3 190.30 1.22E-
05 
6.10 
Q3UMR5 Mcu  Calcium uniporter 
protein, mitochondrial  
3 130.49 1.43E-
05 
5.73 
Q62465 Vat1  Synaptic vesicle 
membrane protein 
VAT-1 homolog  
3 195.20 2.85E-
05 
5.66 
P53026 Rpl10a  60S ribosomal protein 
L10a  
2 55.75 2.67E-
05 
5.54 
P97449 Anpep  Aminopeptidase N  4 118.97 3.53E-
05 
5.47 
O88990 Actn3  Alpha-actinin-3  8 449.56 2.18E-
04 
5.45 
P50285 Fmo1  Dimethylaniline 
monooxygenase [N-
oxide-forming] 1  
2 67.52 3.49E-
04 
5.41 
P54116 Stom  Erythrocyte band 7 
integral membrane 
protein  
5 308.74 8.74E-
05 
5.34 
Q923B6 Steap4  Metalloreductase 
STEAP4  
3 79.01 1.16E-
04 
5.30 
P29788 Vtn  Vitronectin  2 93.59 6.84E-
09 
5.29 
Q64449 Mrc2  C-type mannose 
receptor 2  
3 112.73 2.78E-
06 
5.25 
P10107 Anxa1  Annexin A1  3 191.03 1.28E-
05 
5.25 
Q8VHX6 Flnc  Filamin-C  4 62.16 3.76E-
05 
5.13 
P62702 Rps4x  40S ribosomal protein 
S4, X isoform  
4 68.24 9.56E-
06 
5.05 
O08917 Flot1  Flotillin-1  3 191.19 2.01E-
03 
4.93 
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Q61738 Itga7  Integrin alpha-7  3 102.60 4.70E-
05 
4.83 
P12970 Rpl7a  60S ribosomal protein 
L7a  
2 88.31 9.78E-
08 
4.78 
P27773 Pdia3  Protein disulfide-
isomerase A3  
4 122.02 5.40E-
05 
4.76 
Q9DBS1 Tmem43  Transmembrane protein 
43  
3 97.03 2.21E-
08 
4.70 
P08226 Apoe  Apolipoprotein E  5 200.72 2.40E-
05 
4.61 
Q8CC88 Vwa8  von Willebrand factor 
A domain-containing 
protein 8  
2 50.68 2.81E-
03 
4.59 
Q8VDD5 Myh9  Myosin-9  3 119.65 2.12E-
06 
4.57 
P70302 Stim1  Stromal interaction 
molecule 1  
2 3.20 3.28E-
05 
4.56 
P13595 Ncam1  Neural cell adhesion 
molecule 1  
3 71.50 1.57E-
05 
4.48 
Q9EQK5 Mvp  Major vault protein  2 57.29 7.84E-
06 
4.45 
Q60634 Flot2  Flotillin-2  4 267.14 3.60E-
07 
4.41 
Q61830 Mrc1  Macrophage mannose 
receptor 1  
12 491.66 5.40E-
04 
4.38 
Q3U7R1 Esyt1  Extended 
synaptotagmin-1  
3 51.30 1.35E-
05 
4.34 
Q9DCN2 Cyb5r3  NADH-cytochrome b5 
reductase 3  
2 103.89 4.05E-
07 
4.31 
Q07113 Igf2r  Cation-independent 
mannose-6-phosphate 
receptor  
3 50.15 8.66E-
05 
4.22 
A2ASS6 Ttn  Titin  105 3529.12 9.91E-
04 
4.19 
Q9DC69 Ndufa9  NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 9, 
mitochondrial  
2 141.66 7.94E-
04 
4.05 
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Table 4.3: List of identified proteins with a significantly decreased abundance in 5-
month old mdx-4cv enriched sarcolemma versus age-matched wild-type enriched 
sarcolemma as determined by label-free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
P11531 Dmd  Dystrophin  8 255.88 1.26E-
05 
2708.22 
P27573 Mpz  Myelin protein P0  2 4.58 2.84E-
05 
33.85 
O55103 Prx  Periaxin  15 566.64 1.95E-
11 
21.81 
Q8BKZ9 Pdhx  Pyruvate 
dehydrogenase protein 
X component, 
mitochondrial  
2 98.21 1.76E-
05 
16.84 
Q62165 Dag1  Dystroglycan  2 51.58 1.03E-
07 
14.83 
P41216 Acsl1  Long-chain-fatty-acid--
CoA ligase 1  
3 174.03 9.99E-
04 
12.21 
Q99LC3 Ndufa10  NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 10, 
mitochondrial  
2 62.50 1.97E-
04 
8.21 
Q8VCT4 Ces1d  Carboxylesterase 1D  2 82.19 1.64E-
04 
6.75 
Q70IV5 Synm  Synemin  2 47.71 4.99E-
06 
5.30 
P16330 Cnp  2',3'-cyclic-nucleotide 
3'-phosphodiesterase  
3 85.49 2.10E-
04 
4.92 
P12367 Prkar2a  cAMP-dependent 
protein kinase type II-
alpha regulatory subunit  
2 3.25 6.95E-
05 
4.92 
A2A863 Itgb4  Integrin beta-4  5 160.70 8.49E-
05 
4.31 
P82347 Sgcd  Delta-sarcoglycan  3 57.59 3.78E-
04 
3.99 
P82350 Sgca  Alpha-sarcoglycan  2 118.46 3.63E-
06 
3.74 
Q8R1G2 Cmbl  Carboxymethylenebute
nolidase homolog  
2 43.07 3.15E-
03 
3.53 
P09411 Pgk1  Phosphoglycerate 
kinase 1  
2 3.16 2.01E-
06 
3.32 
P05064 Aldoa  Fructose-bisphosphate 
aldolase A  
2 49.25 3.86E-
05 
3.28 
Q64521 Gpd2  Glycerol-3-phosphate 
dehydrogenase, 
mitochondrial  
2 83.59 2.75E-
04 
3.25 
Q8BH59 Slc25a12  Calcium-binding 
mitochondrial carrier 
protein Aralar1  
3 129.87 1.55E-
03 
3.21 
Q8R3Z5 Cacnb1  Voltage-dependent L-
type calcium channel 
subunit beta-1  
2 95.19 1.25E-
05 
3.14 
O09165 Casq1  Calsequestrin-1  2 50.25 3.30E-
04 
3.02 
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P07310 Ckm  Creatine kinase M-type  2 72.74 6.54E-
03 
2.89 
Q03265 Atp5a1  ATP synthase subunit 
alpha, mitochondrial  
3 107.23 2.52E-
05 
2.57 
P61982 Ywhag  14-3-3 protein gamma  2 57.27 5.13E-
06 
2.44 
Q61554 Fbn1  Fibrillin-1  4 183.34 2.41E-
03 
2.18 
Q7TQ48 Srl  Sarcalumenin  3 5.57 4.52E-
03 
1.67 
P14824 Anxa6  Annexin A6  3 216.75 1.17E-
03 
1.58 
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4.2.6 Bioinformatics of differential proteins in wild-type versus mdx-4cv enriched 
sarcolemma 
A variety of software packages were employed to investigate the differential proteins 
in more detail. PANTHER analysis of the 163 proteins with elevated abundance in 
mdx-4cv dystrophic skeletal muscle revealed a huge variety of altered protein classes 
(Figure 4.7), with the highest proportion of increased proteins belonging to the class 
of nucleic acid binding proteins. The 27 proteins with decreased abundance belonged 
predominantly to transferase, transporter, calcium-binding and hydrolase protein 
classes (Figure 4.8). Figures 4.9 and 4.10 depict the medium confidence evidence view 
from STRING for elevated and reduced proteins respectively. STRING analysis of 
increased abundance proteins reveals two primary proteins clusters; that of the 
ribosomal proteins (the protein cluster on the left-hand-side in Figure 4.9) and that of 
the structural proteins titin, vimentin, biglycan, vitronectin and various isoforms of 
myosin, collagen, tubulin and annexin (the cluster to the bottom-right in Figure 4.9). 
Dystrophin deficiency is thereby suggested to result in compensatory increases in 
protein translation and cytoskeletal restructuring. STRING analysis of the decreased 
proteins identifies the well-characterised interactions of dystrophin with dystroglycan 
and α- sarcoglycan and δ-sarcoglycan. In turn this complex is putatively connected to 
the structural myelin proteins periaxin and myelin protein zero.  
 The DAVID bioinformatics resource was used to identify enriched protein 
clusters of biological significance. The 163 proteins with elevated abundance were 
converted to DAVID IDs and analysed using the functional annotation clustering tool, 
with classification stringency set to high. This identified 29 clusters of interest, of 
which the cluster associated with ribosomal proteins had the highest enrichment score 
of 21.52. Similarly STRING functional enrichment analysis also identified ribosomes 
as the top enriched KEGG pathway in proteins with elevated abundance in the 
dystrophic mouse, indicating drastic increases in ribosomal protein synthesis. Shown 
in Figure 4.11 are the top 5 enriched KEGG pathways for both elevated and reduced 
proteins.  
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Figure 4.7: PANTHER analysis of proteins with increased abundance in mdx-4cv 
muscle sarcolemma 
The 163 proteins with elevated abundance were grouped into their respective protein 
class using the freely available PANTHER software package.  
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Figure 4.8: PANTHER analysis of proteins with decreased abundance in mdx-
4cv muscle sarcolemma 
The 27 proteins with reduced abundance were grouped into their respective protein 
class using the freely available PANTHER software package. 
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Figure 4.9: STRING analysis of proteins with increased abundance in mdx-4cv 
muscle sarcolemma 
Depicted is the STRING evidence view analysis of potential protein interactions 
(medium confidence) of the 163 proteins with increased abundance in mdx-4cv muscle 
sarcolemma.  
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Figure 4.10: STRING analysis of proteins with decreased abundance in mdx-4cv 
muscle sarcolemma 
Depicted is the STRING evidence view analysis of potential protein interactions 
(medium confidence) of the 27 proteins with reduced abundance in mdx-4cv muscle 
sarcolemma.  
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Figure 4.11: Enriched KEGG pathways of proteins with altered abundance in 
mdx-4cv muscle sarcolemma 
Depicted are the top 10 enriched KEGG pathways of proteins with elevated abundance 
(blue columns) and reduced abundance (red columns) based on STRING functional 
enrichment analysis.  
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4.2.7 Comparative immunoblotting of differential proteins in wild-type versus mdx-
4cv enriched sarcolemma 
Comparative immunoblotting using a panel of select antibodies against crude 
homogenates from hind-leg skeletal muscle of 5-month old wild-type and age-
matched mdx-4cv mice was used to independently evaluate novel protein candidates 
of DMD. Equal loading was confirmed by silver stain analysis along with an 
immunoblot against laminin, as illustrated in Figure 4.12. Decreased abundance of 𝛽-
dystroglycan is a known deficit arising from the absence of its interaction partner 
dystrophin in muscular dystrophy and was confirmed in the mdx-4cv animal model 
here by both mass spectrometry (Table 4.3) and immunoblotting (Figure 4.13). 
Although not identified by mass spectrometric analysis of the sarcolemma enriched 
fraction, proteomic analysis of the dystrophin complex enriched fraction has identified 
desmoglein-1 as a potential interaction partner of the DGC and one which shows 
reduced abundance in skeletal muscle from the mdx animal model (Figures 4.4 and 
4.5). This reduction in desmoglein-1 is confirmed here in crude hind limb 
homogenates of the mdx-4cv model (Figure 4.13). Dramatically reduced abundance 
was detected for myelin protein zero and this finding was confirmed by 
immunoblotting (Figure 4.14). Since the immunoblot analysis of myelin binding 
protein zero was only successful for membranes loaded with 50 µg protein per lane 
(all other membranes contain 25 µg protein per lane) a separate laminin equal loading 
immunoblot is also shown for this membrane (Figure 4.14). Although only identified 
by a single peptide, fibronectin (P11276, ANOVA=2.27E-07, 11.54-fold increase) is 
a well-established marker of reactive myofibrosis in muscular dystrophy and so its 
elevated abundance was evaluated by immunoblotting, where statistically significant 
increases of fibronectin were identified in dystrophic crude hind leg homogenates 
(Figure 4.15). Increased abundance was also confirmed for the proteoglycan biglycan, 
although this was not found to be statistically significant (Figure 4.15). Figure 4.16 
depicts statistically significant increases in the abundance of annexin A2 and dysferlin, 
which were each detected by a single unique peptide (annexin A2; P07356, 
ANOVA=3.65E-06, 5.35-fold increase and dysferlin; Q9ESD7, ANOVA= 0.0028, 
2.84-fold increase).  
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Figure 4.12: Electrophoretic and immunoblot analysis of wild-type and mdx-4cv 
muscle 
Shown is a silver stained 1D gel (A) and immunoblot and statistical analysis of bands 
labelled with laminin (B). The silver stained gel shows comparable protein banding 
patterns for wild-type and mdx-4cv muscle preparations. Molecular weight marker is 
given on the left-hand-side of the image in kDa. Laminin immunoblotting did not show 
significant changes in concentration between wild-type and mdx-4cv samples and so 
it serves as a loading control for comparative immunoblotting. Graphical 
representation of the immuno-decoration level for laminin is shown (mean values ± 
SEM, Student’s t-test; unpaired; n=4). 
 
 
 
 
 
 
 
 
 
 
A) Silver Stain B) Laminin 
wt    mdx 
         4cv 
 
 Laminin
w
t
m
dx
-4
cv
0
50
100
150
%
 C
o
n
tr
o
l
wt    mdx 
         4cv 
 
 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Comparative immunoblot analysis of proteins with decreased 
abundance in dystrophic mdx-4cv enriched sarcolemma 
Shown are representative immunoblots with immuno-decorated bands labelled with 
an antibody to β-dystroglycan (A) and desmoglein-1 (B). Statistical analysis of 
immuno-decoration was performed with Student’s t-test (mean values ± SEM; 
unpaired; n=4, *p≤0.05, ***p≤0.001). 
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Figure 4.14: Comparative immunoblot analysis of myelin protein zero in 
dystrophic mdx-4cv enriched sarcolemma 
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to laminin (A) and myelin protein zero (B). These immunoblots were 
performed using 50 µg protein per lane. Statistical analysis of immuno-decoration was 
performed with Student’s t-test (mean values ± SEM; unpaired; n=4, **p≤0.01). 
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Figure 4.15: Comparative immunoblot analysis of proteins with increased 
abundance in dystrophic mdx-4cv enriched sarcolemma 
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to fibronectin (A) and biglycan (B). Statistical analysis of immuno-
decoration was performed with Student’s t-test (mean values ± SEM; unpaired; n=4, 
**p≤0.01). 
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Figure 17: Comparative immunoblot analysis of proteins with increased abundance in 
dystrophic mdx-4cv enriched sarcolemma 
Shown are immunoblots labelled with an antibody to annexin A2 (A) and dysferlin (B). Statistical 
evaluation of immuno-decoration is depicted in the corresponding graph (mean values ± SEM, 
Student’s t-test; unpaired; n=4; *p<0.05) 
 
 
 
 
 
 
Figure 4.16: Comparative immunoblot analysis of proteins with increased 
abundance in dystrophic mdx-4cv enriched sarcolemma 
Shown are are representative immunoblots with immuno-decorated bands labelled 
with antibodies to annexin A2 (A) and dysferlin (B). Statistical analysis of immuno-
decoration was performed with Student’s t-test (mean values ± SEM; unpaired; n=4, 
*p≤0.05). 
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4.3 Discussion 
In the modern era of technology-driven proteomic methodologies, subcellular 
fractionation procedures have been crucial in reducing sample complexity, predicting 
protein subcellular localisation and establishing the protein constituents of a number 
of organelles (Gatto et al., 2010), including the nucleus (Schirmer et al., 2003, 
Andersen et al., 2005), mitochondria (Mootha et al., 2003), the Golgi complex (Wu et 
al., 2004) and the plasma membrane (Zhang et al., 2003a, Oh et al., 2004). Such 
subcellular fractionation procedures can greatly reduce the protein dynamic range, 
enabling the mass spectrometric analysis of lower abundance proteins against which 
there is an intrinsic bias in mass spectrometric analyses of crude homogenates. In 
muscular dystrophy research, few comparative proteomic studies have identified 
dystrophin nor its associated glycoproteins, owing to technical difficulties associated 
with its large size, low abundance and supramolecular assembly (Hoffman et al., 1987, 
Ohlendieck and Campbell, 1991b). Here, organelle separation coupled with affinity 
purification of distinct membrane vesicles across an optimized fractionation scheme 
has been used to i) enrich for the dystrophin complex to facilitate the identification of 
potential novel interaction partners, and ii) enrich for the muscle sarcolemma to 
evaluate the secondary alterations which occur at the muscle membrane in muscular 
dystrophy.   
However, pure organelles, with the exception of the mitochondria and 
chloroplasts are difficult to obtain (Gatto et al., 2010), and so contaminating proteins 
were evident in both the dystrophin complex enriched fraction and the sarcolemma 
enriched fraction. In skeletal muscle, cross-contamination from the highly abundant 
sarcoplasmic reticulum is a particular issue. This cross-contamination from abundant 
membrane systems is likely due to complex changes that occur during tissue 
homogenisation and subcellular fractionation, including protein desorption/adsorption 
processes, the entrapment of proteins and smaller vesicles in larger membrane 
vesicles, and the formation of mixtures of membrane sheets, inside-out vesicles and 
right-side-out vesicles. Other contaminating proteins arise from the mitochondria, the 
cytosol, the ribosomes, the contractile apparatus and serum. In addition, complex 
pathophysiological processes, such as inflammation, necrosis and fibrosis, along with 
cellular adaptations in dystrophic muscle, may distort the efficient isolation of distinct 
organelles and subsequent comparative proteomic profiling of mutant versus wild-
type membrane systems. However, independent verification experiments using 
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immunoblotting or immunofluorescence microscopy can usually be used to confirm 
key findings from mass spectrometric surveys, and thus enable the objective 
evaluation of the validity of pathoproteomic profiles.   
Proteomic analysis of the dystrophin complex enriched fraction has enabled 
the identification of putative novel dystrophin interaction partners. Only a small 
number of proteins co-purified with the dystrophin-enriched complex. Of the 24 
proteins identified when searched against the Oryctolagus cuniculus database and 
filtered for a minimum of two unique peptides, the only identified proteins apart from 
the known components of the dystrophin associated glycoprotein complex were a 
number of cytokeratins (KRT10, KRT3, KRT5, KRT1, KRT14, KRT2 and KRT16), 
the anion exchange protein, voltage-dependent L-type calcium channel subunit alpha-
1S, myosin 4, fast SERCA calcium transporting ATPase, and two uncharacterised 
proteins; G1TQ93 (thought to have actin binding properties) and G1TL92 (postulated 
to have calcium ion binding activity). Detection of a number of cytokeratins suggests 
the linkage of the contractile apparatus to dystrophin at the sarcolemma as previously 
described (Stone et al., 2005). Detection of voltage-dependent L-type calcium channel 
subunit alpha1s, myosin 4, and fast SERCA calcium transporting ATPase represent 
possible contamination from the dihydropyridine receptor (as this also binds to wheat 
germ lectins), the highly abundant contractile apparatus and the sarcoplasmic 
reticulum respectively. Additional searching of the mass spectrometric data through a 
Mammalia database identified 35 proteins with ≥ 2 unique peptides. This included 
mainly similar proteins to that identified by the search against the Oryctolagus 
cuniculus database, namely several cytokeratins and the core dystrophin-associated 
glycoproteins.  
However, a number of additional proteins of interest were also identified, in 
particular desmoplakin, desmoglein-1 and desmocollin-1. Identification of these three 
proteins suggests the co-purification of a desmosome-like protein complex with the 
dystrophin complex. These cadherin-type proteins are found in desmosomes, and are 
particularly associated with cellular adhesion in epithelial cells where mutations 
and/or alterations in their abundance are associated with a loss of cellular adhesion 
and blistering of the skin (Hammers and Stanley, 2013). Aside from the skin, 
desmosomes have also been found to play an important role in other tissues which are 
subject to high levels of mechanical stress, including cardiac tissue (Lowndes et al., 
2014), as illustrated in Figure 4.17.  Mutations in genes encoding desmocollin 2, 
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desmoglein 2 and desmoplakin are all connected to cardiomyopathy, in particular 
dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy (Phelan 
et al., 2013). However, the potential roles of these cytolinker proteins in skeletal 
muscle is less well understood (Kljuic and Christiano, 2003). It is possible that these 
proteins may play a role in cellular adhesion in skeletal muscle, similar to the protein 
complexes that exist in the skin and the heart. Immunoblotting against desmoglein-1 
in quadriceps femoris and longissimus dorsi muscle from 100-day old wild-type and 
mdx mice revealed i) the detection of desmoglein-1 by immunoblotting in healthy 
skeletal muscle and ii) significantly reduced levels of this cellular adhesion protein in 
dystrophic skeletal muscle. Desmoglein-1 co-purifies with the dystrophin complex 
and suffers a similar pathobiochemical fate as the dystrophin-associated glycoproteins 
(Ohlendieck and Campbell, 1991b), thus it may represent a potential dystrophin-
associated protein of low abundance that is possibly involved in cellular adhesion in 
skeletal muscle. Its reduced abundance may have a negative impact on the dystrophic 
phenotype, as cellular adhesion is required for muscle regeneration. Cellular adhesion 
is necessary for the fusion of myoblasts to form multinucleated myotubes during 
muscle regeneration, and this has long thought to be primarily mediated by M-cadherin 
(Karalaki et al., 2009), although other studies suggest that N-cadherin can be used as 
a substitute (Hollnagel et al., 2002).  
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Figure 4.17: Localisation of desmosomes in cardiac tissue 
In cardiac tissue, the desmosome forms a junction between adjacent cardiomyocytes 
and links to the cytoskeleton via the intermediate filament desmin. Several proteins 
form the desmosome protein complex including; desmoplakin, desmoglein, 
plakophilin, plakoglobin and desmocollin. With the exception of plakoglobin, 
mutations in the genes encoding these proteins are associated with dilated 
cardiomyopathy. However, the role of these proteins in skeletal muscle is less well 
characterised. Reduced abundance of desmoglein-1 in dystrophic skeletal muscle, as 
shown in immunoblot analyses, shows that desmoglein-1 suffers the same fate as 
members of the DGC in dystrophinopathy.  
 
*Image modified from Phelan et al., 2013 
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Comparative proteomics of the enriched sarcolemma fraction from the mdx-
4cv model of DMD revealed altered abundance for 190 distinct protein species; 163 
of which were elevated in abundance and 27 of which were decreased in abundance. 
This analysis identified a number of distinct pathological alterations in muscle fibres; 
including reactive myofibrosis, compensatory up-regulation of cytoskeletal networks, 
perturbed Na+/K+- and Ca2+- pumping, shifts in bioenergetic pathways, increased 
protein synthesis, elevated cellular stress, impaired ion buffering, disturbed excitation-
contraction coupling, activation of the innate immune response and impaired 
sarcolemmal integrity.  
 A variety of bioinformatics tools, including STRING, DAVID and KEGG all 
identified the ribosome as a key enriched biological category (Figures 4.9 and 4.11) . 
Elevated abundance was detected for a considerable number of both 40S (S2, S3, S3a, 
S4, S6, S8, S9, S11, S13, S15a, S16, S18, S23, S25 and SA)  and 60S (L4, L6, L7a, 
L7, L8, L10a, L12, L13, L14, L18, L35 and L36) ribosomal proteins. This is indicative 
of an increased rate of protein synthesis and of major regeneration occuring during 
muscle repair. In particular, enhanced protein synthesis of cytoskelelal and mechanical 
proteins may occur in order for structural remodelling to take place. This is evident in 
the substantial number of structural and cytoskeletal proteins with elevated abundance 
in mdx-4cv tissue, including clathrin heavy polypeptide, myosin binding protein C, 
myosin light chain fast skeletal muscle, tubulin alpha 4a, vimentin, actinin alpha 1, 
actinin alpha 2, actinin alpha 3, gelsolin and various integrin isoforms. The 22.7-fold 
increase in the embryonic myosin heavy chain 3 is further indicative of a regenerative 
process in the dystrophin-deficient skeletal muscle (Schiaffino et al., 2015).  
 The immune response has been recognised as a key propagator of the 
dystrophic phenotype, although the exact role of the immune system is still poorly 
understood (Villalta et al., 2015). A prominent role for the immune response is also 
evident here in the mass spectrometry data of enriched sarcolemma from the mdx-4cv 
mouse with the top three increased proteins; eosinophil peroxidase, H-2 class II 
histocompatibility antigen gamma chain and caspase recruitment domain-containing 
protein 19, associated with immunity (Table 4.2). Eosinophil peroxidase is the 
dominant component of  eosinophilic granulocytes (Wang and Slungaard, 2006) and 
is associated with eosinophil migration, the generation of potent oxidising species 
(Acharya and Ackerman, 2014) and positive regulation of IL-4, a cytokine involved 
in the differentiation of naïve helper T cells into Th2 cells (Wehling-Henricks et al., 
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2008). Initially associated with host defence through a substrate-dependent ability to 
kill bacteria, viruses and parasites as demonstrated by the Klebanoff group (Jong et 
al., 1981, Henderson et al., 1980), eosinophil peroxidase has been more recently 
implicated in disease pathology, for example in the pathogenesis of ulterative colitis 
(Forbes et al., 2004). In the context of DMD eosinophil invasion into skeletal muscle 
has been previously identified (Cai et al., 2000). The associated increase in levels of 
eosinophil peroxidase, as seen here in the sarcolemma enriched fraction from murine 
hind leg, may result in elevated levels of IL-4 which may prove beneficial for the 
recruitment and fusion of satellite cells involved in muscle regeneration. However, the 
IL-4-induced shift to a a prolonged Th2 immune reponse could potentially contribute 
to chronic inflammation and fibrosis (Wehling-Henricks et al., 2008). In addition, the 
production of the potent toxins hypohalous acids and peroxynitrate catalysed by 
eosinophil peroxidase may exacerbate skeletal muscle damage (Wehling-Henricks et 
al., 2008). The 60.7-fold increase in the caspase recruitment domain-containing 
protein Card19 is an interesting finding considering it has previously been shown to 
play a role in inhibiting the effects of BCL10-induced activation of NF-κB (Woo et 
al., 2004). This increase in Card19 possibly represents a compensatory mechanism to 
counteract excessive activation of NF-κB, whereby skeletal muscle-specific activation 
of NF-κB occurs even prior to the onset of dystrophic damage in the mdx mouse 
(Kumar and Boriek, 2003) and inhibition of NF-κB improves muscle function and 
reduces skeletal muscle degeneration in the mdx mouse model (Messina et al., 2006, 
Messina et al., 2009).  
Dramatically elevated abundances were also evident for two subunits of the 
histocompatibility complex; 117.4-fold increase for H-2 class II histocompatibility 
antigen gamma chain and 20.1-fold increase for H-2 class I histocompatibility antigen, 
K-B alpha chain. While major histocompatibility complex I proteins are present on 
most nucleated cells and have previously been found at increased levels on muscle 
fibres from DMD patients (McDouall et al., 1989), major histocompatibility complex 
II proteins are normally only present on professional antigen-presenting cells and so 
the large increase in H-2 class II histocompatibility antigen gamma chain deteccted in 
this study likely reflects the infiltration of antigen-presenting cells into dystrophic 
skeletal muscle (Evans et al., 2009). Other immune proteins of interest include 
receptor-type tyrosine-protein phosphatase C which is positive regulator of T-cell co-
activation (Mustelin and Taskén, 2003) and the macrophage-restricted marker 
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sialoadhesin and macrophage mannose receptor 1 which are indicative of macrophage 
infiltration and inflammation (O'Neill et al., 2013).  
 A number of proteins are associated with sarcolemmal alterations (as 
illustrated in Figure 4.18), an expected result given that the disease primarily affects 
the DGC of the sarcolemma. Decreased abundance was detetected for protein 
components of this complex, namely dystrophin, β-dystroglycan, α-sarcoglycan and 
δ-sarcoglyan, as origianlly described in 1991 (Ohlendieck and Campbell, 1991b). The 
loss of dystrophin and concomitant perturbation of the DGC appears to trigger a 
number of secondary alterations at the sarcolemma, with a variety of proteins showing 
elevated abundance, including the α1 and α2 subunits of Na+/K+-ATPase and the 
plasma membrane calcium transporting ATPase 1 (PMCA1). This indicates altered 
ion exchange across the muscle membrane, whereby the increase in the Na+/K+-
ATPase may represent a compensatory mechanism to counteract abnormal ion fluxes 
across the dystrophin-deficient membrane (Murphy et al., 2015a, Dunn et al., 1995). 
PMCA is responsible for the extrusion of Ca2+ out of the cell and the establishment of 
a Ca2+ gradient with low levels in the cytosol and higher levels outside of the cell, and 
PMCA levels have been demonstrated to increase in response to raised cytoplasmic  
Ca2+ concentrations (Abell et al., 2011). Heightened levels of PMCA have been 
previously identified in EDL muscle from mdx mice (Cully et al., 2012), where it has 
been proposed that PMCA activity is affected by increased Ca2+ leakage across the 
dystrophic membrane, and thus its abundance is augmented to maintain an activity 
similar to that seen in wild-type mice.  
In addition, increased abundance was measured for integrin α7, the membrane 
repair proteins myoferlin and dysferlin and the actin-crosslinking protein filamin C. 
Myoferlin and dysferlin are highly related proteins of the ferlin family which are 
proposed to mediate membrane fusion events in response to Ca2+, and thus are 
involved in the maintenance and repair of the plasma membrane (Bansal and 
Campbell, 2004). The importance of these proteins in membrane repair is evident by 
the fact that mutations in dysferlin are responsible for limb-girdle muscular dystrophy 
(type 2B) and Miyoshi myopathy and that increased abundance of myoferlin mRNA 
and protein have been identified in damaged myofibres from γ-sarcoglycan null mice 
and mdx mice (Demonbreun et al., 2010). Here, elevated abundance was detected for 
both myoferlin and dysferlin in the sarcolemma enriched fraction from mdx-4cv mice, 
indicating a potential compensatory mechanism to help repair micro-ruptures in the 
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dystrophin-deficient membrane. Indeed, increased abundance was also detected for 
annexin A1 and annexin A2 (P07356, 1 unique peptide, 5.35-fold increase), proteins 
previously proposed to be involved in dysferlin-mediated membrane repair (Lennon 
et al., 2003). The filamins are a class of actin-crosslinking proteins with three isoforms 
filamin A, B and C. Filamin C is a skeletal and cardiac muscle-specific isoform which 
localises to the myotendinous junction, sarcolemma, costameres, Z-disks and 
intercalated disks where it interacts with the DGC, integrins and a number of Z-disk 
proteins including myotilin (van der Ven et al., 2000) and myopodin (Linnemann et 
al., 2010). Recent results from a medaka mutant with a nonsense mutation in a filamin 
C homolog indicate that filamin C is involved in the maintenance of Z-disk structures, 
the attachment of myofibrils to the sarcolemma and the stabilisation of myofibrils at 
the myotendinous junction (Fujita et al., 2012). The elevated abundance of filamin C 
seen here may be attritutable to a compensatory increase to stabilise the weakened 
muscle, help protect against mechanical stress and to improve actin linkage and 
structual stability in the absence of dystrophin. The 4.8-fold increase in the abundance 
of integrin alpha 7, a transmembrane link betweeen the basal lamina and the muscle 
fibre, is a potential compensatory mechanism that may partially offset the negative 
impact of dystrophin deficiency on muscle fibre architecture. Indeed transgenic 
expression of rat integrin alpha 7 in severely dystrophic mdx/utr−/− mice missing both 
dystrophin and its homologous protein utrophin improves lifespan, mobility and 
muscle function and reduces kyphosis and hindlimb joint contractures in these mice 
(Burkin et al., 2001). 
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Figure 4.18: Impaired sarcolemmal integrity in the mdx-4cv model of Duchenne 
muscular dystrophy 
Mass spectrometric analysis reveals alterations in abundance for 190 proteins in the 
mdx-4cv mouse model of dystrophinopathy. A number of these proteins are associated 
with the sarcolemma, a select panel of which are illustrated above, indicating that 
dystrophin deficiency in the mdx-4cv mouse model is accompanied by impaired 
sarcolemmal integrity. Proteins to the left of the y-axis line are those with decreased 
abundance, while proteins to the right are those with elevated abundance in the mdx-
4cv model. Except for dysferlin all proteins were detected by a minimum of two unique 
peptides.  
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 In the many types of muscular dystrophy, moderate fibre type conversions are 
evident, whereby fast type IIb fibres have been shown to be more susceptible to 
degenerative processes (Webster et al., 1988). Indeed 25% of muscle fibres in 
Duchenne patients only express the adult slow isoform of myosin heavy chain (Marini 
et al., 1991). In this study focusing on a sarcolemma-enriched fraction, co-purifying 
proteins from other abundant systems identified some impact on fibre speciation, with 
increased abundance seen for MyHC-2x (myosin-1), MyHC-2b (myosin-4) and fast 
myosin-binding protein C. However, no clear fibre type switching is evident, likely 
due to the fact that the original sample consisted of combined muscles of the hind-
limb which would contain a heterogeneous mix of fibre types. Encouraging 
improvements in mass spectrometric analyses of muscle have recently enabled single 
muscle fibre proteomic analysis which has the capacity to detect fibre-type specific 
features of human aging, with glycolysis and glycogen metabolism increased in slow 
but decreased in fast muscle fibres during fibre senescence (Murgia et al., 2017). Such 
an approach could potentially be used to elucidate the pathophysiology of DMD in a 
sub-type specific manner, which could be especially interesting given the observed 
augmented vulnerability of fast muscle fibres to disintegration.  
 An interesting finding is the 5.3-fold decrease in the intermediate filament 
protein synemin; of which two splice variants exist in humans, α-synemin and β-
synemin (also known as desmuslin), with α-synemin predominantly expressed in the 
brain and and β-synemin predominantly expressed in skeletal muscle (Mizuno et al., 
2004). β-synemin was originally shown to interact with the other major intermediate 
filaments desmin and vimentin to form heteropolymeric intermediate filaments where 
it contributes to cellular resilience (Bellin et al., 1999), with later studies also 
suggesting an interaction with components of the DGC; namely α-dystrobrevin 
(Mizuno et al., 2001), dystrophin, and utrophin (Bhosle et al., 2006). Confocal 
microscopy localises β-synemin mainly to the muscle Z-line, the costamere and the 
neuromuscular and myotendinous junctions of a myofibre, suggesting  a functional 
role for β-synemin in maintaining muscle integrity during excitation-contraction-
relaxation cycles (Mizuno et al., 2004). Thus, reduced levels of β-synemin are possibly 
involved in the secondary pathobiochemical changes that render dystrophin-deficient 
fibres more susceptible to micro-rupturing of the disintegrating sarcolemma.  
This finding is particularly interesting when considered alongside the observed 
decrease in the abundance of the myelin specific proteins periaxin and myelin binding 
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protein zero. Myelin binding protein zero displayed the second highest fold decrease 
with a fold change of -33.8 in mdx-4cv sarcolemma. Reduced abundance was also 
detected for myelin basic protein and myelin associated glycoprotein although these 
proteins were only identified by a single unique peptide (myelin basic protein: 
accession number P04370; confidence 3.18; Anova (p) 8.9E-05; fold decrease 16.8 
and myelin-associated glycoprotein: accession number P20917; confidence 2.64; 
Anova (p) 2.6E-03; fold decrease 33.5). Myelin basic protein belongs to the basic 
group of myelin proteins; proteins with a high positive charge and thus basic 
isoelectric point, and is one of the predominant proteins in central nervous system 
myelin, where it is responsible for maintaining the stability and integrity of the myelin 
sheath (Han et al., 2013). It also interacts with a number of proteins including the 
calcium sensor calmodulin (Grand and Perry, 1980), actin, tubulin (Boggs, 2006) and 
Src homology-3 domain containing proteins, and thus may act as a signalling molecule 
modulating the myelin membrane and cytoskeletal assembly (Polverini et al., 2008). 
Myelin protein zero, a cell adhesion molecule of the immunoglobulin family, 
is the most abundant myelin protein in the peripheral nervous system (Han et al., 
2013). It plays an important role in normal myelination, with mutations in the myelin 
protein zero gene resulting in a vast array of neuropathies, including Charcot-Marie-
Tooth disease type 1, Dejerine-Sottas syndrome and congenital hypomyelination 
(Nelis et al., 1999). Another member of the immunoglobulin family is myelin-
associated glycoprotein which is present in both central and peripheral system myelin 
(Han et al., 2013). It has been shown to be involved in the inhibition of neuronal 
regeneration in developing cerebellar and adult dorsal root ganglion neurons 
(Mukhopadhyay et al., 1994). The reduced abundance of a number of myelin proteins, 
including myelin protein zero, myelin basic protein, myelin associated glycoprotein 
and periaxin, likely reflects a general muscular dystrophy-induced perturbation of the 
motor neuron system and in particular myelination.  
Interestingly, a recent study demonstrated a role for dystrophin in 
developmental myelination (Aranmolate et al., 2017), which may help explain the 
reduced levels of myelination specific proteins in the absence of dystrophin, as 
observed here in the dystrophin-deficient muscle sarcolemma. Indeed the study by 
Aranmolate identified reduced levels of total myelin basic protein in the cerebral 
cortex of mdx mice at early stages of development suggesting that myelination is 
developmentally delayed in this model. Periaxin was originally described in 1994 as 
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a novel protein of myelinating Schwann cells (Gillespie et al., 1994), and was later 
found by the same group to be linked to a dystroglycan complex at the Schwann cell 
plasma membrane through interactions with dystrophin-related protein DRP2 
(Sherman et al., 2001). Given DRP2 is specifically depleted in the absence of L-
periaxin, L-periaxin potentially acts as a scaffolding protein for the DRP2 dystrophin 
associated glycoprotein complex in Schwann cells, and its ability to homodimerise 
may help to cluster the complex (Sherman et al., 2001). Since dystroglycan interacts, 
albeit weakly, with DRP2 presumably anchoring the periaxin/DRP2 protein complex 
to the Schwann cell plasma membrane, the reduced abundance of β-dystroglycan in 
DMD may destabilise the Schwann cell dystroglycan complex thus leading to the 
reduced abundance of periaxin as detected here by mass spectrometry. As such a 
hypothesis remains to be tested experimentally, all that can be concluded with 
confidence is that reduced abundance of periaxin indicates muscular-dystrophy related 
changes in the motor neuron system, particularly related to peripheral nerve 
myelination whereby a periaxin/DRP2/dystroglycan complex could act as a signalling 
complex which regulates myelin sheath thickness and stability (Wrabetz and Feltri, 
2001).  
 In contrast to these Schwann cell markers, elevated abundance was identified 
for the neural cell adhesion molecule N-CAM1 and the synaptic vesicle membrane 
protein VAT-1. VAT-1 is an abundant integral membrane protein of cholinergic 
synaptic vesicles, with early evidence for the structure and function of this protein 
coming from studies using VAT-1 isolated from the Torpedo electric organ (Linial et 
al., 1989). The VAT-1 protein is involved in vesicular transport and plays a role in 
neurotransmitter storage and release at cholinergic synapsis. N-CAM1 is a cell 
adhesion glycoprotein with particularly high expression in the central nervous system 
where it is involved in cellular adhesion, neurite outgrowth and cell migration, 
profileration and survival. N-CAM is also initially expressed at the muscle 
sarcolemma during skeletal muscle development, and while its levels decrease 
significantly following muscle fibre innervation, its abundance increases once again 
in both the fibre cytoplasm and sarcolemma in response to denervation and nerve crush 
(Moore and Walsh, 1986). Moreover, Walsh and Moore also observed increased N-
CAM staining associated with regenerating myofibres in biopsies of patients with 
neuromuscular disease, including Becker and Duchenne muscular dystrophy, limb 
girdle muscular dystrophy, polymyositis and mitochondrial myopathy (Walsh and 
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Moore, 1985). This finding was also more recently confirmed by Prattis and 
colleagues where immunohistochemistry identified elevated N-CAM abundance in 
dystrophic mdx mice and GRMD dogs (Prattis et al., 1994). Thus, the ocurrence of 
increased N-CAM1 levels detected here agrees with degeneration-regeneration cycles 
in the neuromuscular system.  
 
4.3.1 Conclusions 
Mass spectrometry-based proteomics has been instrumental in developing the field of 
muscle proteomics and in identifying proteome-wide alterations in muscle disease. In 
DMD, the large size, complexity, low-abundance and hydrophobicity of the DGC 
renders its proteomic characterisation technically challenging. In this chapter, lectin 
affinity chromatography has enabled the successful enrichment of the DGC and the 
sarcolemma from skeletal muscle. Interaction proteomics of the dystrophin complex 
enriched fraction has established the cytolinkers desmoglein-1 and desmoplakin as 
potential novel dystrophin-associated proteins. Immunoblotting of desmoglein-1 in 
quadriceps femoris and longissimus dorsi muscle from the mdx mouse and crude 
skeletal muscle homogenates from the mdx-4cv mouse has identified significantly 
lower levels of desmoglein-1 in these dystrophic mouse models. Thus, this 
desmosomal protein suffers a similar pathobiochemical fate to the known protein 
members of the DGC in the absence of dystrophin. The comparative proteomic 
profiling of the sarcolemma enriched fraction from the mdx-4cv mouse could 
furthermore establish the initiation of membrane repair involving myoferlin, dysferlin 
and annexins, compensatory increases in cytoskeletal proteins, infiltration of immune 
cells, enhanced cellular stress and an increased rate of protein synthesis suggested by 
increases in a large number of ribosomal protein subunits. Besides well-established 
decreases in dystrophin and its associated glycoproteins, reduced protein abundances 
were also detected for the scaffolding protein periaxin and myelin protein zero of 
Schwann cells, which may be indicative of altered myelination levels of motor neurons 
in muscular dystrophy. 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter Five 
 
Proteomic profiling of the aged mdx-4cv heart; implications 
for dystrophinopathy-related cardiomyopathy 
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5.1 Introduction 
Dystrophin, a large sub-sarcolemmal cytoskeletal protein of 427 kDa, is responsible 
for linking the actin cytoskeleton to components of the extracellular matrix through 
the DGC. Mutations affecting the Dmd gene encoding for dystrophin lead to 
dystrophinopathies including DMD, BMD and X-linked dilated cardiomyopathy 
(XLDCM) (Ferlini et al., 1999). Duchenne and Becker muscular dystrophies both 
involve progressive degeneration of the skeletal muscle with some cardiac 
involvement, with DMD representing the more severe form of the allelic disorder. 
XLDCM meanwhile is characterised by progressive cardiac dysfunction leading to 
heart failure in the absence of any skeletal muscle degeneration (Johnson et al., 2012). 
Similar to skeletal muscle, the DGC also exists in the sarcolemma of cardiomyocytes 
where it maintains membrane integrity and acts as a scaffold for signalling molecules 
such as nitric oxide. However, unlike in skeletal muscle where regeneration is 
facilitated by the activation of the satellite stem cell pool, there is little evidence of 
regeneration in the dystrophin-deficient heart despite the progressive loss of 
cardiomyocytes (Heydemann and McNally, 2007). Cardiac complications are usually 
detected later than skeletal muscle symptoms, with the earliest changes typically 
identified between the ages of 10 to 15 years (McNally, 2007). However, in one study, 
up to 25% of DMD patients with a mean age of 10.7 years already displayed abnormal 
left ventricle function, as indicated by a left ventricular ejection fraction < 55% 
(Duboc et al., 2005). This indicates that the delay in overt cardiomyopathy is not due 
to a later age of onset but instead it may remain undetected possibly as a result of 
reduced physical activity due to skeletal muscle weakness.  
Cardiac complications in DMD include abnormal left ventricle function and 
size, reduced systolic function and cardiac arrhythmias. Angiotensin-converting 
enzyme inhibitors and β-adrenergic blockers are standard therapy for cardiomyopathy 
in general and so are typically also used in the treatment of muscular dystrophy-
associated cardiomyopathy. These therapies usually improve left ventricular function 
and size towards normal levels (Heydemann and McNally, 2007). Other approaches 
are also being investigated, such as the use of the non-ionic triblock co-polymer 
poloxamer 188 as a membrane sealant. Pre-treatment of dystrophin-deficient 
cardiomyocytes with poloxamer 188 induced sufficient sealing of the membrane to 
prevent stretch-induced injury. In addition, in vivo administration of poloxamer 188 to 
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dystrophic mdx mice blocked the development of acute cardiac failure following 
infusion of the cardiovascular stressor dobutamine (Yasuda et al., 2005). A long-term 
beneficial effect has also been illustrated in the larger and more severely affected 
GRMD canine model using chronic infusion of poloxamer 188 (Townsend et al., 
2010).  
 A number of studies have indicated that the survival rate of patients with DMD 
is increasing due to improvements in the management of the disorder. In particular, 
advances in respiratory care such as non-invasive ventilation and tracheostomy have 
led to a longer life-span (Passamano et al., 2012). However, since respiratory failure, 
previously the main cause of death in patients, is now more manageable progressive 
cardiomyopathy has become a leading cause of morbidity and mortality (Yilmaz and 
Sechtem, 2012). Several potential therapies for DMD are currently being trialled and 
some, including exon skipping and stem cell therapy, have shown promise in 
ameliorating the dystrophic phenotype in animal models of the disorder (Sampaolesi 
et al., 2006, Alter et al., 2006). However, while these treatments appear to show 
beneficial effects in skeletal muscle, the heart remains largely untreated (Lu et al., 
2005). Caution needs to be excised with such therapies as studies with animal models 
have demonstrated that treatment of the skeletal muscle alone may actually accelerate 
cardiac disease (Townsend et al., 2008). It is possible that increases in physical activity 
as a result of improvements in skeletal muscle strength may cause heightened cardiac 
injury in untreated dystrophin-deficient hearts, ultimately progressing to heart failure. 
Thus, studies investigating the pathobiochemistry of DMD-associated 
cardiomyopathy are required in order to best manage cardiac care in patients to further 
improve long-term survival.  
 Previous proteomic studies of dystrophic cardiomyopathy have focused on the 
mdx model of DMD. Both 2D-DIGE and label-free LC approaches coupled with mass 
spectrometry have been used to characterise the dystrophic heart. Such studies have 
identified alterations in energy metabolism, the contractile apparatus and the cellular 
stress response (Holland et al., 2013, Lewis et al., 2010). Building upon these 
comparative proteomic studies, a highly sensitive LC-MS/MS approach was used to 
investigate the molecular pathogenesis of cardiomyopathy in an alternative animal 
model; the mdx-4cv mouse model of DMD. This study has identified significant 
decreases for a variety of mitochondrial proteins, the basal membrane protein laminin, 
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various components of the DGC and the calcium-handling protein sarcalumenin in the 
aged dystrophic heart. Loss of full-length dystrophin appears to be correlated with 
elevated levels of fibrotic proteins such as lumican, asporin and periostin, proteins of 
the extracellular matrix and the cytoskeleton, and various heat shock proteins. Overall, 
cardiomyopathy in the senescent mdx-4cv heart appears to be associated with altered 
metabolism, calcium handling, the cellular stress response and the cytoskeletal 
network, similar to that seen in the mdx model.  
 
5.1.1 Experimental Design  
To determine the effects of dystrophin deficiency on the senescent cardiac proteome, 
label-free mass spectrometric analysis was performed on 20-month old cardiac tissue 
from the mdx-4cv animal model of DMD. The urea soluble protein constellation was 
prepared from whole hearts of age-matched wild-type and mdx-4cv mice (n=4). 
Following protein digestion and acidification, the samples were kept on ice for 30 min, 
centrifuged at 14,000 × g at 4 °C for 20 min and the supernatant was transferred to 
vials for mass spectrometric analysis. Cardiac samples were analysed by label-free 
LC-MS/MS using an Ultimate 3000 NanoLC system (Dionex Corporation, Sunnyvale, 
CA, USA) coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific). 
Peptides generated from cardiac proteins were eluted using the following binary 
gradient: solvent A [2% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade water] 
and 0-90% solvent B [80% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade 
water]: 2-40% solvent B for 120 min, 40-90% solvent B for 2.5 min, 90% solvent B 
for 9 min and 2% solvent B for 43 min. Relative quantification and identification of 
mass spectrometry raw files (wild-type n=4, mdx-4cv n=3) was performed with 
Progenesis QI for Proteomics software, using Sequest HT and MASCOT search 
engines and the UniProtKB-SwissProt database. Bioinformatics analysis was 
conducted using the PANTHER database of protein families and STRING software. 
Key proteins of interest were independently verified by comparative immunoblotting 
to confirm altered protein abundance levels of cardiac proteins revealed by label-free 
mass spectrometry.  
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5.2 Results 
A deeper understanding of the cardiomyopathy arising from dystrophin deficiency is 
essential given the high proportion of cardiac complications in Duchenne patients. For 
this reason, proteomic profiling of wild-type versus mdx-4cv hearts obtained from 20-
month old mice was conducted. This age group was chosen as it represents the end 
stage of the disease and thus may provide insights into the proteomic basis behind 
cardiac failure. Label-free LC-MS/MS identified alterations in the expression of 98 
proteins, a number of which were subsequently verified by immunoblotting. Of these 
98 proteins, 54 display increased expression in the mdx-4cv heart while the remaining 
44 proteins are decreased in abundance in dystrophin-deficient hearts. 
 
5.2.1 Qualitative analysis of wild-type versus mdx-4cv senescent heart  
Advances in mass spectrometry have accelerated in recent years. While the 
introduction of 2D-DIGE was heralded as a major breakthrough just under 20 years 
ago in terms of its ability to circumvent issues of gel-to-gel variation and 
reproducibility (Unlü et al., 1997), the proteomic era has taken another step forward 
with the consistently improving resolution of LC-MS/MS. Gel-based proteomic 
studies have largely failed to identify very large molecular weight proteins, or have 
identified them but by very few peptides and little sequence coverage (Lewis and 
Ohlendieck, 2010a). In this proteomic survey, qualitative analysis of the aged heart 
identified 1,803 proteins in wild-type samples, with 1,350 of these proteins detected 
by at least two unique peptides. 1,660 proteins were identified in mdx-4cv cardiac 
samples of which 1,263 proteins possessed a minimum of two unique peptides. A 
number of components of the DGC were identified in wild-type cardiac samples 
including the full-length Dp427 isoform of dystrophin, α-, β-, δ- and γ-sarcoglycan, 
dystroglycan, isoform 7 of α-dystrobrevin and α1-syntrophin. Dystrophin was 
identified by 24 unique peptides, a major analytical achievement given the large size, 
low abundance and hydrophobicity of this sarcolemmal protein. 
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5.2.2 Quantitative analysis of cardiac dystrophin and members of the dystrophin-
glycoprotein complex 
Quantitative analysis of wild-type versus mdx-4cv aged cardiac tissue identified 
reduced abundance for several components of the DGC. The full-length Dp427 
isoform of dystrophin exhibits a 8.6-fold decrease in mdx-4cv cardiac tissue, agreeing 
with the dystrophic status of this animal model and its low rate of revertant fibres 
(Danko et al., 1992). Other members of the cardiac DGC which display reduced 
abundance in dystrophic cardiac preparations are α1-syntrophin, α-sarcoglycan, β-
sarcoglycan and δ-sarcoglycan (Table 5.1 and Figure 5.1). Although confident 
identification of proteins by LC-MS/MS typically requires the detection of a minimum 
of two peptides, the identification of α-, β-, and δ-sarcoglycan by a single unique 
peptide is shown in Table 5.1 as their small size, low abundance and highly 
hydrophobic nature typically results in insufficient coverage during routine proteomic 
screens of crude tissue homogenates. The identification of reduced expression of the 
cardiac DGC enabled simultaneous proteomic analysis of dystrophin deficiency and 
corresponding secondary abnormalities within the same animal and within a single 
analytical run. 
 
 
 
Table 5.1: Components of the DGC with reduced expression in 20-month mdx-4cv 
heart 
 
Accession 
Number 
Protein Name Unique 
Peptides 
Confidence 
Score 
ANOVA Fold Change 
P11531 Dystrophin 24 1299.27 1.79E-04 
 
-8.56 
Q61234 Alpha-1-
syntrophin 
2 139.43 2.37E-03 
 
-4.36 
P82349 Beta-
sarcoglycan 
1 81.6 5.90E-03 
 
-4.01 
P82350 Alpha-
sarcoglycan 
1 39.57 6.19E-03 
 
-3.33 
P82347 Delta-
sarcoglycan 
1 50.49 5.97E-04 
 
-3.31 
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Figure 5.1: Reduction in the expression of DGC proteins as identified by LC-
MS/MS 
Graphical representation of the reduction in dystrophin, α-1-syntrophin, α-
sarcoglycan, β-sarcoglycan and δ-sarcoglycan in 20-month old mdx-4cv hearts, as 
determined by label-free LC-MS//MS. Values are for normalised protein abundances 
from Progenesis QI for Proteomics software analysis, and statistical analysis was 
performed using an unpaired Student’s t-test (n≥3; wt=4, mdx-4cv=3, mean ± SEM, 
*p≤0.05, **p≤0.01, ***p≤0.001). 
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5.2.3 Label-Free LC/MS-MS analysis of protein species with reduced expression in 
mdx-4cv crude heart extracts 
Aside from the reduced expression of protein components of the DGC, a number of 
other proteins were found to be reduced in abundance indicating proteomic alterations 
in the absence of dystrophin. Mitochondrial metabolism in particular appears to be 
severely affected, given the large decreases in the expression of lipoamide 
acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex 
and succinyl-CoA ligase (22-fold decrease and 10.2-fold decrease respectively). 
Reduced expression is seen for a variety of different protein classes including 
metabolic proteins (lactate dehydrogenase, adenylosuccinate synthetase, perilipin, 
phosphofructokinase, lipid-transfer protein, glycogen phosphorylase, hydroxysteroid 
dehydrogenase-like protein 2), cytoskeletal proteins (spectrin, plectin), ion-regulatory 
proteins (sarcalumenin, SERCA Ca2+-ATPase and Na+/K+-ATPase) and proteins of 
the extracellular matrix (laminin alpha-2 and beta-2). The 44 proteins with decreased 
abundance are listed in Table 5.2 below.  
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Table 5.2: List of identified proteins with a significantly reduced abundance in 20-
month old mdx-4cv heart versus age-matched wild-type heart as determined by label-
free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
P53395 Dbt  Lipoamide 
acyltransferase 
component of branched-
chain alpha-keto acid 
dehydrogenase complex, 
mitochondrial  
2 98.81 4.51E-
02 
22.09 
Q9Z2I9 Sucla2  Succinyl-CoA ligase 
[ADP-forming] subunit 
beta, mitochondrial  
3 174.01 8.02E-
03 
10.20 
P11531 Dmd  Dystrophin  24 1299.27 1.79E-
04 
8.56 
P16125 Ldhb  L-lactate dehydrogenase 
B chain  
2 64.80 5.83E-
03 
6.10 
P48962 Slc25a4  ADP/ATP translocase 1  4 107.16 3.09E-
02 
5.59 
P01869 Ighg1  Ig gamma-1 chain C 
region, membrane-
bound form  
2 51.72 4.41E-
03 
4.37 
Q61234 Snta1  Alpha-1-syntrophin  2 139.43 2.37E-
03 
4.36 
Q61102 Abcb7  ATP-binding cassette 
sub-family B member 7, 
mitochondrial  
2 112.89 7.73E-
03 
3.80 
P28650 Adssl1  Adenylosuccinate 
synthetase isozyme 1  
2 115.81 1.21E-
02 
2.99 
P07901 Hsp90aa1  Heat shock protein HSP 
90-alpha  
2 113.80 6.95E-
03 
2.67 
P08032 Spta1  Spectrin alpha chain, 
erythrocytic 1  
2 120.03 1.35E-
02 
2.62 
O88492 Plin4  Perilipin-4  9 516.88 2.68E-
04 
2.55 
P12382 Pfkl  ATP-dependent 6-
phosphofructokinase, 
liver type  
2 118.00 1.10E-
02 
2.35 
Q9QXS1 Plec  Plectin  7 346.77 1.32E-
02 
2.23 
P01872 Ighm  Ig mu chain C region  6 313.39 8.48E-
03 
2.21 
Q7TQ48 Srl  Sarcalumenin  3 154.53 1.63E-
02 
2.07 
Q05793 Hspg2  Basement membrane-
specific heparan sulfate 
proteoglycan core 
protein  
5 318.10 8.26E-
03 
2.03 
Q60675 Lama2  Laminin subunit alpha-2  13 632.93 1.31E-
03 
1.98 
Q9DC70 Ndufs7  NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 7, mitochondrial  
2 86.91 8.07E-
03 
1.87 
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Q02566 Myh6  Myosin-6  5 420.64 2.10E-
02 
1.84 
P09411 Pgk1  Phosphoglycerate kinase 
1  
4 354.81 7.72E-
03 
1.83 
Q9JIF9 Myot  Myotilin  3 103.24 4.45E-
04 
1.78 
Q8VDN2 Atp1a1  Sodium/potassium-
transporting ATPase 
subunit alpha-1  
3 116.76 1.80E-
02 
1.75 
P50544 Acadvl  Very long-chain specific 
acyl-CoA 
dehydrogenase, 
mitochondrial  
4 258.76 1.69E-
03 
1.71 
Q9R0P3 Esd  S-formylglutathione 
hydrolase  
2 48.47 4.21E-
02 
1.70 
Q60597 Ogdh  2-oxoglutarate 
dehydrogenase, 
mitochondrial  
4 210.69 1.95E-
03 
1.70 
P52825 Cpt2  Carnitine O-
palmitoyltransferase 2, 
mitochondrial  
13 760.94 3.67E-
04 
1.70 
Q8BMS1 Hadha  Trifunctional enzyme 
subunit alpha, 
mitochondrial  
9 561.61 1.67E-
04 
1.68 
Q8R429 Atp2a1  Sarcoplasmic/endoplasm
ic reticulum calcium 
ATPase 1  
2 41.78 4.22E-
02 
1.64 
P32020 Scp2  Non-specific lipid-
transfer protein  
2 125.82 1.78E-
02 
1.63 
Q9WUB3 Pygm  Glycogen 
phosphorylase, muscle 
form  
4 253.34 8.33E-
03 
1.60 
P02469 Lamb1  Laminin subunit beta-1  2 105.58 8.01E-
03 
1.54 
Q78IK4 Apool  MIC complex subunit 
Mic27  
3 65.98 1.04E-
02 
1.51 
Q99JY0 Hadhb  Trifunctional enzyme 
subunit beta, 
mitochondrial  
10 462.29 6.73E-
03 
1.48 
Q8CI94 Pygb  Glycogen 
phosphorylase, brain 
form  
10 492.48 3.95E-
04 
1.46 
Q8VHX6 Flnc  Filamin-C  2 116.85 2.42E-
02 
1.39 
P62897 Cycs  Cytochrome c, somatic  2 200.47 1.26E-
02 
1.38 
Q8BWT1 Acaa2  3-ketoacyl-CoA thiolase, 
mitochondrial  
3 228.54 1.73E-
02 
1.35 
Q99MN9 Pccb  Propionyl-CoA 
carboxylase beta chain, 
mitochondrial  
2 116.79 2.97E-
02 
1.34 
Q2TPA8 Hsdl2  Hydroxysteroid 
dehydrogenase-like 
protein 2  
2 81.26 2.75E-
02 
1.32 
Q9CQQ7 Atp5f1  ATP synthase F(0) 
complex subunit B1, 
mitochondrial  
2 83.06 1.02E-
02 
1.30 
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Q9CQJ8 Ndufb9  NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 9  
2 56.39 1.26E-
02 
1.28 
P47934 Crat  Carnitine O-
acetyltransferase  
5 270.16 1.10E-
02 
1.26 
Q61292 Lamb2  Laminin subunit beta-2  3 166.26 1.61E-
02 
1.26 
 
 
 
5.2.4 Label-Free LC/MS-MS analysis of protein species with increased expression 
in mdx-4cv crude heart extracts 
The global picture of increased protein abundance is suggestive of fibrosis, 
exemplified by the increases in a number of key pro-fibrotic proteins in the mdx-4cv 
heart. Such proteins include periostin, lumican, asporin and collagen VI. Myosin light 
chain kinase 3 represents the protein with the highest increase in expression (413.9-
fold increase), suggesting alterations in cardiac cells in relation to the regulation of 
force and the rate of cross-bridge recruitment. Proteins associated with metabolism 
again show major alterations, indicating that changes in cardiac metabolism are a 
consequence of dystrophinopathy. Such metabolic proteins include hypoxanthine-
guanine phosphoribosyl-transferase, apolipoprotein A-I, creatine kinase, alcohol 
dehydrogenase, adenylate kinase, triosephosphate isomerase, enolase, 
glyceraldehyde-3-phosphate dehydrogenase, prostaglandin reductase and aldolase. 
Compensatory stabilisation of the weakened cytoskeletal network is implied by the 
increases in myosin-9/non-muscle myosin heavy chain A, dynactin, talin, cofilin, 
vinculin and tubulin. The 54 proteins with elevated abundance are listed in Table 5.3 
below.  
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Table 5.3: List of identified proteins with a significantly increased abundance in 20-
month old mdx-4cv heart versus age-matched wild-type heart as determined by label-
free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
Q3UIZ8 Mylk3  Myosin light chain 
kinase 3  
4 121.10 1.56E-
02 
413.99 
Q9D051 Pdhb  Pyruvate 
dehydrogenase E1 
component subunit 
beta, mitochondrial  
2 93.71 5.45E-
03 
35.88 
P00493 Hprt1  Hypoxanthine-
guanine 
phosphoribosyltrans
ferase  
5 212.70 6.17E-
04 
4.75 
O08677 Kng1  Kininogen-1  2 65.97 7.71E-
03 
4.73 
Q62009 Postn  Periostin  3 124.97 1.19E-
02 
4.23 
P35441 Thbs1  Thrombospondin-1  3 169.18 1.13E-
02 
4.22 
Q8VDD5 Myh9  Myosin-9  2 147.69 3.20E-
02 
4.08 
P51885 Lum  Lumican  2 59.86 1.72E-
02 
3.91 
P97457 Mylpf  Myosin regulatory 
light chain 2, 
skeletal muscle 
isoform  
4 218.82 1.86E-
02 
3.46 
Q91Z83 Myh7  Myosin-7  5 294.66 1.21E-
02 
3.42 
P05977;Q3
USB7 
Myl1  Myosin light chain 
1/3, skeletal muscle 
isoform  
2 106.65 5.33E-
03 
3.24 
Q99MQ4 Aspn  Asporin  2 111.00 9.41E-
03 
3.09 
P16546 Sptan1  Spectrin alpha 
chain, non-
erythrocytic 1  
2 110.55 2.03E-
02 
3.08 
Q3TTY5 Krt2  Keratin, type II 
cytoskeletal 2 
epidermal  
2 119.19 2.76E-
02 
3.01 
Q00898 Serpina1e  Alpha-1-antitrypsin 
1-5  
4 412.30 2.05E-
02 
2.87 
Q99KJ8 Dctn2  Dynactin subunit 2  2 52.08 6.17E-
03 
2.87 
P26039 Tln1  Talin-1  6 415.57 3.76E-
02 
2.29 
Q00623 Apoa1  Apolipoprotein A-I  11 551.29 1.02E-
02 
2.25 
P18760 Cfl1  Cofilin-1  3 254.02 4.63E-
03 
2.12 
Q64727 Vcl  Vinculin  2 141.01 3.16E-
02 
1.93 
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P07310 Ckm  Creatine kinase M-
type  
2 148.17 2.55E-
02 
1.88 
A2AQ07 Tubb1  Tubulin beta-1 
chain  
2 145.13 2.80E-
02 
1.85 
Q61598 Gdi2  Rab GDP 
dissociation 
inhibitor beta  
2 102.58 4.11E-
03 
1.85 
O70433 Fhl2  Four and a half LIM 
domains protein 2  
11 556.10 2.59E-
03 
1.81 
Q9CZR8 Tsfm  Elongation factor 
Ts, mitochondrial  
2 152.73 3.48E-
03 
1.77 
P11983 Tcp1  T-complex protein 1 
subunit alpha  
2 84.52 3.70E-
02 
1.69 
P56480 Atp5b  ATP synthase 
subunit beta, 
mitochondrial  
3 208.90 2.55E-
03 
1.69 
P07724 Alb  Serum albumin  8 495.17 5.81E-
03 
1.69 
P28474 Adh5  Alcohol 
dehydrogenase 
class-3  
2 260.69 1.91E-
02 
1.68 
Q8VCW8 Acsf2  Acyl-CoA 
synthetase family 
member 2, 
mitochondrial  
3 56.15 1.55E-
03 
1.67 
P62874 Gnb1  Guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) 
subunit beta-1 
2 227.99 1.65E-
02 
1.66 
P46412 Gpx3  Glutathione 
peroxidase 3  
2 114.99 1.78E-
02 
1.62 
Q9R0Y5 Ak1  Adenylate kinase 
isoenzyme 1  
3 130.53 1.29E-
02 
1.62 
P14602 Hspb1  Heat shock protein 
beta-1  
2 67.52 3.72E-
03 
1.60 
P51174 Acadl  Long-chain specific 
acyl-CoA 
dehydrogenase, 
mitochondrial  
2 133.23 1.86E-
02 
1.54 
O70468 Mybpc3  Myosin-binding 
protein C, cardiac-
type  
6 411.07 4.62E-
03 
1.54 
Q9R062 Gyg1  Glycogenin-1  2 96.89 4.30E-
05 
1.53 
P63038 Hspd1  60 kDa heat shock 
protein, 
mitochondrial  
3 175.68 7.95E-
03 
1.51 
P17751 Tpi1  Triosephosphate 
isomerase  
3 224.15 1.63E-
02 
1.51 
Q60932 Vdac1  Voltage-dependent 
anion-selective 
channel protein 1  
3 247.18 2.08E-
03 
1.51 
P17182 Eno1  Alpha-enolase  2 155.79 1.07E-
02 
1.50 
P09103 P4hb  Protein disulfide-
isomerase  
2 155.88 1.47E-
02 
1.49 
Q9DBG5 Plin3  Perilipin-3  2 101.50 1.88E-
02 
1.48 
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Q9D0E1 Hnrnpm  Heterogeneous 
nuclear 
ribonucleoprotein 
M  
2 125.83 6.89E-
03 
1.47 
P16858 Gapdh  Glyceraldehyde-3-
phosphate 
dehydrogenase  
3 307.82 1.27E-
02 
1.45 
P42125 Eci1  Enoyl-CoA delta 
isomerase 1, 
mitochondrial  
2 189.00 1.11E-
02 
1.43 
P60843 Eif4a1  Eukaryotic 
initiation factor 4A-
I  
2 124.47 2.63E-
02 
1.42 
P63017 Hspa8  Heat shock cognate 
71 kDa protein  
3 186.17 1.59E-
02 
1.40 
Q8VDQ1 Ptgr2  Prostaglandin 
reductase 2  
3 172.64 1.91E-
02 
1.39 
Q99L13 Hibadh  3-
hydroxyisobutyrate 
dehydrogenase, 
mitochondrial  
2 145.44 1.62E-
02 
1.38 
Q9JKS4 Ldb3  LIM domain-
binding protein 3  
4 186.65 5.03E-
03 
1.35 
P05064 Aldoa  Fructose-
bisphosphate 
aldolase A  
2 153.50 3.42E-
02 
1.33 
P11499 Hsp90ab1  Heat shock protein 
HSP 90-beta  
3 133.41 3.10E-
04 
1.33 
P51667 Myl2  Myosin regulatory 
light chain 2, 
ventricular/cardiac 
muscle isoform  
4 148.23 3.49E-
02 
1.28 
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5.2.5 Distribution of protein changes in dystrophic mdx-4cv cardiac tissue 
To obtain a wider overview of the physiological roles of the proteins with altered 
abundance in dystrophic cardiac tissue the bioinformatics software packages 
PANTHER and STRING were used. PANTHER analysis was applied to group 
differentially expressed proteins based on their protein class (Figure 5.2). The majority 
of altered protein species belong to the class of cytoskeletal proteins (12.7%), which 
agrees with the idea of muscular dystrophy as a cytoskeletal disorder. The altered 
abundance of cytoskeletal proteins reflects both the reduction in key cytoskeletal 
proteins of the DGC and the concomitant increases in other cytoskeletal proteins such 
as tubulin and vimentin as a compensatory mechanism to rescue cytoskeletal stability. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5.2: PANTHER analysis of altered protein species in dystrophic heart 
The 98 differentially expressed cardiac-associated proteins were grouped into their 
respective protein class using the freely available PANTHER software package. This 
analysis identified cytoskeletal proteins as those with the greatest number of 
alterations in the dystrophic heart. 
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STRING analysis was also employed to investigate potential protein interactions 
(Figures 5.3 and 5.4). Differential proteins were analysed by STRING for medium 
confidence interactions using the evidence view. Medium confidence was used here 
as at high confidence the known interaction of the full-length Dp427 isoform of 
dystrophin with laminin was lost. This systems biology approach revealed that certain 
protein networks are particularly affected by dystrophin deficiency. Dystrophic 
cardiac tissue appears to have increased protein levels associated with metabolic 
pathways, fibrosis and remodelling of the extracellular matrix and cytoskeletal 
restructuring, as depicted in Figure 5.3. Dystrophin deficiency also appears to be 
tightly connected to the decrease in the laminin complex as seen in Figure 5.4. 
STRING analysis was also used to identify enriched gene ontology terms and KEGG 
pathways. The top twelve terms (based on FDR) for KEGG pathways are shown for 
increased abundance and decreased abundance proteins in Figures 5.5 and 5.6 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
197 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: STRING analysis of the 54 proteins with increased expression in mdx-
4cv heart 
STRING analysis reveals a tightly interconnected protein network in aged dystrophic 
heart. Dystrophin deficiency appears to trigger compensatory up-regulation of proteins 
involved in the maintenance of cytoskeletal networks. Fibrosis is a defining 
characteristic of dystrophic tissue and is exemplified here by the increases in a number 
of pro-fibrotic mediators.  
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Figure 4: STING analysis of the 44 proteins with diminished expression in mdx-4cv cardiac 
tissue 
Bioinformatics analysis illustrates the absence in dystrophin in the heart causes a number of 
secondary abnormalities; in particular alterations in the expression of a number of laminin isoforms.  
 
 
Figure 5.4: STRING analysis of the 44 proteins with diminished expression in 
mdx-4cv cardiac tissue 
Bioinformatics analysis illustrates the absence in dystrophin in the heart causes a 
number of secondary abnormalities; in particular alterations in the expression of a 
number of laminin isoforms.  
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Figure 5.5: Enriched KEGG terms in proteins with increased abundance in the 
aged dystrophic heart 
Depicted is the top twelve enriched terms for KEGG pathways, based on STRING 
analysis of proteins with increased abundance in the mdx-4cv heart. 
 
 
 
 
 
 
 
 
Figure 5.6: Enriched KEGG terms in proteins with decreased abundance in the 
aged dystrophic heart 
Depicted is the top twelve enriched terms KEGG pathways, based on STRING 
analysis of proteins with decreased abundance in the mdx-4cv heart 
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5.2.6 Comparative immunoblot analysis of wild-type versus mdx-4cv 20-month heart 
In order to verify the mass spectrometric data comparative immunoblotting of aged 
wild-type and mdx-4cv cardiac tissue was performed with a select panel of antibodies. 
The silver-stained gel depicted in Figure 5.7 shows a similar protein banding pattern 
between normal and dystrophic preparations. Equal loading was confirmed using this 
silver-stained gel and immunoblotting against the nuclear marker laminB1 whose 
levels do not appear to be affected by dystrophin deficiency in the aged heart (Figure 
5.7). The reduced expression of laminin and lactate dehydrogenase was confirmed by 
immunoblotting, with decreases in laminin found to be statistically significant (Figure 
5.8). The overall trend of increased expression of myosin light chain 2 (statistically 
significant elevation) and VDAC-1 were also confirmed by comparative immunoblot 
analysis (Figure 5.9). The increased levels of the fibrosis-associated proteins collagen 
VI, periostin, lumican and asporin (Figure 5.9 and Figure 5.10) were confirmed in the 
senescent dystrophic heart, for which elevations of periostin, lumican and asporin 
were found to be statistically significant.  
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Figure 5.7: Electrophoretic and immunoblot analysis of wild-type and mdx-4cv 
heart 
Shown is a silver stained 1D gel (A) and immunoblot and statistical analysis of bands 
labelled with lamin B1 (B). The silver stained gel shows comparable protein banding 
patterns for wild-type and mdx-4cv cardiac preparations. Molecular weight marker is 
given on the left-hand-side of the image in kDa. Lamin B1 immunoblotting did not 
show significant changes in concentration between wild-type and mdx-4cv samples 
and so it serves as a loading control for comparative immunoblotting. Graphical 
representation of the immuno-decoration level for lamin B1 is shown (mean values ± 
SEM, Student’s t-test; unpaired; n=4). 
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Figure 5.8: Comparative immunoblot analysis of proteins with decreased 
abundance in dystrophic mdx-4cv cardiac tissue  
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to laminin (A) and lactate dehydrogenase (LDH) (B). Statistical analysis of 
immuno-decoration was performed with Student’s t-test (mean values ± SEM; 
unpaired; n=4, *p≤0.05). 
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Figure 5.9: Comparative immunoblot analysis of proteins with increased 
abundance in dystrophic mdx-4cv cardiac tissue 
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to myosin light chain 2 (MLC2) (A), VDAC1 (B) and collagen VI (C). 
Statistical analysis of immuno-decoration was performed with Student’s t-test (mean 
values ± SEM; unpaired; n=4, *p≤0.05). 
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Figure 5.10: Comparative immunoblot analysis of proteins with increased 
abundance in dystrophic mdx-4cv cardiac tissue 
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to periostin (A), lumican (B) and asporin (C). Statistical analysis of 
immuno-decoration was performed with Student’s t-test (mean values ± SEM; 
unpaired; n=4, *p≤0.05, **p≤0.01). 
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5.3 Discussion  
While advances in therapeutic options available for DMD have improved both the 
lifespan and quality of life of patients, cardiomyopathy still remains as a major 
complicating factor in the disease pathogenesis. Indeed, recent studies have suggested 
that targeted repair of the skeletal muscle in the absence of concomitant improvements 
of the cardiac dystrophic phenotype actually increases cardiac failure and dilated 
cardiomyopathy (Townsend et al., 2008). This highlights the importance of a need for 
therapies with global effects. An understanding of the molecular mechanisms 
underlying cardiomyopathy in dystrophin-deficient hearts is required before such 
therapies can be developed. 
 This proteomic survey of the aged dystrophic heart has revealed a general 
perturbation of protein expression, primarily involving the extracellular matrix, the 
cytoskeletal network, cycles of fibrosis and necrosis, metabolism, and the cellular 
stress response. Similar to that seen in dystrophic skeletal muscle, the absence of full-
length dystrophin in mdx-4cv cardiac myocytes triggers a corresponding decrease in 
key components of the DGC, including α1-syntrophin, β-sarcoglycan, α-sarcoglycan 
and δ-sarcoglycan. Decreased expression of these key cytoskeletal players was 
identified here by sensitive label-free mass spectrometry in the absence of any pre-
fractionation steps which may introduce analytical artefacts. Dystrophin deficiency 
was identified by an extensive 24 unique peptides, while each of the sarcoglycan 
subunits was only identified by a single unique peptide, possibly owing to their highly 
hydrophobic nature. This establishes the mdx-4cv animal model and the mass 
spectrometric approach used in this study as a model mechanism of studying 
dystrophy-induced cardiomyopathy.  
 Fibrosis is associated with a number of chronic pathologies and it’s especially 
noted for its contribution to severe muscle wasting in DMD. Cycles of muscle 
degeneration and inflammation in dystrophic muscles cause the hyper-proliferation 
and activation of fibrogenic cells, leading to the unwanted deposition of extracellular 
matrix components and eventual replacement of skeletal muscle with non-contractile 
fibrotic tissue (Kharraz et al., 2014). This phenomenon has also been identified in the 
dystrophic heart, where an age-dependent up-regulation of connective tissue growth 
factor (CTGF) may play a role. Elevated levels of CTGF in the dystrophic heart of 
mdx mice have been identified by micro-array analysis, immunoblotting and 
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immunohistochemistry, with the finding that this up-regulation is concurrent with 
cardiac fibrosis and precedes the onset of overt cardiomyopathy (Au et al., 2011). Such 
findings are consistent with the identification of elevated levels of the matricellular 
protein periostin, and the proteoglycans asporin and lumican in this proteomic study. 
Periostin has been identified in a number of dystrophic organs, including the severely 
affected diaphragm (Holland et al., 2015a), the moderately affected hind limb muscles 
(Murphy et al., 2015a) and now the aged heart, establishing it as a potential biomarker 
of reactive fibrosis in dystrophin-deficient tissues. Periostin is an extracellular matrix 
protein, which while ubiquitously expressed during embryonic development, is 
restricted to connective tissues exposed to mechanical stress in post-natal life 
(Ozdemir et al., 2014). Cycles of muscle degeneration/regeneration involving the pro-
inflammatory mediator TGF-β are prevalent in dystrophic muscle (Bernasconi et al., 
1995) and this process culminates in increased expression of pro-fibrotic proteins such 
as those identified by this proteomic survey. TGF-β signalling increases the expression 
of periostin, causing enhanced fibrosis and worsening of the dystrophic phenotype. 
This negative impact of elevated abundance of periostin has been well-documented, 
with studies indicating that sarcoglycan/periostin null mice display reduced tissue 
fibrosis and increased expression and activity of matrix metalloproteinase 9 (Lorts et 
al., 2012). Overall this suggests the absence of periostin reduces fibrosis and promotes 
beneficial remodelling of the extracellular matrix, which enhances extracellular matrix 
stability and reduces micro-rupturing of dystrophic sarcolemma.  
 In analogy to this fibrotic process identified in the heart and the skeletal 
muscle, the LC-MS/MS study of mdx-4cv brain has revealed increased levels of the 
glial fibrillary acidic protein GFAP (Murphy et al., 2015c). High levels of GFAP have 
previously been associated with astrogliosis (Eng et al., 2000), a normal physiological 
response to brain injury which can become pathological if the insult is not resolved, 
resulting in the formation of glial scars. Elevated levels of GFAP thus strongly suggest 
reactive astrogliosis in the dystrophin-deficient brain. As such it appears that tissue 
scarring and loss of elasticity is a pathophysiological hallmark of dystrophin deficient 
tissue and one which affects the skeletal musculature, the cardiac system and the 
central nervous system.  
 The loss of dystrophin has different effects on skeletal myocytes and cardiac 
myocytes. This is illustrated by the fact cardiac abnormalities, similar to those evident 
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in male Duchenne patients, have been observed in some female carriers of the disease, 
in the absence of overt skeletal muscle pathology (Hoogerwaard et al., 1999). In 
analogy to such findings, differences have been observed in the protein expression 
profile of the dystrophic heart versus the skeletal muscle. As identified in this study, 
laminin, a crucial component of the basal lamina, displays reduced expression in the 
aged mdx-4cv heart, similar to that seen in previous proteomic studies of the heart 
(Holland et al., 2013). This contrasts with the skeletal muscle, where levels of laminin 
remain unaffected despite the disintegration of the DGC.  
 Oxidative stress has been suggested to play a role in the pathogenesis of 
dystrophinopathies. The deficiency in dystrophin at the sarcolemma causes nNOS to 
be redistributed from the sarcolemma to the cytosol, where its aberrant activity can 
result in oxidation of free radicals (Abdel et al., 2007), which prove toxic to myocytes. 
Indirect evidence of a role for oxidative stress in DMD has been provided by Ragusa 
and colleagues. In response to hyperoxia (a known inducer of oxidative stress) control 
mice develop changes in the activity of superoxide dismutase and catalase, and 
develop levels of by-products of lipid peroxidation (thiobarbituric acid reactive 
substances) similar to those seen in normoxic mdx skeletal muscle (Ragusa et al., 
1997). It thus appears that dystrophin deficiency triggers oxidative stress which 
culminates in an adaptive response by skeletal muscle. Alterations in the efficacy of 
this response may contribute to the severity of muscle damage in individual muscle 
types. For example extraocular muscles of the eye are largely spared in DMD (Porter 
et al., 1998). These muscles, involved in the fast and almost continuous eye twitch 
movements, experience high levels of oxidative stress even under normal conditions 
and thus may be better adapted to cope with the enhanced levels of free radicals seen 
in muscular dystrophy (Ragusa et al., 1997). Similarly, in this proteomic survey of the 
aged dystrophic heart elevated levels of anti-oxidants are evident. For example the 
increased levels of glutathione peroxidase 3, an enzyme responsible for catalyzing the 
reduction of hydrogen peroxide, lipid peroxides and organic hydroperoxide, may 
represent a compensatory mechanism by the dystrophin-deficient heart to counteract 
oxidative-stress-induced cellular damage (Khouzami et al., 2010). Chaperone-
mediated autophagy is a constitutive process only found in mammalian cells which 
serves to maintain cellular homeostasis, which has been shown to be further activated 
by oxidative stress (Kiffin et al., 2004). Since this type of autophagy relies on the 
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interaction between HSP70, lysosome-associated membrane protein 2A and HSP90 
(Linton et al., 2015), the elevated levels of HSP90-β and heat shock cognate 71kDa 
protein identified here in dystrophic cardiac tissue may indicate increased oxidative 
stress in the aged, dystrophin-deficient heart.  
 Age-related cardiac dysfunction is well-discussed in the literature with 
hypertrophy, fibrosis and alterations in autophagy appearing as factors involved in 
aged-associated cardiomyopathy in both murine and human hearts (Linton et al., 2015, 
Boyle et al., 2011, Olivetti et al., 1991). Fibrosis in the aged murine heart has been 
associated with increased levels of collagen and cardiac hypertrophy, indicating that 
even in otherwise healthy mice, aging alone induces expansion of the extracellular 
matrix, with impairment of left ventricular systolic function evident by 18 months of 
age (Boyle et al., 2011). The fact that numerous fibrotic proteins, including lumican, 
asporin, periostin and collagen isoform α1 (VI), display elevated expression in the 
aged dystrophic heart as compared to the control aged heart (20 months) indicates that 
dystrophin absence in cardiac tissue induces a degree of fibrosis worse than that caused 
by aging alone. Thus, cardiomyopathy and subsequent cardiac failure remain as major 
risk factors for Duchenne boys during aging. 
 While the primary role of the full-length dystrophin protein is the maintenance 
of structural stability, its absence affects not only cytoskeletal structure but also 
cellular metabolism. Indeed, it has been reported that the dystrophic heart displays 
changes in energy metabolism prior to the onset of overt cardiomyopathy (Khairallah 
et al., 2007). On a proteomic level, the reduction in the expression of a number of key 
mitochondrial proteins of lipid metabolism seen here agree with both a previous gel-
based study (Lewis et al., 2010) and with Khairallah and colleagues observation of a 
shift away from the utilisation of fatty acids as a fuel source in dystrophin-deficient 
hearts (Khairallah et al., 2007). Decreased expression of acyl-CoA dehydrogenase, an 
enzyme involved in the mitochondrial fatty acid beta-oxidation pathway (Kurtz et al., 
1998), is indicative of an impaired lipid metabolism in the dystrophic heart. Reduced 
levels of this enzyme may worsen the cardiac phenotype in dystrophic mice, given that 
long-chain acyl-CoA dehydrogenase knockout mice display myocardial degeneration 
and cardiac lipidosis in response to fasting (Kurtz et al., 1998). Pyruvate 
dehydrogenase, an enzyme responsible for the conversion of pyruvate (the end product 
of glycolysis) to acetyl-CoA (a component of the tricarboxylic acid cycle) 
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(Ohlendieck, 2010) displays elevated expression in the aged dystrophin-deficient 
cardiac tissue. In analogy a large number of glycolytic enzymes were also revealed to 
be increased in expression, suggesting a possible compensatory up-regulation of an 
anaerobic pathway to counteract the alterations seen in mitochondrial metabolism. 
Such glycolytic enzymes include triosephosphate isomerase, enolase, glyceraldehyde-
3-phosphate dehydrogenase and aldolase. However, levels of lactate dehydrogenase 
are slightly decreased, indicating that the pyruvate produced by glycolysis is not 
converted to lactate at an increased rate in the mdx-4cv heart.  
 A whole host of other proteins display altered expression levels in dystrophic 
tissues. Cofilin, a small protein of 19 kDa, regulates actin polymerisation and 
depolymerisation, and thus is involved in cell motility (Bravo-Cordero et al., 2013). 
Cofilin plays a role in foetal muscle development, where it is associated with the fusion 
of embryonic myoblasts to form myotubes (Bamburg and Wiggan, 2002), but is 
normally expressed at low levels during postnatal skeletal muscle development. The 
expression of cofilin-1, as detected here by label-free LC-MS/MS, is higher in the 
dystrophic heart tissue. Given that cofilin is normally associated with foetal muscle 
development, its elevated abundance may indicate the presence of regenerating muscle 
fibres in dystrophic cardiac tissue. The increased expression of predominantly 
prenatal/perinatal proteins has also been identified by previous proteomic work in 
dystrophic leg tissue, where elevated levels of perinatal myosin 8 suggest the 
recruitment of newly differentiated myofibres. Other studies have also identified 
cofilin expression in regenerating muscle fibres as well as pre-existing muscle fibres 
in the chicken and mouse models of muscular dystrophy (Hayakawa et al., 1993). 
Overall, increased cofilin expression appears to suggest remodelling in dystrophic 
muscle fibres. 
 Voltage-dependent anion selective channel (VDAC) is associated with the 
outer mitochondrial membrane, where it interacts with the adenine nucleotide 
translocator located in the inner mitochondrial membrane (Crompton et al., 1998), to 
maintain the movement of ADP/ATP in and out of the mitochondria (Rostovtseva and 
Colombini, 1997). Viola and colleagues have found that the deficiency in dystrophin 
and concurrent disruption of cytoskeletal networks in mdx cardiac myocytes leads to 
impaired communication between the L-type calcium channel and VDAC, which in 
turn appears to at least partially account for the reduction seen in metabolic activity in 
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the dystrophic heart (Viola et al., 2014). This proteomic survey has identified a slight 
increase in the expression of VDAC1 (1.5-fold) in the mdx-4cv heart. Such an increase 
may represent a compensatory mechanism in dystrophin-deficient cardiomyocytes to 
maintain metabolism and meet the heart’s energy demands in the face of impaired 
communication between some of the key players of mitochondrial metabolism.  
 Many proposed therapies for DMD, such as exon skipping, have primarily 
shown restoration of dystrophin expression in the skeletal muscle while failing to 
target the heart (Lu et al., 2005). However, the emerging CRISPR-Cas9 technology 
has shown promise in rescuing dystrophin expression in both skeletal muscle and 
cardiomyocytes in postnatal mdx mice (Long et al., 2016). Such studies have validated 
the therapeutic benefit by measuring dystrophin expression, by analysing the 
histopathological hallmarks of muscular dystrophy and by using the grip-strength test 
to examine muscle function (Long et al., 2014). However, it may be interesting to 
examine whether such therapies also ameliorate the secondary abnormalities 
associated with the disease. A label-free LC-MS/MS approach, similar to that used in 
this investigation, may be of benefit in identifying protein biomarkers associated with 
an improvement in disease pathogenesis following treatment. Similar types of studies 
have been performed for examining the efficacy of exon skipping. For example Doran 
and colleagues demonstrated, using a 2D-DIGE approach, that exon skipping of exon 
23 in the mdx mouse reversed some of the downstream secondary abnormalities in the 
treated dystrophic diaphragm (Doran et al., 2009b).  
  
5.3.1 Conclusion 
Improvements in respiratory care for Duchenne patients such as mechanical 
ventilation have dramatically increased survival. However, cardiac complications 
remain as critical issues affecting a large majority of patients and which have severe 
impacts on quality of life and survival. In this chapter, proteomic profiling of the aged 
dystrophic heart is described and used to elucidate potential molecular mechanisms 
responsible for cardiac impairment. Mass spectrometric analysis revealed reduced 
abundance of core proteins of the DGC; dystrophin, α1-syntrophin, α-sarcoglycan, β-
sarcoglycan and δ-sarcoglycan, in senescent mdx-4cv cardiac tissue. Reductions in this 
stabilising protein complex of the sarcolemma is accompanied by a range of secondary 
abnormalities, particularly related to metabolic alterations, cytoskeletal remodelling, 
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cellular stress and altered ion homeostasis. A number of proteins associated with 
fibrosis were found to be increased in abundance in dystrophic hearts, as shown by 
mass spectrometry and immunoblot analysis. Such protein species include collagen, 
asporin, lumican and periostin. This reveals fibrosis as a major contributor to 
cardiomyopathy in which excessive deposition of matricellular and extracellular 
matrix proteins and subsequent tissue scarring may negatively impact normal cardiac 
function. Thus, these proteins may serve as both potential protein markers of cardiac 
dysfunction and therapeutic targets to counteract cardiomyopathy.  
  
 
 
 
 
 
 
 
 
Chapter Six 
 
Glial fibrillary acidic protein as a marker of neurotoxicity in 
the mdx-4cv model of dystrophinopathy 
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6.1 Introduction 
DMD is a paediatric disorder of the skeletal musculature which is characterised by a 
variety of alterations in muscle fibres, including changes in myofibre size, fibre 
branching, necrosis, central nucleation, regeneration, immune cell invasion and the 
infiltration of fatty and connective tissue. A number of secondary complications are 
also associated with the disorder, including cardiomyopathy, respiratory insufficiency, 
orthopaedic issues linked to muscle contractures and the development of scoliosis, 
cognitive impairments, and endocrinological issues related to growth and weight gain 
(Murphy et al., 2015b).  
 Investigations into the pathogenesis of DMD are complicated by the presence 
of multiple promoters that facilitate the expression of various dystrophin isoforms 
ranging in size from 71 to 427 kDa. While all genetic mutations in the Dmd gene result 
in the loss of the full-length isoform of dystrophin, the loss of the other dystrophin 
isoforms depends on the location of the genetic mutation in relation to the location of 
the promoters. Three full-length isoforms of dystrophin exist; Dp427-M expressed in 
muscles, Dp427-B expressed in the brain and Dp427-P expressed in cerebellar 
Purkinje cells (Perronnet and Vaillend, 2010). In addition, four shorter isoforms which 
arise from transcription from different promoters in the Dmd gene also exist. These 
are Dp260-R found in the retina, Dp140-B/K expressed in the brain and kidney, 
Dp116-S in Schwann cells and Dp71-B/U in brain and non-muscle tissue (Culligan et 
al., 2001). These alternative isoforms of dystrophin differ not only in their cellular 
location, but also in their size and composition, with only Dp427 expressing an actin-
binding domain. The absence of this domain from the remaining dystrophin isoforms 
suggest that dystrophin may have roles other than linkage of intracellular actin to the 
extracellular matrix. While the impacts of dystrophin deficiency on skeletal muscle, 
cardiac muscle and the diaphragm have been studied extensively (Holland et al., 2013, 
Holland et al., 2015a, Wang et al., 2015), its effect on cognition is largely unresolved. 
This is in spite of the fact that non-progressive cognitive defects are a clinical symptom 
of DMD, originally observed by Duchenne in some of his patients. Cognitive deficits 
affect approximately one-third of all patients, are non-progressive and have been 
shown to affect verbal more than non-verbal intelligence (Cotton et al., 2001).  
Moderate memory and attention impairments are seen in almost all DMD sufferers, 
suggesting a role for full-length Dp427 in its pathogenesis. However, mutations 
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affecting the Dp140 and Dp71 isoforms are correlated with a higher incidence and 
severity of cognitive impacts (Culligan et al., 2001). 
 Full-length isoforms of brain dystrophin are present in the neurons of the 
cerebellar cortex and the hippocampus along with cerebellar Purkinje cells (Snow et 
al., 2013). The Dp140 isoform is most highly expressed during brain development 
(Lidov et al., 1995), while the most abundant brain isoform, Dp71, is present in 
neurons and glia cells of the dentate gyrus and the olfactory bulb (Culligan et al., 
2001). Transcriptomic analysis of the developing human brain revealed that Dp427 
expression is low during foetal development, shows a slight increase at two years of 
age and remains low during middle adulthood. Dp140 is highly expressed in mid-
foetal stages and is expressed throughout middle adulthood. Dp71 expression is high 
during foetal stages and remains high after birth and throughout life (Doorenweerd et 
al., 2017). Dystrophin and the brain DGC (including α- and β-dystroglycan, β2-
syntrophin and dystrobrevin but not the sarcoglycan complex) may play a role in 
neuronal development, and thus, abnormalities seen in the brain may arise as a result 
of altered calcium-mediated signalling and/or disruption of cellular proteins which 
normally would interact with the DGC (Mehler, 2000). Loss of dystrophin in mdx 
mouse models is associated with a large reduction in the size and number of GABAA 
(gamma-aminobutyric acid) receptor clusters in the hippocampus cerebellum and 
amygdalon (Sekiguchi et al., 2009, Knuesel et al., 1999) and increases in choline-
containing compounds. Thus, dystrophin and its associated glycoproteins likely play 
a role in the stability of receptors and in synaptic function in the brain. It has been 
suggested that compensatory mechanisms to maintain functional stability may actually 
contribute to disruption of neuronal function through continuous perturbations (Cohen 
et al., 2015).  
 Animal models have been especially useful in determining the downstream 
abnormalities induced by dystrophin absence. In particular, the mdx mouse model has 
been used to illustrate the cognitive deficits induced by dystrophin deficiency. Such 
studies have revealed slower learning in bar-pressing tasks and reduced performance 
at long time delays in tests measuring recognition and spatial memories (Muntoni et 
al., 1991). Dystrophin deficiency has also been shown to impair long-term object 
recognition memory and long-term spatial memory in dystrophic mice (Vaillend et al., 
2004). Since the mdx-4cv animal model has been studied less extensively, despite 
representing an improved pathobiochemical phenotype, label-free LC-MS/MS has 
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been performed here on brain tissue obtained from 12-month old wild-type and mdx-
4cv mice to investigate the secondary abnormalities in dystrophin-deficient brain. This 
study was undertaken with the aim of improving understanding of the impact of 
dystrophin deficiency on proteostasis in the brain and to elucidate the 
pathophysiological mechanisms that facilitate impaired brain function in muscular 
dystrophy. The unbiased, technology-driven proteomics approach used in this study 
has identified a number of altered proteins of interest, including the intermediate 
filament protein vimentin, the membrane repair protein annexin A5, glial fibrillary 
acidic protein, the calcium binding protein calretinin and the plasma membrane Ca2+-
ATPase. In analogy to the effects on cardiac and skeletal muscle, the loss of dystrophin 
in brain tissue would appear to trigger cytoskeletal remodelling, membrane repair and 
altered Ca2+ handling. In addition, proteins more specific to the nervous system were 
also found to be differentially abundant, including the dendritic spine protein drebrin 
suggested to participate in neuronal growth, protein bassoon involved in the 
organisation of the cytomatrix at the active zone of nerve terminals, and syntaxin-1B 
and syntaxin-binding protein 1 involved in synaptic vesicle docking. These disturbed 
neuronal proteins illustrate the complexity of the molecular pathogenesis in the central 
nervous system of dystrophic mdx-4cv mice. 
 
6.1.1 Experimental Design  
Since approximately one-third of patients with dystrophinopathy also present with 
mild cognitive impairments it was of interest to investigate potential proteomic 
alterations in the dystrophin-deficient brain. Whole brain samples from 12-month old 
wild-type and age-matched mdx-4cv mice (n=4) were prepared for this proteomic 
study. Crude brain homogenates were analysed by label-free LC-MS/MS using an 
Ultimate 3000 nanoLC system (Dionex) coupled to an LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific) in the Proteomics Facility of the National 
Institute for Cellular Biotechnology, Dublin City University. Brain-tissue derived 
peptides were eluted with the following binary gradients: solvent A [2 % (v/v) ACN 
and 0.1 % (v/v) formic acid in LC–MS grade water] and 0–25 % solvent B [80 % ACN 
and 0.08 % (v/v) formic acid in LC–MS grade water] for 240 min and 25–50 % solvent 
B for a further 60 min. Relative quantification and identification was performed with 
Progenesis QI for Proteomics software, using Sequest HT and MASCOT search 
engines and the UniProtKB-SwissProt database. Bioinformatics analysis was 
216 
 
conducted using the PANTHER database of protein families and STRING software. 
Comparative immunoblot analysis was used as an orthogonal method to verify altered 
protein abundance. Immunoblotting was also used to confirm the tissue specificity of 
GFAP, and for this analysis protein extracts from the liver, diaphragm, heart and 
skeletal muscle of wild-type mice were used.  
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6.2 Results 
In order to investigate the potential effect of muscular dystrophy on the brain, as 
suggested by cognitive defects in a sub-group of patients with DMD, proteomic 
profiling of 12-month old wild-type versus age-matched mdx-4cv brain was 
conducted. A label-free LC-MS/MS approach was used to identify protein alterations 
in the dystrophin-deficient brain. Consequently, key proteins of interest were verified 
by comparative immunoblotting.  
 
6.2.1 Label-Free LC/MS-MS analysis of altered protein species in total mdx-4cv 
brain extracts 
In contrast to proteomic profiling of skeletal muscle from mdx-4cv animal models of 
dystrophinopathy, in which large alterations in protein expression have been identified 
(Murphy et al., 2015a), relatively few alterations were identified in dystrophin-
deficient brain tissue. LC-MS/MS analysis of brain-derived proteins identified 
alterations in the abundance of 46 proteins; 7 of which were decreased in expression 
(Table 6.1) and 39 of which displayed increased abundance (Table 6.2). In addition, 
the majority of these proteins showed only minor differences in their abundance, with 
only plasma membrane calcium-transporting ATPase 2 displaying a reduction in 
expression by more than two-fold (-2.77) in dystrophin-deficient brain tissue. 
Meanwhile 11 proteins depicted increases in expression by more than two-fold in mdx-
4cv preparations, with hemopexin showing the highest increase at a fold increase of 
5.64. While these results may seem surprising given that up to one-third of DMD boys 
suffer from some degree of mental impairment (Bresolin et al., 1994), it may be partly 
contributed to the animal model used in this study. The mdx-4cv mouse model carries 
a non-sense mutation in exon 53 of the Dmd gene, which renders it highly attractive 
for studying the efficacy of novel therapeutic strategies such as exon skipping, given 
that this exon is a major mutation hotspot in the human disorder (Mitrpant et al., 2009). 
In analogy to the human condition this model fails to express the Dp427 isoform of 
dystrophin, which is the major muscle isoform involved in stabilisation of the 
sarcolemma through interactions with other membrane associated glycoproteins to 
form the DGC. However, Im et al., have shown that this model does express the Dp71 
dystrophin isoform which is predominantly found in the brain and other non-muscle 
tissues (Im et al., 1996). The expression of the Dp71 isoform of dystrophin may prove 
protective for the maintenance of brain function given that a study by Moizard et al., 
218 
 
has indicated that mutations in the Dp71 isoform of dystrophin, leading to premature 
termination of translation, are more closely correlated with severe mental retardation 
(Moizard et al., 2000). Hence proteomic profiling of mouse models lacking this brain-
specific dystrophin isoform (such as the mdx-3cv model) may show a higher degree of 
differential protein expression. Proteomic profiling of the mdx-4cv model used in this 
study is still useful given that this model closely represents the human disorder. 
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Table 6.1: List of identified proteins with a significantly reduced abundance in 12-
month old mdx-4cv brain versus age-matched wild-type brain as determined by label-
free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max fold 
change 
Q9R0K7 Stx1b  Plasma membrane 
calcium-
transporting 
ATPase 2  
2 108.25 1.78E-
02 
2.77 
Q9WV92 Stxbp1  Band 4.1-like 
protein 3  
3 218.67 8.93E-
03 
1.90 
O08599 Epb41l3  Syntaxin-binding 
protein 1  
4 315.93 1.97E-
02 
1.54 
P07901 Rab7a  Heat shock protein 
HSP 90-alpha  
2 109.14 3.84E-
02 
1.54 
P51150 Atp2b2  Ras-related protein 
Rab-7a  
3 106.89 1.10E-
02 
1.51 
Q02053 Hsp90aa1  Ubiquitin-like 
modifier-activating 
enzyme 1  
2 131.59 4.44E-
02 
1.41 
P61264 Uba1  Syntaxin-1B  4 356.83 1.22E-
03 
1.28 
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Table 6.2: List of identified proteins with a significantly increased abundance in 12-
month old mdx-4cv brain versus age-matched wild-type brain as determined by label-
free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
Q91X72 Hpx  Hemopexin  3 131.20 1.16E-
03 
5.64 
P29699 Ahsg  Alpha-2-HS-
glycoprotein  
2 125.19 1.72E-
03 
3.47 
P22599 Serpina1b  Alpha-1-antitrypsin 
1-2  
2 114.76 1.45E-
02 
3.29 
P02088 Hbb-b1  Hemoglobin subunit 
beta-1  
3 260.19 1.05E-
03 
3.24 
P01942 Hba  Hemoglobin subunit 
alpha  
5 370.80 2.13E-
04 
3.22 
Q00623 Apoa1  Apolipoprotein A-I  8 316.97 5.23E-
03 
2.88 
P07758 Serpina1a  Alpha-1-antitrypsin 
1-1  
4 108.28 1.74E-
02 
2.52 
P07724 Alb  Serum albumin  16 1174.48 4.94E-
04 
2.51 
Q923D2 Blvrb  Flavin reductase 
(NADPH)  
3 203.95 1.72E-
03 
2.51 
Q921I1 Tf  Serotransferrin  8 374.59 1.66E-
02 
2.18 
P03995 Gfap  Glial fibrillary 
acidic protein  
8 491.51 3.53E-
02 
2.00 
Q08331 Calb2  Calretinin  2 94.24 4.02E-
02 
1.93 
P48036 Anxa5  Annexin A5  2 132.70 3.20E-
02 
1.56 
P20152 Vim  Vimentin  2 213.31 4.40E-
03 
1.55 
Q9R0P9 Uchl1  Ubiquitin carboxyl-
terminal hydrolase 
isozyme L1  
3 165.79 2.31E-
02 
1.51 
P46460 Nsf  Vesicle-fusing 
ATPase  
2 134.05 1.10E-
03 
1.44 
Q9D0E1 Hnrnpm  Heterogeneous 
nuclear 
ribonucleoprotein 
M  
3 63.46 1.49E-
02 
1.44 
O08788 Dctn1  Dynactin subunit 1  2 126.53 1.03E-
02 
1.44 
P38647 Hspa9  Stress-70 protein, 
mitochondrial  
6 476.79 1.76E-
03 
1.42 
P48758 Cbr1  Carbonyl reductase 
[NADPH] 1  
2 119.09 1.33E-
02 
1.42 
P00920 Ca2  Carbonic anhydrase 
2  
2 135.96 2.81E-
02 
1.42 
P14733 Lmnb1  Lamin-B1  2 150.58 2.92E-
02 
1.41 
Q6IRU5 Cltb  Clathrin light chain 
B  
2 125.00 4.20E-
02 
1.40 
Q8R3V5 Sh3glb2  Endophilin-B2  4 201.90 2.06E-
02 
1.39 
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Q8QZT1 Acat1  Acetyl-CoA 
acetyltransferase, 
mitochondrial  
4 215.23 6.81E-
03 
1.36 
P27773 Pdia3  Protein disulfide-
isomerase A3  
5 295.10 1.30E-
02 
1.35 
Q91VR2 Atp5c1  ATP synthase 
subunit gamma, 
mitochondrial  
4 251.82 2.56E-
03 
1.35 
Q6ZWY9 Hist1h2bc  Histone H2B type 
1-C/E/G  
2 121.60 4.21E-
02 
1.34 
Q61171 Prdx2  Peroxiredoxin-2  2 141.40 1.28E-
02 
1.33 
Q9D051 Pdhb  Pyruvate 
dehydrogenase E1 
component subunit 
beta, mitochondrial  
4 262.12 4.09E-
03 
1.32 
O35737 Hnrnph1  Heterogeneous 
nuclear 
ribonucleoprotein H  
2 100.27 1.67E-
02 
1.31 
Q03265 Atp5a1  ATP synthase 
subunit alpha, 
mitochondrial  
6 480.06 5.82E-
03 
1.30 
P20029 Hspa5  78 kDa glucose-
regulated protein  
2 150.07 2.51E-
02 
1.29 
Q9QXS6 Dbn1  Drebrin  3 142.39 1.93E-
02 
1.28 
P62259 Ywhae  14-3-3 protein 
epsilon  
2 103.44 2.86E-
02 
1.27 
O88737 Bsn  Protein bassoon  3 215.46 1.33E-
02 
1.25 
Q811D0 Dlg1  Disks large 
homolog 1  
2 110.76 6.40E-
03 
1.25 
P14873 Map1b  Microtubule-
associated protein 
1B  
2 126.07 5.00E-
03 
1.24 
P16546 Sptan1  Spectrin alpha 
chain, non-
erythrocytic 1  
3 197.38 1.49E-
02 
1.24 
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6.2.2 Distribution of protein changes in dystrophic mdx-4cv brain tissue 
To more closely examine the role of these alterations in the expression of brain-derived 
proteins, standard bioinformatics software was employed. PANTHER analysis was 
conducted to investigate the distribution and molecular function of the affected 
proteins. This analysis revealed alterations in anti-oxidant activity (2.0%), binding 
(25.5%), catalytic activity (37.3%), enzyme regulator activity (7.8%), receptor activity 
(2.0%), structural molecule activity (15.7%) and transporter activity (9.8%). Of the 
15.7% proteins involved in structural molecule activity, 87.5% of these were 
associated with the cytoskeleton, with the remaining proteins connected to ribosomal 
structure. The PANTHER database was also applied to illustrate the protein class of 
identified proteins with altered abundance (Figure 6.1). The majority of altered protein 
species again belong to the class of cytoskeletal proteins, suggesting that dystrophin 
deficiency causes restructuring of the cytoskeleton in the brain. These cytoskeletal 
proteins include drebrin, microtubule associated protein 1B, vimentin, endophilin B2, 
glial fibrillary acidic protein, spectrin α1 chain, dynactin and lamin-B1. All of these 
proteins display increased abundance in dystrophic samples, indicating compensatory 
up-regulation of cytoskeletal and stabilising components in order to counter-act 
dystrophin deficiency. This agrees with the classification of X-linked muscular 
dystrophy as a primary disorder of the membrane cytoskeleton. STRING analysis was 
also performed to examine potential interaction networks between the altered proteins. 
Figure 6.2 shows the overall interaction patterns amongst altered protein species.  
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Figure 6.1: Graphical representation of changed protein classes with altered 
abundance in mdx-4cv brain tissue 
The bioinformatics software programme PANTHER was applied to identify the 
clustering of protein classes based on the mass spectrometric identification of altered 
protein species in control versus dystrophin-deficient brain preparations.  
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Figure 6.2: Interaction map of altered proteins from mdx-4cv brain tissue 
The bioinformatics STRING database was applied to generate a protein interaction 
map with known and predicted protein associations, based on both direct physical and 
indirect functional protein interactions  
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6.2.3 Verification of proteomic alterations in dystrophin-deficient brain tissue by 
immunoblotting 
In order to verify some of the key proteomic findings from the comparative analysis 
of wild-type versus mdx-4cv brain tissue, immunoblotting against select protein hits 
(listed in Tables 6.1 and 6.2) was carried out. For loading controls, a silver-stained 
protein gel and the unchanged abundance of lactate dehydrogenase was used and is 
presented in Figure 6.3. The trend of increased abundance of lamin-B1 was confirmed 
by immunoblotting (Figure 6.4). Increased abundance of both annexin A5 and 
vimentin and reduction in the expression of the plasma membrane calcium-
transporting ATPase 2 were also verified by immunoblotting (Figure 6.4 and Figure 
6.5 respectively) and their altered abundance was found to be statistically significant. 
These findings are in agreement with the proteomic data in this report and suggests an 
overall restructuring of the cytoskeleton and alterations in ion homeostasis in 
dystrophin-deficient conditions. 
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Figure 6.3: Electrophoretic and immunoblot analysis of wild-type and mdx-4cv 
brain 
Shown is a silver stained 1D gel (A) and immunoblot and statistical analysis of bands 
labelled with lactate dehydrogenase (B). The silver stained gel shows comparable 
protein banding patterns for wild-type and mdx-4cv brain preparations. Molecular 
weight marker is given on the left-hand-side of the image in kDa. Lactate 
dehydrogenase immunoblotting did not show significant changes in concentration 
between wild-type and mdx-4cv samples and so it serves as a loading control for 
comparative immunoblotting. Graphical representation of the immuno-decoration 
level for lactate dehydrogenase is shown (mean values ± SEM, Student’s t-test; 
unpaired; n=4). 
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Figure 6.4: Comparative immunoblot analysis of proteins with increased 
abundance in dystrophic mdx-4cv brain tissue 
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to annexin A5 (A), lamin-B1 (B) and vimentin (C). Statistical analysis of 
immuno-decoration was performed with Student’s t-test (mean values ± SEM; 
unpaired; n=4, *p≤0.05, **p≤0.01). 
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Figure 6.5: Comparative immunoblot analysis of proteins with decreased 
abundance in dystrophic mdx-4cv brain tissue 
Shown is a representative immunoblot with immuno-decorated bands labelled with an 
antibody to the plasma membrane calcium-transporting ATPase 2 (Calcium ATPase, 
A). Statistical analysis of immuno-decoration was performed with Student’s t-test 
(mean values ± SEM; unpaired; n=4, ***p≤0.001). 
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6.2.4 Immunoblot and immunofluorescence microscopy analysis of GFAP as a 
marker of reactive gliosis  
The 2-fold increase in the expression of GFAP in the dystrophin-deficient brain as 
identified by label-free mass spectrometry is an important proteomic finding given its 
elevated expression is an indicator of astrogliosis. To further investigate the potential 
induction of astrogliosis in the mdx-4cv brain in the absence of dystrophin, 
immunoblot analysis and immunofluorescence microscopy was performed. Figure 6.6 
illustrates the specificity of the GFAP antibody used in this proteomic analysis. While 
the cytosolic enzyme lactate dehydrogenase and the nuclear envelope marker laminB1 
are present in crude extracts from wild-type mouse liver, diaphragm, skeletal muscle, 
cardiac tissue and the brain, GFAP is only detected in the brain extracts (Figure 6.6). 
A silver-stained gel depicting different protein banding patterns for the different 
tissues is also depicted. Previous immunoblot analyses of GFAP protein have shown 
a tight banding pattern with two to three protein bands with slightly different 
electrophoretic mobility (Singh et al., 2009). Similarly, as shown in Figure 6.7, higher 
levels of brain protein per lane result in a broader banding pattern for GFAP. Based 
on these results, an intermediate level of brain protein was used for comparative 
immunoblot analysis.  
 Immunoblot analysis of 12-month old wild-type versus mdx-4cv brain 
preparations confirmed the elevation of this protein and was found to be statistically 
significant (Figure 6.8). To examine whether this increase is stage-specific, 
immunoblotting was conducted with wild-type and mdx-4cv brain samples at 2-
months-old, 8-months-old and 12-months-old (Figure 6.9). At all ages tested, levels 
of GFAP were found to be higher in the dystrophic preparations, suggesting that this 
process of astrogliosis occurs throughout the disease.  
 In order to determine whether increased abundance of GFAP may serve as a 
marker of neurodegeneration, GFAP expression in the wobbler mouse model of 
amyotrophic lateral sclerosis (ALS) was investigated by immunoblotting. ALS is 
characterised by the progressive degeneration of motor neurons, which affects 
signalling cascades and culminates in progressive muscle paralysis (Rowland and 
Shneider, 2001). Immunoblotting confirmed the increased abundance of GFAP in 
brain tissue extracted from 2-month old wobbler mice compared to age-matched 
control mice (n=4) (Figure 6.10). This suggests that elevated levels of GFAP are 
associated with reactive gliosis in response to damage to the brain. This supports the 
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hypothesis that dystrophin deficiency in the mdx-4cv brain may trigger astrogliosis 
and glial scar formation.  
 Analysis of GFAP expression in the brain by immunofluorescence microscopy 
also confirmed the results obtained by proteomic analysis and immunoblotting. As 
shown in Figure 6.11, dystrophin-deficient brain sections display substantially higher 
levels of GFAP labelling than wild-type brain sections. This data agrees with the idea 
of astrogliosis as a consequence of progressive central nervous system damage in the 
dystrophin-deficient brain.  
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Figure 6.6: Immunoblot analysis of the specificity of the GFAP antibody 
Depicted is a silver-stained gel (A) and corresponding immunoblots to the cytoplasmic 
enzyme lactate dehydrogenase (B), the nuclear marker lamin B1 (C) and the glial 
fibrillary acidic protein GFAP (D). Lanes 1 to 5 correspond to crude extracts from 
wild-type mouse liver, diaphragm, cardiac tissue, skeletal muscle and the brain 
respectively. While lactate dehydrogenase and lamin B1 were detected in all tissue 
extracts, GFAP was only detected by the brain tissue, illustrating the specificity of the 
ab7260 antibody to GFAP; a brain-specific protein.  
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Figure 6.7: Dilution series of the GFAP antibody 
Shown is an immunoblot depicting an increase in signal of the GFAP protein in a 
dilution series. Increasing amounts of mouse brain protein per lane (from 0µg to 80µg) 
results in a broader immuno-labelled GFAP pattern at higher concentrations. 
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Figure 6.8: Comparative immunoblot analysis of the glial fibrillary acidic 
protein GFAP in wild-type versus mdx-4cv brain specimens 
Shown is a representative silver-stained gel (A) and immunoblot (B) and statistical 
analysis of bands labelled with lactate dehydrogenase. The silver stained gel shows 
comparable protein banding patterns for wild-type and mdx-4cv 12-month old brain. 
Molecular weight marker is given on the left-hand-side of the image in kDa. Lactate 
dehydrogenase immunoblotting did not show significant changes in concentration 
between wild-type and mdx-4cv samples and so it serves as a loading control for 
comparative immunoblotting. Also shown is an immunoblot to GFAP (C). Graphical 
representation of the immuno-decoration levels for lactate dehydrogenase and GFAP 
is shown (mean values ± SEM, Student’s t-test; unpaired; n=4; *p≤0.05).  
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Figure 6.9: Comparative immunoblot analysis of the glial fibrillary acidic protein 
GFAP in wild-type versus mdx-4cv brain specimens from 2-12 months  
Shown are representative silver-stained gels (A, D) and immunoblot analysis of bands 
labelled with lactate dehydrogenase (B, E). Images A, B and C correspond to 2-month 
old, 8-month old and 12-month old brain samples from wild-type mice while images 
D, E and F depict 2-month old, 8-month old and 12-month old brain specimens from 
mdx-4cv mice. The silver stained gels show comparable protein banding patterns for 
wild-type and mdx-4cv brain. Molecular weight marker is given on the left-hand-side 
of the image in kDa. Lactate dehydrogenase immunoblotting did not show significant 
changes in concentration between wild-type and mdx-4cv samples and so it serves as 
a loading control for comparative immunoblotting. Also shown is an immunoblot to 
GFAP (C, F).  
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Figure 6.10: Comparative immunoblot analysis of the glial fibrillary acidic 
protein GFAP in wild-type versus wobbler brain specimens 
Shown is a representative silver-stained gel (A) and immunoblot (B) and statistical 
analysis of bands labelled with lamin B1. The silver stained gel shows comparable 
protein banding patterns for wild-type and wobbler 2-month old brain. Molecular 
weight marker is given on the left-hand-side of the image in kDa. Lamin B1 
immunoblotting did not show significant changes in concentration between wild-type 
and wobbler samples and so it serves as a loading control for comparative 
immunoblotting. Also shown is an immunoblot to GFAP (C). Graphical representation 
of the immuno-decoration levels for lamin B1 and GFAP is shown (mean values ± 
SEM, Student’s t-test; unpaired; n=4; **p≤0.01).  
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Figure 6.11: Immunofluorescence microscopy of GFAP in wild-type versus mdx-
4cv brain sections 
Shown is the immunofluorescence staining of brain sections with GFAP (a, b). The 
mdx-4cv brain tissue exhibits an increased level of GFAP labelling (b) as compared to 
wild-type brain sections (a). This agrees with the mass spectrometry data and 
immunoblot analysis presented in this report.  
 
* Image from Murphy et al., 2015c 
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6.3 Discussion 
Despite a relatively large proportion of DMD patients expressing some degree of 
cognitive impairment, most comparative proteomic surveys have focused on the 
severely fibrotic diaphragm and heart, the moderately affected limb muscles, and 
protected muscles such as extraocular muscle (Carberry et al., 2013, Holland et al., 
2015a, Ge et al., 2003). This proteomic survey aimed to identify alterations in protein 
expression in the mdx-4cv brain through a combination of mass spectrometry and 
western blotting. This methodology has uncovered alterations in proteins involved in 
calcium homeostasis, structural re-organisation, the cellular stress response, iron 
homeostasis and neurotransmission. These changes in the dystrophin-deficient brain 
may represent contributing factors to mental impairment in X-linked 
dystrophinopathies.  
 The observed elevation in the levels of hemopexin (5.64-fold increase), 
haemoglobin subunit β1 (3.24-fold increase), haemoglobin subunit α (3.22-fold 
increase) and serotransferrin (2.18-fold increase) suggests altered blood-flow and 
disturbed iron homeostasis in muscular dystrophy. While it could be argued that the 
increased abundance of haemoglobin may be an artefact, given the brain samples were 
not perfused, the fact that increased abundance is seen for both the α and β1 subunits, 
and that their fold changes are closely correlated may indicate higher vascularisation 
and hence increased blood-flow to dystrophin-deficient brains (Holland et al., 2014). 
Serotransferrin is an essential iron transporter serving a number of important roles. It 
is the main distributor of iron to tissue, and it also acts as a sink to sequester 
extracellular iron and thus prevents cytotoxic stress from excess free iron in plasma 
(Szőke and Panteghini, 2012). Its increased abundance could be linked to altered iron 
homeostasis in the dystrophin-deficient brain. In this proteomic survey the protein 
with the largest increase in abundance was the heme-binding plasma glycoprotein 
hemopexin. Serum hemopexin levels have been observed to be increased in response 
to elevated levels of free heme, in which case it may serve to scavenge free heme and 
thus provide antioxidant protection (Delanghe and Langlois, 2001). In DMD, the 
dystrophin-deficient sarcolemma is weakened, enabling the leakage of muscle-
associated proteins, such as myoglobin into plasma. This has the potential to lead to 
the production of myoglobin-derived heme in plasma, which may explain the 
increased levels of hemopexin seen in neuromuscular disease (Adornato et al., 1978). 
The increased abundance of these two iron-regulating proteins suggests a protective 
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role against potential iron overload in the dystrophin-deficient brain, which may 
otherwise prove cytotoxic. Elevated levels of the important anti-inflammatory agent 
anti-trypsin suggest the induction of a protective mechanism in response to potential 
brain inflammation (Miravitlles, 2012). The classification of mental impairments as a 
clinical hallmark of DMD is supported by the proteomic identification of increased 
levels of fetuin-A, a previously identified biomarker of general neuro-degeneration 
(Mori et al., 2011).  
 A large proportion of the altered protein species in dystrophin-deficient brain 
samples belong to the class of cytoskeletal proteins (14.3%). Similar to other tissue 
types such as skeletal muscle, the deficit in dystrophin expression in the mdx-4cv brain 
appears to induce compensatory up-regulation of cytoskeletal proteins as a means of 
counteracting dystrophin deficiency-induced weakness and susceptibility to 
mechanical stress (Law et al., 1994). In the absence of the actin-binding Dp427 
isoform of dystrophin, levels of the actin-regulatory protein drebrin may be increased, 
as seen in this proteomic survey. Drebrin, through its co-localisation with actin 
filaments, has been proposed to be integral to synaptic plasticity (Shim and Lubec, 
2002), and hence reduced levels of drebrin have been associated with 
neurodegenerative conditions (Harigaya et al., 1996). Drebrin is also involved in 
regulating the assembly of actin filaments and in this regard its elevated levels in the 
dystrophin-deficient brain may suggest compensatory stabilisation of the actin 
cytoskeleton in order to maintain an internal scaffold capable of absorbing mechanical 
stress. Recent reports have also suggested a role for nuclear structural integrity in 
resistance against mechanical stress (Houben et al., 2007), with potential roles 
established for the nuclear membrane, the nuclear lamina and lamina-associated 
proteins such as A- and B-type lamins. B-type lamins appear to have particular 
importance given that that they are expressed in virtually all cell types, and thus may 
represent the essential component of the nuclear lamina (Broers et al., 2006). Increased 
abundance of lamin-B1 has been identified by both mass spectrometry and 
immunoblotting in this proteomic survey, agreeing with the role of lamina-associated 
proteins in maintaining nuclear integrity which is essential for cell survival. This role 
of lamin-B1 is further validated by the observed increase in histone H2B type 1-C/E/G. 
Histones serve as components of the nucleosome and play roles in DNA repair and 
replication and in chromosomal stability. Thus, the increase in histone H2B may 
represent an attempt by the mdx-4cv brain to maintain nuclear and thus cellular 
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integrity in the absence of Dp427. The increased expression of these two proteins may 
be responsible for safeguarding the nuclear structure, thus increasing the “mechanical 
stiffness” of the cell. This may enhance the ability of cells to endure the mechanical 
stress prevalent in weakened, dystrophin-deficient cells.  
 Glial fibrillary acidic protein (GFAP) is an intermediate filament III protein 
unique to astrocytes, enteric glial cells and non-myelinating Schwann cells in the 
peripheral nervous system (Eng, 1985). This brain-specific protein plays key structural 
roles in provision of the cytoskeletal structure of glial cells and maintenance of glial 
cell mechanical strength (Yang and Wang, 2015), along with maintaining the blood-
brain barrier, regulating ion and fluid homeostasis and controlling central nervous 
system blood-flow (Sofroniew and Vinters, 2010). Thus, in this role as a supporting 
intermediate filament its elevated abundance in the mdx-4cv brain is consistent with 
the hypothesis of structural re-organisation in dystrophic tissue to counteract 
dystrophin-deficiency. This claim is further substantiated by the increased abundance 
of vimentin, a closely related intermediate filament protein. Together, the increased 
abundance of these structural proteins may partially restore mechanical strength to 
cells made fragile by the absence of the large structural protein dystrophin. Increases 
in the expression of GFAP may also be indicative of astrogliosis (Eng et al., 2000), in 
which either the genetic deficiency in dystrophin and/or the secondary abnormalities 
which ensue may cause the activation of astrocytes. Reactive astrocytes, characterised 
by hypertrophy of their cellular processes and increased expression of GFAP, are 
essential for reducing the spread and persistence of inflammatory cells, repairing the 
blood brain barrier, and isolating affecting regions from neighbouring healthy tissue 
to limit the lesion size and subsequent tissue damage (Pekny et al., 2014). GFAP 
induction and associated gliosis are also associated with neuro-regeneration (Yang and 
Wang, 2015). While neuro-regeneration may initially be a positive, reparative 
response, in cases where the triggering factor for astrogliosis is unresolved it has the 
potential to lead to tissue scarring and inhibition of axon regeneration. Similarly in 
dystrophic skeletal muscle, excess connective tissue is produced in response to muscle 
damage (Holland et al., 2015a). Over time this fibrosis becomes pathological and 
contributes to the worsening phenotype seen in DMD. Perhaps the gliosis, induced 
neuro-regeneration and potential tissue scarring in the dystrophin-deficient brain is the 
equivalent to the severe fibrosis seen in skeletal muscle. Interestingly, TGF-β has been 
shown to induce GFAP gene transcription, resulting in elevated levels of GFAP 
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protein (Reilly et al., 1998). In skeletal muscle fibrosis is also modulated by TGF-β, 
since it stimulates the secretion of pro-fibrotic proteins such as collagen and periostin 
(Lorts et al., 2012, Vidal et al., 2008). Thus, this inflammatory mediator may 
contribute to tissue scarring in both dystrophin-deficient brain tissue and skeletal 
muscle. Astrogliosis and concomitant increases in GFAP have also been identified in 
brain tissue from individuals with Alzheimer’s disease, in cerebral freeze-injury and 
in the experimental autoimmune encephalomyelitis model of multiple sclerosis (Eng 
et al., 2000, Rodríguez et al., 2009). In addition, in this study immunoblotting of brain 
tissue from the wobbler mouse model of ALS revealed elevated levels of GFAP. 
Therefore, GFAP appears to represent a potential biomarker of neurotoxicity. In the 
absence of dystrophin, constant neuronal loss and alterations in calcium homeostasis 
may trigger non-specific reactive gliosis which may represent the underlying 
mechanism that triggers developmental cognitive defects in DMD. Indeed a previous 
case report of a Duchenne patient with severe mental retardation described multifocal 
glial nodules in the cerebellar cortex with proliferating glial cells showing an intense 
immunoreactivity for GFAP (Itoh et al., 1999).  
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Figure 6.12: A potential role for astrogliosis in the pathophysiology of mental 
impairment in the dystrophin-deficient brain 
In healthy tissue astrocytes are involved in maintaining homeostasis. In DMD the 
absence of dystrophin may lead to neuronal death which in turn may trigger 
astrogliosis. Unresolved astrogliosis may lead to the formation of glial scars and this 
process may represent the underlying mechanism responsible for cognitive 
deficiencies in DMD.  
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The abnormal expression of syntaxin-binding protein 1, syntaxin-1B and 
protein bassoon are indicative of variations in neurotransmission. Neurotransmission 
is a key biological process tightly regulated by a multitude of proteins that form the 
exocytosis release machinery, of which syntaxin-1 is a member (Yang et al., 2015). 
Syntaxin-binding protein 1, the binding partner of syntaxin, is also involved in 
neurotransmitter release via regulation of the protein receptor syntaxin. Both syntaxin-
binding protein 1 and syntaxin-1B display reduced abundance in mdx-4cv brain 
preparations, indicating a potential reduction in neurotransmission in the dystrophin-
deficient brain. Such reductions in glutamate neurotransmission have been identified 
in Alzheimer’s disease patients, where it has been suggested to contribute to cognitive 
impairment (Lin et al., 2003). Thus, a similar process may be responsible for cognitive 
deficits in X-linked muscular dystrophy. However, a slight increase in the expression 
of protein bassoon was also observed in dystrophin-deficient brain tissue. This protein 
is involved in the organisation of the cytomatrix at the nerve terminals active zone 
(Dick et al., 2003), where it regulates neurotransmitter release from brain 
glutamatergic synapses. Its increased expression may represent an attempt to promote 
neurotransmission in the face of reduced levels of other regulatory proteins. 
Alternatively, taken together the altered expression of syntaxin-binding protein 1, 
syntaxin-1B and protein bassoon may indicate a global disturbance of 
neurotransmission in dystrophin-deficient brain tissue.  
 The calcium hypothesis of DMD remains a key player in investigations of the 
disorder’s pathobiochemistry. This model postulates that the absence of functional 
dystrophin and concomitant ablation of the DGC weakens the sarcolemma enabling 
micro-rupturing and excess influx of Ca2+ into the sarcoplasm (Millay et al., 2009). 
Elevated levels of cytosolic calcium are thought to alter ion homeostasis, cellular 
signalling and activate protein degradation in affected muscle fibres. Absence of the 
DGC from the brain may affect neuronal membranes in the same fashion as the 
sarcolemma of muscle fibres. This hypothesis is supported by the observation that 
cerebellar granule-cell neurones from mdx mice have 24% more free calcium than 
normal wild-type mice (Hopf and Steinhardt, 1992). This may explain the observed 
increase in the calcium-binding protein calretinin in dystrophin-deficient brain evident 
in this proteomic survey (1.93-fold increase). Excessively high levels of intracellular 
calcium can induce cell death and thus the apparent up-regulation of calretinin may 
act as a compensatory mechanism in which calretinin acts as a calcium-buffering 
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protein to protect against calcium influx (Carretta et al., 2003). This may be 
particularly beneficial in emerging neurons where alterations in calcium ion 
homeostasis initiates cell death during development.  
 It has been recently proposed that the calcium-binding membrane repair 
proteins, the annexins, represent universal biomarkers of dystrophinopathy. Elevated 
levels of this protein class have been identified in the severely dystrophic mdx 
diaphragm, the moderately affected soleus and extensor digitorum longus mdx 
muscles and the relatively mildly affected interosseus and flexor digitorum brevis mdx 
muscles (Holland et al., 2015b). Elevated cytoplasmic calcium triggers the 
translocation of annexins to the membrane, with each annexin isoform having a 
particular calcium threshold (Draeger et al., 2011). While annexins 1 and 2 are widely 
known to be involved in membrane repair (McNeil et al., 2006, Lennon et al., 2003), 
a novel role for annexin A5 in this essential biological process has recently been 
suggested. Upon calcium activation annexin A5 has been shown to self-assemble into 
2D arrays on membranes with the aim of re-sealing membrane tears. Both annexin 
A5-null cells and cells expressing mutant annexin A5 which cannot form 2D arrays 
exhibit a severe membrane repair defect (Bouter et al., 2011). Hence, the elevated 
levels of annexin A5 in dystrophin-deficient brain may represent a marker of neuronal 
membrane damage, which is consistent with the hypothesis that dystrophin-deficient 
membrane is highly susceptible to injury.  
 Alterations in calcium homeostasis are also suggested by the drastic reduction 
in the expression of the plasma membrane calcium transporting ATPase 2 (PMCA), 
an essential component for maintaining cellular calcium homeostasis. PMCAs are the 
protein products of a multigene family with PMCA 1 and 4 expressed almost 
ubiquitously while PMCA 2 and 3 are restricted to neurons (Stauffer et al., 1995). In 
neuronal cells calcium homeostasis is maintained predominantly by a combination of 
sarcoplasmic/endoplasmic reticulum calcium ATPases, responsible for calcium 
uptake into the organelles, and the PMCAs, responsible for calcium extrusion (Fresu 
et al., 1999). The absence of dystrophin isoforms (Dp71, Dp116, Dp140, Dp260, 
Dp427, one or more of which may be absent depending on the genetic mutation) at the 
neuronal membrane induces susceptibility to membrane micro-injury, as suggested by 
elevated levels of the membrane repair protein annexin A5. Such injuries have been 
shown to facilitate the entry of Ca2+, which in the absence of efficient calcium 
pumping proteins such as PMCA 2 may build up to cytotoxic levels. Excessive 
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cytosolic calcium may be partially responsible for the neurotoxicity of these neuronal 
cells in dystrophin-deficient brain, which ultimately may contribute to impaired 
cognitive ability in some DMD patients.  
 The issue of a link between cognitive impairment and DMD is a highly debated 
and contentious one. While some argue that mental deficits represent an artefact, 
others suggest that brain function may be impaired by the extent of physical disability 
in Duchenne patients. On the other hand, mental impairment may represent a true 
clinical feature of X-linked dystrophinopathy. Meta-analysis of recorded intelligence 
quotients (IQ) in 721 DMD patients by Emery and Muntoni indicated that the overall 
mean IQ was approximately one standard deviation below the population mean. Of 
those patients, 19% demonstrated an IQ below 70 (the generally accepted cut-off value 
for a diagnosis of mental retardation) while 3% presented with an IQ less than 50, 
indicating moderate to severe mental retardation. A number of studies have focused 
their attention on investigating the contribution of physical disability to mental acuity. 
Some have questioned the suitability of complete Wechsler tests to measure IQ in 
patients with DMD, given that this type of assessment includes a physical aspect, in 
which the IQ measured may not be a true reflection of the subject’s intelligence but 
may instead reflect the motor handicap. However, a study by Ogasawara identified 
significantly lower total IQ in 44 DMD adolescents (IQ 83.4) compared to 10 patients 
with spinal muscular atrophy (SMA) (IQ 95.1). Since patients with SMA have a 
similar degree of motor impairment to DMD patients, the lower IQ in DMD patients 
may not be attributed to physical disability (Ogasawara, 1989). Other studies have 
shown that older children and adolescents with SMA perform significantly better on 
the verbal IQ scale than non-affected peers (von Gontard et al., 2002), with the 
suggestion that these disabled children may compensate for their physical handicap 
through attaining cognitive skills and knowledge. Taken together these reports suggest 
that the mental impairment seen in approximately one-third of DMD patients is a 
clinical manifestation of the disease, due to mutations in the gene encoding dystrophin. 
The proteomic data presented in this report also point to this hypothesis. PANTHER 
analysis of altered protein species identified that the largest class of affected proteins 
was that of cytoskeletal proteins, which correlates well with proteomic alterations seen 
in dystrophic skeletal muscle. The observed increase in cytoskeletal elements may 
serve as a compensatory mechanism to counteract dystrophin absence at the neuronal 
membrane. In particular, the increased abundance of annexin A5 is indicative of 
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membrane perturbations, suggesting that the loss of dystrophin at neuronal membranes 
results in membrane fragility and increased susceptibility to micro-rupturing (Bouter 
et al., 2011). The proteomic data also provides evidence of astrogliosis, which may be 
indicative of neurotoxicity (Brahmachari et al., 2006). Thus, the absence of the full-
length Dp427 isoform of dystrophin appears to have significant neurological effects 
which may be responsible for impaired cognitive function in a subset of DMD patients. 
The non-progressive nature of mental retardation may perhaps reflect the success of 
compensatory mechanisms in halting further damage and stabilising brain 
functionality.  
 
6.3.1 Conclusions 
DMD is primarily a disorder of the skeletal muscle triggering severe muscle necrosis 
and the replacement of skeletal muscle with adipose and connective tissue. Muscle 
degeneration causes loss of ambulation, respiratory and cardiac failure, and premature 
death. However, mild non-progressive cognitive impairments also represent a clinical 
characteristic of X-linked dystrophinopathy in subset of patients. In this chapter label-
free LC-MS/MS has been used to illustrate that dystrophin deficiency causes similar 
secondary abnormalities in the dystrophin-deficient brain to those commonly seen in 
dystrophic skeletal and cardiac muscle. Such abnormalities include altered calcium 
and iron homeostasis, compensatory up-regulation of components of the cytoskeletal 
lattice and membrane alterations. However, brain-specific defects were also observed; 
in particular elevated levels of GFAP were identified by mass spectrometry, 
immunoblotting and immunofluorescence microscopy. This intermediate filament 
protein has been previously suggested as a marker of neurotoxicity and has been 
shown here to also be increased in brain samples from the wobbler mouse model of 
ALS. Overall this proteomic survey of brain tissue from the mdx-4cv mouse indicates 
that dystrophin deficiency has consequences for the central nervous system, and this 
may contribute to non-progressive cognitive deficits.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Seven 
 
Proteomic profiling of serum and saliva in the mdx-4cv 
model of dystrophinopathy 
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7.1 Introduction 
DMD is a devastating, life-limiting neuromuscular disease. The disorder is due to 
primary abnormalities on the Dmd gene encoding the cytoskeletal protein dystrophin 
(Koenig et al., 1989), it predominantly affects males, and is characterised by severe 
and progressive skeletal muscle wasting. On a histopathological level, dystrophic 
muscles are identified by alterations in fibre size, infiltration of adipose and connective 
tissue, sterile inflammation, and central nucleation which is indicative of cycles of 
muscle fibre degeneration/regeneration.  
 Currently disease progression and response to therapeutic intervention are 
largely monitored by physiological tests, mainly the six-minute walk test and the 
North Star Ambulatory Assessment (NSAA). The six-minute walk test records the 
distance covered by a participant walking for six minutes (Enright, 2003). The NSAA 
covers a range of physical movement including standing, standing on one leg, 
jumping, rising from a lying position to a sitting position and a standing position, 
climbing and descending from a box step and running for 10 meters (Mazzone et al., 
2010). While useful, these methods have disadvantages in that they can only be used 
on patients who are still ambulatory and the results can be affected by the motivation 
of the participant to complete the tasks (Geiger et al., 2007). For this reason, molecular 
measurements reflective of the severity of the disease and responsiveness to therapy 
are required. At present, creatine kinase is used in the diagnosis of the disease 
(Okinaka et al., 1961, Cacchiarelli et al., 2011). However, it suffers a number of 
downfalls in that i) its levels can vary from day to day, ii) it is indicative of muscular 
damage but is not specific to DMD, iii) its levels can be easily influenced by exercise 
and iv) its levels decrease with age rendering it impractical for monitoring disease 
progression or therapeutic benefit (Hathout et al., 2016). Thus, a panel of biomarkers 
holds the most promise for the specific and sensitive diagnosis, prognosis and therapy 
monitoring of patients afflicted with DMD.  
 While tissue proteomics has greatly aided the search for protein biomarkers 
representative of dystrophinopathy (Holland et al., 2015b, Carberry et al., 2012, 
Murphy et al., 2015b, Lorts et al., 2012, Ge et al., 2003), tissue biopsy is highly 
invasive. Thus, circulating biomarkers may be advantageous for translation to the 
clinic. A plethora of different fluids exist in the human body, including blood, saliva, 
urine, cerebrospinal fluid and tears, and with advances in proteomic profiling 
alterations in the proteomes of these biofluids in heath and disease have been 
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extensively characterised (Jung et al., 2017, Finehout et al., 2007, Doecke et al., 2012, 
Dowling et al., 2008, Rouillon et al., 2014). These biofluids could potentially be mined 
for the presence of protein markers which may reflect the health status of an individual. 
Indeed a number of biofluids have already gained momentum in this regard, including 
bronchoalveolar fluid as a proximal biofluid for the discovery of lung cancer 
biomarkers (Hmmier et al., 2017), cerebrospinal fluid as a source of markers of 
Alzheimer’s disease (Andreasen and Blennow, 2005) and urine as a non-invasive 
starting point for the detection of prostate cancer indicators (Dijkstra et al., 2014). 
Mass spectrometry-based proteomic methodologies offer an unbiased approach for the 
identification of global alterations in protein abundance and can identify hundreds to 
thousands of differentially expressed proteins. Such protein biomarkers could be 
easily integrated into current biochemical assays, such as enzyme-linked 
immunosorbent assays, in a clinical setting (Coenen-Stass et al., 2015). One of the 
major challenges facing the mass spectrometric profiling of biofluids, particularly 
blood, serum and urine, is the huge dynamic range that exists between the proteins of 
highest and lowest abundance. In blood/serum the top twenty most abundant proteins 
(including albumin, immunoglobulins, transferrin, and fibrinogen) account for more 
than 90% of total protein (Hortin et al., 2008). The large dynamic range, estimated to 
span 10-12 orders of magnitude (Hortin and Sviridov, 2010), far exceeds the 
maximum dynamic range capacity of modern mass spectrometers. This can result in 
ion suppression whereby peptides from higher abundance proteins are repeatedly 
selected for fragmentation, resulting in limited identification of peptides arising from 
lower abundance proteins (Qian et al., 2006), which are more likely to represent 
clinically relevant protein biomarkers (Zolotarjova et al., 2008).  
Multiple strategies exist for simplifying the serum proteome (Whiteaker et al., 
2007), including enrichment of a specific sub-proteome (Zhang et al., 2003b, Gao et 
al., 2015), biophysical fractionation (Tirumalai et al., 2003) and immuno-depletion of 
the most highly abundant proteins (Smith et al., 2011). The immuno-depletion method 
typically removes one or more of the following proteins depending on the specific 
immuno-depletion resin used; albumin, immunoglobulins, haptoglobin, fibrinogen, 
transferrin and antitrypsin. Since albumin alone accounts for approximately 50% of 
the total protein content of serum (Tirumalai et al., 2003) it is frequently targeted for 
removal by immuno-depletion. Given its physiological role as a carrier and transport 
protein in the blood, albumin binds to a multitude of molecules including hormones, 
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lipids, proteins, peptides, cytokines and chemokines and thus its depletion from serum 
samples may result in the concomitant depletion of any molecules bound to it (Zhou 
et al., 2004, Gundry et al., 2007).  Immuno-depletion of serum prior to mass 
spectrometric analysis is therefore a compromise, in which sample complexity is 
reduced enabling for an enriched pool of low-abundance proteins and the prevention 
of ion suppression by high abundance proteins, at the expense of losing some 
potentially important protein species which may be co-eluted with the intended targets 
of immuno-depletion. Thus, analysis of serum samples is highly complex and ideally 
multiple methodologies should be used in tandem to provide the optimum in-depth 
coverage of the serum proteome.  
Saliva is composed of secretions from the salivary glands (the three paired 
major salivary glands; parotid, submandibular and sublingual glands, and the hundreds 
of minor salivary glands), food deposits, blood-derived compounds, desquamated 
epithelial cells and micro-organisms (Loo et al., 2010). Saliva also contains fluids 
originating from upper airways secretions, gastrointestinal reflux and the gingival 
crevice (Chiappin et al., 2007). Despite having a composition of almost 99% water, 
saliva also contains a wide range of proteins, many of which with either a salivary 
gland (α-amylase, cystatins, lysozymes, lactotransferrin and mucins) or serum 
(albumin) origin (Lima et al., 2010). Recent ultra-deep salivary proteome analysis has 
identified more than 5,500 proteins (Grassl et al., 2016) and this depth of information 
provided by salivary proteomics along with low-cost and non-invasive saliva 
collection methods suggests that salivary proteomics may become a useful addition to 
the range of diagnostic and prognostic tools currently available. As a result, saliva is 
currently under investigation as a source of biomarkers in a variety of disorders 
ranging from infectious disease such as hepatitis and HIV, to head and neck cancer to 
autoimmune disorders such as Sjogren’s Syndrome (Lima et al., 2010). Although not 
currently used in clinical practice, salivary proteomics for the diagnosis and therapy 
monitoring of DMD represents an attractive option, particularly for paediatric patients.  
With the explosion of mass-spectrometry- and proteomics-driven biomarker 
research, several potential biomarkers of DMD have been identified. Such potential 
biomarkers include miRNA in serum of both animal models and human patients 
(Cacchiarelli et al., 2011), titin fragments in clinical urine samples (Rouillon et al., 
2014) and circulating protein biomarkers, particularly fibronectin (Cynthia Martin et 
al., 2014), myoglobin (Hathout et al., 2014, Hathout et al., 2015) and carbonic 
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anhydrase 3 (Ayoglu et al., 2014). In this study, label-free LC-MS/MS has been used 
to identify potential protein biomarkers in serum and saliva samples from 6-month old 
mdx-4cv mice. In the serum proteome 371 differentially abundant proteins (greater 
than two-fold change) were identified. Similar to previous studies, elevated abundance 
was identified for myoglobin, carbonic anhydrase 3, parvalbumin, lactate 
dehydrogenase, fatty acid binding protein and titin (Hathout et al., 2014). Interestingly, 
a dramatic increase in abundance was observed for haptoglobin. Elevations in serum 
haptoglobin was identified by gel electrophoretic analyses of serum obtained from 
DMD patients in the late 1980s (John and Purdom, 1989), but has remained largely 
unexplored as a potential biomarker. In addition, 14 proteins with altered abundance 
were characterised in the saliva proteome, with perturbations evident for proteins 
associated with inflammation, extracellular matrix remodelling and protease activity.  
 
7.1.1 Experimental Design  
Since there is an urgent need for improved protein biomarkers for the diagnosis, 
prognosis and therapy-monitoring of dystrophinopathy, a proteomic survey of two 
distinct biofluids (serum and saliva) from 6-month old wild-type and age-matched 
mdx-4cv mice was conducted. Given the large dynamic range and complexity of the 
serum proteome, serum samples were immuno-depleted prior to mass spectrometric 
analysis. Serum samples were prepared for mass spectrometry as described in the 
methods section 2.2.12, whereas filter-aided sample preparation (FASP) was used to 
prepare saliva samples for mass spectrometry. Both serum and saliva samples were 
analysed by label-free LC-MS/MS, using an Ultimate 3000 NanoLC system (Dionex 
Corporation, Sunnyvale, CA, USA) coupled to a Q-Exactive mass spectrometer 
(Thermo Fisher Scientific). Peptides from serum samples were eluted over 180 min 
using the following binary gradient solvent A [2% (v/v) ACN and 0.1% (v/v) formic 
acid in LC-MS grade water] and 0-90% solvent B [80% (v/v) ACN and 0.1% (v/v) 
formic acid in LC-MS grade water]: 5-45% solvent B for 120 min, 45-90% solvent B 
for 2.5 min, 90% solvent B for 9 min and 2% solvent B for 43 min. Peptides from 
saliva samples were eluted over 65 min using the following binary gradient [solvent 
A: (2% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade water and solvent B: 
80% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade water]: 3-10% solvent B 
for 5 min, 10-40% solvent B for 30 min, 40-90% solvent B for 5 min, 90% solvent B 
for 5 min and 3% solvent B for 10 min. For the quantitative analysis of the serum 
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proteome Progenesis QI for Proteomics software using Sequest HT and MASCOT 
search engines and the UniProtKB-SwissProt database was employed. The analysis of 
alterations in the saliva proteome was performed using MaxQuant with the 
Andromeda search engine and the UniProtKB-SwissProt database, and Perseus 
software. Bioinformatics analysis was conducted using Cytoscape and the PANTHER 
database of protein families. Comparative immunoblot analysis and enzyme-linked 
immunosorbent assays were used to confirm some of the major protein hits from the 
serum data.  
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7.2 Results 
Serum represents a major source of potential biomarkers given it contains both 
circulatory proteins and tissue-derived proteins that may leak into circulation 
following tissue damage. In DMD a number of circulating biomarkers; creatine kinase, 
lactate dehydrogenase, parvalbumin and myoglobin have been described, but such 
markers are generally indicative of muscular damage in general and not DMD 
specifically. Thus, a larger panel of biomarkers is required for the effective diagnosis, 
prognosis and therapeutic monitoring of dystrophinopathies. One of the major issues 
hindering the proteomic profiling of serum samples is the enormous dynamic range of 
proteins, with highly abundant proteins masking the lower abundance proteins. To 
overcome this issue an immuno-depletion protocol was used to reduce sample 
complexity prior to label-free LC-MS/MS. This comparative proteomic profiling 
approach compared serum samples from 6-month old wild-type and mdx-4cv mice. In 
addition to profiling of the serum proteome, mass spectrometry-based proteomics was 
used to identify potential protein markers of dystrophinopathy in saliva samples from 
mdx-4cv mice. 
 
7.2.1 Gel electrophoretic and immunoblot analysis of immuno-depleted serum 
samples 
To confirm the removal of the highly abundant proteins immunoglobulin and albumin 
from immuno-depleted serum samples, gel electrophoresis and immunoblotting was 
employed. Gel electrophoresis indicated the large reduction in a protein band at 
approximately 60-70 kDa, suggesting the removal of albumin. Immunoblotting using 
antibodies against albumin and immunoglobulin confirmed the removal of the vast 
majority of albumin and the heavy and light chains of immunoglobulin by immuno-
depletion. Immuno-depleted samples were then used for mass spectrometric analyses.  
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A) Silver Gel                       B) Transferrin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Gel electrophoretic and immunoblot analysis of albumin depletion in 
wild-type and mdx-4cv serum 
Shown is a representative silver-stained gel (A) and immunoblot and statistical 
analysis of bands labelled with transferrin (B). The silver stained gel shows reduced 
levels of albumin in immuno-depleted serum. Molecular weight marker is given on 
the left-hand-side of the image in kDa. Transferrin immunoblotting did not show 
significant changes in concentration between wild-type and mdx-4cv crude and 
immuno-depleted samples and so it serves as a loading control for comparative 
immunoblotting. Also shown is an immunoblot to albumin (C), which shows greatly 
reduced levels in immuno-depleted serum. Lanes 1, 2, 3 and 4 refer to wild-type crude 
serum, wild-type immuno-depleted serum, mdx-4cv crude serum and mdx-4cv 
immuno-depleted serum respectively. Graphical representation of the immuno-
decoration levels for transferrin and albumin is shown (mean values ± SEM, Student’s 
t-test; unpaired; n=4; *p≤0.05, **p≤0.01).  
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Figure 7.2: Immunoblot analysis of immunoglobulin depletion in wild-type and 
mdx-4cv serum 
Shown are representative immunoblots and statistical analysis of mouse 
immunoglobulins (A, B). Both immunoblots illustrate the reduced abundance of 
immunoglobulin heavy chain (50 kDa bands) and immunoglobulin light chain (25 kDa 
bands) in immuno-depleted serum samples. Lanes 1, 2, 3 and 4 refer to wild-type crude 
serum, wild-type immuno-depleted serum, mdx-4cv crude serum and mdx-4cv 
immuno-depleted serum respectively. Graphical representation of the immuno-
decoration levels for immunoglobulin heavy and light chains is shown (mean values 
± SEM, Student’s t-test; unpaired; n=4; *p≤0.05, **p≤0.01, ***p≤0.001).  
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7.2.2 Qualitative analysis of the serum proteome 
Qualitative analysis of immuno-depleted serum samples identified a total of 1,030 
proteins in wild-type serum and 1,278 proteins in mdx-4cv serum. 12.5% of wild-type 
proteins and 16.1% of mdx-4cv proteins had a percentage sequence coverage greater 
than 50%. The proteins with highest percentage coverages in wild-type and mdx-4cv 
serum include haemoglobin subunit alpha (100% coverage), carbonic anhydrase 3 
(89.62% in wild-type and 92.69% in mdx-4cv), carbonic anhydrase 1 (88.12% in wild-
type and 87.74% in mdx-4cv), complement C3 (86.71% in wild-type and 85.87% in 
mdx-4cv) and fructose-bisphosphate aldolase A (81.59% in wild-type and 83.79% in 
mdx-4cv).  
 
7.2.3 Quantitative label-free LC-MS/MS analysis of wild-type versus mdx-4cv serum 
The removal of the vast majority of the highly abundant serum proteins albumin and 
immunoglobulins sufficiently reduced sample complexity to allow a relatively in-
depth comparative proteomic analysis of serum obtained from wild-type and 
dystrophic mice. Overall, mass spectrometry identified a total of 371 differentially 
expressed proteins based on a p-value ≤0.05, at least two unique peptides and a 
minimum fold change of 2. Of these proteins 334 were increased in abundance in mdx-
4cv serum while the remaining 37 proteins displayed reduced abundance. 26.6% of all 
proteins (increased and decreased) displayed a fold change ≥ 10. Greater fold changes 
were seen for the proteins with elevated abundance; maximum fold change of 384.81 
and 54% of increased abundance proteins displaying a fold change ≥5. All proteins 
with decreased abundance had a fold change <4, with the highest fold change seen for 
angiotensin-converting enzyme (-3.48-fold decrease). The mass spectrometric data 
indicates a severely disturbed serum proteome, with inflammation (increased 
abundance of inflammatory markers haptoglobin and serum amyloid A), alterations in 
enzymatic activity and calcium homeostasis, and muscle degeneration (presence of 
muscle-specific proteins, such as titin fragments, in serum) evident.  
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Table 7.1: List of identified proteins with ≥ 12.7-fold increased abundance in 6-
month old mdx-4cv serum versus age-matched wild-type serum as determined by 
label-free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
P70441 Slc9a3r1  Na(+)/H(+) exchange 
regulatory cofactor NHE-
RF1  
2 128.77 3.47E-
05 
384.81 
Q9D5J6 Shpk  Sedoheptulokinase  3 181.59 4.21E-
03 
213.06 
Q19LI2 A1bg  Alpha-1B-glycoprotein  3 201.11 2.07E-
03 
199.86 
Q99020 Hnrnpab  Heterogeneous nuclear 
ribonucleoprotein A/B  
2 120.87 2.40E-
04 
131.39 
P09405 Ncl  Nucleolin  2 66.85 2.14E-
04 
104.30 
Q62446 Fkbp3  Peptidyl-prolyl cis-trans 
isomerase FKBP3  
2 69.16 3.01E-
04 
89.12 
Q8BG05 Hnrnpa3  Heterogeneous nuclear 
ribonucleoprotein A3  
2 132.17 2.62E-
05 
72.76 
Q08331 Calb2  Calretinin  5 174.30 5.09E-
04 
59.85 
P07361 Orm2  Alpha-1-acid glycoprotein 
2  
2 101.47 9.48E-
09 
56.75 
P00493 Hprt1  Hypoxanthine-guanine 
phosphoribosyltransferase  
2 73.54 1.28E-
03 
53.30 
Q61646 Hp  Haptoglobin  14 826.52 4.25E-
07 
50.28 
Q9D0R2 Tars  Threonine--tRNA ligase, 
cytoplasmic  
5 187.79 5.00E-
03 
48.44 
P48428 Tbca  Tubulin-specific 
chaperone A  
2 59.15 1.78E-
03 
46.75 
Q99KP3 Cryl1  Lambda-crystallin 
homolog  
3 173.73 3.22E-
02 
43.29 
A2ABU4 Myom3  Myomesin-3  9 588.37 6.71E-
12 
38.64 
Q99KC8 Vwa5a  von Willebrand factor A 
domain-containing 
protein 5A  
2 41.66 4.64E-
05 
37.21 
P05366 Saa1  Serum amyloid A-1 
protein  
2 135.98 2.54E-
08 
36.98 
Q8VC12 Uroc1  Urocanate hydratase  10 751.33 9.91E-
04 
36.87 
P47199 Cryz  Quinone oxidoreductase  4 206.42 1.61E-
04 
36.77 
Q91X52 Dcxr  L-xylulose reductase  2 99.38 1.76E-
05 
32.75 
Q8VCX1 Akr1d1  3-oxo-5-beta-steroid 4-
dehydrogenase  
5 177.09 1.74E-
04 
31.24 
Q9WTP6 Ak2  Adenylate kinase 2, 
mitochondrial  
2 67.03 4.27E-
03 
31.23 
A3KMP2 Ttc38  Tetratricopeptide repeat 
protein 38  
4 177.89 5.40E-
04 
30.60 
Q5SX40 Myh1  Myosin-1  62 4670.12 3.89E-
13 
30.35 
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A2ASS6 Ttn  Titin  88 4357.28 6.29E-
13 
30.22 
P99027 Rplp2  60S acidic ribosomal 
protein P2  
2 162.50 3.75E-
03 
30.11 
Q8VCT4 Ces1d  Carboxylesterase 1D  5 114.10 9.04E-
05 
26.83 
P53026 Rpl10a  60S ribosomal protein 
L10a  
2 97.35 3.71E-
03 
26.48 
P68040 Gnb2l1  Guanine nucleotide-
binding protein subunit 
beta-2-like 1  
2 48.55 8.01E-
05 
25.64 
Q9QXE0 Hacl1  2-hydroxyacyl-CoA lyase 
1  
4 252.90 6.70E-
03 
24.50 
Q9D8Y0 Efhd2  EF-hand domain-
containing protein D2  
3 162.57 2.00E-
04 
23.88 
Q9CXN7 Pbld2  Phenazine biosynthesis-
like domain-containing 
protein 2  
5 346.95 1.25E-
03 
23.72 
P61458 Pcbd1  Pterin-4-alpha-
carbinolamine 
dehydratase  
5 239.45 5.34E-
03 
23.22 
Q60866 Pter  Phosphotriesterase-related 
protein  
3 145.96 3.01E-
02 
21.53 
Q9QUR6 Prep  Prolyl endopeptidase  5 266.66 6.31E-
03 
20.99 
P35492 Hal  Histidine ammonia-lyase  13 939.85 2.36E-
03 
20.94 
Q8CHR6 Dpyd  Dihydropyrimidine 
dehydrogenase 
[NADP(+)]  
4 219.69 3.46E-
03 
20.71 
Q8VCN5 Cth  Cystathionine gamma-
lyase  
9 552.72 3.10E-
03 
19.52 
Q9DCT1 Akr1e2  1,5-anhydro-D-fructose 
reductase  
2 84.60 1.09E-
02 
19.07 
P12246 Apcs  Serum amyloid P-
component  
7 427.15 3.61E-
11 
18.85 
Q05816 Fabp5  Fatty acid-binding 
protein, epidermal  
8 385.47 1.66E-
05 
18.32 
P13412 Tnni2  Troponin I, fast skeletal 
muscle  
3 131.21 9.00E-
08 
18.23 
Q99L47 St13  Hsc70-interacting protein  2 81.37 5.54E-
03 
18.01 
Q00915 Rbp1  Retinol-binding protein 1  3 212.04 5.19E-
05 
17.83 
P12658 Calb1  Calbindin  4 280.34 1.54E-
03 
17.82 
Q8VC28 Akr1c13  Aldo-keto reductase 
family 1 member C13  
6 353.98 6.05E-
04 
17.47 
Q9DCG6 Pbld1  Phenazine biosynthesis-
like domain-containing 
protein 1  
9 531.49 1.04E-
03 
17.19 
P97328 Khk  Ketohexokinase  4 336.94 9.67E-
04 
16.98 
Q9DBF1 Aldh7a1  Alpha-aminoadipic 
semialdehyde 
dehydrogenase  
8 432.11 1.52E-
04 
16.74 
P50431 Shmt1  Serine 
hydroxymethyltransferase
cytosolic  
16 811.20 5.67E-
03 
16.48 
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Q9EQF5 Dpys  Dihydropyrimidinase  10 449.94 1.01E-
02 
16.48 
Q9CWS0 Ddah1  N(G),N(G)-
dimethylarginine 
dimethylaminohydrolase 
1  
4 138.62 2.81E-
04 
16.39 
Q8VDK1 Nit1  Nitrilase homolog 1  2 125.41 1.20E-
04 
16.35 
Q91V76 N/A Ester hydrolase C11orf54 
homolog  
8 449.50 1.05E-
03 
15.78 
O08997 Atox1  Copper transport protein 
ATOX1  
2 71.42 1.84E-
05 
15.57 
Q8CAY6 Acat2  Acetyl-CoA 
acetyltransferase, 
cytosolic  
8 542.64 3.46E-
03 
15.57 
P08074 Cbr2  Carbonyl reductase 
[NADPH] 2  
2 86.35 9.01E-
03 
15.47 
Q8BTY1 Ccbl1  Kynurenine--oxoglutarate 
transaminase 1  
6 252.66 1.59E-
04 
15.29 
P62897 Cycs  Cytochrome c, somatic  5 543.08 9.05E-
12 
15.24 
Q5SX39 Myh4  Myosin-4  23 1562.66 2.27E-
11 
14.90 
P05063 Aldoc  Fructose-bisphosphate 
aldolase C  
9 679.32 3.04E-
04 
14.82 
Q8R1G2 Cmbl  Carboxymethylenebutenol
idase homolog  
6 242.97 1.07E-
04 
14.68 
Q91X91 Qprt  Nicotinate-nucleotide 
pyrophosphorylase 
[carboxylating]  
7 359.79 4.04E-
04 
14.61 
Q64374 Rgn  Regucalcin  16 1310.14 9.81E-
04 
14.34 
P29391 Ftl1  Ferritin light chain 1  9 768.17 4.80E-
05 
14.09 
P30115 Gsta3  Glutathione S-transferase 
A3  
8 498.65 6.05E-
04 
13.72 
Q9JHW2 Nit2  Omega-amidase NIT2  12 604.83 8.05E-
04 
13.56 
P47857 Pfkm  ATP-dependent 6-
phosphofructokinase, 
muscle type  
22 1691.19 2.42E-
13 
13.49 
P97457 Mylpf  Myosin regulatory light 
chain 2, skeletal muscle 
isoform  
8 505.80 2.55E-
10 
13.28 
Q8VHX6 Flnc  Filamin-C  7 418.63 7.68E-
09 
13.27 
P58044 Idi1  Isopentenyl-diphosphate 
Delta-isomerase 1  
2 91.15 6.85E-
08 
13.25 
O09173 Hgd  Homogentisate 1,2-
dioxygenase  
20 1081.44 1.69E-
03 
13.11 
P62204 Calm1  Calmodulin  2 103.84 8.39E-
06 
12.91 
P28271 Aco1  Cytoplasmic aconitate 
hydratase  
7 318.28 1.73E-
04 
12.87 
P35505 Fah  Fumarylacetoacetase  18 1386.08 7.13E-
04 
12.73 
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Table 7.2: List of identified proteins with a significantly decreased abundance in 6-
month old mdx-4cv serum versus age-matched wild-type serum as determined by 
label-free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max fold 
change 
P09470 Ace  Angiotensin-
converting 
enzyme  
2 97.76 1.75E-
03 
3.48 
O35930 Gp1ba  Platelet 
glycoprotein Ib 
alpha chain  
11 865.35 9.65E-
07 
3.40 
Q07456 Ambp  Protein AMBP  4 362.51 1.26E-
02 
3.06 
P28665 Mug1  Murinoglobulin-1  116 12973.81 2.62E-
06 
2.91 
B5X0G2 Mup17  Major urinary 
protein 17  
5 231.60 1.04E-
03 
2.77 
Q00898 Serpina1e  Alpha-1-
antitrypsin 1-5  
14 1024.28 3.78E-
03 
2.69 
P05208 Cela2a  Chymotrypsin-
like elastase 
family member 
2A  
3 230.49 1.16E-
07 
2.69 
O08742 Gp5  Platelet 
glycoprotein V  
5 601.56 7.52E-
04 
2.62 
Q03311 Bche  Cholinesterase  7 362.36 4.76E-
06 
2.61 
P01942 Hba  Hemoglobin 
subunit alpha  
7 448.81 1.14E-
02 
2.61 
P42703 Lifr  Leukemia 
inhibitory factor 
receptor  
28 2444.33 1.78E-
07 
2.49 
Q62351 Tfrc  Transferrin 
receptor protein 1  
5 278.54 9.37E-
06 
2.48 
Q9DBB9 Cpn2  Carboxypeptidase 
N subunit 2  
15 1509.87 1.77E-
07 
2.43 
Q8QZR3 Ces2a  Pyrethroid 
hydrolase Ces2a  
2 114.66 6.44E-
03 
2.42 
Q8BPB5 Efemp1  EGF-containing 
fibulin-like 
extracellular 
matrix protein 1  
4 182.66 7.38E-
04 
2.41 
O88968 Tcn2  Transcobalamin-2  9 577.32 5.17E-
05 
2.40 
Q61704 Itih3  Inter-alpha-
trypsin inhibitor 
heavy chain H3  
7 627.52 5.34E-
03 
2.40 
Q03734 Serpina3m  Serine protease 
inhibitor A3M  
9 788.27 3.49E-
03 
2.39 
E9Q414 Apob  Apolipoprotein B-
100  
35 1947.84 1.90E-
03 
2.38 
Q07235 Serpine2  Glia-derived 
nexin  
5 234.21 1.91E-
03 
2.37 
P07758 Serpina1a  Alpha-1-
antitrypsin 1-1  
11 1371.40 5.81E-
03 
2.37 
Q61247 Serpinf2  Alpha-2-
antiplasmin  
3 294.61 4.79E-
04 
2.36 
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P06683 C9  Complement 
component C9  
21 1327.94 3.07E-
03 
2.28 
P32261 Serpinc1  Antithrombin-III  5 669.57 5.00E-
03 
2.24 
O70165 Fcn1  Ficolin-1  8 539.88 6.24E-
06 
2.22 
P35917 Flt4  Vascular 
endothelial 
growth factor 
receptor 3  
4 201.55 2.09E-
08 
2.18 
Q61703 Itih2  Inter-alpha-
trypsin inhibitor 
heavy chain H2  
18 1687.48 4.61E-
04 
2.18 
P28666 Mug2  Murinoglobulin-2  3 214.49 5.86E-
05 
2.17 
P22599 Serpina1b  Alpha-1-
antitrypsin 1-2  
11 1257.05 9.64E-
04 
2.15 
O09159 Man2b1  Lysosomal alpha-
mannosidase  
3 205.08 2.05E-
05 
2.14 
Q8BH35 C8b  Complement 
component C8 
beta chain  
24 2136.71 2.76E-
03 
2.12 
Q08879 Fbln1  Fibulin-1  3 124.02 1.84E-
03 
2.11 
Q8CIZ8 Vwf  von Willebrand 
factor  
2 104.40 3.34E-
05 
2.08 
Q8K182 C8a  Complement 
component C8 
alpha chain  
27 2579.27 5.51E-
04 
2.08 
Q01279 Egfr  Epidermal growth 
factor receptor  
21 1995.68 1.38E-
05 
2.07 
Q61702 Itih1  Inter-alpha-
trypsin inhibitor 
heavy chain H1  
18 1267.61 7.88E-
04 
2.02 
Q9JJN5 Cpn1  Carboxypeptidase 
N catalytic chain  
13 1198.91 1.97E-
06 
2.00 
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7.2.4 Distribution of protein alterations in dystrophic serum 
Standard bioinformatics analysis was used to visualise the proteomic changes in 
serum from dystrophic mdx-4cv mice. As depicted in the PANTHER analysis in 
Figure 7.3 and Figure 7.4, the proteomic analysis revealed the highest number of 
increased abundance proteins belong to the hydrolase protein class (21.2%), while 
the largest number of decreased abundance proteins belong to the enzyme 
modulator protein class (48.1%). This suggests that mdx-4cv serum reflects 
several changes in enzymatic activity in the mdx-4cv model of dystrophinopathy. 
It is postulated the degeneration of necrotic muscle fibres results in the release of 
muscle-derived proteins into the circulatory system. To investigate this 
phenomenon, the ClueGO plug-in of the Cytoscape bioinformatics package was 
used to identify enriched cellular components associated with proteins that display 
an increased abundance in mdx-4cv serum. As seen in Figure 7.5, several enriched 
cellular component categories were those associated with skeletal muscle, 
including myofibril, I, M and A bands, myosin complex, actin cytoskeleton and 
actomyosin, indicating the leakage of muscle proteins into the serum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
262 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: PANTHER analysis of proteins with increased abundance in mdx-4cv 
serum 
The 334 proteins with elevated abundance were grouped into their respective protein 
class using the freely available PANTHER software package. This analysis identified 
the class of hydrolase as containing the most altered protein species in mdx-4cv serum. 
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Figure 7.4: PANTHER analysis of proteins with decreased abundance in mdx-
4cv serum 
The 37 proteins with reduced abundance were grouped into their respective protein 
class using the freely available PANTHER software package. This analysis identified 
the class of enzyme modulator as containing the most altered protein species in mdx-
4cv serum. 
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Figure 7.5: ClueGO analysis of proteins with increased abundance in mdx-4cv serum 
The ClueGO plug-in app in Cytoscape was used to identify significantly enriched cellular component GO terms of the proteins  
with elevated abundance in mdx-4cv serum samples.
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7.2.5 Independent verification of differentially abundant proteins by 
immunoblotting 
Immunoblotting using a panel of select antibodies was used to verify some of the 
differentially abundant proteins identified by label-free LC-MS/MS. Equal loading 
was confirmed by a combination of silver-stained gels and immunoblots to transferrin, 
a loading control used for serum, as shown in Figure 7.6. Lactate dehydrogenase, 
parvalbumin and fatty-acid binding protein 1 (FABP-1) were identified as having 
increased levels in serum from mdx-4cv mice by LC-MS/MS, and this was confirmed 
by immunoblotting, for which only the increases in lactate dehydrogenase and FABP-
1 were found to be statistically significant (Figure 7.7). In contrast to other studies 
(Hathout et al., 2014), myoglobin (accession P04247; 3 unique peptides; confidence 
score 258.55) was found to be slightly decreased in mdx-4cv serum (-1.88-fold 
decrease) although immunoblot analysis shows little difference in myoglobin 
abundance between wild-type and mdx-4cv serum (Figure 7.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
266 
 
 
 
 
 
 
 
 
 
 
A) Silver Gel                 B) Transferrin 
  
 
 
  
 
 
 
 
Figure 7.6: Electrophoretic and immunoblot analysis of wild-type and mdx-4cv 
serum 
Shown is a silver stained 1D gel (A) and immunoblot and statistical analysis of bands 
labelled with transferrin (B). The silver stained gel shows comparable protein banding 
patterns for wild-type and mdx-4cv serum. Molecular weight marker is given on the 
left-hand-side of the image in kDa. Transferrin immunoblotting did not show 
significant changes in concentration between wild-type and mdx-4cv samples and so 
it serves as a loading control for comparative immunoblotting. Graphical 
representation of the immuno-decoration level for transferrin is shown (mean values 
± SEM, Student’s t-test; unpaired; n=4). 
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Figure 7.7: Comparative immunoblot analysis of proteins with increased 
abundance in dystrophic mdx-4cv serum 
Shown are representative immunoblots with immuno-decorated bands labelled with 
antibodies to lactate dehydrogenase (A), parvalbumin (B) and FABP-1 (C). Statistical 
analysis of immuno-decoration was performed with Student’s t-test (mean values ± 
SEM; unpaired; n=4, *p≤0.05, ***p≤0.001). 
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Figure 7.8: Comparative immunoblot analysis of proteins with decreased 
abundance in dystrophic mdx-4cv serum 
Shown is a representative immunoblot with immuno-decorated bands labelled with an 
antibody to myoglobin (A). Statistical evaluation of immuno-decoration was 
performed with Student’s t-test (mean values ± SEM; unpaired; n=4). 
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7.2.6 Immunoblot analysis of the increased abundance of haptoglobin in mdx-4cv 
serum 
Despite the observed increase in haptoglobin levels in plasma from patients with DMD 
by gel electrophoresis in 1989, there have been few other reports of this phenomenon. 
We have here identified a very large increase (50.28-fold) in the abundance of 
haptoglobin in serum isolated from the mdx-4cv animal model of dystrophinopathy by 
LC-MS/MS. The LC-MS/MS analysis identified 14 unique peptides belonging to the 
haptoglobin protein, providing excellent coverage of the whole protein (Figure 7.9). 
Increased abundance of haptoglobin was confirmed by immunoblot analysis using two 
distinct haptoglobin antibodies; ab131236 and ab157714 (Figure 7.10). To further 
investigate this protein as a potential serum biomarker of DMD, its abundance in 
serum from 12-month old wild-type and mdx-4cv mice was also analysed by 
comparative immunoblotting (Figure 7.12). Immunoblotting confirmed the trend of 
increased abundance of haptoglobin in mdx-4cv serum, although this was not found to 
be statistically significant. The abundance of FABP-1 in serum from 12-month old 
wild-type and mdx-4cv mice was also investigated by comparative immunoblotting 
and was found to be significantly increased in mdx-4cv serum as illustrated in Figure 
7.13.  
 
 
 
Mass Spectrometric Fingerprint of Haptoglobin 
 
 
 
 
 
Figure 7.9: Mass spectrometric fingerprint of haptoglobin 
The 14 peptides used in the identification of haptoglobin are highlighted in bold and 
underlined, showing good coverage of the entire haptoglobin protein by LC-MS/MS.  
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MRALGAVVTLLLWGQLFAVELGNDAMDFEDDSCPKPPEIANGYVEHLVRYRCRQF
YRLRAEGDGVYTLNDEKQWVNTVAGEKLPECEAVCGKPKHPVDQVQRIIGGSMDA
KGSFPWQAKMISRHGLTTGATLISDQWLLTTAKNLFLNHSETASAKDITPTLTLY
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VRATDLKDWVQETMAKN 
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Figure 7.10: Comparative immunoblot analysis of haptoglobin in dystrophic 6-
month mdx-4cv serum  
Shown are representative immunoblots with immuno-decorated bands labelled with 
two separate antibodies to haptoglobin; ab131236 (A) and ab157714 (B). Statistical 
analysis of immuno-decoration was performed with Student’s t-test (mean values ± 
SEM; unpaired; n≥5; wt=5, mdx-4cv=8; **p≤0.01). 
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A) Silver Gel                     B) Transferrin 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11: Electrophoretic and immunoblot analysis of wild-type and mdx-4cv 
12-month old serum  
Shown is a silver stained 1D gel (A) and immunoblot and statistical analysis of bands 
labelled with transferrin (B). The silver stained gel shows comparable protein banding 
patterns for wild-type and mdx-4cv serum. Molecular weight marker is given on the 
left-hand-side of the image in kDa. Transferrin immunoblotting did not show 
significant changes in concentration between wild-type and mdx-4cv samples and so 
it serves as a loading control for comparative immunoblotting. Graphical 
representation of the immuno-decoration level for transferrin is shown (mean values 
± SEM, Student’s t-test; unpaired; n=4). 
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Figure 7.12: Comparative immunoblot analysis of haptoglobin in dystrophic 12-
month mdx-4cv serum  
Shown is a representative immunoblot with immuno-decorated bands labelled with an 
antibody to haptoglobin (A). Statistical analysis of immuno-decoration was performed 
with Student’s t-test (mean values ± SEM; unpaired; n=4). 
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Figure 7.13: Comparative immunoblot analysis of FABP-1 in dystrophic 12-
month mdx-4cv serum  
Shown is a representative immunoblot with immuno-decorated bands labelled with an 
antibody to FABP-1 (A). Statistical analysis of immuno-decoration was performed 
with Student’s t-test (mean values ± SEM; unpaired; n=4, ***p≤0.001). 
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7.2.7 ELISA analysis of the increased abundance of FABP-1 and haptoglobin in 
mdx-4cv serum 
Box and whisker plots were constructed based on the findings from the ELISA assays 
and illustrate information regarding the range, the median and the quartiles for FABP-
1 (6-month serum samples) and haptoglobin (6 and 12-month serum samples). Levels 
of FABP-1 increased from an average of 1.64 µg/ml in wild-type samples to 3.13 
µg/ml in mdx-4cv samples, and this increase was found to be statistically significant 
by the Mann Whitney U Test (Figure 7.14). Haptoglobin levels in 6-month serum 
increased from an average of 0.54 µg/ml in wild-type serum to 29.82 µg/ml in mdx-
4cv serum, which was found to be statistically significant (Figure 7.15).  Haptoglobin 
levels in 12-month serum rose from an average of 0.15 µg/ml in wild-type serum to 
15.34 µg/ml in mdx-4cv serum, although this was not found to be statistically 
significant (p=0.0571) (Figure 7.16).  
 Receiver operating characteristic (ROC) curves were also constructed and the 
area under the ROC curve (AUC) was calculated to indicate the discriminating power 
of FABP-1 and haptoglobin to distinguish wild-type samples from mdx-4cv samples. 
FABP-1 shows a sensitivity of 100%, a specificity of 80% and an AUC of 0.95 (Figure 
7.14). At both 6-months and 12-months haptoglobin displays a sensitivity of 100%, a 
specificity of 100% and an AUC of 1.000 (Figures 7.15 and 7.16). AUC values were 
also calculated for the combination of FABP-1 and haptoglobin using logistic 
regression analysis and was found to be equal to 1.000. 
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Figure 7.14: Box and whisker plots and ROC curve for FABP-1 
Shown is the box and whisker plot and the ROC curve calculated from ELISA analysis 
conducted on 5 wild-type mice and 8 mdx-4cv mice. Statistical evaluation was 
performed using the Mann Whitney U test (**p≤0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.15: Box and whisker plots and ROC curve for haptoglobin in 6-month 
serum 
Shown is the box and whisker plot and the ROC curve calculated from ELISA analysis 
conducted on 5 wild-type mice and 7 mdx-4cv mice. Statistical evaluation was 
performed using the Mann Whitney U test (**p≤0.01) 
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Figure 7.16: Box and whisker plots and ROC curve for haptoglobin in 12-month 
serum 
Shown is the box and whisker plot and the ROC curve calculated from ELISA analysis 
conducted on 5 wild-type mice and 7 mdx-4cv mice. Statistical evaluation was 
performed using the Mann Whitney U test.  
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7.2.8 Protein identification in wild-type and mdx-4cv saliva  
Qualitative analysis of the proteomics data using Proteome Discoverer 1.4 revealed 
the core saliva proteome for wild-type and mdx-4cv mice, which consisted of 137 
proteins for wild-type and 112 proteins for mdx-4cv saliva samples. PANTHER 
analysis of the identified proteins revealed they belonged to a variety of protein 
classes, most notably hydrolases, enzyme modulators, transfer/carrier proteins, 
isomerases and signalling molecules, as illustrated in Figure 7.17. In both wild-type 
and mdx-4cv saliva proteomes, nine of the top 10 proteins ranked by sequence 
coverage were isoforms of the kallikrein 1-related peptidases, a sub-group of serine 
proteases which participate in normal physiological processes.  
 
 
 
 
 
 
 
Figure 7.17: Protein class of salivary proteins 
Illustrated is the PANTHER analysis of the 137 and 112 identified proteins in the 
saliva proteome from wild-type and mdx-4cv mice respectively.  
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7.2.9 Comparison of the wild-type saliva core proteome with the wild-type serum 
proteome  
Comparison of the 137 proteins identified in wild-type saliva with the 1,030 proteins 
identified in wild-type immuno-depleted serum reveals 78 proteins in common. Thus 
56.9% of the identified salivary proteins are also identified in serum, suggesting that 
serum proteins are reflected in saliva. The webgestalt analysis software was used to 
compare the salivary and serum proteomes from wild-type mice based on their gene 
ontology (GO) in relation to biological function, cellular component and molecular 
function as illustrated in Figures 7.18, 7.19 and 7.20 respectively. The GO data is 
based on the 750 (of 1,030) and 108 (of 137) proteins which were unambiguously 
mapped to unique Entrez Gene IDs in serum and saliva respectively. Both biofluids 
show similar protein distributions in terms of biological process (Figure 7.18). In terms 
of cellular component, both biofluids show the highest proportion of proteins 
belonging to vesicle, membrane, extracellular space and macromolecular complex, but 
with higher levels of proteins associated with the nucleus and cytoskeletal in the 
salivary proteome than the serum proteome (Figure 7.19). In addition, the distributions 
of salivary proteins are enhanced in hydrolase activity while serum proteins are 
increased in ion binding in relation to molecular function (Figure 7.20).  
 Thus, while serum and saliva clearly have their unique properties, the high 
proportion of salivary proteins which are also reflected in serum, and the significant 
similarities across GO categories suggests that saliva may represent a potential source 
of disease markers which could be used for non-invasive disease diagnosis and 
monitoring. Indeed, kallikrein 1-related peptidases, several members of which have 
already been proposed as cancer markers (Schmitt et al., 2013), which were detected 
with high sequence coverage in wild-type and mdx-4cv saliva, have also been detected 
in serum samples. 14 of the 78 proteins shared by wild-type serum and salivary 
proteomes belong to the kallikrein 1 serine protease family, as depicted in Table 7.3.  
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Figure 7.18: Biological process analysis of the serum versus saliva proteome 
Depicted is the GO category biological process for wild-type saliva and serum 
proteomes, based on results from the webgestalt software. 
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Figure 7.19: Cellular component analysis of the serum versus saliva proteome 
Depicted is the GO category cellular component for wild-type saliva and serum 
proteomes, based on results from the webgestalt software. 
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Figure 7.20: Molecular function analysis of the serum versus saliva proteome 
Depicted is the GO category molecular function for wild-type saliva and serum 
proteomes, based on results from the webgestalt software. 
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Table 7.3: Identification of kallikrein 1 and kallikrein 1-related peptidases in wild-
type serum and saliva 
 
Accession Protein Name Unique 
peptides in 
saliva 
% 
Coverage 
in saliva 
Unique 
peptides in 
serum 
% 
Coverage 
in serum 
P00756 Kallikrein 1-related 
peptidase b3 
4 39.46 8 77.01 
P15946 Kallikrein 1-related 
peptidase b11 
5 44.83 13 73.56 
P00755 Kallikrein 1-related 
peptidase b1 
4 41.76 10 72.8 
P15948 Kallikrein 1-related 
peptidase b22 
5 27.03 13 71.81 
P07628 Kallikrein 1-related 
peptidase b8 
7 49.43 8 70.5 
P15949 Kallikrein 1-related 
peptidase b9 
5 45.98 10 68.97 
P04071 Kallikrein 1-related 
peptidase b16 
7 44.83 9 60.92 
Q9JM71 Kallikrein 1-related 
peptidase b27 
3 41.83 6 58.17 
P36369 Kallikrein 1-related 
peptidase b26 
3 42.53 5 57.47 
Q61759 Kallikrein 1-related 
peptidase b21 
2 37.55 2 49.43 
P15945 Kallikrein 1-related 
peptidase b5 
4 30.27 6 47.51 
P00757 Kallikrein 1-related 
peptidase-like b4 
6 33.98 10 43.75 
Q61754 Kallikrein 1-related 
peptidase b24 
3 38.4 4 42.59 
P15947 Kallikrein-1 2 27.59 3 38.7 
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7.2.10 Quantitative analysis of wild-type versus mdx-4cv saliva 
Quantitative analysis of saliva-derived protein samples using the MaxQuant and 
Perseus workflow identified 14 proteins with statistically significant differential 
abundance between wild-type and mdx-4cv samples. 7 proteins were found to be 
elevated in abundance while 7 were decreased, as listed in Tables 7.4 and 7.5 
respectively. This comparative analysis identified kallikrein-1 and three kallikrein 1-
related peptidases (b1, b5 and b22) as having elevated abundance in mdx-4cv saliva. 
Interestingly, elevated abundance for kallikrein-1 was also detected in mdx-4cv serum, 
where a 6.4-fold increase was identified (Table 7A.1). Illustrated in Figure 7.21 is a 
silver stained protein gel showing the typical banding pattern for wild-type and mdx-
4cv saliva, along with the mass spectrometric identification of elevated levels of 
kallikrein-1 in mdx-4cv serum and saliva. Shown is the kallikrein-1 sequence with the 
three unique peptides identified in serum shown in bold and the three unique peptides 
detected in saliva shown as underlined. Two of the identified peptides were detected 
in both saliva and serum, with one additional unique peptide identified each in serum 
and saliva. Representative MS/MS scans for the three unique peptides for kallikrein-1 
identified in wild-type and mdx-4cv saliva samples are shown in Figure 7.22. Higher 
peak intensities are evident for all three peptides in mdx-4cv saliva compared to wild-
type saliva.  
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Figure 7.21: Mass spectrometric fingerprint of kallikrein-1 
Shown in bold are the three unique peptides identified as having elevated abundance 
in serum from 6-month old mdx-4cv mice, while shown as underlined are the 3 unique 
peptides detected with increased levels in saliva samples from 6-month old mdx-4cv 
mice.  
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Figure 7.22: Proteomic identification of kallikrein isoform Klk1 in saliva from 
the mdx-4cv mouse model of Duchenne muscular dystrophy 
Shown are representative MS/MS scans of the three unique Klk-1 peptides 
NNFLEDEPSAQHR, LGSTCLASGWGSITPVK and VLNFNTWIR which were 
identified and compared in wild-type versus mdx-4cv saliva, respectively. 
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Table 7.4:  List of identified proteins with a significantly increased abundance in 6-
month old mdx-4cv saliva versus age-matched wild-type saliva as determined by label-
free LC-MS/MS  
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Score  Anova 
(p) 
Fold 
Change 
P15947 Klk1 Kallikrein-1 3 189.70 8.23E-
03 
4.16 
Q07797 Lgals3bp Galectin-3-binding 
protein 
4 33.37 7.88E-
04 
3.54 
O09159 Man2b1 Lysosomal alpha-
mannosidase 
21 323.31 1.93E-
03 
3.36 
P15948 Klk1b22 Kallikrein 1-related 
peptidase b22 
9 323.31 1.02E-
02 
1.97 
P00755 Klk1b1 Kallikrein 1-related 
peptidase b1 
6 215.37 6.03E-
03 
1.96 
P15945 Klk1b5 Kallikrein 1-related 
peptidase b5 
5 323.31 3.20E-
02 
1.49 
P01139 Ngf Beta-nerve growth 
factor 
4 323.31 1.88E-
02 
1.34 
 
 
 
 
 
 
 
 
 
Table 7.5:  List of identified proteins with a significantly decreased abundance in 6-
month old mdx-4cv saliva versus age-matched wild-type saliva as determined by label-
free LC-MS/MS  
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Score Anova 
(p) 
Fold 
Change 
P07743 Bpifa2 BPI fold-containing 
family A member 2 
6 289.80 7.21E-
03 
0.11 
Q91Z98 Chil4 Chitinase-like protein 4 7 95.18 3.15E-
03 
0.15 
Q3UU35 Ovos Ovostatin homolog 6 323.31 3.47E-
04 
0.34 
P04104 Krt1 Keratin, type II 
cytoskeletal 1 
5 323.31 3.98E-
02 
0.37 
P10126; 
P62631 
Eef1a1 
Eef1a2 
Elongation factor 1-
alpha 1; Elongation 
factor 1-alpha 2 
7 100.44 1.31E-
02 
0.41 
Q8K1H9 Obp2a Odorant-binding 
protein 2a 
3 75.90 4.57E-
02 
0.42 
P03958 Ada Adenosine deaminase 4 56.58 1.78E-
02 
0.44 
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Figure 7.23 Volcano plots of all identified proteins based on relative abundance 
differences between wild-type and mdx-4cv saliva 
Volcano plot illustrating the distribution of quantified proteins according to p value 
(−log10 p-value) and fold change (log2 mean LFQ intensity difference). Boxes 
represent proteins where boxes coloured red are those with decreased abundance in 
mdx-4cv saliva, and blue boxes are proteins with increased abundance in mdx-4cv 
saliva. All coloured boxes are statistically significant (p-value≤0.05), and coloured 
boxes above the line are those which also pass an FDR criterion of 0.05.   
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7.3 Discussion 
While the primary deficiency in DMD is the loss of the full-length isoform of 
dystrophin, chronic inflammation represents a major secondary pathology and one 
which contributes to disease progression. Dystrophinopathy-induced secondary 
abnormalities of sarcolemmal instability and micro-rupturing, altered ion homeostasis, 
abnormal calcium ion fluxes, elevated extracellular ATP and increased proteolysis 
may serve as damage-associated molecular patterns which initiate a non-infectious 
inflammatory response. The initial immune response is a typical Th1 inflammatory 
response mediated by neutrophils and classically activated M1 macrophages with a 
pro-inflammatory phenotype (Tidball and Villalta, 2010). The recruitment of these M1 
macrophages serves to phagocytose myofibre debris (Madaro and Bouché, 2014), but 
they also release pro-inflammatory cytokines, such as tumour necrosis factor alpha 
(TNF-α), the blockade of which has been shown to reduce muscle necrosis, contractile 
dysfunction and fibrosis and improve muscle function in the mdx mouse model 
(Hodgetts et al., 2006, Grounds and Torrisi, 2004). There is a subsequent invasion of 
alternatively activated M2 macrophages, which are associated with tissue repair and 
regeneration (Kharraz et al., 2013). M1 macrophages contain inducible nitric oxide 
synthase (iNOS) with M2 macrophages possessing arginase. Arginase and iNOS 
compete for arginine and thus increased numbers of M2 macrophages reduces the 
amount of arginine available to iNOS (Chang et al., 1998) and thus reduces the nitric-
oxide mediated lysis of muscle cells.  
In addition, M2 macrophages secrete IL-10 and IL-4; IL-10 is an anti-
inflammatory cytokine and helps to dampen the immune response, and along with IL-
4 it promotes satellite cell activation and muscle regeneration (Villalta et al., 2009). 
M1 macrophages are hypothesised to represent the primary macrophage phenotype 
during peak muscle necrosis (4 weeks) in mdx mice with a transition to a higher 
proportion of M2 macrophages during muscle regeneration (Villalta et al., 2009). Our 
mass spectrometric data supports this hypothesis given elevated serum concentrations 
of arginase-1 (6.8-fold increase), expressed by M2 macrophages, in mdx-4cv mice. 
These elevated levels of arginase-1 may have detrimental effects on the pathogenesis 
of the disease given that it has been shown recently that arginase metabolism by 
macrophages of the M2 phenotype promotes fibrosis in the mdx mouse model 
(Wehling-Henricks et al., 2010). Indeed, arginase 1 produces the amino acid proline 
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which is a prerequisite for collagen synthesis (Wynn, 2004), with excessive collagen 
deposition associated with the onset of fibrosis.  
Haptoglobin is an acute phase plasma protein which is largely known for its 
role in binding to free haemoglobin with high affinity (Lim et al., 1998). This plasma 
glycoprotein also has anti-oxidant properties with its main site of synthesis occurring 
in the liver (Alper et al., 1965). In this chapter, substantial elevations in the abundance 
of serum haptoglobin in the mdx-4cv animal model of dystrophinopathy has been 
identified by three orthogonal methods; label-free LC-MS/MS, comparative 
immunoblotting and ELISA. Haptoglobin has been shown to be transcriptionally 
activated by pro-inflammatory cytokines such as IL-6 (Oliviero and Cortese, 1989) 
and so it is possible that the pro-inflammatory environment in dystrophic muscle may 
result in increased transcription of the haptoglobin gene thus resulting in the elevated 
abundance of serum haptoglobin as identified in this study, as outlined in Figure 7.24. 
Since serum haptoglobin is induced by pro-inflammatory cytokines it has potential to 
serve as a biomarker candidate of sterile inflammation in DMD. Its advantages are 
numerous in that it is detectable by three independent methodologies, it displays a 
significant elevation in its abundance (50.3-fold by mass spectrometry), ROC curve 
analysis showed promising specificity and sensitivity values (although this would need 
to be verified using a large cohort of clinical samples) and it is easily accessible and 
thus represents a non-invasive biomarker. Although activated by pro-inflammatory 
cytokines, haptoglobin itself has anti-inflammatory activity. It is a potent anti-oxidant 
agent and inhibits the biosynthesis of the prostaglandin pro-inflammatory mediators. 
It also specifically inhibits the tissue protease cathepsin B (Snellman and Sylvén, 
1967) (which was found in elevated abundance in mdx-4cv serum) and thus may play 
a regulatory role in tissue proteolysis associated with inflammation. The elevated 
abundance of serum haptoglobin as identified here by comparative proteomics agrees 
with an earlier pre-proteomic study in which 2D gel electrophoresis and densitometric 
scanning identified elevated levels of haptoglobin in Duchenne patients (John and 
Purdom, 1989). Thus, haptoglobin represents a potential non-invasive serum 
biomarker candidate of sterile inflammation in dystrophinopathy.  
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Figure 7.24: The role of the immune system in dystrophinopathy  
Two main phases exist in DMD; the necrotic phase and the regeneration phase. During 
the necrotic phase there is an infiltration of M1 macrophages with a pro-inflammatory 
phenotype. M2 macrophages dampen the immune response and promote muscle 
growth and repair during the regeneration phase. The pro-inflammatory environment 
in dystrophic muscle may act as the stimulus for the transcriptional activation of 
haptoglobin, resulting in elevated serum haptoglobin which could serve as a biomarker 
candidate of sterile inflammation in DMD. 
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High levels of other acute phase proteins, such as the 36.98-fold increase in 
the abundance of serum amyloid A-1 protein, further substantiates a role for 
inflammation in the disease aetiology. Serum concentrations of serum amyloid A have 
been shown to increase by up to 1,000-fold following infection/inflammation and 
more modest elevations have been identified in chronic inflammatory diseases such as 
rheumatoid arthritis (O'Hara et al., 2000). Unlike haptoglobin, which has anti-
inflammatory activity and which may serve to bind to heme proteins released from 
injured and degenerating muscle fibres, serum amyloid A propagates the immune 
response. This effect is thought to be mediated by its ability to stimulate cytokine 
production, with research by Patel and colleagues showing an ability of serum amyloid 
A to induce IL-1β release in vitro (Patel et al., 1998), and through its chemoattractant 
effects on monocytes and neutrophils (Badolato et al., 1994, Su et al., 1999). 
Muscle-derived proteins represent an important class of potential biomarkers 
of dystrophinopathy given their elevated levels in serum are typically representative 
of muscle fibre degeneration and the release of muscle-associated proteins into the 
circulatory system. Here, elevated abundance of the FABP-1 isoform of fatty acid 
binding protein was identified in serum from dystrophic mdx-4cv mice. This result is 
concurrent with the observation of reduced levels of FABP-1 in muscle specimens as 
identified by LC-MS/MS of mdx quadriceps muscle (-8.54-fold decrease in dystrophic 
quadriceps) (Murphy et al., 2017a). Several structural components of the muscle have 
also been identified as having an increased abundance in mdx-4cv serum, perhaps 
indicating the disintegration of muscle fibres. Such protein components include 
myomesin-3, a key component of the M-band in striated muscle (Schoenauer et al., 
2008), which has previously been identified as having elevated abundance in 
dystrophinopathy (Hathout et al., 2014), and titin, fragments of which have been 
detected in the urine of patients with DMD (Rouillon et al., 2014).  
A number of “typical” markers of DMD as identified by a large cohort of 
investigations have also been identified by this LC-MS/MS approach, as listed in 
Table 7.6. These circulatory biomarkers include in particular myofibrillar proteins 
(titin and myomesin 3), muscle-derived proteins (fatty acid binding protein, carbonic 
anhydrase III) and metabolic enzymes (lactate dehydrogenase, creatine kinase, 
pyruvate kinase, triosephosphate isomerase, alanine aminotransferase). The 
appearance of myofibrillar proteins in mdx-4cv serum and in patient samples (Rouillon 
et al., 2015, Rouillon et al., 2014) indicates muscle necrosis and the remodelling of 
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damaged muscle fibres. This is further substantiated by the observed increased 
abundance of structural and cytoskeletal proteins in dystrophic skeletal muscle 
samples, reflecting a potential compensatory mechanism to help counterbalance the 
loss of dystrophin and the DGC (Murphy et al., 2015a). The presence of muscle-
derived proteins in mdx-4cv serum likely reflects leakage from degenerating muscle 
fibres. However, previous studies have also identified elevated levels of muscle-
derived proteins such as FABP-3, aldolase A and actin in serum of mdx mice at 7 days, 
prior to the onset of muscle necrosis (Hathout et al., 2014). Such pre-necrosis markers 
were hypothesised to possibly reflect exosomal shedding and/or sarcolemmal 
permeability. The increase in metabolic enzymes in serum from the dystrophic mouse 
model possibly indicates an impairment of muscle energy metabolism which has 
previously been reviewed in detail (Dowling et al., 2014b). 
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Table 7.6: Major circulating protein biomarkers of dystrophinopathy common to our 
LC-MS/MS data and the literature 
 
*Adiponectin was detected as having a fold decrease of 1.46 in our analysis (accession 
number Q60994; 3 unique peptides; confidence score 197.1) 
 
Protein Marker Abundance in 
dystrophinopathy 
References 
Creatine Kinase Increased  (Mokuno et al., 1987) 
Lactate dehydrogenase Increased (Yasmineh et al., 1978) 
Fibronectin Increased (Cynthia Martin et al., 2014) 
Pyruvate Kinase Increased (Zatz et al., 1991) 
Carbonic Anhydrase III Increased (Ohta et al., 1991) 
Titin Increased (Rouillon et al., 2014) 
(Hathout et al., 2015) 
Troponin I fast skeletal Increased (Hathout et al., 2015) 
Myomesin 3 Increased (Rouillon et al., 2015) 
Triosephosphate isomerase Increased (Rouillon et al., 2015, 
Coenen-Stass et al., 2015) 
Alanine aminotransferase Increased (Zhu et al., 2015) 
Adiponectin* Decreased (Hathout et al., 2014) 
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Large elevations in abundance were detected for the neuronal calcium binding 
protein calretinin (59.8-fold) and for GFAP, a protein specifically associated with 
astrocytes in the central nervous system, in mdx-4cv serum. GFAP was only identified 
by a single unique peptide (accession number: P03995, confidence score: 57.48, p 
value: 2.50E-02) but was detected to have a 1,289.8-fold increase in mdx-4cv serum. 
Increased abundance of calretinin and GFAP has been previously reported in mdx-4cv 
brain tissue (Murphy et al., 2015c). In the dystrophin-deficient brain, elevated 
abundance of GFAP may represent a reactive astrogliosis response (Yang and Wang, 
2015) to dystrophin deficiency in the central nervous system, similar to the fibrotic 
response evident in dystrophin-deficient skeletal muscle, diaphragm and cardiac tissue 
(Holland et al., 2015a, Murphy et al., 2016b, Mann et al., 2011). Calretinin belongs to 
the family of EF-hand calcium binding proteins (Palczewska et al., 2003), and contains 
a well-conserved helix-loop-helix motif, responsible for binding to calcium ions with 
high affinity (Schwaller et al., 2002). Its elevated abundance in the mdx-4cv brain may 
represent a possible compensatory mechanism to counterbalance abnormal calcium 
fluxes within the central nervous system. The presence of these glial and neuronal 
proteins in serum may reflect damage occurring in the dystrophin-deficient brain, as 
previously shown by Vos and colleagues, in which levels of GFAP, S100b and neuron 
specific enolase in serum significantly correlated with the severity of traumatic brain 
injury and with poorer prognosis (Vos et al., 2004). The presence of brain-derived 
proteins in serum possibly has the potential to serve as surrogate biomarkers for 
monitoring dystrophinopathy in the brain. This is an important consideration given 
that approximately one-third of Duchenne patients display some degree of non-
progressive cognitive impairments (Chamova et al., 2013).  
Although fewer in number (37 proteins) and with more modest fold changes 
(largest fold decrease being 3.5 for angiotensin-converting enzyme), the class of 
proteins displaying reduced abundance in mdx-4cv serum is of interest. Their reduced 
abundance cannot be as easily explained as those proteins with elevated abundance 
whereby in a large proportion of cases their increased levels in mdx-4cv serum likely 
reflects release from necrotic and degenerating muscle fibres. KEGG pathway analysis 
of the 37 proteins with decreased abundance illustrates that they are predominantly 
involved in complement and coagulation cascades (9 proteins were identified as being 
involved in these cascades), as depicted in Figure 7.25. These proteins include von 
Willebrand factor, complement component C9, complement component C8 alpha 
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chain, complement component C8 beta chain, anti-thrombin III, and the serine 
protease inhibitors alpha-2-antiplasmin, alpha-1-antitrypsin 1-1, alpha-1-antitrypsin 
1-2 and alpha-1-antitrypsin 1-5. Overall this suggests a dysregulation of the 
complement and coagulation cascades. This is in contrast to a number of other studies 
which have generally reported elevated levels of proteins associated with coagulation 
and fibrinolysis in patients with DMD, particularly those patients with cardiac 
involvement (Saito et al., 2005). This elevation appears to be in response to factors 
released from degenerating and necrotic muscle fibres. This disparity in results may 
be due to the animal model used, as there may not always be a direct correlation 
between animal models of disease and human counterparts. In addition, the serum 
samples used in this study were obtained from 6-month old mdx-4cv mice, a stage in 
which cardiac involvement may not be as apparent. Alternatively, the difference seen 
could potentially be because different markers of coagulation and fibrinolysis were 
used.  
Previous studies have generally utilised levels of fibrin and fibrinogen 
degradation products as markers of coagulation and fibrinolysis, for which elevated 
levels have been identified in dystrophinopathy (Saito et al., 2001, Saito et al., 2005). 
These molecules were not found to be differentially expressed in our mass 
spectrometric data of mdx-4cv serum. However, decreased plasminogen, as identified 
in this study (accession number: P20918, confidence score: 3881.77, p value: 2.49E-
05, fold decrease: 1.74) is associated with early fibrinolytic events following severe 
trauma (Amara et al., 2008), and thus its reduced abundance in mdx-4cv serum may 
represent fibrinolysis following muscle degeneration. Decreased levels of von 
Willebrand have also been identified in other forms of muscular dystrophy (Bertin et 
al., 1989). The reduced abundance of several components of the complement cascade 
in mdx-4cv serum possibly reflects its recruitment to necrotic muscle fibres. This 
recruitment to muscle fibres may contribute to the disease pathophysiology by forming 
a membrane attack complex (Sewry et al., 1987). The activation of the complement 
cascade can trigger the assembly of a membrane attack complex, usually responsible 
for inserting into and lysing host pathogens, particularly gram-negative bacteria (Serna 
et al., 2016). However, these membrane attack complexes have also been associated 
with neuromuscular diseases, such as dysferlinopathy (Brunn et al., 2006), 
amyotrophic lateral sclerosis (Bahia El Idrissi et al., 2016), dermatomyositis (Dalakas, 
1991) and DMD (Engel and Biesecker, 1982). While Engel and Biesecker illustrated 
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that necrotic fibres in DMD biopsy specimens were reactive for membrane attack 
complex antigens, the presence of a membrane attack complex in DMD is 
controversial. Spuler and Engel were only able to identify sarcolemmal membrane 
attack complex deposits in samples of inflammatory myopathy but their study focused 
on the presence of such a complex on non-necrotic fibres, of which they were unable 
to find any in the BMD and DMD samples (Spuler and Engel, 1998). Similar to the 
study by Engel and Biesecker, Louboutin and colleagues demonstrated 
immunostaining of necrotic fibres in DMD specimens using antibodies against 
membrane attack complex (Louboutin et al., 2003). Thus, while the presence and 
potential role of such a complex requires further investigation, the difference in results 
obtained may be due to the type of muscle fibre studied. Indeed CD59, a membrane 
attack complex inhibitor glycoprotein (Meri et al., 1990), was immunolocalised to the 
sarcolemma of non-necrotic fibres, but not necrotic muscle fibres (Louboutin et al., 
2003).
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Figure 7.25: Complement and coagulation cascades in Mus musculus 
Shown are the complement and coagulation cascades in Mus musculus. Proteins highlighted in pink are those with  
reduced abundance in mdx-4cv serum. The image was generated using KEGG search and colour pathway.
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Proteomic profiling of serum samples has revealed potential novel protein 
markers of muscular dystrophy and these could potentially be translated to clinical 
applications. In the field of muscle pathology, clinical biofluid analyses are typically 
restricted to simple blood tests with a focus on muscle-derived serum proteins that are 
indicative of skeletal muscle damage, including creatine kinase and myoglobin. 
However, the more evenly distributed concentration of the saliva proteome as 
compared to the serum/plasma proteome negates the necessity for pre-fractionation 
and so may establish the salivary proteome as an alternative clinical biofluid which is 
non-invasive and amenable to systemic sampling even in paediatric patients. 
Importantly, salivary glands also exhibit a high permeability for their surrounding 
capillaries, which enables the infiltration of circulating peptides and proteins from 
blood, and saliva may be representative of the serum/plasma proteome. In a proof-of-
concept study, label-free LC-MS/MS was used to identify alterations in protein 
abundance in mdx-4cv saliva samples. Preliminary findings suggest that with further 
research saliva could serve as a non-invasive surrogate for serum samples. 
Serine proteases comprise approximately one-third of proteolytic enzymes and 
are involved in a variety of biological processes related to immunity, blood 
coagulation, development and digestion. Their catalytic activity is determined by the 
presence of a nucleophilic serine amino acid residue in their active site which attacks 
the carbonyl moiety in the substrate peptide bond (Page and Di Cera, 2008). Given 
their potentially devastating protease activity, as seen in auto-immune disease and 
tumour metastasis, the activity of the serine proteases is tightly regulated, for example 
by the presence of a superfamily of serine protease inhibitors known as serpins 
(Heutinck et al., 2010, Law et al., 2006). Kallikrein-related peptidases (KLKs) 
comprise a family of 15 highly conserved chymotrypsin- or trypsin-like serine 
proteases (KLKs 1-15), encoded by genes which are tightly clustered on the 19q13.33–
13.41 chromosome region (Stefanini et al., 2015). They are involved in numerous 
physiological processes including innate immunity, semen liquefaction, remodelling 
of the extra-cellular matrix and skin desquamation (Sotiropoulou et al., 2009). Mass 
spectrometric analysis of saliva has here identified increased abundance for kallikrein-
1 and three kallikrein 1-related peptidases (KLKs b1, b5 and b22) in mdx-4cv saliva 
samples. Kallikrein-1 is functionally conserved in its ability to cleave the circulating 
protein kininogen to release the vasoactive peptide bradykinin. This kallikrein/kinin 
and bradykinin signalling axis of vasoactive peptides is involved in blood pressure 
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regulation, tissue homeostasis and renal function. Bradykinin has two receptors; a 
constitutive B2 receptor and an inducible B1 receptor. Blockade of these receptors 
using antagonists resulted in increased muscle damage, fibrosis and immune cell 
infiltration in the mdx mouse, suggesting that the kallikrein kinin system may play a 
protective role in muscular dystrophy (Acuña et al., 2017). In support of this 
hypothesis, over-expression of tissue kallikrein and kinin restored cardiac function in 
rats post myocardial infarction by inhibiting fibrosis and promoting angiogenesis. 
(Yao et al., 2007). The increased abundance of kallikrein-1 and kallikrein 1-related 
peptidases identified in mdx-4v saliva may be reflective of an attempt to limit fibrosis. 
Quantitative transcriptomics analysis of 27 different human organs and tissues 
identified highest expression of kallikrein-1 in the pancreas and salivary glands, with 
very low levels of expression evident in the other tested tissues (Fagerberg et al., 
2014). The kallikrein-related peptidases have a well-established role in the 
degradation of extracellular matrix components, and kallikrein-1 can activate latent 
matrix metalloprotease 9 (MMP-9) (Sotiropoulou and Pampalakis, 2010). Increased 
serum levels of MMP-9 has been previously identified in Duchenne patients, where it 
was suggested as a potential biomarker to monitor disease progression (Nadarajah et 
al., 2011). Augmented abundance of MMP-9 in muscular dystrophy is suggested to 
contribute to the muscle pathogenesis through excessive remodelling of the 
extracellular matrix and basement membrane leading to fibrosis, the recruitment of 
macrophages, and the activation of TGF-β, a predominant mediator of fibrosis (Ogura 
et al., 2014). Indeed both genetic ablation and pharmacological inhibition of MMP-9 
in mdx mice reduces muscle fibrosis, improves muscle structure and significantly 
increases muscle regeneration (Li et al., 2009). Therefore, elevated levels of kallikrein-
1 in serum and saliva as detected here in mdx-4cv mice, may contribute to extracellular 
matrix remodelling and inflammation, key drivers of the disease pathophysiology. 
However, expression of MMP-9 is also modulated by NF-κB and activator protein 1 
transcription factors. Given their role in extracellular matrix remodelling, members of 
the kallikrein family of serine proteases have been suggested to be involved in tissue 
remodelling, angiogenesis, and/or metastasis in cancer, particularly in hormone-
dependent malignancies, and represent both cancer biomarkers and therapeutic targets 
(Borgoño and Diamandis, 2004). Indeed, prostate specific antigen/kallikrein-3 
represents the most valuable clinical biomarker for prostate cancer diagnosis. 
Kallikrein-1 and its related peptidases have limited utility in diagnosis of DMD given 
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this lack of specificity but may still prove useful for monitoring disease progression 
and response to therapy. 
 Increased abundance was also detected for galectin-3-binding protein, a 60-90 
kDa protein which interacts with its ligand galectin-3 to mediate cell-to-cell adhesion. 
Galectin-3 is also proposed to play a role in the inflammatory process through 
leukocyte recruitment, chemotaxis of monocytes and macrophages, and the induction 
of IL-1 production in macrophages (Almkvist and Karlsson, 2002). Galectin-3 and 
galectin-3 binding protein are also involved in tissue fibrosis (Li et al., 2014), with 
elevated abundance of galectin-3 binding protein correlated to fibrosis and cirrhosis in 
both hepatitis C related- and alcohol related- liver disease (Cheung et al., 2010). In 
addition, increased abundance of galectin-3 has been previously identified in crude 
microsomes from skeletal muscle of the mdx-4cv animal model of DMD (Murphy et 
al., 2015a). The augmented levels of galectin-3 binding protein identified here in saliva 
of mdx-4cv mice may be reflective of the fibrotic and inflammatory processes 
occurring in response to dystrophin deficiency. Other proteins with increased 
abundance in mdx-4cv saliva include lysosomal alpha-mannosidase and beta-nerve 
growth factor. Elevated abundance of lysosomal alpha-mannosidase is in agreement 
with previous studies which demonstrated its increased activity in muscle biopsy 
samples from Duchenne patients, where it was suggested to reflect the infiltration of 
leukocytes into dystrophic muscle (Kawai et al., 1995). Nerve growth factor is a 
neurotrophin produced during muscle development, and which has been found at 
elevated levels in regenerating muscle fibres in muscular dystrophy (Toti et al., 2003).  
 Reduced abundance for a variety of proteins was also detected in saliva 
samples from mdx-4cv mice. Overall these proteins appear to be involved in catalytic 
activity but are not especially associated with muscular dystrophy. BPI fold-
containing family A member 2 is an abundantly expressed protein in salivary 
secretions where, as a member of the bactericidal/permeability-increasing protein 
family, it is involved in host defence against bacteria. Chitinase-like protein 4 is a 
member of the chitinase-like protein family which are lectins that combine the 
properties of cytokines and growth factors. While expressed in rodents it is absent in 
humans (Kzhyshkowska et al., 2016). Other members of the chitinase-like protein 
family are however expressed in humans and some, particularly chitinase-3-like 
protein 1, have been associated with inflammation, cancer, diabetes and 
cardiovascular disease. Chitinase-3-like protein 1 is also involved in extracellular 
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matrix remodelling and can stimulate the proliferation of human connective tissue 
cells such as fibroblasts and chondrocytes (Rathcke and Vestergaard, 2009). Indeed 
transcriptomic analysis of cranial sartorius muscle from the GRMD dog model of 
DMD identified increased levels of chitinase-3-like protein 1, where it was suggested 
to participate in disease progression through promotion of fibrosis (Brinkmeyer-
Langford et al., 2018). The decreased abundance of chitinase-like protein 4 identified 
in saliva samples of the mdx-4cv mouse here contrasts with these previous studies 
where increased abundance of the chitinase-like proteins is associated with 
inflammation and fibrosis, classical hallmarks of dystrophinopathy. Given that the 
chitinase-like protein 4 detected here is only expressed in rodents it is possible that it 
may play an undiscovered alternative role to that of its associated chitinase-like 
proteins which are expressed in both rodents and humans.  
Ovostatin homolog belongs to the proteinase inhibitor I39 (alpha-
macroglobulin) family; a group of protease inhibitors with the ability to inhibit 
proteases from all catalytic classes. Reduced abundance of alpha-2-macroglobulin has 
been previously identified in plasma samples from mdx mice (Colussi et al., 2010), 
and in a muscle proteomic analysis of 2-day old dystrophic pigs, an uncharacterised 
protein with homology to alpha-2-macroglobulin was detected only in wild-type 
muscle samples (Fröhlich et al., 2016). The reduced abundance of ovostatin homolog 
identified here by mass spectrometric analysis of saliva may be reflective of alterations 
in the serum and muscle proteomes of dystrophic animal models. Reduced abundance 
of the alpha-macroglobulin proteases may exacerbate the dystrophic phenotype by 
increasing protease activity.  
Elongation factors regulate muscle protein synthesis by facilitating the 
delivery of aminoacyl-tRNA to the ribosome. Increased abundance of elongation 
factor 1-alpha 1 and elongation factor 1-alpha 2 may therefore be associated with 
increased protein synthesis associated with muscle regeneration and their elevated 
expression has been identified in dystrophic mdx diaphragm, soleus, extensor 
digitorum longus and interosseus muscle (Holland et al., 2015b), and increased 
abundance of elongation factor 1-alpha 1 was detected in mdx-4cv serum samples 
(Table A7.1). However, decreased abundance of elongation factor 1-alpha 1 and 
elongation factor 1-alpha 2 was found in aged mdx cardiac tissue (Holland et al., 2013), 
indicating a potential effect of age and/or tissue type on the abundance of the 
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elongation factors. Overall the altered levels of these proteins in dystrophic tissue and 
biofluids may reflect perturbed protein synthesis. 
 
7. 3.1 Conclusions 
There is an urgent requirement for novel biofluid-derived protein markers for DMD 
which are i) highly sensitive and specific and can be used for disease diagnosis, 
prognosis and therapy-monitoring, and ii) minimally invasive or non-invasive to 
facilitate repeated sampling, particularly for monitoring prognosis and therapy 
outcomes. Mass spectrometry-based proteomics offers an unbiased technology-driven 
approach for the global analysis of alterations in protein abundance. Label-free LC-
MS/MS has been performed on serum and saliva samples from the mdx-4cv animal 
model of DMD. A vast number of potential protein markers were identified in the 
immuno-depleted serum proteome, with 90% of the differentially abundant proteins 
showing elevated levels in mdx-4cv serum. This high proportion of increased 
abundance as opposed to decreased abundance proteins, and the bioinformatics 
analysis showing enrichment of muscle-derived proteins indicates that many of these 
are muscle proteins that are leaked into the serum upon muscle necrosis and 
degeneration. Of particular interest is the inflammation-inducible plasma protein 
haptoglobin which shows a 50.28-fold increase, and which was verified by both 
comparative immunoblotting and ELISA analyses. A smaller number of differentially 
abundant proteins were detected in the saliva proteome, with the identified proteins 
largely related to inflammation, extracellular matrix remodelling and protease activity. 
Kallikrein-1 and a number of kallikrein-1 related peptidases demonstrated elevated 
abundance in saliva samples from dystrophic mice. Interestingly, augmented levels of 
kallikrein-1 were also identified in mdx-4cv serum samples, suggesting that this 
protein represents a potential circulatory biomarker of inflammation in 
dystrophinopathy. Since the serum and saliva proteome are modified by stress, 
exercise, diet, inflammation, trauma, and drug use, these confounding factors would 
need to be taken into consideration when transferred to a Duchenne patient population. 
However, the proteomic studies described here offer proof-of-principle that easily 
accessible biofluids such as serum and saliva may have clinical utility in serving as 
important sources of novel disease biomarkers of progressive muscular dystrophy.  
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8.1 Discussion 
The application of 2D-GE to skeletal muscle has played an essential role in the 
development of skeletal muscle proteomics and the characterisation of the muscle 
proteome in both health and disease. Publications relating to gel electrophoretic 
analysis of skeletal muscle have increased dramatically since 1976, with a spiked 
increase evident following the incorporation of mass spectrometry-based proteomics 
for the routine analysis of skeletal muscle tissues since 2004 (Murphy et al., 2016a). 
Such studies have also been instrumental in identifying some of the secondary 
abnormalities associated with dystrophin deficiency in DMD. However, given the 
large size, hydrophobicity and low-abundance of the DGC, the majority of previous 
proteomic surveys have failed to detect or could only partially detect the main 
members of the complex. Alternative strategies have employed immuno-precipitation 
(Yoon et al., 2012) and gradient centrifugation (Turk et al., 2016). In Chapter 3, an in-
solution digestion protocol coupled to mass spectrometry analysis using an improved 
Q-Exactive mass spectrometer enabled the identification of reduced abundance of 
dystrophin and α1-syntrophin in crude homogenates from hind-limb samples from 
wild-type versus mdx-4cv mice. This mass spectrometric detection of dystrophin 
within a highly complex crude muscle homogenate represents a technological 
achievement and one with implications for future mass spectrometry-based 
quantification of dystrophin in muscle.  
At present, several clinical trials aimed at restoring dystrophin expression are 
in progress and a key biochemical outcome measure for these trials is the accurate 
quantification of dystrophin. Immunoblotting and immunofluorescence microscopy 
are typically used to evaluate dystrophin expression in clinical trials, however these 
methods are challenging for the detection of the very large and low abundance 
dystrophin, are only semi-quantitative (Aartsma-Rus, 2014) and in the absence of 
standard operating procedures significant levels of intra- and inter-laboratory 
variability have been reported (Anthony et al., 2014). Thus, mass spectrometry may 
offer an alternative for the more robust absolute quantification of dystrophin in human 
muscle biopsies (Brown et al., 2012). Given that mass spectrometry would only give 
an indication of total dystrophin levels, it may be prudent to combine such an analysis 
with immunofluorescence microscopy which has the capacity to also examine 
dystrophin localisation to the sarcolemma which has functional implications. The 
identification of reduced dystrophin abundance in dystrophic skeletal muscle in 
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Chapter 3 enabled a direct correlation between dystrophin deficiency and secondary 
abnormalities. These secondary effects were found to be especially related to 
myofibrosis, cytoskeletal remodelling, muscle regeneration, membrane repair, ion 
homeostasis, and impaired calcium buffering. Large increases in protein abundance 
were particularly evident for fibrotic proteins, including fibronectin, biglycan, 
collagen, fibrinogen, asporin and decorin. These proteins represent potential 
biomarkers for DMD, particularly as some, including fibronectin, have also been 
identified in serum samples from the mdx-4cv mouse (Murphy et al., 2017b) and from 
Duchenne patients (Cynthia Martin et al., 2014). These proteins may also act as novel 
therapeutic targets, as treatments aimed at reducing fibrosis may improve the disease 
phenotype while also increasing the amount of muscle available for treatment by novel 
therapeutic agents. Dystrophin deficiency and the simultaneous disintegration of the 
DGC results in severe perturbations of the muscle proteome in terms of both protein 
abundance and protein oligomerisation. In Chapter 3, chemical cross-linking of a 
membrane-enriched fraction from wild-type and dystrophic skeletal muscle was 
coupled to gel electrophoretic shift analysis and mass spectrometry to evaluate 
alterations in protein interaction patterns. Augmented oligomerisation was evident for 
proteins related to membrane repair, cytoskeletal remodelling, fatty acid oxidation, 
metabolism, and chaperoning. These enhanced protein networks likely occur as 
compensatory mechanisms to rescue the dystrophic phenotype and offer novel insights 
into the disease pathophysiology.  
 While the proteomic profiling approach illustrated in Chapter 3 provides a 
global overview of proteomic alterations in dystrophic skeletal muscle, in Chapter 4 a 
combination of organelle proteomics, on-membrane digestion and label-free mass 
spectrometric analyses were used to i) characterise the DGC and ii) give a detailed 
map of proteomic alterations at the dystrophin-deficient sarcolemma. Standard 2D 
gels are typically incapable of resolving large molecular weight proteins, whereas 1D 
gradient gels can resolve very large proteins of up to 2,000 kDa (Ohlendieck, 2011c). 
Indeed, recent proteomic analysis of a myofibrillar fraction from a dried and long-term 
stored 1D polyacrylamide gel identified a large number of proteins including titin of 
approximately 3,400 kDa (Murphy and Ohlendieck, 2018). Thus, differential 
centrifugation, digitonin detergent solubilisation, ion exchange chromatography, 
lectin affinity chromatography and density gradient centrifugation were used to 
generate a dystrophin-complex enriched fraction from wild-type skeletal muscle 
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which was separated on a 1D 3-12% gradient gel and transferred to a nitrocellulose 
membrane. Muscle proteins absorbed onto nitrocellulose sheets appear to be more 
accessible to proteases, resulting in improved digestion efficiency and the superior 
detection of large membrane proteins (Ohlendieck, 2011c). This study identified both 
the core members of the DGC and proteins which potentially interact with or exist in 
close proximity to the complex. Of particular interest was the identification of the 
desmosomal cadherins desmoglein-1 and desmoplakin. Comparative immunoblotting 
identified greatly reduced abundance for desmoglein-1 in both mdx and mdx-4cv 
skeletal muscle preparations, indicating that it suffers the same pathobiochemical fate 
as components of the core DGC. Thus, this protein may warrant further attention to 
fully elucidate its role in normal muscle and in X-linked muscular dystrophy. An 
organelle proteomics approach was used to specifically focus on the fate of proteins 
closely linked to the muscle sarcolemma in the absence of dystrophin. This proteomic 
profiling of the dystrophic sarcolemma confirmed a number of perturbations 
previously identified, including structural remodelling, molecular chaperoning, 
elevated cellular stress, increased protein synthesis, altered ion handling, inflammation 
and membrane repair. Importantly, this study also offered novel insights, especially in 
relation to the identification of reduced levels of the intermediate filament protein 
synemin which has previously been suggested to interact with components of the 
DGC, and decreased abundance of the myelin specific proteins periaxin and myelin 
binding protein zero, indicating a potential perturbation of motor neuron myelination 
in dystrophic tissue.   
 Chapters 3 and 4 give insights into proteomic alterations in skeletal muscle, 
which is severely and progressively impaired in DMD. However, cardiorespiratory 
difficulties are a major complication for Duchenne patients, and in a subset of patients 
mild and non-progressive cognitive impairments are also evident. To ascertain a 
proteomic basis for these observations, label-free LC-MS/MS proteomic profiling was 
extended to dystrophin-deficient cardiac and brain tissue in Chapters 5 and 6. 
Cardiomyopathy is a serious complication in muscular dystrophy, and further research 
in this area is crucial as i) it is a clinical manifestation in approximately 90% of 
patients, ii) heart failure is responsible for an estimated 20% of deaths, iii) there is no 
cure, and iv) emerging potential therapies not only fail to treat the heart but treatment 
of skeletal muscle alone may actually accelerate heart disease (Fayssoil et al., 2010). 
The DGC in cardiomyocytes has a costameric distribution, and is present in the 
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sarcolemma, T-tubules and in intercalated discs, where it is involved in transduction 
of mechanical force to the extracellular matrix. Similar to skeletal muscle, the loss of 
dystrophin and its associated glycoprotein complex in cardiac tissue culminates in 
increased vulnerability to mechanical stress, micro-rupturing of the sarcolemma, and 
dysregulated ion influx and efflux resulting in elevated Ca2+ concentration. Increased 
intracellular Ca2+ results in the activation of calpains which degrade muscle proteins 
leading to necrosis, and mitochondrial-mediated cell death (Tsuda and Fitzgerald, 
2017). Death of cardiomyocytes is then followed by immune cell infiltration and 
myofibrosis where fibroblasts invade damaged cardiac tissue and contribute to the 
deposition of extracellular matrix proteins and scar formation. This process of 
cardiomyopathy first affects the posterobasal and lateral walls of the left ventricle 
(LV), which is later accompanied by an increase in wall stress. Over time, systolic LV 
function decreases and myocardial oxygen consumption increases, resulting in LV 
dilation and dysfunction (Fayssoil et al., 2010). Since cardiac dysfunction progresses 
slowly before an abrupt onset of acute cardiomyopathy at later stages of the disease, 
pharmacological treatment is given before the commencement of cardiac symptoms 
to delay the onset of heart failure. Corticosteroids and angiotensin-converting-enzyme 
inhibitors are typically used to prevent/delay LV dysfunction (D'Amario et al., 2017). 
In Chapter 5 proteomic profiling of senescent mdx-4cv cardiac tissue was performed 
to identify proteomic alterations in the aged heart which may give insights into the 
pathology of cardiomyopathy. This approach identified 98 proteins with an altered 
abundance in the dystrophic heart, 54 of which were increased in abundance and 44 
of which showed decreased levels.  
In analogy to the profiling of dystrophic skeletal muscle in Chapter 3, reduced 
abundance was detected for dystrophin, α1-syntrophin, α-sarcoglycan, β-sarcoglycan 
and δ-sarcoglycan in dystrophic hearts, enabling the simultaneous evaluation of 
dystrophin deficiency and downstream secondary abnormalities. One of the major 
alterations identified in the aged heart is that of myofibrosis, evident by elevated 
abundance of the matricellular protein periostin, the proteoglycans asporin and 
lumican, and the extracellular matrix protein collagen. Comparative proteomics also 
revealed augmented levels of molecular chaperones, anti-proteases and anti-
inflammation factors, suggesting a compensatory mechanism to limit proteotoxic 
effects. In conjunction with elevated abundance of a range of cytoskeletal proteins, 
these alterations represent an attempt to rescue the dystrophic phenotype. A potentially 
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useful new heart-associated marker of cardiomyopathy is myosin light chain kinase 3, 
which showed the largest elevation in dystrophic hearts with a 414-fold increase. 
Myosin light chain kinase 3 is a key enzyme that is responsible for the phosphorylation 
of specific light and heavy chains of cardiac myosin, involved in potentiating the force 
and rate of cross-bridge recruitment in cardiac fibres (Murphy et al., 2016b). The 
drastically elevated levels of myosin light chain kinase 3 indicate considerable 
changes in the regulation of myosin interactions in the mdx-4cv heart. 
 Approximately one-third of patients with DMD display cognitive impairments 
which are usually mild and non-progressive, although there is large variation in 
cognitive function amongst Duchenne patients. A neuropsychological study 
performed on DMD children and a matched control group of children with SMA found 
that the SMA group showed no signs of cognitive dysfunction, despite progressive 
muscle wasting and premature death. This suggests that the cognitive deficits seen in 
Duchenne patients are specific to the loss of dystrophin and not the psychological 
consequence of a degenerative disease (Billard et al., 1992). General intellect has been 
reported to be relatively comparable between DMD patients and healthy age-matched 
controls, and between DMD patients and controls with a different neuromuscular 
disorder, and so cognitive impairments appear to affect only specific functions, with 
major deficits specifically seen in short-term memory which may contribute to 
impaired intellectual development (Wicksell et al., 2004).  While the muscle isoform 
Dp427m is the principal dystrophin isoform in skeletal muscle, a plethora of 
dystrophin isoforms exist in the brain, including the cortical Dp427c isoform in 
neurons of the cortex and in the cornu ammonis of the hippocampus, the Purkinje 
isoform Dp427p expressed in cerebellar Purkinje cells, Dp140 predominantly 
expressed in the foetal brain, and Dp71 which is ubiquitously expressed but with 
highest levels in the central nervous system (Doorenweerd et al., 2017). Recent studies 
have suggested that a correlation exists between cognitive defects and the location of 
the dystrophin gene mutation. More distal mutations affect increasing numbers of 
dystrophin isoforms, and the severity of cognitive impairment is proposed to be linked 
to the cumulative loss of distal central nervous system expressed dystrophin isoforms, 
particularly Dp140 and Dp71 (Taylor et al., 2010).  
To facilitate a molecular understanding of the effect of dystrophin deficiency 
on brain tissue, a label-free LC-MS/MS study was performed on brain tissue from 12-
month old wild-type and age-matched mdx-4cv mice, which due to a premature stop 
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codon in exon 53 expresses neither Dp427, Dp260 nor Dp140, but stably expresses 
Dp71 (Im et al., 1996). As described in Chapter 6, proteomic profiling revealed altered 
abundance for 46 proteins, 39 of which were increased in abundance and 7 of which 
were decreased. Overall, proteomic perturbations in the brain proteome are similar to 
those seen in skeletal muscle and the heart, where increased abundance of cytoskeletal 
components such as vimentin, spectrin and drebrin may represent a compensatory 
mechanism to partially restore mechanical strength to dystrophin-deficient cells. 
Elevated abundance of annexin A5 is indicative of membrane repair whilst reduced 
abundance of plasma membrane calcium transporting ATPase 2 suggests altered 
calcium ion homeostasis (Murphy et al., 2015b). The largest fold increase was seen 
for the heme-binding serum glycoprotein hemopexin, whose increased abundance may 
be linked to altered iron metabolism in the mdx-4cv brain, which has previously been 
described in the mdx heart (Holland et al., 2013). One finding of particular interest 
was the 2.00-fold increase in the abundance of GFAP, an intermediate filament protein 
of the central nervous system, the abundance of which was further investigated by 
immunoblotting and immunofluorescence microscopy. Augmented levels of GFAP 
are indicative of cellular hypertrophy and/or proliferation of astrocytes usually in 
response to a central nervous system insult (Eng et al., 2000). Prolonged astrocyte 
activation can lead to glial scar formation and tissue scarring. Similar to infiltration of 
myofibroblasts and the deposition of extracellular matrix proteins leading to fibrosis 
in dystrophic skeletal muscle and the heart, dystrophin deficiency in the central 
nervous system may lead to the activation of astrocytes, non-specific reactive 
astrogliosis and tissue scar formation. Thus, GFAP represents a protein marker with 
great potential to be exploited to further improve understanding of muscular 
dystrophy-associated cognitive impairments. This is particularly relevant given a 
previous case report of a Duchenne patient with severe mental retardation who 
possessed multifocal glial nodules with intense immunoreactivity for GFAP in the 
cerebral cortex (Itoh et al., 1999). Astrogliosis may also represent a therapeutic target. 
There is growing evidence for a pathogenic role of glia cells (microglia and astrocytes) 
in several neurodegenerative disorders, such as Alzheimer’s disease, ALS and 
Parkinson’s disease, where glia-induced inflammation can amplify the disease 
pathology and contribute to disease progression (Colangelo et al., 2012). Inhibition of 
neuro-inflammation may reduce the production of factors that contribute to 
neurotoxicity and thus have clinical benefit.  
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 There is an urgent need for a superior biomarker panel for DMD, ideally based 
on quantifiable molecules which are easily accessible (Hathout et al., 2015). Unlike 
protein markers identified in tissue samples, the detection of biomarkers in biofluids 
such as blood, urine and saliva is minimally invasive and thus is amenable to repeated 
sampling. An improved biofluid-based protein biomarker panel could be used i) in 
disease diagnosis, ii) in pharmacodynamics to monitor therapy safety and efficacy, 
and iii) to improve understanding of disease pathophysiology and identify novel 
therapeutic targets (Hathout et al., 2016). To address this issue comparative proteomic 
profiling was performed on serum and saliva samples from 6-month old wild-type and 
mdx-4cv mice in Chapter 7. Serum proteomics identified 371 differentially abundant 
proteins; 334 of which were increased in abundance and 37 of which displayed 
reduced abundance. Cellular component analysis of the augmented proteins revealed 
that a large majority of them were muscle-derived proteins, thus their increased levels 
in serum reflects leakage from muscle through the damaged sarcolemma, and muscle 
necrosis and degeneration. Two proteins of particular interest were haptoglobin and 
FABP-1, whose elevated abundance as detected by label-free LC-MS/MS was verified 
by immunoblotting and ELISA analysis. Increased abundance of the inflammation-
inducible plasma protein haptoglobin suggests sterile inflammation, and thus 
haptoglobin may serve as a potential biomarker candidate of inflammation in 
dystrophinopathy. Elevated abundance of FABP-1 in serum agrees with its reduced 
levels in mdx muscle samples (Murphy et al., 2017a). Its increased abundance in serum 
may therefore reflect skeletal muscle degeneration and the release of muscle proteins 
into the circulatory system. Both biomarker candidates offer potential for their use in 
developing a superior biomarker panel of X-linked muscular dystrophy, however they 
would need to be first validated in a large cohort of clinical samples.  
Saliva proteomics uncovered 14 proteins with differential abundance; 7 of 
which were increased in abundance and 7 of which were found to be decreased in 
abundance. Overall, this pilot study of saliva proteomics identified altered proteins 
associated with protein signalling, extracellular matrix remodelling and inflammation. 
Of particular importance was the detection of increased abundance of kallikrein-1, 
kallikrein 1-related peptidase b1, kallikrein 1-related peptidase b5 and kallikrein 1-
related peptidase b22 in mdx-4cv saliva. The kallikrein family play diverse roles in 
extracellular matrix remodelling, inflammation and in the vasoactive peptide system. 
Kallikrein-1 is especially interesting given it was also found to be increased by 6.28-
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fold in mdx-4cv serum, indicating that it is a potentially useful circulatory marker for 
muscular dystrophy. Together, these studies of serum and saliva establish liquid 
biopsy procedures as a suitable bioanalytical tool for the survey of potential biomarker 
candidates of DMD. These initial proteomic surveys have identified a number of 
possible biomarker candidates, including haptoglobin, FABP-1 and kallikrein-1. 
However, further studies are required to investigate the influence of age, gender, 
ethnicity, diet, general lifestyle, physical activity, stress, co-morbidities and 
pharmacological side effects on the levels of these protein markers. 
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Figure 8.1 Overview of muscular dystrophy-induced changes in skeletal muscle, the heart, brain, serum and saliva 
Illustrated is an overview of the principal secondary abnormalities downstream of dystrophin deficiency, as identified by the  
mass spectrometric analysis of dystrophin-deficient tissues and biofluids described in this work.
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Tissue proteomics has identified statistically significant altered abundance for 
199 proteins in 6-month old crude skeletal muscle (Chapter 3), 190 proteins in 5-
month old sarcolemma-enriched muscle homogenates (Chapter 4), 98 proteins in 
senescent 20-month old cardiac tissue (Chapter 5) and 46 proteins in 12-month old 
brain tissue (Chapter 6). To investigate whether any of these proteins could represent 
global protein markers of dystrophinopathy, irrespective of age and/or tissue type, a 
cross-comparison of all altered proteins from each tissue proteomics study was 
performed, as illustrated in Figure 8.2. While no single protein was identified to be 
differentially abundant in all four tissues, 69 proteins were found in two of the four 
tissues and 12 proteins were found to be differentially abundant in three of the four 
tissue proteomes. These 12 proteins are listed in Table 8.1. While the majority of these 
proteins show the same trend of increased versus decreased abundance, in some cases 
proteins elevated in skeletal muscle and sarcolemma were found to be decreased in 
cardiac tissue (Na+/K+-ATPase subunit alpha-1, Ig mu chain C region, and filamin C). 
This may reflect differences in the response of cardiac tissue versus skeletal muscle to 
dystrophin deficiency and/or may be age-related given that in this work only the 
cardiac tissue is representative of the end stage of the disease. Importantly, reduced 
levels of dystrophin were detected in skeletal muscle, the sarcolemma and the heart, 
thus verifying the mutant status of the mdx-4cv mouse model used in this research.  
 Myosin 9, a cellular myosin involved in cytokinesis and cytoskeletal 
reorganisation was found to be increased in abundance in skeletal muscle, the 
sarcolemma and the heart. Elevated levels of myosin 9 have also been previously 
reported in the severely dystrophic diaphragm of mdx-4cv mice, further establishing 
myosin 9 as a potential biomarker candidate of X-linked muscular dystrophy (Holland 
et al., 2015a). Its augmented levels in dystrophin-deficient tissue likely reflect 
cytoskeletal remodelling, enhanced cellular proliferation and increased synthesis of 
components of the matrisome (Murphy et al., 2015b).  
 Increased abundance was also detected for the alpha-1 subunit of the integral 
membrane protein Na+/K+-ATPase in skeletal muscle and the sarcolemma. This 
suggests that damaged skeletal muscle fibres attempt to compensate abnormal ion 
fluxes by increasing the availability of this ion pump to stabilise the membrane 
potential (Dunn et al., 1995). However, slightly decreased abundance of this ion pump 
was detected in aged cardiac tissue, indicating that either this compensatory 
mechanism is restricted to skeletal muscle and/or that this attempt to stabilise the 
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membrane potential is lost during senescence. Age-dependant decreases in Na+/K+-
ATPase activity have previously been reported in humans (Maurya and Prakash, 2013) 
and in mouse brain (Tanaka and Ando, 1990). While these studies reported only the 
activity of Na+/K+-ATPase and not its abundance, the potential effect of aging on both 
the abundance and activity of Na+/K+-ATPase would need to be considered should it 
be considered as a potential marker of dystrophinopathy.  
 Raised levels of Ig mu chain C region identified in the skeletal muscle and 
sarcolemma may be reflective of autoimmunity. It has been speculated that instability 
of the DGC and the chronic inflammatory environment in dystrophic tissue may 
contribute to an autoimmune response to proteins of the DGC or other muscle-derived 
proteins (Villalta et al., 2015). Such auto-antibodies may be present in skeletal muscle 
through infiltration of the leaky dystrophin-deficient sarcolemma (Holland et al., 
2013). This appears to affect skeletal muscle more than cardiac muscle, given reduced 
levels of Ig mu chain were detected in the heart.  
 Filamin C is a muscle-specific, actin-crosslinking protein which localises at Z-
discs, myotendinous junctions, costameres, and intercalated disks in mammalian 
skeletal and cardiac muscle. Filamin C interacts with the DGC, integrin, and the Z-
disc proteins myopodin and myotilin, indicating a role in the maintenance of muscle 
integrity (Fujita et al., 2012). Localised myofibrillar damage of live cardiomyocytes  
resulted in the rapid recruitment of filamin C to damaged areas indicating that in 
contrast to previous understanding of filamin C as a static structural protein, filamin 
C may also be involved in myofibrillar remodelling (Leber et al., 2016). Elevated 
abundance of filamin C, as seen in dystrophic skeletal muscle and the sarcolemma 
may therefore be indicative of myofibrillar damage, probably as a result of Ca2+ 
overload, protease activation, protein degradation and muscle necrosis. It also suggests 
a repair response by dystrophic skeletal muscle to mend damaged muscle. The 
reduction of filamin C in 20-month old dystrophin-deficient heart likely represents a 
decrease in the ability of dystrophic muscle to mediate repair mechanisms with age.  
 A variety of heat shock proteins have been shown to be elevated in abundance 
in dystrophic muscle, including cardiovascular heat shock protein/HSPB7 in the mdx 
diaphragm (Doran et al., 2006b), HSP90-beta in mdx soleus, extensor digitorum 
longus and flexor digitorum brevis (Holland et al., 2015b) and HSP90-beta, heat shock 
cognate 71 kDa protein and 60 kDa heat shock protein in mdx gastrocnemius (Gardan-
Salmon et al., 2011). In analogy to these previous studies of the mdx mouse model, 
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increased abundance of HSP90-beta1 has been identified in crude skeletal muscle 
homogenates, the sarcolemma and the aged heart from the mdx-4cv mouse, as 
indicated in Table 8.1. In skeletal muscle, HSPs play key roles in cellular signalling, 
modulation of the immune response, myogenesis, myofibril assembly, and the 
stabilisation of misfolded and denatured proteins following exposure to stress 
(Brinkmeier and Ohlendieck, 2014). Therefore, the increased abundance of HSP90-
beta1 seen in Chapters 3, 4 and 5 suggests elevated cytoprotection of vulnerable 
skeletal and cardiac muscle fibres to limit proteotoxic effects. HSP90-beta1 may 
represent a potential biomarker candidate for the superior diagnosis, prognosis and 
therapy-monitoring of DMD. A partial reversal of muscular dystrophy-induced 
increased abundance of cardiovascular HSP/HSPB7 has been previously described 
following exon-23 skipping in the mdx mouse (Doran et al., 2009b).  Thus, HSPs may 
represent a class of protein markers useful for the evaluation of the ability of emerging 
therapies to reverse secondary changes, such as cellular stress, in dystrophinopathy.  
 Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a large family of 
multi-functional RNA-binding proteins, which are involved in cellular nucleic acid 
metabolism, particularly in relation to alternative splicing, mRNA stabilization, and 
transcriptional and translational regulation. In human cells, hnRNP complexes are 
composed of at least 20 core hnRNP proteins and other less abundant minor hnRNP 
proteins. The core proteins termed hnRNP A1 through to hnRNP U are reported to 
differ in their preferred binding site and in their function, with functional roles ranging 
from splicing to stability to translation (Chaudhury et al., 2010). The reported purpose 
of hnRNP M, shown to have elevated abundance in dystrophin-deficient sarcolemma, 
cardiac and brain tissue, is splicing (Hovhannisyan and Carstens, 2007). Many 
proteins which are essential for striated muscle development exist in multiple isoforms 
which are generated by alternative splicing. This includes transcription factors, 
components of the myofibril, and metabolic enzymes (Pistoni et al., 2010). The 
elevated abundance of hnRNP in dystrophin-deficient sarcolemma, cardiac and brain 
tissue may therefore be necessary for alternative splicing of an increased number of 
muscle proteins. Enhanced protein synthesis is a feature of dystrophic tissue to provide 
enough protein for muscle regeneration, cytoskeletal remodelling and metabolic 
homeostasis.  
 Apolipoprotein A-I is the major protein component of high density lipoprotein 
in plasma, which interacts with apolipoprotein A-I binding protein, and is involved in 
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cholesterol efflux. A 5-6 fold increase in the relative rate of apolipoprotein A-I 
synthesis in mature dystrophic fast-twitch breast muscle has previously been described 
in dystrophic chickens, where this increase was associated with elevated levels of 
apolipoprotein A-I mRNA (Shackelford and Lebherz, 1985). Increased abundance of 
apolipoprotein A-I in mdx-4cv skeletal muscle, heart and brain may indicate a 
compensatory mechanism to counter-act impaired lipid metabolism in dystrophin-
deficient fibres and support the altered metabolic needs of dystrophic tissues.  
Spectrins are large, actin-crosslinking, membrane cytoskeletal proteins, of 
which both non-erythroid and erythroid isoforms exist in skeletal and cardiac muscle. 
Erythroid spectrin has been suggested to localise at the costameric junction between 
the Z-line and the sarcolemma, while non-erythroid spectrin has been shown to 
localise at Z-line striations and at the neuromuscular junction (Vybiral et al., 1992). 
Spectrin forms heterodimers and through its interactions with actin filaments and 
membrane-bound cytoskeletal proteins, it forms a membrane-cytoskeletal scaffolding 
complex. This complex confers cellular flexibility to erythrocytes and structural 
integrity to non-erythroid cells (Isayama et al., 1993). Given the role of spectrin in 
forming a scaffolding protein complex and providing plasmalemmal integrity 
(Murphy et al., 2016b), its elevated abundance in dystrophin-deficient skeletal muscle, 
cardiac and brain tissue may reflect a compensatory mechanism to maintain structural 
integrity in the absence of the DGC. This would appear to be a conserved response 
across the skeletal, circulatory and central nervous systems in response to dystrophin 
deficiency.  
 Metabolic disturbances are a key hallmark of DMD, with perturbations in the 
cytosolic proteins of glycolysis and the mitochondrial enzymes of the tricarboxylic 
acid cycle and electron transport chain consistently reported in Duchenne patients and 
animal models of the disease (Timpani et al., 2015). This results in reduced ATP 
synthesis which has negative implications for Ca2+-buffering, contractile apparatus 
function, protein synthesis, and muscle regeneration. ATP synthase is a mitochondrial 
complex V enzyme which plays a critical role in the generation of ATP (Holland et 
al., 2013). This protein shows an altered abundance profile, whereby increased 
abundance is detected in crude skeletal muscle homogenates and brain (Chapters 3 
and 6), but reduced abundance is seen in sarcolemma-enriched skeletal muscle 
(Chapter 4). Reduced abundance of ATP synthase in the sarcolemma possibly 
represents an artefact from the extensive subcellular fractionation procedure, or may 
316 
 
be in line with previous studies of aged mdx cardiac tissue in which reduced abundance 
of ATP synthase was linked to impaired mitochondrial metabolism and an inability of 
dystrophic cardiac mitochondria to meet ATP demands (Holland et al., 2013). On the 
other hand, elevated levels of various subunits of ATP synthase in crude skeletal 
muscle (ATP synthase F(0) complex subunit B1, ATP synthase subunit O, and ATP 
synthase subunit alpha) and brain (ATP synthase subunit gamma and ATP synthase 
subunit alpha) possibly indicates a compensatory mechanism to counteract ATP 
insufficiency in dystrophic tissue.  
  The Ca2+-regulated phospholipid- and membrane- binding family of annexin 
proteins and the type III intermediate filament protein vimentin have been previously 
suggested as universal biomarkers of DMD, given their increased abundance in both 
mildly and severely affected mouse skeletal muscle (Holland et al., 2015b).  Both 
annexin A5 and vimentin were shown here to be increased in skeletal muscle, the 
sarcolemma and the brain, where their increased abundance likely reflects membrane 
repair processes and structural remodelling respectively.  
 Overall, the 12 proteins listed in Table 8.1 offer unique insights into the 
pathophysiology of DMD and the effect of tissue type and age on the disease process. 
They reveal enhanced cellular stress, cytoskeletal remodelling, ion homeostasis, 
membrane repair, and metabolism as key altered processes within dystrophin-deficient 
tissue. These proteins offer huge potential to be exploited as possible protein 
biomarkers for the improved diagnosis, prognosis and therapy-monitoring of 
dystrophinopathy. Future work should evaluate such biomarker candidates in a large 
cohort of clinical samples and attempt to link their status to disease progression and/or 
response to therapy. 
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Figure 8.2 Cross-comparison of differentially abundant proteins in tissue 
proteomic studies 
Venn diagram analysis was used to determine which differentially abundant proteins 
from the skeletal muscle, sarcolemma-enriched, cardiac and brain tissue proteomes 
described in Chapters 3, 4, 5 and 6 are shared by more than one dystrophic proteome.  
 
*Image was generated using Oliveros, J.C. (2007-2015) Venny. An interactive tool 
for comparing lists with Venn's diagrams.  
http://bioinfogp.cnb.csic.es/tools/venny/index.html 
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Table 8.1: Shown are the 12 proteins detected by label-free mass spectrometric 
analysis to have altered abundance in three of four dystrophic proteomes; 6-month old 
crude skeletal muscle, 5-month old sarcolemma, 20-month old heart, and 12-month 
old brain  
 
Accession Protein Name Skeletal 
Muscle 
Sarcolemma Heart Brain 
P11531 Dystrophin 14.6-fold 
decrease 
2,708.2-fold 
decrease 
8.6-fold 
decrease 
- 
Q8VDD5 Myosin-9 15.8-fold 
increase 
4.6-fold 
increase 
4.1-fold 
increase 
- 
Q8VDN2 Sodium/potassium-
transporting ATPase 
subunit alpha-1 
6.1-fold 
increase 
2.0-fold 
increase 
1.7-fold 
decrease 
- 
P01872 Ig mu chain C 
region 
3.7-fold 
increase 
7.4-fold 
increase 
2.2-fold 
decrease 
- 
Q8VHX6 Filamin-C 2.1-fold 
increase 
5.1-fold 
increase 
1.4-fold 
decrease 
- 
P14602 Heat shock protein 
beta-1 
2.0-fold 
increase 
2.2-fold 
increase 
1.6-fold 
increase 
- 
Q9D0E1 Heterogeneous 
nuclear 
ribonucleoprotein M 
- 32.3-fold 
increase 
1.5-fold 
increase 
1.44-fold 
increase 
Q00623 Apolipoprotein A-I 4.6-fold 
increase 
- 2.3-fold 
increase 
2.9-fold 
increase 
P16546 Spectrin alpha 
chain, non-
erythrocytic 1 
3.7-fold 
increase 
- 3.1-fold 
increase 
1.2-fold 
increase 
Q03265 ATP synthase 
subunit alpha, 
mitochondrial 
2.1-fold 
increase 
2.6-fold 
decrease 
- 1.3-fold 
increase 
P20152 Vimentin 2.4-fold 
increase 
2.5-fold 
increase 
- 1.6-fold 
increase 
P48036 Annexin A5 2.7-fold 
increase 
2.5-fold 
increase 
- 1.6-fold 
increase 
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 Proteomics is an evolving field, with major advances including the emergence 
of 2D-DIGE which greatly reduced issues of reproducibility and gel-to-gel variability, 
and LC-MS/MS which offers an alternative to gel-based approaches which have 
limited resolving power for large proteins, hydrophobic proteins and those with 
extreme pI values. Thus, the integration of gel-based and liquid chromatography-based 
mass spectrometry can provide complementary information in the quest to characterise 
complete proteomes. Discovery proteomics is frequently employed as an initial tool 
to identify and quantify the protein components of a biological system, and such 
analyses typically use data-dependent acquisition (DDA), where only the most 
abundant precursor ions are selected for fragmentation (Collins et al., 2017). As a 
result, precursor ion selection is stochastic, and this can lead to issues with 
irreproducibility and missing values in proteomics datasets, whereby a peptide may be 
detected in some but not all the samples analysed. An alternative emerging approach 
is that of data-independent acquisition (DIA), of which SWATH (sequential window 
acquisition of all theoretical fragment ion spectra) mass spectrometry is one of the 
most widely used. In this method all precursor ions within a user defined m/z window 
are fragmented, thus eliminating the stochastic nature of DDA. Protein identification 
is achieved using targeted data extraction to query the acquired fragment ion maps for 
the presence and quantity of specific peptides, using a priori information contained in 
spectral libraries (Gillet et al., 2012). This type of DIA mass spectrometry may be 
particularly suited to the analysis of skeletal muscle proteomes, where the extensive 
dynamic range between the most highly abundant proteins such as the contractile 
proteins and low abundance proteins such as signalling molecules, limits the detection 
of lower abundance proteins in DDA mass spectrometry (Ohlendieck, 2011c).  
Ebhardt and co-workers have recently applied SWATH mass spectrometry to 
skeletal muscle proteomics of cancer-induced muscle wasting (cancer cachexia) and 
found the cancer cachexia proteome to be distinct from all other investigated control 
groups (weight-stable cancer, healthy non-sarcopenic and age-related sarcopenia). 
Three distinct protein networks were found to distinguish cancer cachexia from all 
other groups; the Fo complex, electron transport chain and contractile fibre (Ebhardt 
et al., 2017). Given the success of this pilot study, SWATH mass spectrometry could 
now be applied in the analysis of other neuromuscular disorders, including DMD. 
Such an approach may give unprecedented depth of coverage of alterations in the 
skeletal muscle proteome in health and disease and may offer new insights into the 
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disease mechanisms and identify possible therapeutic targets. SWATH mass 
spectrometry could also be used for the analysis of serum/plasma samples in 
biomarker-based studies as it may circumvent the issue of high dynamic range of 
proteins in serum/plasma which is a current limiting factor in their analysis by mass 
spectrometry.  
 The proteomic characterisation of the mdx-4v animal model of DMD described 
here has identified numerous biomarker candidates with potential applications for the 
improved diagnosis, prognosis and therapy monitoring of dystrophinopathy. However, 
despite an increasing number of proteomic studies identifying novel protein biomarker 
candidates, few of these discovered biomarkers have been incorporated into routine 
clinical care. One of the major bottlenecks in the biomarker pipeline is the verification 
of candidates generated in discovery-phase studies. Currently, verification of potential 
biomarkers is performed with established immunoassay such as ELISA, however such 
assays are dependent on the availability of antibodies, and development of a new 
ELISA is time-consuming and expensive (Makawita and Diamandis, 2010). An 
alternative approach which can simultaneously quantify numerous proteins in parallel 
and which can be developed for all novel candidates of interest is multiple reaction 
monitoring (MRM) mass spectrometry. In MRM typically 3-5 proteotyptic peptides 
are picked to serve as representations of the intact protein of interest. For each peptide 
the mass-to-charge ratio (m/z) of the precursor ion and its optimum product ions is 
known, is referred to as a “transition” and is used to select for the target peptide. In a 
typical MRM mass spectrometry analysis, the sample of interest, for example serum, 
is added to the LC-MS/MS system and only the precursor ions of the target protein are 
selected and subjected to fragmentation. The optimum product ions are then selected 
and quantified. Peptide intensities can subsequently be compared between two 
experimental conditions for relative quantification or to reference intensities generated 
by standards of known concentration for absolute quantification (Meng and Veenstra, 
2011). MRM is currently being investigated for its use in clinical proteomics as a 
means of biomarker verification in a number of diseases. Kim and co-workers used 
MRM to evaluate 12 biomarker candidates for diabetic retinopathy that they had 
previously identified in a discovery study (Kim et al., 2010). In oncology studies, a 
similar approach to MRM known as parallel reaction monitoring (PRM) has been used 
to verify differential abundance of the activation peptide of the coagulation factor XIII 
in serum samples of colorectal cancer. PRM analysis revealed statistically significant 
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differences in the abundance of this peptide between control and colorectal samples 
and showed a diagnostic accuracy of 0.93 in a cohort of 73 samples (27 cancer patients 
and 46 controls), confirming the potential use of this peptide as a serum biomarker of 
colorectal cancer (Peltier et al., 2018). Future studies in muscular dystrophy research 
could harness the potential of MRM and PRM mass spectrometry for the relatively 
high-throughput verification of previously identified serum/plasma and tissue 
candidate biomarkers. The most promising candidates could then be further verified 
by immunoassays and potentially be translated for clinical use. Such an approach may 
help overcome the bottleneck in the biomarker pipeline and result in tangible health 
benefits for muscular dystrophy patients.  
 Proteomic analysis of skeletal muscle, aged heart tissue, serum and saliva 
samples from the mdx-4cv mouse model of DMD has revealed increased abundance 
of numerous proteins associated with extracellular matrix remodelling and fibrosis. 
Thus, tackling fibrosis represents a clear therapeutic target to help improve muscle 
function. Anti-fibrotic research has been mainly conducted with mdx mice, where 
studies have largely focused on i) blocking fibrotic cytokine signalling to reduce gene 
expression and protein synthesis of extracellular matrix proteins, ii) suppressing 
inflammation to reduce the production of pro-fibrotic cytokines and iii) promoting 
muscle regeneration (Zhou and Lu, 2010). An interesting new area of fibrosis research 
which may be applicable to DMD is the use of in vitro models of fibrosis. Engineered 
tissues can serve as excellent models to mimic tissue fibrosis, to give insights into the 
response of cells and the extracellular matrix to individual stimuli, and to facilitate the 
screening of new therapeutics (van Spreeuwel et al., 2017). A cardiac micro-tissue 
platform consisting of an extracellular matrix containing hydrogel with a mixture of 
cardiomyocytes and fibroblasts was used to recapitulate cardiac fibrosis, where 
altering either the number of fibroblasts or the amount of collagen was performed to 
mimic the different features of fibrosis. Measuring the dynamic contraction force of 
the micro-tissues revealed that while increasing collagen accumulation had no effect 
on contraction, contraction force was significantly decreased in response to increased 
numbers of fibroblasts. The average beating frequency also decreased significantly in 
micro-tissues containing more than 50% fibroblasts (van Spreeuwel et al., 2017). Liver 
fibrosis and cirrhosis are major risk factors for liver failure and the development of 
liver cancer. Currently, one of the most popular in vitro models of liver fibrosis is the 
culture of hepatic stellate cells (HSC) on plastic tissue culture dishes in the presence 
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of serum which induces trans-differentiation to myofibroblasts (van Grunsven, 2017). 
However, while HSC activation can be achieved through culture, the mechanisms by 
which it is mediated is thought to differ substantially from in vivo HSC activation. 
Therefore, intense research has aimed to produce 3D tissue models. While further 
optimisation is still required, hepatocyte damage-induced HSC activation and fibrosis 
has been reported in precision-cut liver slice cultures, bio-printed liver tissue cultures, 
and co-cultured spheroids (van Grunsven, 2017). The engineering of skeletal muscle 
for in vitro screening is likely to be highly complex given that engineered skeletal 
muscle tissue will require the generation of a microenvironment that provides 
anisotropic cues to promote uniaxial alignment, 3D matrices to provide a biomimetic 
microenvironment, mechanical and electrical stimuli, and interaction with support 
cells and tissues such as endothelial cells and motor neurons of the peripheral nervous 
system (Smith et al., 2016).  
However, given that a large number of different mutations in the dystrophin 
gene have been discovered so far in patients with DMD (Bladen et., 2015), and this 
heterogeneity cannot be currently modelled by animal models, patient-specific 
dystrophic myotubes derived from human induced pluripotent stem cells (iPSCs) 
could revolutionise the field of muscular dystrophy research. iPSCs are an extremely 
useful research tool as they can provide a limitless supply of cells that can be 
differentiated into a range of cell types and retain the genotype and phenotype of the 
donor. Gaun and co-workers have successfully created beating cardiomyocytes using 
iPSCs generated from urine-derived stem cells from healthy volunteers and a 
Duchenne patient (Guan et al., 2014). Dystrophin expression was undetectable in 
DMD iPSC cardiomyocytes by immunofluorescence and by immunoblotting 
demonstrating that these cells retained their dystrophic phenotype. In addition, DMD 
iPSC cardiomyocytes showed abnormal Ca2+ handling and increased susceptibility to 
mechanical stress compared to iPSC cardiomyocytes derived from healthy controls 
(Guan et al., 2014). A model for cardiomyopathy was chosen as experimental 
protocols to differentiate stem cells to cardiomyocytes are more advanced than similar 
approaches available for the generation of skeletal muscle. However, Chal and 
colleagues could differentiate striated, contractile fibres supporting a niche of Pax7⁺ 
cells that resemble satellite cells from embryonic stem cells and human iPSCs (Chal 
et al., 2015). Muscle fibres derived from embryonic stem cells of the mdx mouse 
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showed an abnormal branched phenotype typical of that described in vivo. Advances 
in tissue-engineering strategies coupled with emerging iPSC-related technologies 
suggests the ability to generate in vitro disease models of human muscle tissue. While 
still in its infancy, such an approach has the potential to revolutionise mechanistic 
studies, drug discovery and personalised medicine. Given recent successes in 
generating models of cardiac and liver fibrosis, this may also be extended to modelling 
cardiac and skeletal muscle fibrosis associated with DMD.  
 
8.1.1 Concluding Remarks 
Mass spectrometry-based proteomics has been used extensively throughout this work 
to characterise the mdx-4cv mouse model of DMD. This approach has helped to 
improve understanding of the molecular mechanisms underlying the disease 
pathogenesis in skeletal muscle, the sarcolemma, the aged heart and the brain. The 
differentially abundant proteins identified in these tissue proteomic studies give 
insights into the disease pathophysiology, identify potential therapeutic targets and 
may also be useful as biomarker candidates for the superior diagnosis, prognosis and 
therapy-monitoring of DMD. Since minimally invasive and non-invasive biomarkers 
are preferable to those obtained through invasive muscle biopsy, proteomic profiling 
was also performed on serum and saliva samples from the mdx-4cv mouse. These 
studies particularly identified certain muscle-derived proteins, haptoglobin, and 
kallikrein-1 as potential biomarker candidates of interest. To further progress this 
work, validation is required in a large cohort of clinical samples. In addition, ideally a 
multi-omics approach should be undertaken, integrating genomics, transcriptomics, 
proteomics and metabolomics to give a full picture of the dystrophic phenotype (Hasin 
et al., 2017).  
 In the future, advances in mass spectrometry analyses such as SWATH and 
MRM mass spectrometry may expand the field of muscle proteomics and enable near-
to-complete proteome characterisation. In addition, novel strategies such as the use of 
engineered muscle tissue and iPSCs may drive muscular dystrophy research forward 
towards an improved understanding of dystrophic disease mechanisms and facilitate 
in vitro drug screening and personalised medicine. The ultimate aim of muscular 
dystrophy research is to improve the quality of life of patients with Duchenne muscular 
dystrophy and ultimately provide a therapy or cure. The research presented here is a 
first step in reaching that goal. 
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Table A3.1: List of identified proteins with a significantly increased abundance ≤3.5-
fold in mdx-4cv hind-limb as determined by label-free LC-MS/MS 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
P22599 Serpina1b  Alpha-1-antitrypsin 1-2  3 186.18 4.00E-
03 
3.47 
Q6ZWY9 Hist1h2bc  Histone H2B type 1-
C/E/G  
3 310.51 6.48E-
03 
3.46 
P26039 Tln1  Talin-1  3 199.15 1.18E-
03 
3.37 
P18826 Phka1  Phosphorylase b kinase 
regulatory subunit alpha, 
skeletal muscle isoform  
3 235.73 8.09E-
03 
3.35 
P15864 Hist1h1c  Histone H1.2  2 94.98 1.11E-
02 
3.28 
P62806 Hist1h4a  Histone H4  5 312.46 1.07E-
02 
3.28 
Q8BMS1 Hadha  Trifunctional enzyme 
subunit alpha, 
mitochondrial  
9 762.37 1.15E-
02 
3.25 
P26041 Msn  Moesin  5 180.37 5.63E-
04 
3.23 
P14148 Rpl7  60S ribosomal protein 
L7  
3 181.65 1.33E-
02 
3.23 
Q8VEM8 Slc25a3  Phosphate carrier 
protein, mitochondrial  
5 264.80 1.49E-
02 
3.22 
Q61207 Psap  Sulfated glycoprotein 1  3 122.35 3.19E-
03 
3.14 
Q04857 Col6a1  Collagen alpha-1(VI) 
chain  
3 87.73 1.80E-
02 
3.12 
P61027; 
O35963; 
P61294; 
Q8K386 
Rab10  Ras-related protein Rab-
10  
3 118.38 1.58E-
03 
3.12 
P28654 Dcn  Decorin  5 350.61 1.65E-
02 
3.10 
Q9D783 Klhl40  Kelch-like protein 40  6 330.13 1.03E-
03 
3.10 
P97927 Lama4  Laminin subunit alpha-4  3 144.02 2.28E-
03 
3.03 
O08532 Cacna2d1  Voltage-dependent 
calcium channel subunit 
alpha-2/delta-1  
5 289.94 1.17E-
02 
3.03 
Q8BTM8 Flna  Filamin-A  3 123.04 6.68E-
03 
2.98 
A2AUC9 Klhl41  Kelch-like protein 41  12 774.92 8.24E-
03 
2.97 
P07758 Serpina1a  Alpha-1-antitrypsin 1-1  9 691.92 1.43E-
02 
2.94 
Q9CVB6 Arpc2  Actin-related protein 2/3 
complex subunit 2  
3 154.12 3.07E-
04 
2.92 
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P18760 Cfl1  Cofilin-1  5 305.01 4.51E-
03 
2.90 
Q8CI43 Myl6b  Myosin light chain 6B  2 66.66 7.58E-
03 
2.89 
P48962 Slc25a4  ADP/ATP translocase 1  9 579.28 1.72E-
02 
2.86 
Q9D6F9 Tubb4a  Tubulin beta-4A chain  5 478.95 3.73E-
03 
2.79 
Q8R429;
O55143; 
Q64518 
Atp2a1  Sarcoplasmic/endoplasm
ic reticulum calcium 
ATPase 1  
39 3489.26 1.99E-
02 
2.78 
P09405 Ncl  Nucleolin  2 4.54 5.11E-
03 
2.75 
P24369 Ppib  Peptidyl-prolyl cis-trans 
isomerase B  
2 132.93 5.97E-
04 
2.73 
P13541 Myh3  Myosin-3  5 425.08 1.80E-
02 
2.71 
P48036 Anxa5  Annexin A5  8 459.76 3.11E-
03 
2.71 
P29391 Ftl1  Ferritin light chain 1  9 652.00 5.57E-
03 
2.68 
P62874 Gnb1  Guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) subunit 
beta-1  
3 178.56 1.34E-
03 
2.68 
P32261 Serpinc1  Antithrombin-III  3 178.10 4.70E-
03 
2.66 
P07759 Serpina3k  Serine protease inhibitor 
A3K  
9 716.84 2.93E-
03 
2.65 
Q7TMM9 Tubb2a  Tubulin beta-2A chain  10 632.26 1.38E-
03 
2.64 
P47911 Rpl6  60S ribosomal protein 
L6  
2 145.75 1.12E-
02 
2.59 
Q91X72 Hpx  Hemopexin  13 636.31 1.69E-
02 
2.58 
P14869 Rplp0  60S acidic ribosomal 
protein P0  
3 86.01 5.00E-
03 
2.57 
Q9JK53 Prelp  Prolargin  5 227.25 5.28E-
03 
2.57 
P48678 Lmna  Prelamin-A/C  25 1641.09 3.50E-
04 
2.56 
Q9CQQ7 Atp5f1  ATP synthase F(0) 
complex subunit B1, 
mitochondrial  
5 211.76 3.67E-
03 
2.55 
Q9CZM2 Rpl15  60S ribosomal protein 
L15  
2 104.98 2.48E-
02 
2.52 
P62962 Pfn1  Profilin-1  4 270.97 1.55E-
02 
2.49 
Q91VI7 Rnh1  Ribonuclease inhibitor  7 339.14 1.34E-
02 
2.49 
Q07076 Anxa7  Annexin A7  2 120.89 1.60E-
03 
2.47 
Q8R4E4 Myoz3  Myozenin-3  2 100.52 1.18E-
03 
2.45 
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P62141 Ppp1cb  Serine/threonine-protein 
phosphatase PP1-beta 
catalytic subunit  
2 177.19 1.51E-
03 
2.45 
Q70IV5 Synm  Synemin  2 104.43 1.86E-
04 
2.44 
P20152 Vim  Vimentin  15 1088.58 2.26E-
03 
2.42 
P35980 Rpl18  60S ribosomal protein 
L18  
3 154.74 1.82E-
02 
2.42 
Q62000 Ogn  Mimecan  7 497.76 1.61E-
02 
2.42 
Q60930 Vdac2  Voltage-dependent 
anion-selective channel 
protein 2  
9 649.61 4.09E-
02 
2.37 
Q8BFR5 Tufm  Elongation factor Tu, 
mitochondrial  
9 509.16 4.82E-
03 
2.37 
Q9WTR5 Cdh13  Cadherin-13  3 245.57 6.04E-
03 
2.37 
P47757 Capzb  F-actin-capping protein 
subunit beta  
2 143.11 3.43E-
03 
2.34 
Q9Z1E4 Gys1  Glycogen [starch] 
synthase, muscle  
4 199.63 1.94E-
02 
2.33 
P97384; 
O35639 
Anxa11  Annexin A11  5 201.61 4.23E-
04 
2.32 
P68040 Gnb2l1  Guanine nucleotide-
binding protein subunit 
beta-2-like 1  
6 311.81 6.94E-
04 
2.32 
Q91WD5 Ndufs2  NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 2, mitochondrial  
8 305.45 1.41E-
03 
2.32 
P47963 Rpl13  60S ribosomal protein 
L13  
2 109.22 2.31E-
02 
2.31 
P50543 S100a11  Protein S100-A11  2 136.84 3.35E-
03 
2.30 
Q61425 Hadh  Hydroxyacyl-coenzyme 
A dehydrogenase, 
mitochondrial  
2 115.44 1.28E-
02 
2.30 
P05213 Tuba1b  Tubulin alpha-1B chain  2 209.92 1.60E-
02 
2.30 
P68368 Tuba4a  Tubulin alpha-4A chain  3 305.20 6.36E-
03 
2.28 
Q8BG05 Hnrnpa3  Heterogeneous nuclear 
ribonucleoprotein A3  
2 82.45 4.02E-
02 
2.28 
Q6ZWX6 Eif2s1  Eukaryotic translation 
initiation factor 2 subunit 
1  
2 73.19 1.86E-
02 
2.28 
A2AAJ9 Obscn  Obscurin  9 474.23 4.43E-
03 
2.27 
P62889 Rpl30  60S ribosomal protein 
L30  
4 279.47 1.89E-
03 
2.26 
Q9DC69 Ndufa9  NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 9, 
mitochondrial  
3 184.74 1.44E-
02 
2.26 
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P50544 Acadvl  Very long-chain specific 
acyl-CoA 
dehydrogenase, 
mitochondrial  
3 148.79 2.72E-
03 
2.25 
P63101 Ywhaz  14-3-3 protein zeta/delta  4 390.88 6.99E-
03 
2.23 
Q8BK84 Dupd1  Dual specificity 
phosphatase DUPD1  
2 146.83 4.76E-
03 
2.21 
Q9DB20 Atp5o  ATP synthase subunit O, 
mitochondrial  
4 277.86 1.02E-
02 
2.19 
Q3MI48 Jsrp1  Junctional sarcoplasmic 
reticulum protein 1  
3 145.69 2.10E-
02 
2.18 
P14824 Anxa6  Annexin A6  5 539.07 3.05E-
03 
2.15 
Q03265 Atp5a1  ATP synthase subunit 
alpha, mitochondrial  
11 778.39 1.16E-
03 
2.10 
Q9JJZ2 Tuba8  Tubulin alpha-8 chain  2 68.22 2.36E-
02 
2.10 
Q60605 Myl6  Myosin light polypeptide 
6  
4 300.27 1.04E-
02 
2.10 
Q99JB8 Pacsin3  Protein kinase C and 
casein kinase II substrate 
protein 3  
8 439.70 1.20E-
05 
2.10 
P31001 Des  Desmin  18 1622.83 1.45E-
03 
2.09 
Q61292 Lamb2  Laminin subunit beta-2  5 233.63 1.34E-
02 
2.08 
P40124 Cap1  Adenylyl cyclase-
associated protein 1  
2 52.13 1.47E-
03 
2.08 
Q8VHX6 Flnc  Filamin-C  20 1257.45 3.83E-
02 
2.07 
P51885 Lum  Lumican  5 346.14 2.11E-
02 
2.07 
Q9CZU6 Cs  Citrate synthase, 
mitochondrial  
5 373.29 1.48E-
02 
2.07 
O35129 Phb2  Prohibitin-2  3 122.36 4.05E-
03 
2.07 
Q9DB60 Fam213b  Prostamide/prostaglandi
n F synthase  
2 48.58 1.14E-
03 
2.06 
O88342 Wdr1  WD repeat-containing 
protein 1  
3 205.65 4.63E-
03 
2.05 
P14602 Hspb1  Heat shock protein beta-
1  
6 349.70 2.02E-
03 
2.05 
P14733 Lmnb1  Lamin-B1  5 244.43 1.90E-
03 
2.03 
Q60936 Adck3  Chaperone activity of 
bc1 complex-like, 
mitochondrial  
2 98.44 2.83E-
02 
2.02 
P35979 Rpl12  60S ribosomal protein 
L12  
3 172.68 2.01E-
02 
2.02 
Q02053 Uba1  Ubiquitin-like modifier-
activating enzyme 1  
2 170.90 3.08E-
02 
2.01 
 
 
371 
 
Table A4.1: List of identified proteins with a significantly increased abundance ≤ 4-
fold in mdx-4cv enriched sarcolemma as determined by label-free LC-MS/MS 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
Q5XKE0 Mybpc2  Myosin-binding 
protein C, fast-type  
3 238.99 5.42E-
04 
3.95 
P14131 Rps16  40S ribosomal 
protein S16  
3 137.60 3.60E-
07 
3.93 
P19324 Serpinh1  Serpin H1  3 80.53 2.01E-
05 
3.89 
Q8BY89 Slc44a2  Choline transporter-
like protein 2  
2 54.46 7.41E-
04 
3.84 
P47740 Aldh3a2  Fatty aldehyde 
dehydrogenase  
2 101.65 2.89E-
05 
3.82 
P22315 Fech  Ferrochelatase, 
mitochondrial  
2 3.62 2.79E-
03 
3.80 
P80318 Cct3  T-complex protein 1 
subunit gamma  
2 65.56 4.94E-
05 
3.72 
Q04857 Col6a1  Collagen alpha-1(VI) 
chain  
2 5.45 2.88E-
05 
3.68 
Q61941 Nnt  NAD(P) 
transhydrogenase, 
mitochondrial  
2 62.95 1.25E-
03 
3.67 
Q62159 Rhoc  Rho-related GTP-
binding protein RhoC  
2 60.96 1.22E-
08 
3.66 
P35980 Rpl18  60S ribosomal 
protein L18  
2 53.04 3.20E-
03 
3.62 
P09055 Itgb1  Integrin beta-1  3 5.45 2.28E-
04 
3.60 
P25444 Rps2  40S ribosomal 
protein S2  
3 108.83 4.15E-
06 
3.58 
Q91ZX7 Lrp1  Prolow-density 
lipoprotein receptor-
related protein 1  
4 184.28 4.03E-
04 
3.55 
P48678 Lmna  Prelamin-A/C  5 166.15 1.51E-
06 
3.46 
O55143 Atp2a2  Sarcoplasmic/endopl
asmic reticulum 
calcium ATPase 2  
7 370.13 1.16E-
06 
3.41 
P51863 Atp6v0d1  V-type proton 
ATPase subunit d 1  
3 116.14 6.71E-
05 
3.40 
Q6ZWN5 Rps9  40S ribosomal 
protein S9  
6 212.10 4.32E-
08 
3.35 
Q8BFR5 Tufm  Elongation factor Tu, 
mitochondrial  
2 4.43 2.80E-
03 
3.34 
Q9JI91 Actn2  Alpha-actinin-2  7 251.46 1.86E-
04 
3.32 
Q61475 Cd55  Complement decay-
accelerating factor, 
GPI-anchored  
2 83.81 5.51E-
05 
3.31 
Q64133 Maoa  Amine oxidase 
[flavin-containing] A  
4 196.24 8.22E-
06 
3.31 
Q9JHU4 Dync1h1  Cytoplasmic dynein 1 
heavy chain 1  
2 53.59 2.27E-
08 
3.22 
Q60936 Coq8a  Atypical kinase 
COQ8A, 
mitochondrial  
2 117.46 1.61E-
03 
3.21 
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Q9D517 Agpat3  1-acyl-sn-glycerol-3-
phosphate 
acyltransferase 
gamma  
3 139.69 5.17E-
05 
3.20 
Q8JZQ2 Afg3l2  AFG3-like protein 2  4 94.76 9.47E-
06 
3.08 
Q9CXR1 Dhrs7  Dehydrogenase/reduc
tase SDR family 
member 7  
2 3.62 4.11E-
04 
3.06 
O09161 Casq2  Calsequestrin-2  4 74.31 9.36E-
04 
3.06 
Q68FD5 Cltc  Clathrin heavy chain 
1  
5 191.31 2.18E-
04 
3.02 
Q02788 Col6a2  Collagen alpha-2(VI) 
chain  
3 88.66 1.26E-
06 
3.02 
P14206 Rpsa  40S ribosomal 
protein SA  
2 135.04 4.63E-
04 
3.01 
Q8BIJ6 Iars2  Isoleucine--tRNA 
ligase, mitochondrial  
3 108.15 1.13E-
04 
3.01 
Q9CZR2 Naalad2  N-acetylated-alpha-
linked acidic 
dipeptidase 2  
3 139.01 1.20E-
06 
3.00 
P62852 Rps25  40S ribosomal 
protein S25  
2 102.21 5.17E-
04 
2.99 
P62270 Rps18  40S ribosomal 
protein S18  
4 248.81 4.28E-
04 
2.98 
Q9D0L4 Adck1  Uncharacterized aarF 
domain-containing 
protein kinase 1  
2 102.89 2.46E-
03 
2.98 
Q8VCM8 Ncln  Nicalin  2 51.22 2.21E-
04 
2.92 
P62281 Rps11  40S ribosomal 
protein S11  
2 97.27 2.85E-
05 
2.91 
P97429 Anxa4  Annexin A4  2 94.33 4.42E-
05 
2.91 
P42932 Cct8  T-complex protein 1 
subunit theta  
2 105.73 2.84E-
05 
2.87 
Q61838 Pzp  Pregnancy zone 
protein  
3 143.08 1.04E-
04 
2.83 
Q9Z1E4 Gys1  Glycogen [starch] 
synthase, muscle  
4 72.84 1.36E-
06 
2.81 
Q91V79 Fitm1  Fat storage-inducing 
transmembrane 
protein 1  
3 222.11 1.85E-
04 
2.76 
Q9ET30 Tm9sf3  Transmembrane 9 
superfamily member 
3  
2 51.28 1.94E-
05 
2.72 
P62267 Rps23  40S ribosomal 
protein S23  
2 124.94 2.66E-
04 
2.71 
Q8C129 Lnpep  Leucyl-cystinyl 
aminopeptidase  
2 90.89 8.18E-
06 
2.71 
Q8BW75 Maob  Amine oxidase 
[flavin-containing] B  
5 172.46 5.15E-
07 
2.67 
P97351 Rps3a  40S ribosomal 
protein S3a  
3 63.48 4.12E-
06 
2.63 
Q8VDM4 Psmd2  26S proteasome non-
ATPase regulatory 
subunit 2  
2 113.58 1.94E-
03 
2.61 
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Q61543 Glg1  Golgi apparatus 
protein 1  
2 57.80 3.74E-
05 
2.58 
P47738 Aldh2  Aldehyde 
dehydrogenase, 
mitochondrial  
2 69.34 2.25E-
04 
2.58 
Q8CI59 Steap3  Metalloreductase 
STEAP3  
3 137.05 6.01E-
05 
2.58 
P10852 Slc3a2  4F2 cell-surface 
antigen heavy chain  
2 56.76 6.48E-
05 
2.57 
O70251 Eef1b  Elongation factor 1-
beta  
2 108.59 3.45E-
03 
2.56 
P43406 Itgav  Integrin alpha-V  3 146.70 1.68E-
04 
2.55 
P80317 Cct6a  T-complex protein 1 
subunit zeta  
2 104.89 2.08E-
03 
2.54 
P13020 Gsn  Gelsolin  2 42.35 1.30E-
03 
2.54 
Q811U4 Mfn1  Mitofusin-1  2 112.72 2.31E-
06 
2.51 
P48036 Anxa5  Annexin A5  2 121.80 3.13E-
03 
2.48 
P20152 Vim  Vimentin  4 141.90 1.82E-
04 
2.46 
Q91WC9 Daglb  Sn1-specific 
diacylglycerol lipase 
beta  
2 60.78 8.23E-
03 
2.42 
Q8R127 Sccpdh  Saccharopine 
dehydrogenase-like 
oxidoreductase  
3 119.61 4.02E-
05 
2.42 
E9PZQ0 Ryr1  Ryanodine receptor 1  3 173.44 4.78E-
03 
2.41 
P62242 Rps8  40S ribosomal 
protein S8  
3 122.17 2.16E-
04 
2.40 
Q61334 Bcap29  B-cell receptor-
associated protein 29  
3 54.56 6.40E-
04 
2.40 
Q99P72 Rtn4  Reticulon-4  3 48.54 4.66E-
07 
2.31 
Q921I1 Tf  Serotransferrin  2 96.97 6.81E-
04 
2.30 
Q9WTR5 Cdh13  Cadherin-13  2 66.32 9.61E-
04 
2.29 
Q9WUQ2 Preb  Prolactin regulatory 
element-binding 
protein  
3 165.29 3.41E-
05 
2.28 
Q9WV91 Ptgfrn  Prostaglandin F2 
receptor negative 
regulator  
2 118.63 1.62E-
04 
2.27 
Q9D379 Ephx1  Epoxide hydrolase 1  3 52.48 4.69E-
04 
2.26 
Q9Z2I0 Letm1  LETM1 and EF-hand 
domain-containing 
protein 1, 
mitochondrial  
3 63.22 2.36E-
03 
2.23 
Q924X2 Cpt1b  Carnitine O-
palmitoyltransferase 
1, muscle isoform  
3 187.01 1.92E-
03 
2.22 
Q8C7X2 Emc1  ER membrane 
protein complex 
subunit 1  
3 132.59 8.08E-
04 
2.22 
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P14602 Hspb1  Heat shock protein 
beta-1  
2 83.78 1.21E-
05 
2.18 
P35293 Rab18  Ras-related protein 
Rab-18  
3 74.22 1.55E-
04 
2.15 
Q6PIE5 Atp1a2  Sodium/potassium-
transporting ATPase 
subunit alpha-2  
4 96.25 6.76E-
04 
2.15 
O35114 Scarb2  Lysosome membrane 
protein 2  
3 185.98 3.26E-
04 
2.13 
Q9D6U8 Fam162a  Protein FAM162A  2 4.01 5.57E-
04 
2.12 
Q9DBH5 Lman2  Vesicular integral-
membrane protein 
VIP36  
7 188.62 9.85E-
06 
2.12 
Q05144 Rac2  Ras-related C3 
botulinum toxin 
substrate 2  
2 49.74 1.72E-
04 
2.12 
Q91YQ5 Rpn1  Dolichyl-
diphosphooligosacch
aride--protein 
glycosyltransferase 
subunit 1  
5 237.36 2.92E-
03 
2.10 
Q6PD26 Pigs  GPI transamidase 
component PIG-S  
2 101.18 1.32E-
04 
2.09 
P68040 Rack1  Receptor of activated 
protein C kinase 1  
3 143.91 5.88E-
03 
2.07 
P58252 Eef2  Elongation factor 2  2 43.37 1.97E-
03 
2.05 
Q01339 Apoh  Beta-2-glycoprotein 1  2 102.53 1.16E-
05 
2.04 
P47758 Srprb  Signal recognition 
particle receptor 
subunit beta  
2 88.21 4.38E-
04 
2.01 
P62908 Rps3  40S ribosomal 
protein S3  
2 118.03 7.18E-
05 
2.00 
Q8VDN2 Atp1a1  Sodium/potassium-
transporting ATPase 
subunit alpha-1  
5 225.57 3.96E-
05 
1.97 
Q8VEE1 Lmcd1  LIM and cysteine-
rich domains protein 
1  
2 68.63 1.60E-
05 
1.95 
G5E829 Atp2b1  Plasma membrane 
calcium-transporting 
ATPase 1  
3 148.47 5.71E-
04 
1.90 
Q9Z2I9 Sucla2  Succinate--CoA 
ligase [ADP-forming] 
subunit beta, 
mitochondrial  
2 93.87 3.30E-
03 
1.87 
P68368 Tuba4a  Tubulin alpha-4A 
chain  
3 99.25 3.01E-
03 
1.85 
P09470 Ace  Angiotensin-
converting enzyme  
3 54.45 2.47E-
04 
1.80 
A2AUC9 Klhl41  Kelch-like protein 41  3 45.52 2.74E-
04 
1.70 
Q9ERI6 Rdh14  Retinol 
dehydrogenase 14  
2 95.91 7.16E-
05 
1.63 
 
 
375 
 
Table A7.1: List of identified proteins with a significantly increased abundance 
 ≤ 12.7-fold in mdx-4cv serum as determined by label-free LC-MS/MS 
 
Accession Gene 
Name 
Protein Name Unique 
peptides 
Confidence 
score 
Anova 
(p) 
Max 
fold 
change 
Q8R0Y6 Aldh1l1 Cytosolic 10-
formyltetrahydrofol
ate dehydrogenase 
40 2619.27 9.28E-
04 
12.66 
P58771 Tpm1 Tropomyosin alpha-
1 chain 
6 325.91 6.97E-
06 
12.62 
Q9D6Y7 Msra  Mitochondrial 
peptide methionine 
sulfoxide reductase  
6 228.52 1.56E-
03 
12.47 
P05977 Myl1  Myosin light chain 
1/3, skeletal muscle 
isoform  
9 561.43 7.93E-
09 
12.01 
O08553 Dpysl2  Dihydropyrimidinas
e-related protein 2  
14 885.02 3.79E-
06 
11.83 
Q8BH00 Aldh8a1  Aldehyde 
dehydrogenase 
family 8 member A1  
5 250.25 2.17E-
02 
11.82 
Q99KK7 Dpp3  Dipeptidyl peptidase 
3  
6 322.74 2.99E-
02 
11.57 
Q9JI75 Nqo2  Ribosyldihydronicot
inamide 
dehydrogenase 
[quinone]  
6 262.85 7.40E-
05 
11.51 
O88844 Idh1  Isocitrate 
dehydrogenase 
[NADP] 
cytoplasmic  
17 1420.19 1.90E-
04 
11.45 
O35490 Bhmt  Betaine--
homocysteine S-
methyltransferase 1  
20 1756.08 3.42E-
03 
11.27 
P00329 Adh1  Alcohol 
dehydrogenase 1  
11 771.25 5.93E-
04 
10.70 
P52480 Pkm  Pyruvate kinase 
PKM  
46 4564.30 2.03E-
12 
10.39 
Q9Z2Y8 Prosc  Proline synthase co-
transcribed bacterial 
homolog protein  
2 88.56 1.55E-
02 
10.14 
Q9QXD6 Fbp1  Fructose-1,6-
bisphosphatase 1  
19 1633.89 3.53E-
03 
10.01 
Q5XKE0 Mybpc2  Myosin-binding 
protein C, fast-type  
12 688.24 1.56E-
08 
9.90 
Q9R0P9 Uchl1  Ubiquitin carboxyl-
terminal hydrolase 
isozyme L1  
6 349.78 1.27E-
03 
9.76 
Q3THE2 Myl12b  Myosin regulatory 
light chain 12B  
2 147.06 2.42E-
02 
9.67 
Q9JLJ2 Aldh9a1  4-
trimethylaminobutyr
aldehyde 
dehydrogenase  
2 66.79 1.09E-
02 
9.65 
Q9ET01 Pygl  Glycogen 
phosphorylase, liver 
form  
36 2184.82 9.16E-
08 
9.65 
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P52760 Hrsp12  Ribonuclease 
UK114  
8 633.43 1.77E-
03 
9.65 
P16546 Sptan1  Spectrin alpha 
chain, non-
erythrocytic 1  
2 92.39 9.98E-
03 
9.32 
G3X982 Aox3  Aldehyde oxidase 3  11 598.26 1.28E-
03 
9.31 
P06801 Me1  NADP-dependent 
malic enzyme  
20 1095.95 1.98E-
04 
9.21 
Q91Z53 Grhpr  Glyoxylate 
reductase/hydroxyp
yruvate reductase  
9 414.87 2.50E-
04 
9.13 
Q78JT3 Haao  3-
hydroxyanthranilate 
3,4-dioxygenase  
15 902.31 4.31E-
03 
9.02 
Q9QXF8 Gnmt  Glycine N-
methyltransferase  
11 854.76 5.01E-
03 
8.98 
P54728 Rad23b  UV excision repair 
protein RAD23 
homolog B  
3 113.01 1.45E-
05 
8.94 
Q9DBA8 Amdhd1  Probable 
imidazolonepropion
ase  
5 227.18 2.09E-
03 
8.82 
P10518 Alad  Delta-
aminolevulinic acid 
dehydratase  
6 340.77 2.29E-
03 
8.81 
Q8K183 Pdxk  Pyridoxal kinase  4 344.80 5.29E-
05 
8.79 
Q8K157 Galm  Aldose 1-epimerase  5 192.81 9.04E-
03 
8.75 
Q9DBB8 Dhdh  Trans-1,2-
dihydrobenzene-1,2-
diol dehydrogenase  
7 392.04 1.04E-
03 
8.74 
P49429 Hpd  4-
hydroxyphenylpyru
vate dioxygenase  
21 1181.72 2.62E-
03 
8.65 
P99025 Gchfr  GTP cyclohydrolase 
1 feedback 
regulatory protein  
2 129.86 2.95E-
02 
8.60 
P24472 Gsta4  Glutathione S-
transferase A4  
6 295.90 1.81E-
04 
8.58 
Q9CRB3 Urah  5-hydroxyisourate 
hydrolase  
2 110.41 1.03E-
02 
8.50 
O35215 Ddt  D-dopachrome 
decarboxylase  
8 595.48 1.83E-
04 
8.50 
P14824 Anxa6  Annexin A6  14 567.16 3.24E-
06 
8.49 
P12710 Fabp1  Fatty acid-binding 
protein, liver  
11 928.62 6.11E-
04 
8.43 
P57776 Eef1d  Elongation factor 1-
delta  
2 159.07 4.32E-
06 
8.42 
P68134 Acta1  Actin, alpha skeletal 
muscle  
9 1086.68 5.87E-
09 
8.41 
Q04447 Ckb  Creatine kinase B-
type  
17 1492.20 1.47E-
04 
8.15 
Q9JJU8 Sh3bgrl  SH3 domain-
binding glutamic 
acid-rich-like 
protein  
3 202.84 1.87E-
06 
7.88 
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P51855 Gss  Glutathione 
synthetase  
3 187.20 4.46E-
04 
7.82 
Q02053 Uba1  Ubiquitin-like 
modifier-activating 
enzyme 1  
3 135.72 2.75E-
04 
7.75 
P55264 Adk  Adenosine kinase  13 870.80 6.13E-
04 
7.71 
P63158 Hmgb1  High mobility group 
protein B1  
4 220.94 5.05E-
04 
7.69 
Q9CQM5 Txndc17  Thioredoxin 
domain-containing 
protein 17  
3 170.56 5.62E-
06 
7.61 
P11499 Hsp90ab1  Heat shock protein 
HSP 90-beta  
4 202.62 2.66E-
05 
7.56 
Q9Z2V4 Pck1  Phosphoenolpyruvat
e carboxykinase, 
cytosolic [GTP]  
3 149.38 5.46E-
03 
7.55 
P09528 Fth1  Ferritin heavy chain  8 503.24 2.02E-
04 
7.53 
P61979 Hnrnpk  Heterogeneous 
nuclear 
ribonucleoprotein K  
2 126.56 1.60E-
05 
7.42 
P10649 Gstm1  Glutathione S-
transferase Mu 1  
21 1827.86 3.30E-
04 
7.33 
Q91XD4 Ftcd  Formimidoyltransfer
ase-cyclodeaminase  
4 228.30 4.06E-
03 
7.30 
Q64442 Sord  Sorbitol 
dehydrogenase  
17 1504.41 4.76E-
03 
7.15 
Q9WVL0 Gstz1  Maleylacetoacetate 
isomerase  
4 200.18 7.76E-
03 
7.09 
O88569 Hnrnpa2b1  Heterogeneous 
nuclear 
ribonucleoproteins 
A2/B1  
4 271.37 6.18E-
07 
7.04 
Q9WUB3 Pygm  Glycogen 
phosphorylase, 
muscle form  
48 4290.78 6.10E-
10 
7.01 
Q9JII6 Akr1a1  Alcohol 
dehydrogenase 
[NADP(+)]  
16 893.69 2.28E-
04 
6.97 
P40936 Inmt  Indolethylamine N-
methyltransferase  
9 621.80 2.08E-
04 
6.87 
Q8BVI4 Qdpr  Dihydropteridine 
reductase  
11 711.78 6.14E-
04 
6.81 
Q61176 Arg1  Arginase-1  13 862.80 1.29E-
03 
6.81 
O35381 Anp32a  Acidic leucine-rich 
nuclear 
phosphoprotein 32 
family member A  
3 173.99 5.36E-
04 
6.79 
P28474 Adh5  Alcohol 
dehydrogenase 
class-3  
13 829.45 9.68E-
04 
6.75 
P26041 Msn  Moesin  4 116.72 9.54E-
03 
6.73 
O88587 Comt  Catechol O-
methyltransferase  
5 189.20 5.21E-
05 
6.73 
Q9D819 Ppa1  Inorganic 
pyrophosphatase  
3 209.39 1.27E-
03 
6.73 
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P15626 Gstm2  Glutathione S-
transferase Mu 2  
6 316.36 7.01E-
05 
6.71 
Q00519 Xdh  Xanthine 
dehydrogenase/oxid
ase  
7 408.00 5.65E-
04 
6.64 
P16045 Lgals1  Galectin-1  4 288.16 2.39E-
07 
6.59 
P09103 P4hb  Protein disulfide-
isomerase  
13 624.22 9.79E-
05 
6.59 
Q91X83 Mat1a  S-
adenosylmethionine 
synthase isoform 
type-1  
5 206.43 6.77E-
04 
6.55 
P31786 Dbi  Acyl-CoA-binding 
protein  
7 642.62 1.19E-
04 
6.51 
O88990 Actn3  Alpha-actinin-3  4 223.00 2.76E-
03 
6.51 
P15105 Glul  Glutamine 
synthetase  
18 1100.96 4.68E-
04 
6.39 
P68254 Ywhaq  14-3-3 protein theta  6 296.68 5.28E-
08 
6.38 
P15947 Klk1  Kallikrein-1  3 139.32 3.16E-
02 
6.38 
P70694 Akr1c6  Estradiol 17 beta-
dehydrogenase 5  
16 903.05 1.26E-
03 
6.37 
Q91Y97 Aldob  Fructose-
bisphosphate 
aldolase B  
20 1745.78 2.47E-
04 
6.36 
Q9R257 Hebp1  Heme-binding 
protein 1  
3 214.37 8.84E-
05 
6.35 
Q9CQV8 Ywhab  14-3-3 protein 
beta/alpha  
5 277.42 3.17E-
05 
6.25 
P58774 Tpm2  Tropomyosin beta 
chain  
11 671.83 1.80E-
05 
6.18 
P07724 Alb  Serum albumin  29 2066.14 1.05E-
02 
6.16 
P19639 Gstm3  Glutathione S-
transferase Mu 3  
2 134.13 4.55E-
05 
6.15 
P97807 Fh  Fumarate hydratase, 
mitochondrial  
9 650.71 5.19E-
05 
6.07 
P61982 Ywhag  14-3-3 protein 
gamma  
10 586.96 4.31E-
08 
5.88 
Q61599 Arhgdib  Rho GDP-
dissociation 
inhibitor 2  
2 44.20 6.92E-
05 
5.77 
Q62422 Ostf1  Osteoclast-
stimulating factor 1  
2 86.08 3.30E-
05 
5.75 
P45591 Cfl2  Cofilin-2  6 292.55 2.73E-
08 
5.74 
P17183 Eno2  Gamma-enolase  6 437.74 1.44E-
03 
5.71 
P08249 Mdh2  Malate 
dehydrogenase, 
mitochondrial  
6 274.29 3.87E-
08 
5.66 
Q11136 Pepd  Xaa-Pro dipeptidase  2 83.29 2.77E-
06 
5.63 
P20801 Tnnc2  Troponin C, skeletal 
muscle  
3 192.78 3.63E-
05 
5.59 
379 
 
P50247 Ahcy  Adenosylhomocyste
inase  
25 1596.15 2.31E-
03 
5.55 
Q8VDQ1 Ptgr2  Prostaglandin 
reductase 2  
3 153.65 3.65E-
04 
5.54 
Q91VH6 Memo1  Protein MEMO1  2 57.62 2.99E-
05 
5.53 
P24527 Lta4h  Leukotriene A-4 
hydrolase  
2 81.66 5.06E-
03 
5.46 
P26043 Rdx  Radixin  7 325.80 6.19E-
03 
5.43 
Q9D154 Serpinb1a  Leukocyte elastase 
inhibitor A  
2 72.78 9.42E-
03 
5.24 
Q8QZR5 Gpt  Alanine 
aminotransferase 1  
13 555.35 9.66E-
03 
5.24 
Q60864 Stip1  Stress-induced-
phosphoprotein 1  
3 114.47 8.05E-
04 
5.16 
Q9JMH6 Txnrd1  Thioredoxin 
reductase 1, 
cytoplasmic  
6 340.28 8.13E-
04 
5.15 
P18760 Cfl1  Cofilin-1  5 406.91 2.94E-
05 
5.11 
Q9D8N0 Eef1g  Elongation factor 1-
gamma  
3 98.33 6.70E-
03 
5.10 
P20152 Vim  Vimentin  4 186.80 2.72E-
06 
5.06 
P08228 Sod1  Superoxide 
dismutase [Cu-Zn]  
4 325.78 2.55E-
02 
5.02 
Q9CPY7 Lap3  Cytosol 
aminopeptidase  
12 627.46 4.46E-
04 
4.99 
P48036 Anxa5  Annexin A5  2 90.78 6.62E-
03 
4.95 
Q9DAK9 Phpt1  14 kDa 
phosphohistidine 
phosphatase  
3 104.93 1.19E-
05 
4.94 
P56565 S100a1  Protein S100-A1  2 127.11 2.24E-
02 
4.92 
Q9R0P5 Dstn  Destrin  6 290.59 2.82E-
04 
4.83 
P05202 Got2  Aspartate 
aminotransferase, 
mitochondrial  
7 361.26 8.32E-
06 
4.78 
P48758 Cbr1  Carbonyl reductase 
[NADPH] 1  
8 368.65 5.26E-
04 
4.75 
Q9CZY3 Ube2v1  Ubiquitin-
conjugating enzyme 
E2 variant 1  
2 107.01 2.33E-
08 
4.67 
P47791 Gsr  Glutathione 
reductase, 
mitochondrial  
4 238.51 2.46E-
06 
4.65 
P26443 Glud1  Glutamate 
dehydrogenase 1, 
mitochondrial  
6 207.62 3.38E-
06 
4.62 
Q9Z1Q5 Clic1  Chloride 
intracellular channel 
protein 1  
4 190.37 2.43E-
06 
4.59 
P62715 Ppp2cb  Serine/threonine-
protein phosphatase 
2A catalytic subunit 
beta isoform  
2 149.69 1.52E-
05 
4.53 
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P16460 Ass1  Argininosuccinate 
synthase  
10 575.46 1.19E-
02 
4.48 
P62259 Ywhae  14-3-3 protein 
epsilon  
12 717.43 2.08E-
07 
4.47 
P59325 Eif5  Eukaryotic 
translation initiation 
factor 5  
2 108.88 7.98E-
05 
4.42 
Q9WV35 Apobec2  C->U-editing 
enzyme APOBEC-2  
2 75.39 2.13E-
03 
4.38 
Q9CRB6 Tppp3  Tubulin 
polymerization-
promoting protein 
family member 3  
2 98.02 1.19E-
05 
4.38 
Q93092 Taldo1  Transaldolase  10 511.02 9.00E-
06 
4.38 
Q9R0Q7 Ptges3  Prostaglandin E 
synthase 3  
3 134.11 3.06E-
04 
4.35 
P28063 Psmb8  Proteasome subunit 
beta type-8  
2 112.96 2.07E-
03 
4.31 
Q91ZZ3 Sncb  Beta-synuclein  3 49.72 3.41E-
05 
4.16 
Q91YI0 Asl  Argininosuccinate 
lyase  
12 754.47 1.31E-
03 
4.12 
Q99KI0 Aco2  Aconitate hydratase, 
mitochondrial  
5 337.46 4.22E-
08 
4.11 
P05201 Got1  Aspartate 
aminotransferase, 
cytoplasmic  
22 1513.62 1.06E-
06 
4.08 
Q9DCS2 1 SV UPF0585 protein 
C16orf13 homolog  
2 74.67 1.11E-
03 
4.08 
P68369 Tuba1a  Tubulin alpha-1A 
chain  
7 691.16 1.79E-
04 
4.05 
P28650 Adssl1  Adenylosuccinate 
synthetase isozyme 
1  
8 490.67 4.31E-
06 
4.05 
Q8R429 Atp2a1  Sarcoplasmic/endop
lasmic reticulum 
calcium ATPase 1  
8 425.26 1.30E-
02 
4.04 
Q9R0P3 Esd  S-formylglutathione 
hydrolase  
10 629.82 3.49E-
04 
4.04 
Q91ZJ5 Ugp2  UTP--glucose-1-
phosphate 
uridylyltransferase  
2 108.32 1.33E-
04 
4.00 
Q99J08 Sec14l2  SEC14-like protein 
2  
4 161.48 9.69E-
04 
3.96 
Q9D0F9 Pgm1  Phosphoglucomutas
e-1  
22 1318.77 9.21E-
06 
3.96 
Q9DBP5 Cmpk1  UMP-CMP kinase  5 276.57 7.84E-
03 
3.90 
Q61316 Hspa4  Heat shock 70 kDa 
protein 4  
20 1146.72 2.76E-
06 
3.89 
P99029 Prdx5  Peroxiredoxin-5, 
mitochondrial  
10 599.57 1.07E-
04 
3.87 
P10126 Eef1a1  Elongation factor 1-
alpha 1  
7 328.86 1.31E-
04 
3.86 
P50396 Gdi1  Rab GDP 
dissociation 
inhibitor alpha  
14 910.39 5.90E-
07 
3.83 
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Q62426 Cstb  Cystatin-B  2 109.40 1.42E-
04 
3.80 
Q9CQI6 Cotl1  Coactosin-like 
protein  
3 155.14 8.91E-
04 
3.76 
P14211 Calr  Calreticulin  7 390.91 3.82E-
04 
3.73 
P53657 Pklr  Pyruvate kinase 
PKLR  
3 119.98 5.29E-
04 
3.71 
P63028 Tpt1  Translationally-
controlled tumor 
protein  
2 165.71 1.88E-
06 
3.71 
P97447 Fhl1  Four and a half LIM 
domains protein 1  
8 346.65 4.55E-
06 
3.71 
Q924M7 Mpi  Mannose-6-
phosphate isomerase  
3 44.41 1.05E-
05 
3.70 
Q6P8J7 Ckmt2  Creatine kinase S-
type, mitochondrial  
10 596.62 8.29E-
07 
3.68 
Q7TMM9 Tubb2a  Tubulin beta-2A 
chain  
6 375.91 5.68E-
03 
3.66 
P23927 Cryab  Alpha-crystallin B 
chain  
4 258.84 5.43E-
04 
3.61 
P63101 Ywhaz  14-3-3 protein 
zeta/delta  
11 876.80 6.15E-
06 
3.61 
Q99KB8 Hagh  Hydroxyacylglutathi
one hydrolase, 
mitochondrial  
4 278.74 2.09E-
04 
3.60 
P68510 Ywhah  14-3-3 protein eta  11 613.82 6.22E-
07 
3.57 
Q8VCT3 Rnpep  Aminopeptidase B  2 79.91 1.53E-
03 
3.53 
Q9QYG0 Ndrg2  Protein NDRG2  8 456.40 5.59E-
05 
3.48 
Q9DBJ1 Pgam1  Phosphoglycerate 
mutase 1  
8 360.93 2.50E-
06 
3.42 
P40142 Tkt  Transketolase  23 1526.70 2.60E-
04 
3.40 
P19096 Fasn  Fatty acid synthase  9 437.49 4.70E-
04 
3.36 
P21107 Tpm3  Tropomyosin alpha-
3 chain  
2 43.67 1.70E-
04 
3.32 
P14602 Hspb1  Heat shock protein 
beta-1  
3 150.33 3.19E-
05 
3.31 
O09131 Gsto1  Glutathione S-
transferase omega-1  
6 244.05 2.28E-
03 
3.31 
O55234 Psmb5  Proteasome subunit 
beta type-5  
4 225.11 1.46E-
08 
3.30 
P27773 Pdia3  Protein disulfide-
isomerase A3  
11 474.25 4.62E-
04 
3.29 
P14152 Mdh1  Malate 
dehydrogenase, 
cytoplasmic  
13 1108.02 8.77E-
06 
3.28 
Q9R1P1 Psmb3  Proteasome subunit 
beta type-3  
5 234.40 8.96E-
07 
3.27 
P10605 Ctsb  Cathepsin B  6 304.18 3.09E-
04 
3.26 
Q63880 Ces3a  Carboxylesterase 3A  2 130.69 1.69E-
03 
3.25 
Q9CPU0 Glo1  Lactoylglutathione 
lyase  
9 504.21 5.25E-
04 
3.23 
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Q01853 Vcp  Transitional 
endoplasmic 
reticulum ATPase  
12 690.82 5.52E-
03 
3.22 
P56376 Acyp1  Acylphosphatase-1  2 111.56 9.44E-
05 
3.17 
Q9JMD3 Stard10  PCTP-like protein  2 106.89 1.38E-
02 
3.17 
Q8CDN6 Txnl1  Thioredoxin-like 
protein 1  
2 69.34 1.56E-
07 
3.15 
Q9R1P3 Psmb2  Proteasome subunit 
beta type-2  
6 433.52 1.59E-
06 
3.15 
Q99LX0 Park7  Protein deglycase 
DJ-1  
12 994.45 4.32E-
07 
3.14 
P61939 Serpina7  Thyroxine-binding 
globulin  
9 398.42 1.86E-
05 
3.13 
P05064 Aldoa  Fructose-
bisphosphate 
aldolase A  
30 3015.50 8.77E-
06 
3.11 
Q61598 Gdi2  Rab GDP 
dissociation 
inhibitor beta  
8 375.33 4.83E-
05 
3.11 
P70296 Pebp1  Phosphatidylethanol
amine-binding 
protein 1  
8 514.05 6.84E-
07 
3.10 
Q91VI7 Rnh1  Ribonuclease 
inhibitor  
7 325.40 4.83E-
06 
3.10 
Q3UGR5 Hdhd2  Haloacid 
dehalogenase-like 
hydrolase domain-
containing protein 2  
2 79.10 2.08E-
04 
3.08 
P26928 Mst1  Hepatocyte growth 
factor-like protein  
2 76.95 7.95E-
03 
3.06 
Q9R1P4 Psma1  Proteasome subunit 
alpha type-1  
6 308.27 5.81E-
07 
3.05 
P17742 Ppia  Peptidyl-prolyl cis-
trans isomerase A  
11 1015.27 1.27E-
05 
2.99 
Q60605 Myl6  Myosin light 
polypeptide 6  
3 134.99 1.14E-
03 
2.97 
Q9JKB1 Uchl3  Ubiquitin carboxyl-
terminal hydrolase 
isozyme L3  
2 97.98 1.27E-
05 
2.95 
Q9Z2U1 Psma5  Proteasome subunit 
alpha type-5  
6 423.30 3.20E-
07 
2.94 
P20029 Hspa5  78 kDa glucose-
regulated protein  
12 810.94 2.07E-
06 
2.94 
P16125 Ldhb  L-lactate 
dehydrogenase B 
chain  
12 1000.89 1.25E-
06 
2.92 
Q9Z2U0 Psma7  Proteasome subunit 
alpha type-7  
6 382.97 4.30E-
07 
2.90 
Q9QUM9 Psma6  Proteasome subunit 
alpha type-6  
9 649.65 9.76E-
07 
2.88 
P06151 Ldha  L-lactate 
dehydrogenase A 
chain  
24 1813.38 5.30E-
08 
2.86 
Q9Z1T2 Thbs4  Thrombospondin-4  7 412.56 1.81E-
05 
2.85 
P56395 Cyb5a  Cytochrome b5  4 212.78 1.42E-
04 
2.85 
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P58252 Eef2  Elongation factor 2  11 549.58 4.43E-
05 
2.81 
P28654 Dcn  Decorin  3 105.99 1.48E-
07 
2.80 
Q9DBE0 Csad  Cysteine sulfinic 
acid decarboxylase  
4 192.16 7.43E-
03 
2.79 
Q9Z2W0 Dnpep  Aspartyl 
aminopeptidase  
5 266.59 1.37E-
04 
2.79 
P13707 Gpd1  Glycerol-3-
phosphate 
dehydrogenase 
[NAD(+)], 
cytoplasmic  
12 629.16 8.02E-
06 
2.77 
P07901 Hsp90aa1  Heat shock protein 
HSP 90-alpha  
4 172.93 7.56E-
04 
2.77 
Q9R1P0 Psma4  Proteasome subunit 
alpha type-4  
8 418.89 5.97E-
07 
2.77 
Q8BWT1 Acaa2  3-ketoacyl-CoA 
thiolase, 
mitochondrial  
3 128.96 5.92E-
03 
2.76 
Q01768 Nme2  Nucleoside 
diphosphate kinase 
B  
12 824.20 6.65E-
07 
2.75 
P63242 Eif5a  Eukaryotic 
translation initiation 
factor 5A-1  
7 617.89 3.10E-
04 
2.73 
Q8K4Z3 Apoa1bp  NAD(P)H-hydrate 
epimerase  
2 93.42 3.60E-
03 
2.73 
Q9D1A2 Cndp2  Cytosolic non-
specific dipeptidase  
4 161.45 4.89E-
03 
2.69 
P49722 Psma2  Proteasome subunit 
alpha type-2  
5 375.45 4.49E-
06 
2.69 
O88342 Wdr1  WD repeat-
containing protein 1  
13 697.04 5.85E-
05 
2.67 
P17182 Eno1  Alpha-enolase  25 1951.59 2.86E-
10 
2.65 
P06745 Gpi  Glucose-6-
phosphate isomerase  
18 1312.49 2.56E-
07 
2.65 
P17751 Tpi1  Triosephosphate 
isomerase  
14 1281.99 3.22E-
06 
2.64 
P61971 Nutf2  Nuclear transport 
factor 2  
3 141.02 1.42E-
05 
2.63 
Q9DCD0 Pgd  6-phosphogluconate 
dehydrogenase, 
decarboxylating  
9 543.35 2.71E-
03 
2.62 
Q60854 Serpinb6  Serpin B6  5 223.18 7.99E-
04 
2.62 
Q11011 Npepps  Puromycin-sensitive 
aminopeptidase  
7 290.64 1.87E-
05 
2.61 
P32848 Pvalb  Parvalbumin alpha  16 1096.30 1.40E-
05 
2.61 
P99026 Psmb4  Proteasome subunit 
beta type-4  
7 375.80 1.31E-
06 
2.60 
O70435 Psma3  Proteasome subunit 
alpha type-3  
5 390.64 9.53E-
07 
2.56 
P63017 Hspa8  Heat shock cognate 
71 kDa protein  
18 1479.96 5.30E-
08 
2.55 
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P16858 Gapdh  Glyceraldehyde-3-
phosphate 
dehydrogenase  
12 1069.11 1.72E-
07 
2.50 
P15532 Nme1  Nucleoside 
diphosphate kinase 
A  
2 55.33 1.41E-
05 
2.48 
P17563 Selenbp1  Selenium-binding 
protein 1  
20 1412.15 1.53E-
03 
2.47 
P16015 Ca3  Carbonic anhydrase 
3  
15 830.57 4.43E-
03 
2.44 
P70349 Hint1  Histidine triad 
nucleotide-binding 
protein 1  
5 237.49 5.30E-
06 
2.43 
Q9D6F9 Tubb4a  Tubulin beta-4A 
chain  
4 186.13 1.95E-
03 
2.42 
P97494 Gclc  Glutamate--cysteine 
ligase catalytic 
subunit  
3 175.08 3.21E-
04 
2.42 
O09061 Psmb1  Proteasome subunit 
beta type-1  
4 304.86 1.01E-
07 
2.41 
P10639 Txn  Thioredoxin  2 106.36 9.73E-
04 
2.40 
P09411 Pgk1  Phosphoglycerate 
kinase 1  
19 1311.93 1.65E-
05 
2.38 
P07310 Ckm  Creatine kinase M-
type  
30 2895.13 5.69E-
06 
2.38 
Q61233 Lcp1  Plastin-2  2 88.51 1.17E-
02 
2.38 
P11276 Fn1  Fibronectin  6 298.37 1.04E-
03 
2.37 
O08709 Prdx6  Peroxiredoxin-6  7 432.41 3.13E-
05 
2.36 
Q8CHP8 Pgp  Phosphoglycolate 
phosphatase  
2 188.24 1.43E-
05 
2.36 
P19157 Gstp1  Glutathione S-
transferase P 1  
9 598.62 5.70E-
03 
2.36 
Q99PT1 Arhgdia  Rho GDP-
dissociation 
inhibitor 1  
3 216.58 1.22E-
05 
2.33 
Q91XR9 Gpx4  Phospholipid 
hydroperoxide 
glutathione 
peroxidase, nuclear  
2 90.93 1.02E-
03 
2.31 
Q8R016 Blmh  Bleomycin 
hydrolase  
11 645.79 6.54E-
07 
2.30 
P04117 Fabp4  Fatty acid-binding 
protein, adipocyte  
9 800.82 3.83E-
03 
2.30 
Q9R0Y5 Ak1  Adenylate kinase 
isoenzyme 1  
3 247.30 5.37E-
03 
2.28 
Q60692 Psmb6  Proteasome subunit 
beta type-6  
6 274.09 2.66E-
03 
2.28 
P35700 Prdx1  Peroxiredoxin-1  10 493.83 2.82E-
05 
2.27 
P11352 Gpx1  Glutathione 
peroxidase 1  
7 402.38 1.78E-
02 
2.24 
Q4KML4 Abracl  Costars family 
protein ABRACL  
2 139.64 1.47E-
03 
2.22 
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P62983 Rps27a  Ubiquitin-40S 
ribosomal protein 
S27a  
3 166.25 6.36E-
03 
2.22 
Q8CG14 C1sa  Complement C1s-A 
subcomponent  
3 195.25 1.20E-
03 
2.21 
O70250 Pgam2  Phosphoglycerate 
mutase 2  
10 714.82 1.19E-
02 
2.20 
P45376 Akr1b1  Aldose reductase  11 505.47 1.24E-
04 
2.20 
P60710 Actb  Actin, cytoplasmic 1  10 939.87 6.62E-
06 
2.18 
Q9CWJ9 Atic  Bifunctional purine 
biosynthesis protein 
PURH  
14 783.17 7.17E-
05 
2.17 
P21550 Eno3  Beta-enolase  23 2090.28 1.67E-
04 
2.16 
P97371 Psme1  Proteasome 
activator complex 
subunit 1  
2 96.03 2.95E-
03 
2.14 
O35945 Aldh1a7  Aldehyde 
dehydrogenase, 
cytosolic 1  
5 288.72 3.19E-
03 
2.11 
O55042 Snca  Alpha-synuclein  2 183.14 4.09E-
02 
2.08 
Q3TMH2 Scrn3  Secernin-3  3 170.80 1.62E-
03 
2.08 
O35350 Capn1  Calpain-1 catalytic 
subunit  
2 111.43 1.68E-
03 
2.02 
P70195 Psmb7  Proteasome subunit 
beta type-7  
4 172.92 1.07E-
03 
2.00 
 
 
 
 
 
 
